


(IdiPAZ) 10[~]

Scientific
Report

2018



(IdiPAZ) 10^o ñ



Index

Scientific
Report

2016
2017
2018

1	Introduction		3
2	Executive summary		5
	2.1 Global Analysis		6
	2.2 Research Structure		13
	2.3 Training Report and Teaching		23
	2.4 Innovation and Transfer Activities		27
	2.5 Quality Committee		40
	2.6 Clinical Trials		43
	2.7 Platforms		68
	2.8 Scientific Production		95
	2.9 CIBERs and RETICs		106
	2.10 Institutional Projects		108
	2.11 Internationalization		110
	2.12 Communication		111
3	Information Groups by Area		113
	3.1 Neuroscience Area		114
	3.2 Cardiovascular Area		135
	3.3 Infectious Diseases and Immunity Area		161
	3.4 Large System Pathologies Area		212
	3.5 Cancer and Human Molecular Genetics Area		278
	3.6 Surgery, Transplant and Health Technologies Area		327
4	Associated Clinicians		351

Introduction



Executive summary

2

Information Groups by Area

3

Associated Clinicians

4



Scientific Report

2016
2017
2018

The Hospital La Paz Institute for Health Research (Instituto de Investigación Sanitaria del Hospital Universitario La Paz)-IdiPAZ was created in 2009, as a result of the relationship that has been forged over the years between La Paz University Hospital (HULP), the Autonomous University of Madrid (UAM), and the Foundation for Biomedical Research of La Paz University Hospital (FIBHULP). Recently, we have incorporated Fuenlabrada University Hospital to our structure, and we are also very excited with the upcoming incorporation of Getafe University Hospital and the European University of Madrid.

Since its establishment, IdiPAZ has promoted the configuration of multidisciplinary teams capable of addressing several facets of translational research, with the mind always focused on the generation of innovation and the transfer of results to the healthcare system. Over the years, we have maintained a progressive growth of our scientific activity, which is organized into six research areas: neurosciences, cardiovascular, infectious diseases and immunity, large system pathologies, cancer and human molecular genetics and surgery, transplants and health technologies. The increasing scientific contributions performed by our research groups over the last years have placed IdiPAZ amongst the top three health research Institutes with the best scientific evaluation of Spain.

The Scientific Report of IdiPAZ provides us an opportunity to recognize these achievements of our researchers, and reflects the effort of the 55 research groups that currently constitute IdiPAZ, as well as the associated clinical groups.

IdiPAZ's excellent position in clinical research is evidenced by its scientific performance figures. Particularly regarding scientific production, we published more than 1,200 articles in 2018, of which 928 were original papers. In addition, the overall impact factor reached almost 5,600 points, exceeding for the first time the 5,000 points threshold. There has been also a consolidation in the quality of the source journals, and more than 514 of the manuscripts were published in journals in the first quartile of their subject area.



Dr. Eduardo López-Collazo
Scientific Director of IdiPAZ

Dr. Rafael Pérez-Santamarina Feijóo
Managing Director of HULP
Chairman of the Board of FIBHULP



Introduction 1

Executive summary 2

Information Groups by Area 3

Associated Clinicians 4

The 2018 Scientific Report also shows data reflecting the commitment of IdiPAZ to biomedical research training. The involvement of the university in most of the research groups has resulted in a high participation in graduate programs, generating 34 Doctoral Theses in 2018; 5 of them being qualified with an International Mention. Additionally, in our attempt to promoting research and science in the society, we hosted many scientific activities as: the European Researchers' Night, the Science and Innovation Week, the International Day of Woman and Girl in Science, and other several events of scientific dissemination, all organized with the aim of actively involving citizens in science, technology and innovation, contributing to join the youngest public, promoting scientific vocations and eliminating gender barriers. In parallel, our institution is making a great effort to promote IdiPAZ brand and collaborations both national and internationally. For this purpose, in 2018 we signed agreements, started projects, organized activities and workshops and initiated relationships with new partners to increase our visibility and current potential, while improving our plans for the future taking into account the internationalization aspects.

Regarding our innovation performance indicators, we must highlight the fact that at December 31 2018, our Innovation Support Unit (UAI) had 184 innovation projects or ideas in active state, 26 of which were in the capture phase, 65 in the evaluation phase, 12 in development, 49 in transfer and 32 in the market. IdiPAZ researchers and groups work in research networks (CIBER and RETICs) that involve collaboration to improve results, as well as in international consortia. Finally, we have done an effort to continue and improve our translational research with a direct application to the care of our patients; and in this strategic process, 371 new contracts for clinical trials were signed in 2018.

The excellence of our research institute is based on the constant struggle of our human capital to improve patient's health; therefore, we would like to express our admiration for them,

who enable IdiPAZ to continue advancing towards a promising future. There have been many achievements and we are confident that we will achieve many more. Our human potential and desire to continue progressing represent the best guarantee of continued success. We are especially grateful to all our researchers, members of the Governing Council, the Executive Committee, Internal Scientific Advisory Board, the External Scientific Advisory Board, Committees, Platforms and all the professionals involved in the day-to-day work of the Institute, for the magnificent performed work during these years and the achieved results.

In 2019, we are celebrating the 10th anniversary of IdiPAZ, thus it represents a pretty special occasion to show and disseminate our strengths and the achievements we have accomplished over this decade. Proudly, we can show to the scientific community and the civilian society all those merits that have allowed our Institution to be national and internationally recognized as a Center of Excellence, and be on a par with the best scientific institutes worldwide.

Scientific Report

2016
2017
2018



Introduction

1

Information
Groups
by Area


3

Associated
Clinicians

4

2

Executive summary



2.1 Global Analysis

- 2.1.1 Scientific Analysis
- 2.1.2 Annual Accounts



2.2 Research Structure



2.3 Training Report and Teaching

- 2.3.1 Training Committee
- 2.3.2 Training Courses
- 2.3.3 Doctoral Theses



2.4 Innovation and Transfer Activities

- 2.4.1 Innovation and Transfer Activities
- 2.4.2 Patents and Trademarks



2.5 Quality Committee



2.6 Clinical Trials



2.7 Platforms

- 2.7.1 Biobank
- 2.7.2 UCICEC
- 2.7.3 Experimental Surgery
- 2.7.4 Simulation Platform (CEASEC)

2.7.5 Cell Culture Unit

2.7.6 Sanger Sequencing Facility

2.7.7 Image Laboratory

2.7.8 Flow Cytometry Laboratory

2.7.9 Radioisotope Laboratory

2.7.10 Biostatistics Section

2.7.11 Documentalist

2.7.12 PAIN Platform

2.7.13 Internationalization Platform

2.7.14 Tissue Engineering and 3D Printing Platform

2.7.15 Food, Nutrition and Health Platform



2.8 Scientific Production

2.8.1 Journal Analysis

2.8.2 High Impact Publications



2.9 CIBERs and RETICs



2.10 Institutional Projects



2.11 Internationalization




2.12 Communication



Scientific
Report

2015
2016
2017
2018

2.1 Global Analysis




2.1.1 Scientific Analysis


In 2018, the scientific production of IdiPAZ included more than 1,200 publications that reached, for the first time, almost 5,600 points of total impact factor. Of the total of publications, 46.7% are documents belong to IdiPAZ, so the author the first, the last or the corresponding author of the publication is a researcher of the institute.

	Total	Impact factor	Mean impact factor
Publications	1,243	5,599.02	4.50
Owned Publications	581	1,974.52	3.40
Un-owned Publications	662	3624.50	5.48
Originals	928	4,360.68	4.70
Owned Originals	368	1127.43	3.06
Un-owned Originals	560	3,233.26	5.77

TOTAL IMPACT FACTOR BETWEEN 2009-2018



MEAN IMPACT FACTOR BETWEEN 2009-2018






2.1 Global Analysis




In 2018, the scientific production of IdiPAZ included more than 1,200 publications that reached, for the first time, almost 5,600 points of total impact factor. Of the total of publications, 46.7% are documents belong to IdiPAZ, so the author the first, the last or the corresponding author of the publication is a researcher of the institute.

TOTAL IMPACT FACTOR FOR ORIGINAL PAPERS BETWEEN 2009-2018



MEAN IMPACT FACTOR FOR ORIGINAL PAPERS BETWEEN 2009-2018






2.1 Global Analysis




Considering originals published by IdiPAZ researchers, 928 articles, we keep the trend of the last years, exceeding the 4,000-point threshold (4,360.7 points). Moreover, about 18% of the originals published in this year were in first-decile journals of their subject area, and 43% were in first quartile journals.

TOTAL IMPACT FACTOR FOR ORIGINAL PAPERS BETWEEN 2009-2018




MEAN IMPACT FACTOR FOR ORIGINAL PAPERS BETWEEN 2009-2018



IdiPAZ researchers evidenced their participation in national and international scientific networks, with near 85% of the total documents published in collaboration, which 88.6% of the originals publications. In addition, collaboration among IdiPAZ research groups is also reflected by the percentage of intramural collaboration, which reached almost 11% for all manuscripts and for originals.

PAPERS WITH INTERNATIONAL COLLABORATION BETWEEN 2009-2018






2.1 Global Analysis



IdiPAZ researchers evidenced their participation in national and international scientific networks, with near 85% of the total documents published in collaboration, which 88.6% of the originals publications. In addition, collaboration among IdiPAZ research groups is also reflected by the percentage of intramural collaboration, which reached almost 11% for all manuscripts and for originals.

OWNED ORIGINALS BETWEEN 2009-2018





2.1 Global Analysis


2.1.2 Annual Accounts

In accordance with the Law 19/2013, of December 9th, of transparency, access to public information and good governance, the Foundation for Biomedical Research of La Paz University Hospital (FIBHULP) makes their information public, with the objective of guaranteeing institutional transparency:


<http://www.idipaz.es/PaginaDinamica.aspx?IdPag=550&Lang=ES>

Economic income 2018

ECONOMIC INCOME 2018



ECONOMIC INCOME OVERHEAD- 2018



Summary

INGRESOS	Ingresos	Peso relativo	Incremento 2018 vs 2017	2018
Ingresos por actividad propia	Proyectos Públicos	33,77%	26,95%	15.460.695,81
Ingresos financieros	Financiación Privada	36,55%	30,14%	36.613,24
Ingresos excepcionales	Estudios y Ensayos Clínicos	29,68%	5,69%	1.030,57
Diferencias de cambio				9.593,21
TOTAL INGRESOS				15.507.932,83
GASTOS				
Ayudas monetarias y otros				112.918,19
Aprovisionamientos				777.715,30
Gastos de personal				6.386.810,51
Otros gastos de explotación				4.098.515,05
Amortizaciones				1.260.794,21
Gastos financieros				144.964,58
Diferencias de cambio				3.755,51
Gastos excepcionales				151,26
Provisión (dotación-exceso)				2.260.668,15
TOTAL GASTOS				15.046.292,76
RESULTADO				461.640,07

In 2018, the FIBHULP received a Nominative Grant of the Consejería de Sanidad de la Comunidad de Madrid in favor of charging the 312D program "Biomedical Research Foundations", to fund the following parts:

- Researchers and personal of support of the I3, I3SNS, Miguel Servet II and Juan Rodés Programs.
- Intensification Programs of health professionals.
- Activities of promotion and dissemination research and scientific culture.
- Accreditations of the research activity.
- Support to the Technical Units or Platforms for Research and Management of I+D+i.



2.1 Global Analysis



Informe de Auditoría de Cuentas Anuales emitido por un Auditor Independiente

Al Patronato de Fundación para la Investigación Biomédica del Hospital Universitario La Paz

Opinión

Hemos auditado las cuentas anuales de la Fundación para la Investigación Biomédica del Hospital Universitario La Paz (la Fundación), que comprenden el balance a 31 de diciembre de 2018, la cuenta de resultados y la memoria correspondientes al ejercicio terminado en dicha fecha.

En nuestra opinión, las cuentas anuales adjuntas expresan, en todos los aspectos significativos, la imagen fiel del patrimonio y de la situación financiera de la Fundación a 31 de diciembre de 2018, así como de sus resultados y flujos de efectivo correspondientes al ejercicio terminado en dicha fecha, de conformidad con el marco normativo de información financiera que resulta de aplicación (que se identifica en la nota 2 de la memoria) y, en particular, con los principios y criterios contables contenidos en el mismo.

Fundamento de la opinión

Hemos llevado a cabo nuestra auditoría de conformidad con la normativa reguladora de la actividad de auditoría de cuentas vigente en España. Nuestras responsabilidades de acuerdo con dichas normas se describen más adelante en la sección Responsabilidades del auditor en relación con la auditoría de las cuentas anuales de nuestro informe.

Somos independientes de la Fundación de conformidad con los requerimientos de ética, incluidos los de independencia, que son aplicables a nuestra auditoría de las cuentas anuales en España según lo exigido por la normativa reguladora de la actividad de auditoría de cuentas. En este sentido, no hemos prestado servicios distintos a los de la auditoría de cuentas ni han concurrido situaciones o circunstancias que, de acuerdo con lo establecido en la citada normativa reguladora, hayan afectado a la necesaria independencia de modo que se haya visto comprometida.

Consideramos que la evidencia de auditoría que hemos obtenido proporciona una base suficiente y adecuada para nuestra opinión.

Aspectos más relevantes de la auditoría

Los aspectos más relevantes de la auditoría son aquellos que, según nuestro juicio profesional, han sido considerados como los riesgos de incorrección material más significativos en nuestra auditoría de las cuentas anuales del periodo actual. Estos riesgos han sido tratados en el contexto de nuestra auditoría de las cuentas anuales en su conjunto, y en la formación de nuestra opinión sobre éstas, y no expresamos una opinión por separado sobre esos riesgos.

C/ Alcalá, 63, 28014 Madrid Teléfono: + 34 916 624 030 Fax: + 34 916 610 224 e-mail: auditoria@mazars.es Oficinas en Alicante, Barcelona, Bilbao, Madrid, Málaga, Valencia, Vigo

MAZARS Auditores, S.L.P. Domicilio Social: Calle Diputación, 290, 08007 Barcelona Registro Mercantil de Barcelona, Tomo 30.734, Folio 212, Hoja B-180111, Inscripción I, N.I.F. B-61622262 Insrita con el número 51169 en el Registro Oficial de Auditores de Cuentas (ROAC)



Inversiones financieras

El activo del balance adjunto a 31 de diciembre de 2018 presenta, en el epígrafe "Inversiones financieras a corto plazo", depósitos bancarios y fondos de inversión por importe de 21.246 miles de euros. Como se indica en la nota 29 de la memoria adjunta, la Fundación ha cumplido con los principios y normas del Código de conducta de las entidades sin ánimo de lucro para la realización de inversiones temporales, aprobado mediante Acuerdo del Consejo de la Comisión Nacional del Mercado de Valores, de fecha 20 de noviembre de 2003. El importe de estos activos representa el 53% del total de activos de la Fundación. Por ello, consideramos su naturaleza y valoración como un aspecto relevante de nuestra auditoría.

Nuestros procedimientos de auditoría han incluido, entre otros, (i) entendimiento y revisión en detalle de la composición de las inversiones, así como su clasificación para su valoración (ii) la confirmación con las entidades depositarias de la naturaleza y los importes de dichos activos financieros a 31 de diciembre de 2018, (iii) la evaluación del cumplimiento del Código de Conducta indicado en el párrafo anterior y (iv) la revisión de que la memoria adjunta, en las notas 4.7 y 29, incluye los desgloses de información que requiere el marco de información financiera aplicable.

Ingresos de la actividad propia

La cuenta de resultados adjunta incluye, dentro del epígrafe "Ingresos de la actividad propia", los ingresos derivados de ensayos clínicos, por un importe de 6.838 miles de euros, y los ingresos procedentes de subvenciones y donaciones, por un importe de 7.214 miles de euros. Los ingresos por ensayos clínicos se reconocen cuando el promotor del ensayo aprueba las visitas realizadas. Las subvenciones y donaciones se imputan a resultados en función del gasto ejecutado en los proyectos durante el ejercicio, junto con el overhead correspondiente. Dichos ingresos contienen diferentes condiciones de aplicación, uso y métodos de justificación que condicionan el registro contable de los mismos. Por ello, consideramos su valoración como un aspecto relevante en nuestra auditoría.

Nuestros procedimientos de auditoría han incluido, entre otros, (i) el entendimiento y la revisión del procedimiento seguido por la Fundación para el control de la gestión de los ensayos clínicos y los proyectos de investigación, (ii) la revisión en detalle de una muestra de ingresos para comprobar si las cantidades contabilizadas se corresponden con los importes acordados y cobrados, (iii) la comprobación del registro contable de dichos ingresos en el periodo correcto, (iv) la confirmación con una muestra de las entidades financiadoras de los importes pendientes de cobro a 31 de diciembre de 2018, (v) el análisis de la recuperabilidad de los saldos deudores a 31 de diciembre de 2018 y (vi) la revisión de que la memoria adjunta, en las notas 4.14 y 14, incluye los desgloses de información que requiere el marco de información financiera aplicable.

Importes pendientes de ejecutar en ensayos clínicos y proyectos de investigación

El pasivo corriente del balance adjunto presenta, en el epígrafe "Provisiones a corto plazo", la cantidad de 15.117 miles de euros. Dicho importe incluye 14.790 miles de euros, correspondientes a los importes pendientes de ejecutar a 31 de diciembre de 2018 en ensayos clínicos y proyectos de investigación, que se encuentran a disposición de los investigadores responsables, según lo estipulado en los contratos y acuerdos suscritos. El importe de este epígrafe representa el 56% del pasivo corriente de la Fundación. Por ello, consideramos su valoración como un aspecto relevante en nuestra auditoría.





2.1 Global Analysis



Nuestros procedimientos de auditoría han incluido, entre otros, (i) el entendimiento y la revisión del procedimiento seguido por la Fundación para el control de los importes pendientes de ejecutar en ensayos clínicos y proyectos de investigación, (ii) la comprobación de que el saldo de la provisión a 31 de diciembre de 2018 coincide con el detalle de los ensayos clínicos y proyectos de investigación; y (iii) la revisión de que la memoria adjunta, en las notas 4.15 y 15, incluye los desgloses de información que requiere el marco de información financiera aplicable.

Responsabilidad de la Directora de la Fundación en relación con las cuentas anuales

La Directora de la Fundación es responsable de formular las cuentas anuales adjuntas, de forma que expresen la imagen fiel del patrimonio, de la situación financiera y de los resultados de la Fundación, de conformidad con el marco normativo de información financiera aplicable a la Fundación en España, y del control interno que considere necesario para permitir la preparación de cuentas anuales libres de incorrección material, debida a fraude o error.

En la preparación de las cuentas anuales, la Directora de la Fundación es responsable de la valoración de la capacidad de la Fundación para continuar como entidad en funcionamiento, revelando, según corresponda, las cuestiones relacionadas con la entidad en funcionamiento y utilizando el principio contable de entidad en funcionamiento excepto si el Patronato de la Fundación tiene intención de liquidar la Fundación o de cesar sus operaciones, o bien no exista otra alternativa realista.

Responsabilidades del auditor en relación con la auditoría de las cuentas anuales

Nuestros objetivos son obtener una seguridad razonable de que las cuentas anuales en su conjunto están libres de incorrección material, debida a fraude o error, y emitir un informe de auditoría que contiene nuestra opinión. Seguridad razonable es un alto grado de seguridad pero no garantiza que una auditoría realizada de conformidad con la normativa reguladora de la actividad de auditoría de cuentas vigente en España siempre detecte una incorrección material cuando existe. Las incorrecciones pueden deberse a fraude o error y se consideran materiales si, individualmente o de forma agregada, puede preverse razonablemente que influyan en las decisiones económicas que los usuarios toman basándose en las cuentas anuales.

Como parte de una auditoría de conformidad con la normativa reguladora de la actividad de auditoría de cuentas vigente en España, aplicamos nuestro juicio profesional y mantenemos una actitud de escepticismo profesional durante toda la auditoría. También:

- Identificamos y valoramos los riesgos de incorrección material en las cuentas anuales, debida a fraude o error, diseñamos y aplicamos procedimientos de auditoría para responder a dichos riesgos y obtenemos evidencia de auditoría suficiente y adecuada para proporcionar una base para nuestra opinión. El riesgo de no detectar una incorrección material debida a fraude es más elevado que en el caso de una incorrección material debida a error, ya que el fraude puede implicar colusión, falsificación, omisiones deliberadas, manifestaciones intencionadamente erróneas, o la elusión del control interno.
- Obtenemos conocimiento del control interno relevante para la auditoría con el fin de diseñar procedimientos de auditoría que sean adecuados en función de las circunstancias, y no con la finalidad de expresar una opinión sobre la eficacia del control interno de la Fundación.
- Evaluamos si las políticas contables aplicadas son adecuadas y la razonabilidad de las estimaciones contables y la correspondiente información revelada por la Directora de la Fundación.



- Concluimos sobre si es adecuada la utilización, por la Directora de la Fundación, del principio contable de entidad en funcionamiento y, basándonos en la evidencia de auditoría obtenida, concluimos sobre si existe o no una incertidumbre material relacionada con hechos o con condiciones que pueden generar dudas significativas sobre la capacidad de la Fundación para continuar como entidad en funcionamiento. Si concluimos que existe una incertidumbre material, se requiere que llamemos la atención en nuestro informe de auditoría sobre la correspondiente información revelada en las cuentas anuales o, si dichas revelaciones no son adecuadas, que expresemos una opinión modificada. Nuestras conclusiones se basan en la evidencia de auditoría obtenida hasta la fecha de nuestro informe de auditoría. Sin embargo, los hechos o condiciones futuros pueden ser la causa de que la Fundación deje de ser una entidad en funcionamiento.
- Evaluamos la presentación global, la estructura y el contenido de las cuentas anuales, incluida la información revelada, y si las cuentas anuales representan las transacciones y hechos subyacentes de un modo que logran expresar la imagen fiel.

Nos comunicamos con la Directora de la Fundación en relación con, entre otras cuestiones, el alcance y el momento de realización de la auditoría planificada y los hallazgos significativos de la auditoría, así como cualquier deficiencia significativa del control interno que identificamos en el transcurso de la auditoría.

Entre los riesgos significativos que han sido objeto de comunicación a la Directora de la Fundación, determinamos los que han sido de la mayor significatividad en la auditoría de las cuentas anuales del periodo actual y que son, en consecuencia, los riesgos considerados más significativos.

Describimos esos riesgos en nuestro informe de auditoría salvo que las disposiciones legales o reglamentarias prohíban revelar públicamente la cuestión.



MAZARS AUDITORES, S.L.P

2019 N.ºm. 0151813078 96,00 EUR

SELLO CORPORATIVO Informe de auditoría de cuentas sujeto a la normativa de auditoría de cuentas española e internacional

Madrid, 25 de junio de 2019

MAZARS AUDITORES, S.L.P. ROAC N.º S1189

Juan Antonio Giménez Miró ROAC N.º 15.588



Introduction

1

Executive
summary

2

2.1 Global Analysis

2.2 Research Structure

2.3 Training Report and
Teaching

2.4 Innovation and
Transfer Activities

2.5 Quality Committe

2.6 Clinical Trials

2.7 Platforms

2.8 Scientific Production

2.9 CIBERs and RETICs

2.10 Institutional Projects

2.11 Internationalization

2.12 Communication

Information
Groups
by Area

3

Associated
Clinicians

4

Scientific
Report

2016
2017
2018

2.2 Research Structure



Scientific Director

Eduardo López-Collazo

Scientific Assistant Director

Ignacio Zapardiel Gutiérrez

Technical Assistant Director

Paloma Gómez Campelo

Executive Committee

Chairman

Rafael Pérez-Santamarina Feijóo. Chairman of the Board of FIBHULP; permanent delegation to Rodolfo Álvarez-Sala Walther

Members

Juan Antonio Vargas Núñez. Dean of UAM Medical School
Eduardo López-Collazo. Scientific Director IdiPAZ
Francisco García Río. HULP Representative
Francisco Arnalich Fernández. UAM Representative

Secretary

Ana Coloma Zapatero. Director of FIBHULP

Governing Council

Chairman

Ana Dávila-Ponce de León Mundo. Health Care Vice Councillor CM

Deputy Chairman

Rafael Garesse Alarcón. Chancellor of UAM

Members

Rafael Pérez-Santamarina Feijóo. Chairman of the Board of FIBHULP
Rodolfo Álvarez-Sala Walther. FIBHULP Patron
Teresa Chavarría Giménez. FIBHULP Patron
José María Muñoz y Ramón. FIBHULP Patron
Juan Antonio Vargas Núñez. FIBHULP Patron
Eduardo López-Collazo. Scientific Director of IdiPAZ
Almudena Castro Conde. FIBHULP Patron
Exuperio Díez Tejedor. FIBHULP Patron
Fernando Rodríguez Artalejo. UAM Representative
Amparo Cano García. UAM Representative
Francisco Javier García-Samaniego Rey. FIBHULP Patron

Secretary

Ana Coloma Zapatero. Director of FIBHULP



2.2 Research Structure

External Scientific Committee

Juan Tamargo Menéndez.

Professor. Institute of Pharmacology and Toxicology, Spanish National Research Council (CSIC)- Complutense University of Madrid. Madrid

Reiner Albert Veitia.

Professor Génomique fonctionnelle Université Denis Diderot, Paris VII. Group leader of the Molecular Oncology and Ovarian Pathologies, l'Institut Jacques Monod. Paris

Joaquín Arribas López.

Principal investigator. Vall d'Hebron Hospital. Barcelona

Jacinta Cecilia Bustamante.

Associate Professor. Paris Descartes University, Laboratory of Human Genetics of Infectious diseases (INSERM U980), Imagine Institut. Center for the Study of Primary Immunodeficiencies, Necker Enfants-Malades Hospital. Paris

Carlos Belmonte Martínez.

Professor. Miguel Hernández University. Institute of Neurosciences. Alicante

Isabel Fabregat Romero.

Centre d'Oncologia Molecular. L'Hospitalet, IDIBELL- Bellvitge Biomedical Research Institute. Barcelona

Carmen Maroto Vela.

Professor. Chief of Microbiology. Clinical Hospital University of Granada. Granada

Santiago Moreno Guillén.

Chief of Infectious diseases Service. Ramón y Cajal Hospital. Professor. Alcalá University. Madrid

Juan Pedro Bolaños Hernández.

Department of Biochemistry and Molecular Biology. University of Salamanca. Institute of Functional Biology and Genomics. Salamanca.

Santiago Rodríguez de Córdoba.

Professor. Cellular and Molecular Medicine Department. Center of Biological Research. CSIC. Madrid

Governing Council

Chairman

Eduardo López Collazo, Scientific Director

Secretary

Inmaculada Ibáñez de Cáceres.

Nora Buta Coll

Members

Committee representatives

Javier de Castro Carpeño, Innovation Support Unit Coordinator

José Jonay Ojeda Feo, Quality Comitee Coordinator

Bárbara Martínez de Miguel, Training Comitee Coordinator

Assistant Directors

Paloma Gómez Campelo

Ignacio Zapardiel Gutiérrez

HULP representatives

Francisco García Río

Antonio Pérez Martínez

Jaime Feliu Batlle

José Luis Merino

María Gutiérrez Fernández

Nuria Vilaboa Díaz

Nora Butta Coll

Blanca Fuentes Gimeno

Inmaculada Ibáñez de Cáceres

María Auxiliadora Bajo

Rosario Perona Abellón

UAM representatives

Amparo Cano García

Guillermo Reglero Rada

Fernando Rodríguez Artalejo

Mercedes Salaices Sánchez

Francisco Arnalich Fernández

Belén Pérez González

Researchers in training representatives

PhD: Alejandro Martín Quirós

Predoctoral: Karla Marina Montalbán





2.2 Research Structure

Research Ethics Committee

President

Almudena Castro Conde. Head of Section of Cardiology Department

Vicepresident

Jesús Frías Iniesta. Head of the Clinical Pharmacology Department. Representative of Research Committee

Technical Secretary

Emma Fernández de Uzquiano. Head of the Technical Secretary

Members

José Manuel Añón Elizalde. Head of Section of Intensive Medicine Department

José Ignacio Bernardino de la Serna. Assistant Physician-Internal Medicine Department

Antonio Buño Soto. Head of Clinical Laboratory Department

Nora Butta Coll. Head of Research Laboratory of Coagulopathies and Alterations of Haemostasis. Researcher of the IdiPAZ

Fernando Cabañas González. Head of Pediatrics and Neonatology. Quiron Salud Madrid University Hospital. Researcher of the IdiPAZ

Filiberto Chuliá Fernández. Lawyer, Head of the legal Department

Mariana Díaz Almiron. Data analyst. Biostatistics Platform

María Dolores Diestro Tejada. Assistant Physician- Gynaecology and Obstetrics Department

Jaime Fernández-Bujarrabal Villoslada. Assistant Physician- Pneumology Department

Elena García Higuera. Assistant Physician-Anesthesia/Resuscitation Department

María Justa García-Matres Cortés. Assistant Physician – Urology Department. Representative of Clinical Ethics Committee

Pedro Herranz Pinto. Head of Dermatology Department

Carlos Lahoz Rallo. Assistant Physician-Internal Medicine Department

Nuria Rodríguez Salas. Assistant Physician -Medical Oncology Department

Miriam Romero Portales. Assistant Physician- Digestive System Department

Filomena Trocoli González. Nurse. Supervisor of Nephrology Department

Elena Villamañán Bueno. Assistant Clinical Pharmacist- Pharmacy Department

Rosa Villanueva Peña. Assistant Physician-Psychiatry Department

Members from outside the institution

Evaristo Moliné Jorques. Layperson and Patient representative

Eva Prieto Utiel. Assistant Clinical Pharmacist of Primary Care-Pharmacy Department

Technical Secretary

Emma Fernandez Uzquiano. Head of Technical Secretary of Research Ethics Committee

Paz Lavilla Uriol. Physician of Technical Secretary of Research Ethics Committee

Sol de Gracia García. Administrative Assistant

María Isabel Arribas Álvarez. Administrative

Animal Welfare Organ

Carmen Fernández Criado. Director of the Veterinary Office of the Faculty of Medicine of the UAM. Specialist in Animal Health and Welfare as an external consultant

Fernando Carceller Benito. Deputy Neurosurgery Service HULP as optional and researcher of the “Neurology and Cerebrovascular Disease” from IdiPAZ

Nuria Vilaboa Díaz. IdiPAZ’s researcher. Internal consultant

Carlota Largo Aramburu. Head of the animal Service HULP Experimental Surgery Specialist in Animal Health and Welfare Center

Quality Assurance Committee

Coordinator

José Jonay Ojeda Feo

Members

Blanca Fuentes Gimeno

Alberto Martín Vega

María Luisa Díaz Martínez

Margarita Rodrigo Angulo

Gema Vallés Pérez

Paloma Gómez Campelo

María Dolores Pérez Garre





2.2 Research Structure

Training Committee

Coordinator

Bárbara Martínez de Miguel

Members

Ana María Briones Alonso
María Fernández Velasco
Julián Nevado Blanco
Alejandro Martín Quirós
Alberto Borobia Pérez
Paloma Gómez Campelo
Inmaculada Ibáñez de Cáceres
Beatriz Vila Cordero
María Isabel Sánchez Pérez
Rocío Rosas Alonso
Víctor Manuel Toledano Real
Mercedes Ruiz Balibrea
Lucía Medina Royo
Silvia Gómez Senent
Pilar Sánchez-Corral Gómez

Equality and Diversity Committee

Members

Eduardo López-Collazo
María Quintanar Jaime
Paloma Gómez Campelo
Nora Butta Coll
Francisco Gil Gadea
José Avendaño Ortiz

Technical Secretary

Mercedes Ruiz Balibrea
Lucía Medina Royo

Documentation Service

Raúl Román Cañizares

FIBHULP

Director

Ana Coloma Zapatero

Human Resources Manager

Head: Ana Gloria Herrera Puerta
María Quintanar Jaime

Private Projects Manager

Head: Francisco Gil Gadea
Nathalia García Quero

Clinical Trial Manager

Head: Sara Moral Álamo
Desirée Hernández López

Public Projects Manager

Head: Silvia Arce Santamaría
Raquel Carmona del Mazo

Institutional Projects Manager

José Luis Narro Villanueva
Marisa Tejedor Botello

International Projects Manager

Santiago Rello Varona
Marta Marín Barba

Contracting Manager and Head of Legal Department

Sara Fernández Morata

Accountants:

Head: Laura López Revuelta
Mónica García López

Researcher Reception and Attention

Carmen García Artiaga



Introduction 1

Executive summary 2

2.1 Global Analysis

2.2 Research Structure

2.3 Training Report and Teaching

2.4 Innovation and Transfer Activities

2.5 Quality Committee

2.6 Clinical Trials

2.7 Platforms

2.8 Scientific Production

2.9 CIBERs and RETICs

2.10 Institutional Projects

2.11 Internationalization

2.12 Communication

Information Groups by Area 3

Associated Clinicians 4

Scientific Report

2016
2017
2018



2.2 Research Structure



Neuroscience Area

Coordinator: *Exuperio Díez Tejedor*

GROUP	DIRECTOR
Psychiatry and Mental Health	Consuelo de Dios Perrino
Neurology and Cerebrovascular Diseases	Exuperio Díez Tejedor
Neuroprotective Strategies in Neurodegenerative Diseases	Antonio Cuadrado Pastor
Involvement of Glycinergic and Glutamatergic Systems in Central Nervous System Pathologies	Francisco Zafra Gómez



Cardiovascular Area

Coordinator: *José Luis López-Sendón Hentschel*

GROUP	DIRECTOR
Research on Invasive Clinical Cardiology – ICCI-Paz	José Luis López-Sendón Hentschel
Cardiovascular Epidemiology and Nutrition	Fernando Rodríguez Artalejo
Coagulopathies and Alterations of Haemostasis	Víctor Jiménez Yuste
Vascular Physiology and Pharmacology	Mercedes Salices Sánchez
Vascular Pharmacology and Metabolism (FARMAVSM)	Carlos F. Sánchez Ferrer
Cardiología HUF	Alejandro Curcio Ruigómez

Introduction 1

Executive summary 2

2.1 Global Analysis

2.2 Research Structure

2.3 Training Report and Teaching

2.4 Innovation and Transfer Activities

2.5 Quality Committee

2.6 Clinical Trials

2.7 Platforms

2.8 Scientific Production

2.9 CIBERs and RETICs

2.10 Institutional Projects

2.11 Internationalization

2.12 Communication

Information Groups by Area 3

Associated Clinicians 4

Scientific Report

2016
2017
2018




2.2 Research Structure



Infectious Diseases and Immunity Area

Coordinator: *Eduardo López-Collazo*

GROUP	DIRECTOR
AIDS and Infectious Diseases	José Ramón Arribas López
Molecular Microbiology	Jesús Mingorance Cruz
Immuno-Rheumatology	María Eugenia Miranda Carús
Innate Immune Response	Eduardo López-Collazo
Diagnosis and Treatment of Diseases associated with Abnormalities of the Complement System	Margarita López Trascasa Pilar Sánchez-Corral Gómez
Lymphocyte Pathophysiology in Immunodeficiencies	Eduardo López Granados
Drug Hypersensitivity and Innate Immune Response	Teresa Bellón Heredia
Pediatric Respiratory, Systemic and Neurological Infections & Host Immune Response	Cristina Calvo Rey
Pediatric Systemic Infections; HIV, tuberculosis, Imported and Emergent Diseases	María José Mellado Peña
Translational Research in Pediatric Oncology, Hematopoietic Transplantation and Cell Therapy	Antonio Pérez Martínez
Enfermedades Intestinales HUF	Fernando Bermejo San José



Large System Pathology Area

Coordinator: *Francisco García Río*

GROUP	DIRECTOR
Internal Medicine and Systemic Diseases	Francisco Arnalich Fernández
Organic Dysfunction and Failure in the Aggression	Abelardo García de Lorenzo y Mateos
Respiratory Diseases	Francisco García Río
Regulation of Gene Expression and by Hypoxia	Luis del Peso Ovalle
Nephrology	Rafael Selgas Gutiérrez
Neonatology	Adelina Pellicer Martínez
Aging and Fragility in the Elderly	Juan Ignacio González Montalvo
Molecular Hepatology	Paloma Jara Vega
Diagnosis and Treatment of Allergic Diseases	Santiago Quirce Gancedo
Gynecologic Oncology	Ignacio Zapardiel Gutiérrez
Patient Blood Management	Manuel Quintana Díaz
Endocrine Diseases	Lucrecia Herranz de la Morena
Urology	Luis Martínez-Piñeiro Lorenzo
Health Care Nurses Research	Jesús Castro Toro
Maternal and Fetal Medicine	José Luis Bartha Rasero
Emergency and Critical Pathology	Alejandro Martín Quirós

Introduction 1

Executive summary 2

2.1 Global Analysis

2.2 Research Structure

2.3 Training Report and Teaching

2.4 Innovation and Transfer Activities

2.5 Quality Committee

2.6 Clinical Trials

2.7 Platforms

2.8 Scientific Production

2.9 CIBERs and RETICs

2.10 Institutional Projects

2.11 Internationalization

2.12 Communication

Information Groups by Area 3

Associated Clinicians 4

Scientific Report

2016
2017
2018




2.2 Research Structure



Cancer and Human Molecular Genetics Area

Coordinator: Amparo Cano García

GROUP	DIRECTOR
INGEMM- Institute of Medical and Molecular Genetics	Pablo Lapunzina Badía
Translational Oncology	Jaime Feliú Battle
Experimental Therapies and Biomarkers in Cancer	Inmaculada Ibáñez de Cáceres Javier de Castro Carpeño
Oto-Neurosurgery Research	Luis Lassaletta Atienza
Cancer Molecular Pathology and Therapeutic Targets	David Hardisson Hernáez
Mechanisms of Tumour Progression	Amparo Cano García
Animal and Cell Models for Detection and Characterization of Leukemic Stem Cells	Carmela Calés Bourguet
Research and Diagnosis of Inherited Metabolic Diseases	María Belén Pérez González
Regulation of Ciliary Structure and Function by Phosphoinositides	Francesc García Gonzalo
Oncología HUF	Manuel Hidalgo Medina



Surgery, Transplant and Health Technologies Area

Coordinator: Leopoldo Martínez Martínez

GROUP	DIRECTOR
Congenital Malformation Surgery	Leopoldo Martínez Martínez
Bone Pathophysiology and Biomaterials	Nuria Vilaboa Díaz
Cellular Engineering	María Paz de Miguel González
Clinical Pharmacology	Jesús Frías Iniesta
Osteoarticular Surgery Research – GICOA	Enrique Gómez Barrena
Reconstructive and Regenerative Research	Luis Landín Jarillo
Transplant	Francisco Hernández Oliveros
Rehabilitación HUF	Juan Carlos Miangolarra Page



2.2 Research Structure

PUBLIC RESEARCH CONTRACTS

Ramón y Cajal Stabilisation Contracts (I3) - CM

- Karen Elise Heath. INGEMM - Institute of Medical and Molecular Genetics Group
- Jesús Mingorance Cruz. Molecular Microbiology Group
- Rebeca Pérez de Diego. Innate Immune Response Group

Miguel Servet Stabilisation Contracts (I2) - ISCIII/ CM

- Teresa Bellón Heredia. Drug Hypersensitivity and Innate Immune Response Group
- Juan Ángel Fresno Vara. Translational Oncology Group
- Ángel Campos Barros. INGEMM - Institute of Medical and Molecular Genetics Group
- María Paz de Miguel González. Cellular Engineering Group
- Eduardo López-Collazo. Innate Immune Response Group
- Juan Antonio Rey Herranz. Oto-Neurosurgery research Group
- Berta Rodés Soldevila. AIDS and Infectious Diseases Group
- Pilar Sánchez-Corral Gómez. Diagnosis and Treatment of Diseases Associated with Abnormalities of the Complement System Group
- María Rosa Torres Jiménez. Metabolic-Vascular Unit Group
- David Vicent López. Molecular Hepatology Group
- Nuria Vilaboa Díaz. Bone Pathophysiology and Biomaterials Group
- Nora Viviana Butta Coll. Coagulopathies and Alterations of Haemostasis Group
- María Inmaculada Ibáñez de Cáceres. Experimental Therapies and Biomarkers in Cancer Group
- Rosa María Rodríguez Pérez. Diagnosis and Treatment of Allergic Diseases Group

Miguel Servet Contracts Type I - ISCIII


- María Dolores Gutiérrez Fernández (MS15/00069). Neurology and Cerebrovascular Diseases Group
- Carolina Cubillos Zapata (MS18/00208). Respiratory Diseases Group

Miguel Servet Contracts Type II - ISCIII

- María Fernández Velasco (CPII16/00047). Innate Immune Response Group
- Laura Saldaña Quero (CPII16/00038). Bone Pathophysiology and Biomaterials Group

Intensification Contracts - ISCIII

- José Ramón Arribas López. AIDS and Infectious Diseases Group
- Francisco José García Río. Respiratory Diseases Group



Río Hortega Contracts - ISCIII

- Rosa de Miguel Buckley (CM17/00064). AIDS and Infectious Diseases Group
- Rosa Gutiérrez Zúñiga (CM18/00175). Neurology and Cerebrovascular Diseases Group

Juan Rodés Contracts - ISCIII

- Talía Sainz Acosta (JR16/00021). Pediatric Systemic Infections; HIV, Tuberculosis, Imported and Emergent Diseases
- Rocío Montejano Sánchez (JR18/00039). AIDS and Infectious Diseases Group

Marie Skłodowska-Curie Actions - Horizon 2020. European Union

- Elie Dahdouh. Molecular Microbiology Group

Juan de la Cierva Contracts – Ministry of Science, Innovation and Universities

- Laura Otero Ortega (IJCI-2017-33505). Neurology and Cerebrovascular Diseases Group

Predocctoral Fellowship - ISCIII

- Andrés Esteban Cantos (FI17/00192). AIDS and Infectious Diseases Group
- María del Carmen Gómez de Frutos (FI17/00188). Neurology and Cerebrovascular Diseases Group
- Fernando Laso García (FI18/00026). Neurology and Cerebrovascular Diseases Group

Predocctoral Contract - Ministry of Science, Innovation and Universities

- Francisca Díaz González (FPU17/04055). INGEMM - Institute of Medical and Molecular Genetics

Predocctoral La Caixa Foundation Contracts

- Karla Marina Montalbán Hernández (INPhiNIT). Innate Immune Response Group

Technical Support Stabilisation Contracts - CM

- Francisco Gayá Moreno. AIDS and Infectious Diseases Group
- María Teresa Vallejo Cremades. Congenital Malformation Surgery Group
- Beatriz Sanz Minguela. Cell Culture Unit



2.2 Research Structure

Bioinformatics Technician Support Research Contracts - ISCIII

- María Solís López (CA18/00033). INGEMM - Institute of Medical and Molecular Genetics

Youth Guarantee Contracts - CM

Graduate


- Alba Pinto García (PEJ-2017-AI/SAL-5716). Psychiatry and Mental Health

Predoctoral

- Marta Cadenas Martín (PEJD-2018-PRE/BMD-8872). Cellular Engineering Group
- Alfonso Navarro Zapata (PEJD-2018-PRE/BMD-9122). Translational Research in Pediatric Oncology, Hematopoietic Transplantation and Cell Therapy Group
- Sonia Alcolea Ruiz (PEJD-2018-PRE/BMD-9430). Pediatric Respiratory, Systemic and Neurological Infections & Host Immune Response Group
- Jorge García Giménez (PEJD-2018-PRE/BMD-9417). Associated Clinician
- Leila Maestro Paramio (PEJD-2018-PRE/BMD-7965). Bone Pathophysiology and Biomaterials Group
- Marta Gil Fernández (PEJD-2018-PRE/BMD-8091). Innate Immune Response Group
- Roberto Mediavilla Torres (PEJD-2018-PRE/BMD-9039). Psychiatry and Mental Health

Technical Support

- Virginia Rufo Rabadán (PEJ-2017-TL/BMD-6201). INGEMM - Institute of Medical and Molecular Genetics
- Sonia Jiménez Rodríguez (PEJ-2017-TL/BMD-6939). Molecular Microbiology Group
- César Vélez Casanova (PEJ-2017-TL/BMD-6873). Diagnosis and Treatment of Diseases Associated with Abnormalities of the Complement System
- Artur Martín Franklin (PEJ-2017-TL/BMD-5831). AIDS and Infectious Diseases Group



Programme	Organisation	Total
Ramón y Cajal Stabilisation Contracts (I3)	CM	3
Miguel Servet Stabilisation Contracts (I2)	ISCIII/ CM	14
Technical Support Stabilisation Contracts	CM	3
TOTAL ESTABLISHED		20
Miguel Servet Contracts CP Type I	ISCIII	2
Miguel Servet Contracts CP Type II	ISCIII	2
Intensification Contracts	ISCIII	2
Río Hortega Contracts	ISCIII	2
Juan Rodés Contracts	ISCIII	2
Marie Skłodowska-Curie Actions	EU	1
Juan de la Cierva Contracts	Ministry of Science, Innovation and Universities	1
Predoctoral Fellowship	ISCIII	3
Predoctoral Contract	Ministry of Science, Innovation and Universities	1
Predoctoral La Caixa Foundation Contracts	La Caixa	1
Bioinformatics Technician Support Research Contracts	ISCIII	1
Youth Guarantee Contracts	CM	12
TOTAL PROGRAMMES		30
TOTAL ESTABLISHED + PROGRAMMES		50
Platforms	ISCIII	7
FIS Projects	ISCIII	9
European Projects	EU	9
Research Network	ISCIII	6
Research Network	CM	5
SAF/MAT	MINECO	1
Commercial clinical trials	EECC Promoters	36
Private projects	Pharmaceutical Industry	67
In-house Projects	FIBHULP	6
RETOS	MINECO	3
Spin-off	CM	1
TOTAL EMPLOYEES DEPENDENT ON RESEARCH PROJECTS		150
Private projects	Pharmaceutical Industry	10
TOTAL FELLOWS DEPENDENT ON RESEARCH PROJECTS		10
TOTAL STAFF DEPENDENT ON RESEARCH PROJECTS		160
Technical Unit Staff	FIBHULP	15
TOTAL TECHNICAL UNIT		15
TOTAL		225




2.2 Research Structure


RESEARCHER PROFILE

This draft classification aims to communicate the various characteristics that researchers of IdiPAZ have in at this moment of their career, and stratified by gender.

EURAXESS RESEARCHER PROFILE



EURAXESS RESEARCHER PROFILE BY GENDER



2.3 Training Report and Teaching



2.3.1 Training Committee

One of the main priorities of IdiPAZ Research Institute is to encourage and develop training programs for researchers, with special attention to the scientific training in research methodology.

IdiPAZ's Training Committee is responsible for designing, planning and evaluating the training activities given by the Institute, as well as ensuring the development of a global Training Plan that meets the proposed objectives. The main objective of IdiPAZ's Training Committee is to draw up, promote and evaluate the training plan, aimed at maintaining or improving the skills or actions of IdiPAZ's basic or clinical researchers.


The committee is composed of competent training professionals from the different structures of IdiPAZ and guarantees the representation of all the different types of IdiPAZ members, as well as the correct coordination between all the training activities that make up the plan.

IdiPAZ's Training Plan includes the HULP training offer, the UAM offer and the implementation of the Institute's own training offer in line with its strategic objectives and linked to the detection of new training needs not covered by the existing training offers from each of those entities. The objective of the Institute's own training offer is to complement the training provided by both HULP and UAM.

The design of the plan includes, as origin and addressees, healthcare professionals with research activity as well as research professionals.

The detection of training needs arises as a result of communication with area coordinators and group directors, analysis of the Needs Assessment Surveys submitted by members of the Institute, reception and analysis of new proposals or suggestions from IdiPAZ members, selection of activities with successive editions planned, reception and analysis of proposals made within the Continuing Medical Training Committee

that meet the requirements of interest in research, analysis of new training proposals by IdiPAZ'S Training Committee itself and other study techniques.





2.3 Training Report and Teaching



2.3.2 Training courses conducted by IdiPAZ

Title	Head	Dates	Assistants	Hours
Curso de inglés científico	Simón Bartlett	13 th -16 th november	15	12
Análisis de datos biomédicos con SPSS: Nivel básico	Rosario Madero Jarabo	21 st -24 th may	21	12
Investigación clínica y lectura crítica. Búsqueda y recuperación de la literatura científica	Juan José Ríos Blanco	10 th -13 th december	-	12

2.3.3 Scientific culture activities

	Title	Date	Speakers
Semana de la Ciencia	Té con ciencia	8 th november	Inmaculada Ibáñez de Cáceres
		13 th november	Antonio Pérez Martínez
		16 th november	Eduardo López Collazo
	Al otro lado del laboratorio: Jornada de puertas abiertas y visita guiada al edificio IdiPAZ y los laboratorios	8 th november	Gema Vallés Pérez Víctor Toledano Real
		13 th november	María Teresa Vallejo Cremades
		16 th november	Irene Cuevas Gordo
Ven a conocer la genética del futuro: Jornada de puertas abiertas y visita guiada al Instituto de Genética del Hospital Universitario La Paz-INGEMM	6 th november	Julián Nevado Blanco	
	13 th november		
	15 th november		Alberto Borobia Pérez Paloma Gómez Campelo Marina Arranz Álvarez
Jornada de puertas abiertas al laboratorio de Microbiología y charla con el investigador Elie Dahdouh	16 th november	Elie Dahdouh	
Impresión 3D en el ámbito hospitalario: Plataforma de Ingeniería Tisular e Impresión 3D (PIT3D)	15 th november	Daniel Cermeño Pampliega Carlos Biec Amigo Mario Juárez Rodríguez	
Día Internacional de la Mujer y la Niña en la ciencia	Fast Meeting: 5 científicas en investigación	11 th february	Inmaculada Ibáñez de Cáceres, Dolores Diestro Tejada Ángela del Pozo Maté Dolores Pérez Garré Olga Vera Puente



2.3 Training Report and Teaching

2.3.4 IdiPAZ Doctoral Theses

Agrifoglio Rotaache A. Farmacocinética de micafungina en una población de pacientes quemados críticos[dissertation]. Madrid: Universidad Autónoma de Madrid: 2018(21/06/2018).

Directors: Cachafeiro Fuciños L, Sánchez Sánchez SM

Benito Muñoz C. Estructura-función del transportador neuronal de glicina GlyT2:localización del sitio Na³ y determinantes de inhibición[dissertation]. Madrid:Autónoma de Madrid: 2018(30/11/2018).

Director: López Corcuera B

Bravo Lubjetic L. Experiencia en el manejo del rabdomiosarcoma orbitario en el hospital universitario La Paz, 1982-2015[dissertation]. Madrid: UAM: 2018(15/06/2018).

Director: Peralta Calvo J

Celaya Puértolas A. Papel del IGF-I en la protección frente a la pérdida auditiva inducida por el ruido [dissertation]. Madrid: UAM: 2018(12/11/2018).

Director: Varela Nieto I

China B. Importancia de la leche humana y sus características nutricionales. Efectos a corto, medio y largo plazo[dissertation]. Madrid: UCM: 2018(21/03/2018).

Director: Saenz Pipaon Marcos M

Corral Sánchez D. Producción de células Natural Killer activadas con interlequina-15 para uso clínico en pacientes pediátricos con cáncer[dissertation]. Madrid: UAM: 2018(22/10/2018).

Director: Pérez Martínez A

Corvillo Rodríguez F. Estudio de los mecanismos inmunopatológicos en lipodistrofias adquiridas de tipo parcial y generalizado[dissertation]. Madrid: UAM: 2018(22/06/2018).

Director: López Trascasa M

Cruz Castellanos P. Expresión de genes relacionados con la angiogénesis como predictores de respuesta al tratamiento combinado (cirugía y quimioterapia) en el carcinoma de ovario seroso de alto grado[dissertation]. Madrid: UAM: 2018(19/12/2018).

Directors: Redondo Sánchez A, Mendiola Sabio M

Francisco Recuero I. Papel de la Aurora quinasa B en la regulación epigenética inducida por el virus de la hepatitis C[dissertation]. Madrid: UAM: 2018(25/10/2018).

Director: García-Samaniego J

Garzón Moll H, López Santamaría M. Tratamiento endovascular de los shunts portosistémicos congénitos[dissertation]. Madrid: UAM: 2018(16/10/2018).

Director: Ponce Dorrego MD

Guillén Sacoto MA. Diabetes gestacional en embarazos múltiples. Impacto del control metabólico materno para el feto. Síndrome metabólico y alteración de l metabolismo hidro carbonado materno postparto[dissertation]. Madrid: UAM: 2018 (04/04/2018).

Director: Herranz de la Morena L

Hernández Oliveros F. Estudio clínico experimental del papel del bazo en la prevención de la enfermedad de injerto contra huésped en el trasplante intestinal[dissertation]. Madrid: UAM: 2018(16/02/2018).

Directors: López Santamaría M, Tovar Larrucea JA

Isidoro García L. Potencial efecto hipotensor de esteroides sexuales masculinos[dissertation]. Madrid: UAM/UNAM: 2018(17/05/2018).

Directors: Ferrer Parra M, Perusquía M

Llorente Ginés P. Role of proteases implicated in the lysosomal pathway on app processing in a cellular model of neurodegeneration [dissertation]. Madrid: UAM: 2018(20/12/2018).

Director: Bullido Gómez-Heras MJ

López de Sá y Areses E. Manejo del síndrome post-parada cardiaca[dissertation]. Madrid: UAM: 2018(12/07/2018).

Director: López-Sendón JL

López de Uralde Villanueva I. Indicios de sensibilización central en el dolor crónico inespecífico de cuello con características neuropáticas[dissertation]. Madrid: URJC: 2018(27/06/2018).

Directors: Fernández Carnero J; La Touche Arbizu R

Martínez del Prado MP. Valor pronóstico del análisis de marcadores moleculares mediante proteómica dirigida en cáncer de mama precoz con receptores hormonales positivos[dissertation]. Madrid: UAM: 2018(22/03/2018).

Director: Espinosa Arranz E

Moraleda Pérez S. Eficacia de la toxina botulínica A en el tratamiento de la parálisis facial periférica. Comparación de diferentes escalas en la evaluación de la función facial[dissertation]. Madrid: UAM: 2018(30/11/2018).

Director: Lassaletta Atienza L





2.3 Training Report and Teaching

Moreno Fernández S. Efecto de un hidrolizado de proteínas de clara de huevo en un modelo de obesidad inducido por dieta. Evaluación de su eficacia y seguridad en humanos [dissertation]. Madrid: Universidad Autónoma de Madrid: 2018(23/10/2018).

Directors: Miguel Castro M, Garcés M



Munayco Sánchez AJ. Gestión de Hospitales de Campaña (Cirugía de Control de Daños) para desplazados internos en un teatro de operaciones bélico. Despliegue y activación bajo el fuego [dissertation]. Madrid: UAM: 2018(26/10/2018).

Directors: Quintana Díaz M, Carbayo Herencia J

Pajares Cabetas M. Transcription factor NRF2 regulates de expression of autophagy genes [dissertation]. Madrid: Universidad Autónoma de Madrid: 2018(19/10/2018).

Director: Cuadrado Pastor A



Pardo Rovira P. Valor pronóstico de la reversibilidad bronquial en pacientes con enfermedad pulmonar obstructiva crónica [dissertation]. Madrid: UAM: 2018(19/06/2018).

Director: García Río F

Parra Ramírez PA. Utilidad de la ecografía con contraste en la localización de lesiones paratiroides en pacientes con hiperparatiroidismo primario [dissertation]. Madrid: UAM: 2018 (31/05/2018).

Director: Álvarez Escolá C

Ponce Dorrego MD. Tratamiento endovascular de los shunts portosistémicos congénitos [dissertation]. Madrid: UAM: 2018(16/10/2018).

Directors: Álvarez-Sala Walther R, Garzón Moll G

Rubio Caballero C. Changes in gut microbiota associated to inflammation during ageing and non-alcoholic steatohepatitis [dissertation]. Madrid: Universidad Autónoma de Madrid: 2018(14/12/2018).

Director: Martínez Valverde A



Ruíz Pérez D. Atenuación del rechazo inmunitario con células madre mesenquimales derivadas de tejido adiposo en un modelo experimental murino de trasplante de pulmón [dissertation]. Madrid: UCM: 2018(10/12/2018).

Directors: García Río F, Largo Aramburu C, Álvarez Gómez de Segura I

Silva Obregón JA. Fragilidad como predictor de mortalidad en ancianos ingresados en UCI por patología médica. Modelo predictor de mortalidad hospitalaria [dissertation]. Madrid: UAM: 2018(20/12/2018).

Directors: Quintana Díaz M, Huerta Álvarez C



Tapia Serrano G. Seguridad del paciente neonatal en el uso de productos sanitarios relacionados con la alimentación [dissertation]. Madrid: UCM: 2018(23/02/2018).

Directors: Pacheco del Cerro E, Rivas Paterna AB

Tung Chen Y. Utilidad de la ecografía en el manejo de fluidos y la terapia de transfusión en la hemorragia digestiva en el ámbito de urgencias [dissertation]. Madrid: UAM: 2018(03/12/2018).

Directors: Quintana Díaz M, Blancas Gómez Casero R

Utrilla Contreras MJ. Estudio de las células inmunocompetentes, macrófagos, células cebadas, de la angiogénesis y de la linfangiogénesis en la piel de los bordes quirúrgicos de úlceras por quemaduras [dissertation]. Madrid: UAM: 2018(16/03/2018).

Directors: Hardisson Hernaez D, Regadera Gonzalez JF

Val Blasco A. Role of nucleotide-binding oligomerization domain type 1 (NOD1) in human and experimental heart failure [dissertation]. Madrid: UAM: 2019(11/01/2018).

Director: Fernández Velasco M

Vega Mata N. Diagnóstico molecular de las anomalías vasculares congénitas y su repercusión terapéutica [dissertation]. Oviedo: Universidad de Oviedo: 2018(12/4/2018).

Director: López Gutiérrez JC

Vera Puente O. Regulación epigenética de la expresión de ARNs no codificantes y su implicación en la respuesta terapéutica en cáncer de pulmón no microcítico y cáncer de ovario [dissertation]. Madrid: UAM: 2018(25/05/2018).

Director: Ibáñez de Cáceres I





Villalpando Grajeda DM. Beneficial effects of docosahexaenoic acid supplementation in vascular function of orchidectomized rats [dissertation]. Madrid: UAM: 2018(09/02/2018).

Director: Ferrer Parra M.

Villar Lorenzo A. Papel del sustrato del receptor de la insulina 2 en la susceptibilidad al daño colestático en el hígado [dissertation]. Madrid: Universidad Autónoma de Madrid: 2018(25/10/2018).

Director: Martínez Valverde A

2.4 Innovation and Transfer Activities



2.4.1 Innovation and Transfer Activities

The Innovation Support Unit (or Innovation Unit) of FIBHULP was created in June 2010 within the framework of the ITEMAS Network –currently called ITEMAS Platform- of the Carlos III Institute of Health. Since its creation, the Innovation Support Unit has contributed to promoting and protecting innovative/ground breaking research conducted by IdiPAZ. The Innovation Unit also intends to harness our institute's considerable innovative potential generated, as a step prior to its subsequent transfer to society.

Therefore, one of the main commitments of the Innovation Unit is that researchers and health personnel perceive it as a resource at their service, to provide support and advice in all that relates to the identification, management, protection, transfer, marketing and dissemination of their research results.

ACTIVITIES

The main aim of the Innovation Support Unit is to identify the potential transferable research results generated within our institute and to accompany and support the researcher throughout the whole innovation process: from the birth of the idea to its placement on the market.

Since the Innovation Unit has been in operation, several projects sponsored by the institute itself have been managed and different collaboration agreements have been signed with important private institutions and organisations to promote innovation.

Our main objectives are:

- Promoting a culture of innovation and entrepreneurship within the institute by fostering the generation of innovative ideas and solutions that meet the needs of patients and society, in general, and supporting their development through various initiatives.
- Actively searching and identifying knowledge and research results emerged within the institute and transferable to the market.
- Fostering and managing the protection and transfer of knowledge and research results to society and promoting the current technology portfolio of the institute while getting an economic return which allows its reinvestment in research and development.



2.4 Innovation and Transfer Activities



- Promoting the participation of industry in the innovation process acting as a stakeholder actively involved in it.
- Formalising business alliances, including technology companies as well as industrial and financial partners, to develop collaborative projects and to transfer the results to the market.
- Generating resources that achieve the greatest impact on society, enabling a better quality health care and at the same time contributing to the sustainability of the National Health System.
- Boosting a fruitful collaboration among all entities that make up the ITEMAS Platform.

In the last years the UAI has definitely consolidated its presence and visibility in the whole environment Hospital-Institute. Its impact in the Hospital has been strengthened by the creation of both the Innovation Platform and the Innovation Committee as two linked structures within the organisation. The Innovation Platform is an initiative launched from the Hospital's Management Board in order to promote, extend, enhance and stimulate innovation throughout the Hospital. The main mission of the Innovation Platform is to build a culture of innovation among all Hospital and Institute staff. The Innovation Unit is integrated into this platform as its main driver and, as such, it establishes its objectives and marks its lines of action and will be responsible for channelling the entire workload. It also forms part of the Innovation Committee, a decision-making body on the ideas to be supported by FIBHULP.

Among the greatest achievements of the Innovation Support Unit are the following:

- 1. The UAI has become one of IdiPAZ's most in-demand and requested platforms as it is responsible for promoting, supporting and managing all innovation projects.**
At December 31 2018, the UAI had 184 innovation projects or ideas in active state, 26 of which were in the capture phase, 65 in the evaluation phase, 12 in development, 49 in transfer and 32 in the market. According to these data, it follows that 17% of the projects have been successfully exploited and positioned in the market, very positive percentage (although far lower than the aspired figure) given the precariousness of the times we go through and the resources (both human and financial) with which the UAI counts. Among the various types of projects handled by the UAI it is particularly noteworthy the volume of medical device-type projects, followed by projects such as "Bio", "Health ICT" and "eHealth". Although the UAI has more than nine years of experience, most of the activity (157 projects) and its achievements have taken place in the last five years, period 2014-2018.
- 2. The UAI has built a wide and diverse technology portfolio. Each year the number of innovation projects managed by the UAI increases with respect to the previous year, also increasing the number of Hospital services, re-**

search groups and professionals in general who join IdiPAZ's innovation community.

During the period 2014-2018, the UAI filed 17 priority patents (13 Spanish patents, 3 European patents and 1 US patent) and 15 PCT; 10 national or regional phase entry applications were filed (4 at the EPO, 4 at the USPTO and 2 at other patent offices) and 23 patents were granted (20 at the OEPM, 2 at the EPO and 1 at the USPTO).

UAI's portfolio of patent families in active state during period 2014-2018 reached the figure of 46 patent families.

As for the software, during the period 2014-2018 the UAI registered 18 new computer applications.

Special mention should also be made to the UAI trademark portfolio. During the period 2014-2018, 17 trademark applications were filed and 15 were granted.

It is important to note that these trademarks, besides allowing IdiPAZ to distinguish its products or services from competitors' products or services, are associated with the know-how of the institution, know-how that has been transferred along with the distinctive sign in the case of the license agreements signed by the institution in respect of trademarks.

- 3. The UAI has prepared a catalogue of technology offers -based on specification sheets- which includes the complete portfolio of exploitable IdiPAZ results. This catalogue aims to promote the transfer of IdiPAZ's technology portfolio to the industrial sector, generate collaborative projects for technological development and foster the exploitation of research results. Those validated specification sheets are published on IdiPAZ's website. The catalogue is updated as the Institute's technology portfolio grows.**
- 4. The UAI has been, is, and will continue to be the principal architect for the transfer and exploitation of IdiPAZ's technology portfolio. During the period 2014-2018 the UAI succeeded in signing 35 license agreements of intellectual property rights (copyright). On the other hand, during the same period of time the UAI managed to achieve the following values in terms of transfer: 10 patents, 11 software, and 16 trademarks in commercial exploitation, which meant a significant achievement in terms of economic return.**
- 5. Thanks to UAI's support and management it has been possible to create and consolidate the first technology-based company of the Hospital (and also of the region of Madrid) according to the regulations established by the Department of Health of the Community of Madrid. The spin-off concerned, Biomedica Molecular Medicine, exploits the research results in oncology -specifically, a genomic test to determine whether breast cancer patients should have chemotherapy - designed by some members of IdiPAZ.**



2.4 Innovation and Transfer Activities

6. Through the promotion of a culture of innovation, the UAI has managed to create a large community of innovative professionals. Over the last year its promotional activity has consisted in the celebration of several working days, workshops, seminars, etc.:

- “La Paz 3.D: gestión de la tridimensionalidad” Workshop, June 12, 2018
- “La innovación: un nuevo camino hacia la excelencia en La Paz” Workshop, October 10, 2018
- “Día internacional de la mujer y la niña en la ciencia” Workshop, February 11, 2018
- Working meeting between the EPO and the Innovation Support Unit of IdiPAZ, May 8, 2018

In addition, the UAI has collaborated with important institutions and private entities to promote innovation, in particular it has participated in various forums and round tables organised by various stakeholders of the biomedical sector.

7. The UAI has succeeded in creating a wide-ranging network of contacts. By virtue of its membership in the ITEMAS Platform, the Unit has continued to strengthen ties and creating synergies with the members of this Platform in order to achieve its established objectives.

Apart from the above results it is important to emphasize that several innovation projects managed by the Innovation Unit have been awarded with prestigious awards and aids over the last year:

- 2nd and 3rd Award obtained in the third edition of the Healthstart Program for two of our innovation projects: STENT-BAND project led by Rosario Madero Jarabo, former Head of the Biostatistics Service at IdiPAZ; and OSTOCUTTER project led by Paloma de la Quintana Jiménez, stoma therapy nurse at HULP. Healthstart is the program of the Madrimasd Knowledge Foundation (Madri+d Foundation) and the Medical Technology Innovation Platform (ITEMAS Platform), promoted by the Institute of Health Carlos III (ISCIII) for the acceleration of technological start-ups of the Community of Madrid in the healthcare sector;
- Aid intended to carry out Feasibility Studies granted by the Foundation for Health Innovation and Prospective in Spain (FIPSE) to one of our innovation projects. The innovation project is FACE MIRROR, and is led by Dr. Alfonso Gil Martínez.



ORGANISATION

Since its implementation, the Innovation Support Unit has been integrated into the organisational structure of FIBHULP, as one of the Support Platforms for IdiPAZ research.

The Innovation Unit is directed by Dr. Javier de Castro Carpeño, M.D. and Ph.D. in Medicine and a member of the Medical Oncology Department of the La Paz University Hospital/ Autonomous University of Madrid and of the Translational Oncology Unit of IdiPAZ.

The Innovation Unit also consists of a team of two experts in fostering innovation and protecting research results and technology transfer:

- *Estela Sánchez Simón*, Law Graduate; and
- *María Dolores Pérez Garre*, Bachelor of Chemical Sciences.

CONTACT

Coordinator

Javier de Castro Carpeño

javier.decastro@salud.madrid.org

Phone: (+34) 91 207 12 34

Members

Estela Sánchez Simón

e_sanchez.innovacion@idipaz.es

Phone: (+34) 91 207 12 34

María Dolores Pérez Garre

maria.dolores.perez@idipaz.es

Phone: (+34) 91 207 12 34



2.4 Innovation and Transfer Activities

2.4.2 Patents and trademarks



Neuroscience Area

Psychiatry and Mental Health Group

Rodríguez Vega B, authors; FIBHULP, assignee. Brand name: En calma; ESM 3.695.071; 2017 December 12.



Rodríguez Vega B, Mediavilla Torres R, authors; FIBHULP, assignee. Brand name: SocialMind; ESM 3.748.550; 2018 December 17.



Neurology and Cerebrovascular Diseases Group

Ballesteros García P, López Larrubia P, Domínguez Mateo L, Marco Contelles JL, Cerdán García-Esteller S, inventors; Universidad Nacional de Educación a Distancia, CSIC, assignees. Set of magnetic resonance imaging and spectroscopy cell acidity extrinsic indicators comprise polyol derivatives based on alditols. P200300936; 2003 April 23.

Valdivieso Amate F, Bullido Gómez-Heras MJ, Martínez García A, inventors; UAM, assignee. Method of identifying compounds that induce or inhibit endoplasmic reticulum stress or oxidative stress. P200702997, PCT/ES2008/000705, EP2221379, US20100304384; 2007 November 13.

Valdivieso Ámate F, Burgos Muñoz JS, Ramírez Moreno C, Sastre Merlín I, inventors; UAM, CSIC, assignees. Method of identifying therapeutic compounds which can be used for the treatment and/or prevention of infections and diseases caused by human herpes viruses. P200400965, PCT/ES2005/000209, EPI 769677, US20070218004, AT447321, AU2005235319, CA2562787, JP2007533315; 2004 April 21.

Valdivieso Ámate F, Montoliú JL, Pozueta Larios J, inventors; UAM, CSIC, assignees. Alzheimer's disease animal model, method for obtaining same and

uses thereof. P200503002, PCT/ES2006/000673, EPI956091, EP20060841725, US20090222932, CA2638983, JP2009517066; 2005 December 02.


Vergés Milano J, García García A, Ruhí Roura R, Montell Bonaventura E, García López M, Aláez Versón CR, Escaich Ferrer J, Egea Maíquez J, Lorrio González S, Negro Madrigal P, inventors; BIOIBÉRICA S.A., UAM, assignees. Sulphated disaccharides for the treatment of neurodegenerative and/or neurovascular diseases. P200902399, PCT/EP2010/070613, US20120309707, CA20102785237; 2010 December 22.

Neuroprotective Strategies in Neurodegenerative Diseases Group

Cuadrado Pastor A, Innamorato NG, inventors; CSIC, UAM. Use of sulforaphane as supplementary therapy for early-stage neurodegenerative disease. P201231693; 2012 November 06.

León Martínez R, Egea Maíquez J, Buendía Abaitua I, Parada Pérez E, Navarro González de Mesa E, inventors; Fundación para la Investigación Biomédica del Hospital Universitario de La Princesa, UAM, CSIC, DNS NEUROSCIENCE S.A., assignees. Use of 3-(2-isothiocyanatoethyl)-5-methoxy-1H-indole for the treatment of neurodegenerative diseases. P201300667; 2013 July 17.

León Martínez R, Buendía Abaitua I, Navarro González de Mesa E, Michalska P, Gameiro Ros I, López Vivo A, Egea Maíquez J, García López M, García García A, inventors; Fundación para la Investigación Biomédica del Hospital Universitario de La Princesa, UAM, DNS NEUROSCIENCE S.A., assignees. Compounds derived from 3-alkylamine-1H-indolyl acrylate and its use for the treatment of neurodegenerative diseases. P201400810, PCT/ES2015/000139, CA2964309; 2014 October 15.



Cardiovascular Area

Research on Invasive Clinical Cardiology- ICCI-PAZ Group

Riera del Moral LF, inventor; FIBHULP, assignee. Aortic endoprosthesis for the treatment of aneurysm. P201231638, PCT/ES2013/070712; 2012 October 24.



2.4 Innovation and Transfer Activities

Filgueiras Rama D, López de Sá y Areses E, Millet Roig J, Calvo Saiz CJ, inventors; Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), FIBHULP, Universidad Politécnica de Valencia, assignees. Method of predicting or prognosticating neurological performance in patients who have suffered a cardiac arrest and optionally comatose status due to ventricular fibrillation. PCT/EP2015/076893, EP3020333; 2014 November 17.

Vascular Physiology and Pharmacology Group

Garcés Rimón M, Miguel Castro M, López-Alonso Fandiño R, López-Miranda González V, Uranga Ocio J, inventors; CSIC, Universidad Rey Juan Carlos, assignees; Use of multifunctional bioactive products derived from the enzymatic hydrolysis of egg white proteins for treating metabolic syndrome. P201331767, PCT/ES2014/070880; 2013 December 04.

González-Muñiz R, Miguel Castro M, Pérez de Vega MJ, Balsera-Paredes B, S Moreno, inventors; CSIC, assignee. Compounds with antioxidant activity and uses thereof. P201630362; 2016 March 29.

González-Muñiz R, Pérez de Vega MJ, Miguel M, Balsera-Paredes B, Moreno S, inventors; CSIC, assignee. Triazolyl polyphenols with antioxidant activity and uses thereof; P201531450; 2015 November 08.

Miguel Castro M, Garcés Rimón M, López-Alonso Fandiño R, Sandoval Huertas M, inventors; CSIC, Mario Sandoval Huertas, assignees. Healthy food compositions having gel or foam textures and comprising hydrolyzed egg products. P201331886, PCT/ES2014/070902, EP3106042, US9648897, AR098685, JP2015130856, MX2014015135; 2013 December 20.

Miguel Castro M, López-Alonso Fandiño R, Ramos González MM, Aleixandre de Artiñano A, inventors; CSIC, assignee. Production of and antihypertensive properties of peptides derived from egg white proteins. P200501246 PCT/ES2006/070067; 2005 May 23.

Miguel Castro M, López-Alonso Fandiño R, Recio Sánchez MI, Ramos González MM, Aleixandre de Artiñano A, inventors; CSIC, assignee. Bioactive peptides derived from the proteins of egg white by means of enzymatic hydrolysis. P200301829, PCT/ES2004/070059, EP1661913, US8227207, AT388166, DE602004012289, DK1661913, JP2007523045; 2003 July 31.

Pérez Girón JV, Ruiz-Castellanos MJ, de Luis Jiménez O, Pérez Boto V, Sanz González R, Hernández Vélez MC, Mas Gutiérrez JA, Alonso Gordo MJ, Salaices Sánchez M, Ros Pérez M, Coloma Jerez A, Asenjo Barahona A, Sanz Montaña JL, Puente Prieto J, Jensen J, inventors; NANOATE, S.L., assignee. Method for producing biosensors. P201031224, PCT/ES2011/070536; 2010 August 05.

Recio Sánchez MI; Quirós del Bosque A, Hernández Ledesma B, Gómez Ruiz JA, Miguel Castro M, Amigo Garrido L, López Expósito I, Ramos González MM,

Aleixandre de Artiñano A, (Contreras Gómez M), inventors; CSIC, assignee. Bioactive peptides identified in enzymatic hydrolyzates of milk caseins and method of obtaining same. P200501373, PCT/ES2006/070079, EP1905779, EP2495250, US8354502, AU2006256720, BRPI0611729, CA2611416, CN101305017, CN103254278, JP2008545774, KR20080045108, MX2007015528, NO20080103; 2005 June 08.



Infectious Diseases and Immunity Area

AIDS and Infectious Diseases Group

Romero Gómez M, Solá Lamoglia R, González García JJ, inventors; Servicio Andaluz de Salud, Universidad de Sevilla, Fundació Institut Mar D'Investigacions Mèdiques, FIBHULP, assignees. Kit for decision making in patients with Hepatitis C genotypes 1 and 4. P201330731; 2013 May 21.

Molecular Microbiology Group

Vicente Muñoz M, Mingorance Cruz J, Rueda González MS, inventors; CSIC, assignee. Method for determining state of growth and viability of bacterial FTsZ population, whether natural or cultivated, is based on determining existence of FTsZ rings in actively growing individual cells. P200200370; 2002 February 15.

Mingorance Cruz J, Castán García P, Franco de Sarabia Rosado PM, inventors; BIOTOOLS BIOTECHNOLOGICAL & MEDICAL LABORATORIES S.A., assignee. Composition, method and kit for detecting bacteria by means of sequencing. PCT/ES2009/000507, EP2492352, US2013157265, CA2775273, MX2012004627; 2009 October 22.

Mingorance Cruz J, Castán García P, Franco de Sarabia Rosado PM, inventors; 2B BLACKBIO S.L., assignee. Composition, method and kit for detecting fungi and yeasts by means of sequencing. PCT/ES2010/000248; 2010 June 02.

Immuno-Rheumatology Group

Pascual-Salcedo Pascual MD, Balsa Criado A, Plascencia Rodríguez C, authors; FIBHULP, assignee. Brand name: BioDrug Analysis BIDA. CM 13.808.531, 2015 March 10.





2.4 Innovation and Transfer Activities

Fernández Luna JL, Martínez Taboada VM, López Hoyos M, Torices del Val S, Muñoz Cacho P, Varela Egocheaga I, Juliá Cano A, Marsal Barril S, Balsa Criado A, inventors; FIBHULP, Fundación Instituto de Investigación Marqués de Valdecilla, Servicio Cántabro de Salud, Universidad de Cantabria, FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA (VHIR), assignees. Method for predicting the clinical response to anti-inflammatory agent therapies. P201600636, PCT/ES2017/000089; 2016 July 26.

Innate Immune Response Group

Llamas Matías MA, López-Collazo E, inventors; FIBHULP, Llamas Matías MA, Empireo S.L., assignees. Method for determine the risk of developing an infectious disease. P201330768, PCT/ES2014/070434, EP3006570; 2013 May 27.

Diagnosis and Treatment of Diseases Associated with Abnormalities of the Complement System Group

López Trascasa M, authors; FIBHULP, assignee. Brand name: COMPLEMENTest; CM 009.658.791; 2011, January 14.



Lymphocyte Pathophysiology in Immunodeficiencies Group

Van Dongen JJM, Orfao de Matos Correia E, Vale JA, Van Der Burg M, Pérez Andrés M, Van Zelm MC, Kalina T, Vlkova M, López Granados E, Blanco Álvarez E, Kienzler AK, inventors; Erasmus University Medical Center Rotterdam, assignee. Reagents, methods, and kits for diagnosing primary immunodeficiencies. PCT/NL2015/050762, US62/072,498; 2014 Oct 30.

Drug Hypersensibility and Innate Immune Response Group

Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P, Alajarín Fernández R, inventors; FIBHULP, Universidad de Alcalá, assignees. Use of compounds derived from salts of pyridazine[1',6':1,2]pyrido[3,4-b]indolinium as anti-inflammatory agents. P201331143, PCT/ES2014/070603; 2013 July 25.

Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P, Alajarín Fernández R, inventors; FIBHULP, Universidad de Alcalá, assignees. Use of compounds derived from salts of piridazine[3,2-b]benzimidazolium as anti-inflammatory agents. P201430411, PCT/ES2014/070603; 2013 July 25.

Sánchez Niño MD, Ortiz Arduán A; FIBHULP, Instituto de Investigación Sanitaria

Fundación Jiménez Díaz. Pharmaceutical composition and its use in the manufacture of a medicament for treating chronic kidney disease and method for screening compounds. P201430081, PCT/ES2015/070039; 2014 January 27.

Translational Research in Pediatric Oncology, Hematopoietic Transplantation and Cell Therapy Group

Vela Cuenca M, González Navarro P, Valentín Quiroga J, Escudero López A, Pérez Martínez A, Fernández Casanova L, inventors; FIBHULP, CNIO, assignees. Anti-CXCR4 antibody combined with activated and expanded natural killer cells for cancer immunotherapy. 62/642,313 US Provisional Application; 2018 March 13.



Large System Pathologies Area

Organic Dysfunction and Failure in the Agression Group

Herrero Ambrosio A, Ramírez García E, Ojeda Feo JJ, Pérez Rodríguez J, Asensio Martín MJ, González Sánchez ML, Moro Agud M, Lorente Romeo M, López Nieto M, Gómez Rioja R, authors; FIBHULP, assignee. Brand name: SINOIRES; CM 13.080.056; 2014 July 14.



Nephrology Group

Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P, Alajarín Fernández R, inventors; FIBHULP, Universidad de Alcalá, assignees. Use of compounds derived from salts of pyridazine[1',6':1,2]pyrido[3,4-b]indolinium as anti-inflammatory agents. P201331143, PCT/ES2014/070603; 2013 July 25.

Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P, Alajarín Fernández R, inventors; FIBHULP, Universidad de Alcalá, assignees. Use of compounds derived from salts of piridazine[3,2-b]benzimidazolium as anti-inflammatory agents. P201430411, PCT/ES2014/070603; 2013 July 25.

Aguilera Peralta AI, López-Cabrera M, Selgas Gutiérrez R, Steppan S, Passlickdeetjen J, inventors; Fresenius Medical Care Deutschland GMBH, assignee. Pharmaceutical compositions containing steviosides. EPI4191301.2, PCT/EP2015/074955; 2014 October 31.

Introduction 1

Executive summary 2

- 2.1 Global Analysis
- 2.2 Research Structure
- 2.3 Training Report and Teaching
- 2.4 Innovation and Transfer Activities
- 2.5 Quality Committe
- 2.6 Clinical Trials
- 2.7 Platforms
- 2.8 Scientific Production
- 2.9 CIBERs and RETICs
- 2.10 Institutional Projects
- 2.11 Internationalization
- 2.12 Comunication

Information Groups by Area 3

Associated Clinicians 4

Scientific Report 2016 2017 2018



2.4 Innovation and Transfer Activities

López-Cabrera M, Aguilera Peralta AI, Selgas Gutiérrez R, Passlickdeetjen J, Buechel J, Steppan S, inventors; Fresenius Medical Care AG & Co. KGaA, assignee. Method and kit for diagnosing epitelial to mesenchymal transition of the peritoneum (EMT-Chip). DE102015115158.8; 2015 September 09.

Sánchez Niño MD, Ortiz Arduán A; FIBHULP, Instituto de Investigación Sanitaria Fundación Jiménez Díaz. Pharmaceutical composition and its use in the manufacture of a medicament for treating chronic kidney disease and method for selecting compounds. P201430081, PCT/ES2015/070039; 2014 January 27.

Neonatology Group

Segovia Iñigo C, Montes Bueno MT, inventors; Segovia Iñigo C, assignee. Positioning device for neonates (Utility model). U201330102; 2013 January 31.

Diagnosis and Treatment of Allergic Diseases Group

Valenta R, Constantin C, Quirce Gancedo, SE, inventors; Phadia AB, assignee. Novel wheat allergens. PCT/SE2008/051377, EP2225266, US2010305049, AU2008330230, CA2707190, CN101932597, JP2011505134, RU2010126590; 2007 November 30.

Caballero Molina MT, Prior Gómez N, Remor Bitencourt EA, authors, FIBHULP, assignee. Brand name: HAE-QoL HEREDITARY ANGIOEDEMA QUALITY OF LIFE. CM 13.083.068; 2014 July 15.



Sánchez Herreros R, Martínez Fernández J, Castro Morera A, Gasset Vega M, Rodríguez Pérez RM, Pedrosa Delgado M, Quirce Gancedo S, inventors; FIBHULP, CSIC, assignees. Food allergen extracts and methods of producing and using the same. EPI6382413.9 (Publication Number pending); 2016 September 06.

del Pozo Abejón V, Sastre Dominguez J, Rodrigo-Muñoz JM, Sastre Turrión B, Quirce Gancedo S, Cañas Mañas JA, inventors; FIIJSJD, Centro de Investigación Biomédica en Red (CIBER), FIBHULP, Fundación Conchita Rábago de Jiménez Díaz, assignees. In vitro method for identifying severity levels in bronchial asthma patients. P201730739, PCT/ES2018/070390; 2017 May 29.

Gynecologic Oncology Group

Zapardiel Gutiérrez I, de Santiago García J, inventors; FIBHULP, assignee. Laparoscopic surgical instrument. P201230950, PCT/ES2013/000139; 2012 June 18.

Zapardiel Gutiérrez I, de Santiago García J, inventors; FIBHULP, assignee. Surgical device. P201330532, PCT/ES2014/070277; 2013 April, 15.



Urology Group

Botella Cubells LM, Albiñana Díaz V, Villar Gómez de las Heras K, inventors; CSIC, Alianza Española de Familias de Von Hippel-Lindau-VHL, assignee; Compounds for treating von Hippel-Lindau diseases. P201731019, PCT/ES2018/071220; 2018 August 18

Botella Cubells LM, inventor; CSIC, assignee; Inhibidores de TGF-β1 y productores de endoglina para su uso en el tratamiento de epidermólisis bullosa. P201831072; 2018 November 07

Botella Cubells LM, inventor; CSIC, assignee; Treatment and prevention of glioblastoma. EPI8382917; 2018 December 12

Emergency and Critical Pathology

Carballo Cardona C; author; FIBHULP, assignee. Trademark name: Diagether. CM15869911, 2016 September 29.

Associated Clinician

de la Oliva Senovilla P, inventor; FIBHULP, Instituto de Salud Carlos III, assignees. Shut-off valve for the interruption technique used in the analysis of respiratory mechanics. PCT/ES2005/000271, EPI897578; 2005 May 16.



Cancer and Human Molecular Genetics Area

INGEMM- Institute of Medical and Molecular Genetics Group

Friedman S, Li D, Narla G, Martignetti J, Heath K, inventors; Mount Sinai School of Medicine, assignee; Kruppel-like factor 6 (klf6), a tumor suppressor protein, and diagnostics, therapeutics, and screening based on this protein. PCT/US2001/025046, EPI332362, CA2419064, AU8479001, US2005181374, US2011059899; 2000 August 09.

INGEMM, author; FIBHULP, assignee. Brand name: INGEMM INSTITUTO DE GENÉTICA MÉDICA Y MOLECULAR DEL HOSPITAL UNIVERSITARIO LA PAZ; ESM 2.884.849, USM 77.891.143, CM 8.746.869; 2009 July 16, 2009 December 11, 2009 December 10.



Introduction 1

Executive summary 2

- 2.1 Global Analysis
- 2.2 Research Structure
- 2.3 Training Report and Teaching
- 2.4 Innovation and Transfer Activities
- 2.5 Quality Committe
- 2.6 Clinical Trials
- 2.7 Platforms
- 2.8 Scientific Production
- 2.9 CIBERs and RETICs
- 2.10 Institutional Projects
- 2.11 Internationalization
- 2.12 Comunication

Information Groups by Area 3


Associated Clinicians 4

Scientific Report 2016 2017 2018



2.4 Innovation and Transfer Activities

INGEMM, author; FIBHULP, assignee. Brand name: KaryoArray; USM 79.078.751, CM 8.512.907; 2010 January 07, 2009 August 27.



INGEMM, author; FIBHULP, assignee. Brand name: OverGrowthArray; ESM 2.958.709-3, USM 85.334.932, CM 10.009.256; 2010 December 02, 2011 June 01, 2011 May 31.



INGEMM, author; FIBHULP, assignee. Brand name: MetabolArray; ESM 2.958.711-5, USM 85.334.903, CM 10.009.348; 2010 December 02, 2011 June 01, 2011 May 31.



Palomares M, Lapunzina P, Nevado J, Vallespin E, Vallcorba I, Melero J, authors; FIBHULP, Hospital Infanta Cristina (Badajoz) Fundesalud, assignees. Brand name: OncoHematoArray; ESM 2.958.703-4, USM 85.334.842, CM 10.009.181; 2010 December 02, 2011 June 01, 2011 May 31.



INGEMM, author; FIBHULP, assignee. Brand name: OncoArray; ESM 2.962.910, USM 85.363.107, CM 10.091.882; 2011 January 05, 2011 July 05, 2011 July 01.



Lapunzina P, Nevado J, Solera J, Vallespin E, Martínez P, Martínez-González V, authors; FIBHULP, assignee. Brand name: ONCOSeq; USM 85.457.843, CM 9.969.064; 2011 October 27, 2011 May 16.



Moreno JC, Moya CM, Vallespin E, Lapunzina P, Nevado J, authors; FIBHULP, assignee. Brand name: ThyroArray; USM 85.686.688, CM 10.904.951; 2012 July 25, 2012 May 23.



Lapunzina Badía P, Borobia Pérez AM, Carcas Sansuán AJ, Tenorio Castaño JA, Arias Lajara P, Lubomirov Jristov R, authors; FIBHULP, UAM, assignees. Brand name: PharmArray; USM 86.004.412, CM 11.608.403; 2013 July 08, 2013 February 27



Lapunzina Badía PD, Borobia Pérez AM, Carcas Sansuán AJ, Tenorio Castaño JA, Arias Lajara P, Frías Iniesta J, Dapia García I, Muñoz M, authors; FIBHULP, UAM, assignees. Brand name: ClinPharmarray, CM15489511; 2016 May 31, 2016 September 07.



Palomares Bralo M, Vallespín García E, del Pozo Mate A, Santos Simarro F, authors; FIBHULP, assignee. Brand name: RD-Seq Sequencing Rare Diseases; CM 17.911.029; 2018 May 31.



Translational Oncology Group

Cejas Guerrero P, Belda Iniesta C, Feliú Batlle J, de Castro Carpeño J, Moreno García V, Burgos Lizalde E, Casado Sáenz E, Sánchez Hernández JJ, inventors; FIBHULP, UAM, Empresa Pública Hospital del Norte, assignees. Genomic fingerprint for predicting the clinical response to an antitumor therapy in colorectal cancer. P201130863, PCT/ES2012/070379; 2011 May 26.

Cejas Guerrero P, Belda Iniesta C, Feliú Batlle J, González Barón M, de Castro Carpeño J, Casado Sáenz E, Sánchez Hernández JJ, inventors; FIBHULP, UAM, assignees. Genomic fingerprint for the prognosis of the evolution of colorectal adenocarcinoma. P200703229, PCT/ES2008/000756, EP2236626; 2007 December 04.


Cejas Guerrero P, González Barón M, Casado Sáenz E, Sánchez Hernández JJ, Perona Abellón R, inventors; FIBHULP, UAM, CSIC, assignees. Use of trefoil factor family 3 (TFF3) in the prognosis of patients diagnosed with colorectal cancer. P200703230, PCT/ES2008/000757, EP2236625; 2007 December 04.

Espinosa Arranz E, Fresno Vara JA, Gámez Pozo A, López Vacas R, Berges Soria J, inventors; FIBHULP, assignee. Method for tumor subclassification. P201430887, 2014 June 09.

Espinosa Arranz E, Fresno Vara JA, Gámez Pozo A, Sánchez Navarro I, inventors; FIBHULP, assignee. Method for tumor subclassification. P200803509, PCT/ES2009/070533; 2008 December 11.



2.4 Innovation and Transfer Activities



Miranda Utrera N, Castellano D, Villacampa Aubá F, Fresno Vara JA, Gámez Pozo A, inventors; FIBH12O, FIBHULP, assignees. Prognostic method for determining the risk of relapse in renal cancer patients with a clear cell type of renal carcinoma, stages I and II, and kit for same. P201531360, PCT/EP2016/072723, EP16774644.5, US20180346990, CN108174608; 2015 September 23.

Moreno Rubio J, Cejas Guerrero P, Feliú Batlle J, Ramírez de Molina AI, Reglero Rada G, Vargas Alonso T, Molina Arranz S, González-Vallinas Garrachón M, inventors; FIBHULP, Fundación Imdea Alimentación, assignees. Methods and kits for the prognosis of colorectal cancer. P201231918, PCT/ES2013/070864; 2012 December 10.

Redondo Sánchez A, Hardisson Hernaéz D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee. Method to obtain useful data for the prediction of a patient's clinical response to an anticancer treatment. P200930400; 2009 July 01.

Redondo Sánchez A, Hardisson Hernaéz D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee. Method to obtain useful data for the prediction of a patient's pathological response to an anticancer treatment. P200930438; 2009 July 10.

Experimental Therapies and Biomarkers in Cancer Group

Cejas Guerrero P, Belda Iniesta C, Feliú Batlle J, de Castro Carpeño J, Moreno García V, Burgos Lizalde E, Casado Sáenz E, Sánchez Hernández JJ, inventors; FIBHULP, UAM, Empresa Pública Hospital del Norte, assignees. Genomic fingerprint for predicting the clinical response to an antitumor therapy in colorectal cancer. P201130863, PCT/ES2012/070379; 2011 May 26.

Cejas Guerrero P, Belda Iniesta C, Feliú Batlle J, González Barón M, de Castro Carpeño J, Casado Sáenz E, Sánchez Hernández JJ, inventors; FIBHULP, UAM, assignees. Genomic fingerprint for the prognosis of the evolution of colorectal adenocarcinoma. P200703229, PCT/ES2008/000756, EP2236626; 2007 December 04.

Cejas Guerrero P, González Barón M, Casado Sáenz E, Sánchez Hernández JJ, Perona Abellón R, inventors; FIBHULP, UAM, CSIC, assignees. Use of trefoil factor family 3 (TFF3) in the prognosis of patients diagnosed with colorectal cancer. P200703230, PCT/ES2008/000757, EP2236625; 2007 December 04.

Ibáñez de Cáceres I, Belda Iniesta C, Pernía Arias O, Perona Abellón R, Cortés Sempere M; inventors. FIBHULP, CSIC, UAM, Fundación Hospital de Madrid, assignees. Method for predicting the response to a treatment consisting of radiotherapy combined with cisplatin-based chemotherapy. P201330783, PCT/ES2014/070433, EP3006572, US20160122828; 2013 May 29.

Ibáñez de Cáceres I, de Castro Carpeño J, Vera Puente O, Pernía Arias O, Rodrí-

guez Antolín C, González Muñoz VM, Martín Palma ME, Salgado Figueroa AM, inventors; FIBHULP, FIBIOHRC, assignees. MAFG as a potential therapeutic target to restore chemosensitivity in platinum-resistant cancer cells. EP17382610.8 (Publication Number pending), PCT/EP2018/068156; 2017 September 15.

Ibáñez de Cáceres I, Pernía Arias O, de Castro Carpeño J, Vera Puente O, Jiménez Hernández J, Perona Abellón R, Rojo Todo F, inventors; FIBHULP, CSIC, UAM, Instituto de Investigación Sanitaria FJD, assignees. Determination of methylation and miRNA levels in response to a platinum-based antitumor compound. P201530997, PCT/ES2016/070516; 2015 July 09.

Martínez Máñez R, Murguía Ibáñez JR, Perona Abellón R, Agostini A, Mondragón Martínez L, Moreno Torres M, Manguán García C, Marcos Martínez MD, Soto Camino J, Sancenón Galarza F, inventors; Universidad Politécnica de Valencia, CSIC, Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), assignees. Release of substances into senescent cells. P201231370, PCT/ES2013/070581, EP2893923, JP2015529216, US2015306037; 2012 September 04.

Perona Abellón R, Sánchez Pérez I, Machado Pinilla R, Sastre Garzón L, Murguía Ibáñez JR, inventors; CSIC, UAM, Universidad Politécnica de Valencia, assignees. Sequence of nucleotides and peptides GSE 24.2 of dyskerin, which can induce telomerase activity, method for obtaining same, therapeutic compositions and applications thereof. P200502511, PCT/ES2006/070152, EP1947175, US20090202503, US2015337022, AT469212, CA2625981, DK1947175, JP2009511036, JP5560398, PT1947175; 2005 October 14.

Perona Abellón R, Sastre Garzón L, Machado Pinilla R, Sánchez Pérez I, inventors; CSIC, UAM, assignees. Use of inductor agents GSE24.2 for producing pharmaceutical compositions for treating illnesses relating to cellular senescence. P200703106, PCT/ES2008/070212, EP2216043, US2011300115, JP2011504483, CA2706467; 2007 November 23.

Perona Abellón R, Sastre Garzón L, Pintado Berninches L, Carrillo García J, Molina Pachón A, Irradiación Silva L, Manguán García C, inventors; CSIC, UAM, Advanced Medical Projects, Centro de Investigación Biomédica en Red (CIBER), assignees. Peptides derived from GSE 24.2 for treating diseases caused by oxidative stress and damage to DNA. P201331573, AU2014338820, CA2931429, EP3061815 PCT/ES2014/070803; 2013 October 25.

Oto-Neurosurgery Research Group

Polak M, Roca-Ribas Serdà F, Gavilán Bouzas J, Lassaletta Atienza L, Miró Castillo N, Rodrigo Dacosta J, inventors; MED-EL Elektromedizinische Geraete



2.4 Innovation and Transfer Activities

GmbH, assignee. Hearing treatment in patients with questionable cochlear nerve functionality. US2011275953, PCT/US2011/035312; 2010 May 05.

Cobo Parra P, Varela Nieto I, Murillo-Cuesta S, Navares Zaera R, Martínez Vega R, Cediél Algovia R, inventors; CSIC, UCM, assignees. Anechoic acoustic chamber for evaluating the auditory function in laboratory animals. P201031720; 2010 November 23.

Cobo Parra P, Varela Nieto I, Murillo-Cuesta S, Cediél Algovia R, inventors; CSIC, UCM, assignees. Method for designing a reverberating acoustic chamber for hearing test with animals. Procedimiento para diseñar una cámara acústica reverberante para ensayos auditivos con animales. P200802895, PCT/ES2009/070433; 2008 October 14.

Cancer Molecular Pathology and Therapeutics Targets Group

Redondo Sánchez A, Hardisson Hernaéz D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee. Method to obtain useful data for the prediction of a patient's clinical response to an anticancer treatment. P200930400; 2009 July 01.

Redondo Sánchez A, Hardisson Hernaéz D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee. Method to obtain useful data for the prediction of a patient's pathological response to an anticancer treatment. P200930438; 2009 July 10.

Mechanisms of Tumour Progression Group

García García JF, Martín Moreno AM, Roncador G, Martínez Torrecuadra JL, Moreno Bueno G, inventors; Fundación MD Anderson International España, Fundación Centro Nacional de Investigaciones Oncológicas (CNIO), assignees; Method for the diagnosis and/or prognosis of lymphomas. P201231304; 2012 August 14.

Hergueta Redondo M, Sanz PG, Rojo A, García JF, Moreno-Bueno G, inventors; UAM, CSIC, Fundación MD Anderson International España, assignees; Gasdermin B2 as a new biomarker of malignance and resistance of Trastuzumab inhibitor in Her2+ tumors. P201231560; 2012 October 10.

Matías-Guiu Guía FJ, Dolcet Roca FJ, Reventós Puigjaner J, Colás Ortega E, Prat Díaz de Losada J, Palacios Calvo J, Abal Posada M, López López R, Moreno Bueno G, Gil Moreno A, inventors; Institut de Recerca Biomèdica de Lleida Fundació Doctor Pifarré, Universitat de Lleida, Fundació Hospital Universitari Vall d'Hebron-Institut de Recerca, Fundació Institut de Recerca de L'Hospital de la Santa Creu i Sant Pau, Servicio Andaluz de Salud, Servizo Galego de Saúde, Fundación MD Anderson International España, assignees. Method to predict risk of recurrence

in endometrial carcinoma. Annexin-A2 as predictor biomarker of recurrent disease in endometrial cancer. EP14155510.2, PCT/EP2015/053387; 2014 February 18.

Olmeda Casadomé D, Moreno Bueno G, Portillo Pérez F, Cano García A, inventors; UAM, CSIC, assignees. Method for the diagnosis and/or prognosis of breast cancer. P200702342, PCT/ES2008/000563; 2007 August 28.

Olmeda Casadomé D, Peinado Selgas H, Portillo Pérez F, Nieto Toledano MA, Cano García A, inventors; UAM, assignee. Materials and methods for the derepression of the E-cadherin promoter. US20060003956; 2004 March 03.

Animal and Cell Models for Detection and Characterisation of Leukemic Stem Cells Group

Campanero García MR, Molina Privado I, inventors; CSIC, UAM, assignees. Method for identifying patients with sporadic Burkitt's lymphoma, identification method and use of compounds for the treatment of sporadic Burkitt's lymphoma. P200702595, PCT/ES2008/070182; 2007 October 03.

Molina Privado I, Campanero García MR, Rodríguez Martínez M, inventors; CSIC, UAM, assignees; Method for the differential diagnosis between Burkitt lymphoma and diffuse large B-cell lymphoma. P200900651; 2009 March 09.

Zapata Hernández JM, Pérez Chacón G, inventors; CSIC, UAM, assignees; Use of an indolic compound with nucleophilic substituents at C3 and the dimeric variants thereof in the production of a pharmaceutical composition that can be used in the treatment of B-lymphoid neoplasms. P201331397, PCT/ES2014/070726; 2013 September 25.


Research and Diagnosis of Inherited Metabolic Diseases Group

Pérez González B, Ruiz Desviat L, Jorge Finnigan A, Ugarte Pérez M, Martínez Ruiz A, Underhaug J, Barnejee R, inventors; UAM, Universidad de Bergen, Universidad de Michigan, assignees; Compounds useful for the treatment of methylmalonic aciduria. P201330171; 2013 February 11.

Pérez González B, Gámez Abascal A, Yuste Checa P, Arduim Brasil S, Ugarte Pérez M, Martínez Ruiz A, Underhaug J, inventors; UAM, Universidad de Bergen, assignees; Compounds for treating congenital disorders of glycosylation. EP16382373.5; 2016.

Associated Clinician

Glaría Enríquez A, Mañas Rueda A, Velázquez Soto R, inventors; FIBHULP, assignee. Isolation and immobilization device for test animals. P201031519, PCT/ES2011/070709; 2010 October 14.





2.4 Innovation and Transfer Activities



Surgery, Transplant and Health Technologies Area

Bone Pathophysiology and Biomaterials Group

Fabiilli M, Wilson C, Padilla F, Martín Saavedra FM, inventors; The regents of the University of Michigan, assignee. Ultrasound-triggerable agents for tissue engineering; PCT/US2013/044817, US2013/0330389; 2012 June 08.

González Carrasco JL, Benavente Castro R, Cifuentes Cuellar SC, Lieblich Rodríguez M, Olalde Graells B, Atorrasagasti Goyalde G, Argarate Madariaga N, Pacha Olivenza MA, Fernández Calderón MC, Saldaña Quero L, González Martín ML, Pérez Giraldo C, Gallardo Moreno AM, inventors; CSIC, Fundación Tecnalia Research & Innovation, FIBHULP, Universidad de Extremadura, Centro de Investigación Biomédica en Red (CIBER). Moldable, biodegradable, biocompatible and bioresorbable implant material, method for its preparation and uses thereof. P201530683; 2015 May 18.

Martín Saavedra FM, Vilaboa Díaz NE, Cebrián Hernando V, Arruebo Gordo M, Santamaría Ramiro J, Gómez Navascués L, inventors; FIBHULP, CIBER-BBN, Universidad de Zaragoza, assignees. Fibrin hydrogel with plasmonic nanoparticles; P201330894, PCT/ES2014/070484; 2013 June 14.


Vilaboa Díaz NE, Calzado Martín A, Crespo García L, Saldaña Quero L, Moreo Calvo P, Alastrué Vera V, inventors; FIBHULP, CIBER-BBN, assignees. Chamber device for dynamic cell culture on biomaterials; P201330040, PCT/ES2013/070819; 2013 January 16.

Vilaboa Díaz NE, González Carrasco JL, Multigner Domínguez M, Lieblich Rodríguez M, Muñoz Hernández M, Frutos Torres E, Saldaña Quero L, inventors; FIBHULP, CSIC, CIBER-BBN, Universidad Alfonso X El Sabio, assignees. Magnesium/polymer composite biomaterial for biomedical applications; P201030950, PCT/ES2011/070440; 2010 June 21.

Vilaboa Díaz NE, González Carrasco JL, Saldaña Quero L, Frutos Torres E, inventors; FIBHULP, CSIC, CIBER-BBN, assignees. Method to obtain a metallic-coated biomaterial; P201030949, PCT/ES2011/070400; 2010 June 21.

Voellmy R, Vilaboa Díaz NE, inventors; HSF Pharmaceuticals S.A., assignee. Inhibitors of heat shock factor 1 and uses thereof. US 62/495,501; 2016 September 16.

Voellmy R, Vilaboa Díaz NE. Inventors; HSF Pharmaceuticals SA. Assignees.



Compounds that induce protein unfolding and a mitigated response thereto, and methods of use thereof. US 62/764,569. 2018 August 08

Voellmy R, Vilaboa Díaz NE. Inventors; HSF Pharmaceuticals SA. Assignees. Inhibitors of heat shock factors and uses thereof. US62/499,650. 2017 February 17

Cellular Engineering Group

de Miguel González MP, Arnalich Montiel F, Royuela MM, inventors; FIBHULP, Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal, Universidad de Alcalá, assignees. Corneal endothelium injector; P201131222, PCT/ES2012/070543; 2011 July 18.

Clinical Pharmacology Group

Herrero Ambrosio A, Ramírez García E, Ojeda Feo JJ, Pérez Rodríguez J, Asensio Martín MJ, González Sánchez ML, Moro Agud M, Lorente Romeo M, López Nieto M, Gómez Rioja R, authors; FIBHULP, assignee. Brand name: SINOIRES; CM 13.080.056; 2014 July 14.



Carcas Sansuán AJ, author; Carcas Sansuán AJ, assignee. Brand name: IBJ IberoAmerican Journals; ESM 3.063.048; 2013 February 12.



Carcas Sansuán AJ, author; Carcas Sansuán AJ, assignee. Brand name: IberoAmerican Journals Plus; ESM 3.063.052; 2013 February 12.



Carcas Sansuán AJ, author; Carcas Sansuán AJ, assignee. Brand name: IberoAmerican Journals Clinical Pharmacology; ESM 3.063.053; 2013 February 12.




Carcas Sansuán AJ, author; Carcas Sansuán AJ, assignee. Brand name: IberoAmerican Journals Medicine; ESM 3.063.049; 2013 February 12.





2.4 Innovation and Transfer Activities



Lapunzina Badía P, Borobia Pérez AM, Carcas Sansuán AJ, Tenorio Castaño JA, Arias Lajara P, Lubomirov Jristov R, authors; FIBHULP, UAM, assignees. Brand name: PharmArray; USM 86.004.412, CM 11.608.403; 2013 July 08, 2013 February 27.



Carcas Sansuán AJ, Borobia Pérez AM, authors; FIBHULP, assignee. Brand name: CRDataX; CM 13.681.614; 2015 May 28.



Lapunzina Badía PD, Borobia Pérez AM, Carcas Sansuán AJ, Tenorio Castaño JA, Arias Lajara P, Frías Iniesta J, Dapia García I, Muñoz M, authors; FIBHULP, UAM, assignees. Brand name: ClinPharmarray. USM87054978, CM15489511; 2016 May 31, 2016 September 07.



Osteoarticular Surgery Research- GICOA Group

Arenas Vara MA, Conde del Campo A, De Damborenea González JJ, Matykina E, Esteban Moreno J, Gómez Barrena E, Pérez-Jorge Peremarch C, Pérez Tanoira R, inventors; CSIC, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, assignees. Titanium materials anodised with fluorine. P201030720, PCT/ES2011/070342; 2010 May 14.

Transplant Group

Hernández Oliveros F, Nana Gómez Mayoral N, Raya González L, Guijarro Fernández E, authors; FIBHULP, HePA, U-TAD, Guijarro Fernández E, assignees. Brand name: VTR Virtual Transplant Reality; CM 18.000.131; 2018 December 14.

Associated Clinician

Castell Gómez JT, inventor; FIBHULP, assignee. System of "partial" or "total" openings and buttonholes for patient pyjama or nightgown. P200401758; 2004 July 16.

García Fernández J, inventor; FIBHULP, assignee. Anaesthesia machine simulator. P200702128, PCT/ES2008/070109, US20090044803; 2007 July 30.

de Miguel del Campo E, Posadas Mañanes SJ, Reglero Rada GJ, Largo Aramburu C, García Grande A, Merino Martín JJ, Caz Bonillo V, Fornari Reale T, Rodríguez García-Risco M, Señorans Rodríguez FJ, inventors; FIBHULP, UAM, assignees. Composition for the protection of tissues from the digestive tract and the nervous system of radiotherapy patients; P200931189; 2009 December 17.

Goldman Tarlovky L, inventor; FIBHULP, assignee. System and method to obtain data on a patient's breathing cycle. P201030927, PCT/ES2011/070242; 2010 June 16.

de Miguel del Campo E, Reglero Rada GJ, Largo Aramburu C, Fornari Reale T, Rodríguez García-Risco M, Jaime de Pablo L, Santoyo Díez S, Señorans Rodríguez FJ, García Grande A, Merino Martín J, Caz Bonillo JV, Posadas Mañanes SJ, inventors; FIBHULP, UAM, assignees. Composition for the reduction of symptoms associated with menopause; P201031225, PCT/ES2011/070586; 2010 August 05.

Castell Gómez JT, inventor; FIBHULP, assignee. Surgical device for interrupted suture. P201031491, PCT/ES2011/002352, EP2626014, US13/878035; 2010 October 07.

Álvarez Gallego M, inventor; FIBHULP, assignee. Device for the extraction of surgical specimens by insufflation and suction. P201031490, PCT/ES2011/002357; 2010 October 07.

de Miguel del Campo E, Largo Aramburu C, Tabernero Urbieta M, Reglero Rada GJ, Marín Martín F, Fornari Reale T, Prodanov Prodanov M, Ruiz Rodríguez A, Ibáñez Ezequiel E, Jaime de Pablo L, Soler Rivas C, Rodríguez García-Risco M, Santoyo Díez S, González Lorente M, Arranz Gutiérrez E, Gil Ramírez A, inventors; FIBHULP, UAM, CSIC, assignees. Functional heart-healthy beverage containing wine and extracts of hops; P201131014, PCT/ES2012/070443; 2011 June 16.

Reglero Rada GJ, de Miguel del Campo E, Marín Martín F, Fornari Reale T, Prodanov Prodanov M, Ruiz Rodríguez A, Largo Aramburu C, Tabernero Urbieta M, Ibáñez Ezequiel E, Jaime de Pablo L, Soler Rivas C, Rodríguez García-Risco M, Santoyo Díez S, González Lorente M, Arranz Gutiérrez E, Gil Ramírez A, inventors; FIBHULP, UAM, CSIC, assignees. Method to obtain extract of hop and the extract obtained. P201230584, PCT/ES2012/070443; 2011 June 16.

Brian Gahan P, Stroun M, García del Olmo D, García Arranz M, Vega Clemente ML, inventors; Peter Brian Gahan, Maurice Stroun, FIBHULP, assignees. Method for blocking tumour growth. EP2808027; 2013 May 29.

Castell Gómez JT, Carrascal Morillo T, inventors; FIBHULP, UNED, assignees. Synthetic surgical mesh. P201331453, PCT/ES2014/000161; 2013 October 03.

Álvarez Gallego M, Castejón Sisamón C, García Prada JC, Meneses Alonso J, inventors; FIBHULP, UC3M, assignees. Rectoscope. P201630551, PCT/ES2017/070249, EP17788865.8, US20190200853; 2016 April 29.

Froilán Torres C, de María Pallarés P, Díaz Lantada A, Ortego García P, inventors; FIBHULP, UPM, assignees. Endoscopic accessory. P201730569; 2017 March 31.

Azabal Agudo A, Ruiz-Valdepeñas Martín de Almagro S; Julián García Rivera

Introduction 1

Executive summary 2

- 2.1 Global Analysis
- 2.2 Research Structure
- 2.3 Training Report and Teaching
- 2.4 Innovation and Transfer Activities
- 2.5 Quality Committee
- 2.6 Clinical Trials
- 2.7 Platforms
- 2.8 Scientific Production
- 2.9 CIBERs and RETICs
- 2.10 Institutional Projects
- 2.11 Internationalization
- 2.12 Communication

Information Groups by Area 3

Associated Clinicians 4



2.4 Innovation and Transfer Activities

F, de la Quintana Jiménez P, inventors; UP DEVICES AND TECHNOLOGIES, S.L., FIBHULP, assignees. Dispositivo de corte automático de discos de ostomía. P201830718. 2018 July 16.

Ramírez de Molina A, Tabernero Urbieto M, Reglero Rada G, Torres Olivares C, Largo Aramburu C, Santamaría Ramiro M, Polo Paredes G, Ruiz Pérez D, de Miguel del Campo E, Álvarez de Segura I, inventors; Fundación IMDEA Alimentación, UAM, FIBHULP, IGENFARMA, assignees. Composición para la reducción del declive metabólico asociado al envejecimiento y/o el tratamiento de trastornos relacionados al metabolismo lipídico. P201830740; 2018 July 20.

Other Trademarks of IdiPAZ

FIBHULP, author; FIBHULP, assignee. Brand name: IdiPAZ Instituto de Investigación Hospital Universitario La Paz; USM 85.078.878, CM 8.871.873; 2010 July 06, 2010 February 10.



FIBHULP, author; FIBHULP, assignee. Brand name: CEASEC Centro Avanzado de Simulación y Entrenamiento Clínico; ESM 3.567.901-8; 2015 June 22.



FIBHULP, author; FIBHULP, assignee. Brand name: InnoPAZ Plataforma de Innovación Hospital Universitario La Paz; ESM 3.572.575-3; 2015 July 27.



FIBHULP, author; FIBHULP, assignee. Brand name: CEASEC Centro Avanzado de Simulación y Entrenamiento Clínico; ESM 3.567.901-8; 2015 June 22.

Associated Clinician

Gómez Candela C, López Plaza B, Bermejo López L, authors; FIBHULP, assignee. Brand name: NUTRinvest Grupo de investigación en Nutrición y Alimentos Funcionales; ESM 3.649.812-2; 2017 February 02.



De la Quintana Jiménez P, authors; FIBHULP, assignee. Brand name: #OdeOstomía; CM 016922734; 2017 September 21



De la Quintana Jiménez P, authors; FIBHULP, assignee. Brand name: CM 016922858; 2017 September 21



De la Quintana Jiménez P, authors; FIBHULP, assignee. Brand name: Ostomía; CM 017131822; 2017 August 22.



2.5 Quality Committee




The vision of IdiPAZ is to be a reference centre for multidisciplinary translational biomedical research at the national and european level. To achieve this objective, the institution combines its efforts to ensure the quality of all its processes, thus ensuring the provision of the best service, research and teaching. IdiPAZ is committed to a comprehensive quality model backed by the maturity of the quality management team of the IdiPAZ institutions. To support and facilitate quality, the institution maintains a Quality Committee.

During 2018, the Quality Committee fostered these principles but also achieved specific quality goals. Because of the context analysis carried out by the Commission itself, three professionals from the IdiPAZ common platforms have been included as members of the Quality Committee. On the other hand, the IdiPAZ management system has been maintained under the requirements of the ISO 9001:2015 and the UNE 166002:2014, including currently in its scope five units/platforms: the Automatic Sequencing laboratory, the Innovation Support Unit, the Central Research and Clinical Trials Unit, the Technical Secretariat and the Quality Committee itself. A working quality plan for IdiPAZ is still in process to further expand the scope to new platforms and units until the reaccreditation process will take place in 2020.

Moreover, considering that IdiPAZ is a continuously evolving organisation, the Quality activities of our institution has been enriched by the different achievements made by its organizations.

The Hospital Universitario La Paz, with its accumulative experience about quality of care improvement, has continued working intensively during this year. Protocols, clinical pathways and participation in clinical practice guidelines have been developed and reviewed. The attached tables show the clinical pathways reviewed in 2018 as well as the protocols developed or updated in the same period. In addition, the staff members continuously collaborate in the improvement of the institution by participating in clinical committees and creating improvement groups, as well as implementing satisfaction surveys for patients and professionals. Also during 2018 hospital departments quality management systems are being integrated in an overall management system according to the standards ISO 9001:2015, ISO 14001:2015, ISO 22000:2005 and IQNetSR10. The hospital has also 26 accredited units within the Spanish National Accreditation System.



Introduction 1

Executive summary 2

- 2.1 Global Analysis
- 2.2 Research Structure
- 2.3 Training Report and Teaching
- 2.4 Innovation and Transfer Activities
- 2.5 Quality Committe**
- 2.6 Clinical Trials
- 2.7 Platforms
- 2.8 Scientific Production
- 2.9 CIBERs and RETICs
- 2.10 Institutional Projects
- 2.11 Internationalization
- 2.12 Comunication

Information Groups by Area 3

Associated Clinicians 4

Scientific Report 2018



2.5 Quality Committe



Protocol / Clinical pathway	Status
Acompañamiento en el bloque quirúrgico infantil	Review
Acompañamiento en la unidad de reanimación de cuidados críticos quirúrgicos	Review
Activación de reanimación cardiopulmonar en el hospital y su entorno	New
Actuación ante casos sospechosos o confirmados de gripe en adultos	Review
Actuación ante casos sospechosos o confirmados de gripe/VRS en niños	Review
Actuación ante un accidente de trabajo por caída o síncope - UAAN	New
Actuación frente a mordeduras de animales	Review
Alteraciones palpebrales	Review
Analgosedación en el Servicio de Medicina Intensiva	New
Ansiolisis/sedación en Laboratorio de Ecocardiografía	New
Antiagregación/anticoagulación en endoscopia	Review
Ascitis en urgencias	New
Asistencia al parto vaginal normal (poco intervencionista)	Review
Atención en consulta de alto riesgo por cáncer colorrectal y seguimiento de pólipos	Review
Biopsia de ganglio centinela en cáncer de cavidad oral	New
Bore grave de colitis ulcerosa	Review
Cardio-onco-hematología	New
Cataratas congénitas e infantiles	Review
Cierre percutáneo de orejuela	New
Circuito de insulización al alta	New
Coledocolitiasis	Review
Colitis isquémica	Review
Consulta de alta resolución de nódulo tiroideo (implementación)	Review
Control microbiológico en hemodiálisis adultos	New
Control microbiológico en hemodiálisis infantil	New
Creación y mantenimiento de acceso vasculares para hemodiálisis	New
Detección y control de pacientes portadores de microorganismos multirresistentes de transmisión por contacto	Review
Diabetes-II	Review
Diseción endoscópica submucosa	Review
Dislipemia	Review
Dolor precordial	Review
Encefalopatía hepática en urgencias	New
Enfermedad de Chagas	New

Protocol / Clinical pathway	Status
Enfermedad de Fabry	Review
Enfermedad del viajero menos prevalentes	Review
Enfermedad hepática grasa no alcohólica	New
Enfermedad tromboembólica venosa (tratamiento y profilaxis)	Review
Enfermedades tropicales más prevalentes	Review
Esclerosis sistémica	Review
Esofagitis eosinofílica	New
Esofagitis por cáusticos	Review
Estudio de la hiponatremia	New
Fatiga crónica	Review
Gestión de derrames, pérdida y/o desaparición de residuos en el Hospital La Paz, H. Cantoblanco, H. Carlos III y CEPs	Review
Guía de antisépticos	New
Guía de práctica clínica de insuficiencia cardiaca	Review
Guía de transfusión pediátrica	New
Guía obesidad-gestación y documentación para el paciente con obesidad, DG, DM preconcepcional y control preconcepcional	New
Hemorragia digestiva alta no varicosa en urgencias	New
Hemorragia digestiva alta varicosa en urgencias	New
Hepatitis aguda alcohólica	Review
Hipertensión Pulmonar	Review
Hipertensión Arterial	Review
Infección en paciente inmunodeprimido	Review
Infección nosocomial	Review
Ingresos por STEMI (código infarto)	Review
Insertión y mantenimiento de catéteres vasculares centrales	Review
Insuficiencia cardiaca	Review
Insuficiencia hepática aguda	Review
Limpieza y desinfección de endoscopios digestivos	Review
Limpieza y desinfección de endoscopios ginecológicos	Review
Limpieza y desinfección de endoscopios neumológicos	Review
Limpieza y desinfección de endoscopios urológicos	Review
Lupus y síndrome antifosfolípido	Review
Manejo anafilaxia en las consulta de vacunación	New
Manejo de contactos de pacientes con tuberculosis	New

Introduction

1

Executive summary

2

2.1 Global Analysis

2.2 Research Structure

2.3 Training Report and Teaching

2.4 Innovation and Transfer Activities

2.5 Quality Committee

2.6 Clinical Trials

2.7 Platforms

2.8 Scientific Production

2.9 CIBERs and RETICs

2.10 Institutional Projects

2.11 Internationalization

2.12 Communication

Information Groups by Area

3

Associated Clinicians

4

Scientific Report

2016
2017
2018



2.5 Quality Committee

Protocol / Clinical pathway	Status
Manejo de enfermedad inflamatoria intestinal en urgencias	Review
Manejo de la esofagitis eosinofílica	New
Manejo de paciente con enfermedad infecciosa de alto riesgo en la urgencia pediátrica	New
Manejo enfermedad perianal enfermedad inflamatoria intestinal con cirugía	Review
Manejar de paciente con enfermedad infecciosa de alto riesgo en la urgencia	New
Mantenimiento del carro de parada	Review
Microftalmía y anoftalmía	Review
Patología infección VIH	Review
Prevención de endocarditis infecciosa en pacientes portadores de prótesis valvulares cardíacas y dispositivos intravasculares	Review
Prevención de la bacteriemia relacionada con la asistencia sanitaria: manejo de dispositivos intravasculares	Review
Prevención de la infección del tracto urinario relacionada con la asistencia sanitaria	Review
Prevención de la neumonía relacionada con la asistencia sanitaria	Review
Profilaxis antibiótica en prequirúrgica y predesbridamiento enzimático en el paciente quemado	New
Protocolo de actuación ante situaciones de obras	Review
Protocolo de bioseguridad ambiental microbiológica en quirófanos y salas TMO	Review
Protocolo de declaración de enfermedades de declaración obligatoria	Review
Protocolo de gestión de la esterilización	New
Protocolo de gestión de módulos de normohipotermia	New
Protocolo de limpieza hospitalaria	Review
Protocolo de recomendaciones de medicina preventiva en la preparación y conservación de las fórmulas infantiles en polvo y leche materna	New
Protocolo Pie Diabético	New
Ptois palpebral	Review
Queratoplastias en niños	Review
Reanimación inicial del paciente quemado	Review
Recomendación para la reserva de sangre en cirugía programada	Review
Recurrencia de enfermedad inflamatoria intestinal	Review
Retinopatía diabética en niños	Review
Ruta asistencial de atención a pacientes con dolor	New
Ruta asistencial disfunción tiroidea (TSH)	New
Ruta asistencial nódulo tiroideo	New
Sedación paliativa y para el tratamiento de otros síntomas en Cuidados Paliativos Pediátricos	New



Protocol / Clinical pathway	Status
Seguimiento de pólipo	Review
Síndrome metabólico	Review
Solicitud de pruebas de diagnóstico cardiológico: ECG, Holter, Rx tórax, ecocardiografía transtorácica, ecocardiografía transesofágica y 3D, test de isquemia, TC y RM, cateterismo	Review
TC cardíaco y RM cardíaca	Review
Toma de muestras endoscopios digestivos	Review
Toma de muestras endoscopios ginecológicos	Review
Toma de muestras endoscopios neumológicos	Review
Toma de muestras endoscopios urológicos	Review
Transición diabetes (infantil - adulto)	New
Traslado intrahospitalario en urgencias pediátricas	New
Tuberculosis en enfermedad inflamatoria intestinal	Review
Uso de los inmunomoduladores en la enfermedad inflamatoria intestinal	New
Uso de megadosis vit C en el paciente quemado crítico	Review
Utilización de potasio intravenoso	Review
Utilización de sueros de alto riesgo	Review
Vacunación del paciente con asplenia	New
Vacunación del paciente con hepatopatía crónica	New
Vacunación del paciente con implante coclear	New
Vacunación del paciente con insuficiencia renal crónica	New
Vacunación del paciente con trasplante de progenitores hematopoyéticos	New
Vacunación del paciente con trasplante de órgano sólido	New
Vacunación del paciente con trasplante de órgano sólido	New
Vacunación del paciente con tratamiento inmunosupresor	New
Vacunación del paciente con VIH	New
Vasculitis necrotizantes sistémicas	Review
Vía biliar en urgencias	New
Vía clínica de atención al ictus pediátrico	New
Vía clínica de gastrostomía endoscópica percutánea	Review
Vía clínica de hemorragia digestiva alta con hipertensión portal	Review
Vía clínica de hemorragia digestiva alta sin hipertensión portal	Review
Vía clínica de recuperación intensificada en cirugía torácica (RICTO).	New
Vía clínica multiservicio sobre FRA-AKI en unidades de críticos	Review
Vía clínica trasplante renal reciente	Review

2.6 Clinical Trials



Acero Peña A. Estudio observacional retrospectivo para evaluar la efectividad de la inyección intravítrea (IVT) de Aflibercept en la práctica clínica en pacientes sin tratamiento previo con degeneración macular asociada a la edad neovascular (DMAEN I). Type: EPA-OD.

HULP code: PI-3017. Sponsored's protocol code: BAY-AFL-2017-01.
Sponsored by: Bayer Hispania S.L. Signed date: 12/04/2018

Aguilar-Amat Prior MJ. Determinantes de la calidad de vida en pacientes con síndrome de Lennox-Gastaut. Type: EPA-OD.

HULP code: PI-3313. Sponsored's protocol code: EIS-VAL-2017-01.
Sponsored by: EISAI Farmacéutica S.A. Signed date: 14/09/2018

Aguilar-Amat Prior MJ. Estudio de extensión abierto y multicéntrico para evaluar la seguridad y eficacia a largo plazo de Lacosamida como tratamiento complementario para las crisis tónico-clónicas generalizadas primarias no controladas en pacientes con epilepsia idiopática generalizada. Type: Clinical Trial, phase III.

HULP code: Anexo-I 4920. Sponsored's protocol code: EP0012.
Sponsored by: UCB Biosciencias GMBH. Signed date: 11/07/2018

Alcolea Batres S. Estudio observacional retrospectivo para determinar el estado de riesgo de pacientes con hipertensión arterial pulmonar en España. Type: EPA-OD.

HULP code: PI-3044. Sponsored's protocol code: ACT-HAP-01-2017.
Sponsored by: Actelion Pharmaceuticals España. Signed date: 23/01/2018

Alonso Babarro A. Estudio multicéntrico, descriptivo y transversal para determinar la prevalencia, las características clínicas y el tratamiento de la disnea en crisis en pacientes con cáncer de pulmón avanzado. Estudio Inspirados. Type: EPA-OD.

HULP code: PI-2958. Sponsored's protocol code: KYO-DIS-2017-01.
Sponsored by: Kyowa Kirin Farmacéutica S.L.U. Signed date: 05/01/2018

Alonso Dorrego JM. Estudio en fase III, multicéntrico, aleatorizado, doble ciego, de grupos paralelos y controlado con placebo para evaluar la eficacia y la seguridad de uno o más tratamientos intradetrusor con 600 u 800 unidades de Dysport® para el tratamiento de la incont. Type: Clinical Trial, phase III.

HULP code: Anexo-I 4713. Sponsored's protocol code: D-FR-52120-223.
Sponsored by: Ipsen Innovation. Signed date: 22/08/2018

Alonso Dorrego JM. Tratamiento de carcinoma urotelial no invasivo de alto grado de la vejiga mediante N° y dosis estándar de instilaciones intravesicales con una dosis estándar de BCG. Type: Clinical Trial, phase III.


HULP code: 5084. Sponsored's protocol code: EAU-RF-2008-01.
Sponsored by: Fundación Para La Investigación de La Asociación Europea de Urología. Signed date: 04/09/2018

Alonso Melgar A. Estudio en fase III multicéntrico y abierto de ALXN1210 en niños y adolescentes con síndrome hemolítico urinéxico atípico (SHUA). Type: Clinical Trial, phase III.

HULP code: Anexo-I 4796. Sponsored's protocol code: ALXN1210-Ahus-312.



2.6 Clinical Trials



Introduction

1

Executive summary

2

2.1 Global Analysis

2.2 Research Structure

2.3 Training Report and Teaching

2.4 Innovation and Transfer Activities

2.5 Quality Commitment

2.6 Clinical Trials

2.7 Platforms

2.8 Scientific Production

2.9 CIBERs and RETICs

2.10 Institutional Projects

2.11 Internationalization

2.12 Communication

Information Groups by Area

3

Associated Clinicians

4

Scientific Report

2016
2017
2018

Sponsored by: Alexion Pharmaceutical Inc. Signed date: 10/12/2018

Alonso Pacheco ML. Estudio multicéntrico, observacional, no intervencionista, transversal y retrospectivo, para evaluar la calidad de vida en condiciones de práctica clínica habitual, en pacientes con psoriasis moderada a severa tratados con Metotrexato en España (First). Type: EPA-OD.

HULP code: PI-3278. Sponsored's protocol code: NOV-MET-2018-01.

Sponsored by: Novartis Farmacéutica S.A. Signed date: 27/08/2018

Álvarez Román MT. Estudio clínico de fase III, prospectivo, aleatorizado y multicéntrico para comparar la seguridad y la eficacia de BAX 855 tras la profilaxis guiada por FC dirigida a dos concentraciones mínimas de FVIII distintas en sujetos con hemofilia a grave. Type: Clinical Trial, phase III.

HULP code: Anexo-II 4547. Sponsored's protocol code: 261303.

Sponsored by: Baxter Innovations GMBH. Signed date: 20/03/2018

Álvarez Román MT. Estudio de fase I/II internacional, abierto y multicéntrico de la seguridad y del aumento de dosis de BAX 888, un vector de virus adenoasociado de serotipo 8 (VAA8) que expresa un factor VIII con el dominio B (B-DOMAIN DELETED FACTOR VIII, BDD-FVIII) en sujetos con hemofilia a grave administrado como infusión única por vía intravenosa. Type: Clinical Trial, phase I.

HULP code: 4930. Sponsored's protocol code: 201501.

Sponsored by: Baxalta Innovations Gmhb. Signed date: 17/01/2018

Álvarez Román MT. Estudio epidemiológico transversal para comprender el enfoque actual del tratamiento en la atención regular de pacientes con hemofilia B en España y Portugal. Type: EPA-OD.

HULP code: PI-3254. Sponsored's protocol code: IIS-2017-12-04.

Sponsored by: CSL Behring S.A. Signed date: 26/07/2018

Álvarez Román MT. Evaluación en abierto y multicéntrica de la seguridad y la eficacia de la proteína de fusión del factor VIII FC recombinante de la coagulación (RFIIIFC; BIIB031) en la prevención y el tratamiento de episodios de sangrado en pacientes con hemofilia a grave. Type: Clinical Trial, phase III.

HULP code: Anexo-I 4214. Sponsored's protocol code: 997HA306.

Sponsored by: Biogen Idec Ltd. Signed date: 17/09/2018

Álvarez Román MT. Evaluación en abierto y multicéntrico de la seguridad y la eficacia de una proteína de fusión del factor IX recombinante de la coagulación y FC (RFIXFC; BIIB029) en la prevención y el tratamiento de episodios de sangrado en pacientes con hemofilia B grave. Type: Clinical Trial, phase III.

HULP code: Anexo-I 4143. Sponsored's protocol code: 998HB303.

Sponsored by: Biogen Idec Ltd. Signed date: 08/05/2018

Álvarez Román MT. Seguridad y eficacia de Turoctocog Alfa Pegol (N8-GP) en pacientes con hemofilia a no tratados previamente. Type: Clinical Trial, phase IIIa.

HULP code: Anexo-III 4125. Sponsored's protocol code: NN7088-3908.

Sponsored by: Novo Nordisk Pharma S.A. Signed date: 12/04/2018

Álvarez-Sala Walther R. Estudio de fase 3, multicéntrico, aleatorizado, doble ciego y controlado con comparador para evaluar la seguridad y la eficacia de Delafloxacin

intravenoso con cambio a vía oral en sujetos adultos con neumonía bacteriana adquirida en la comunidad. Type: Clinical Trial, phase IIIa.

HULP code: Anexo-I 4545. Sponsored's protocol code: ML-3341-306.

Sponsored by: Melinta Therapeutics Inc. Signed date: 04/01/2018

Álvarez-Sala Walther R. Estudio fase IIB, aleatorizado (estratificado), doble ciego (abierto para promotor), de grupos paralelos, controlado con placebo, de búsqueda de dosis de Nemoralisib (GSK2269557) añadido al estándar de tratamiento frente solo al estándar de tratamiento. Type: Clinical Trial, phase II.

HULP code: 4905. Sponsored's protocol code: 200879.

Sponsored by: Glaxosmithkline S.A. Signed date: 22/01/2018

Álvarez-Sala Walther R. Estudio observacional transversal para caracterizar la EPOC grave en España. Type: EPA-OD.

HULP code: PI-2984. Sponsored's protocol code: CGI-COR-2017-01.

Sponsored by: Chiesi Farmaceutici S.P.A. Signed date: 05/02/2018

Antorrena Miranda MI. Factores de riesgo asociados con la progresión de la insuficiencia cardíaca (IC) en pacientes con fibrilación auricular tratados con un anticoagulante oral directo (Rivaroxaban). Type: EPA-SP.

HULP code: PI-3015. Sponsored's protocol code: BAY-RIV-2017-01 FARAON.

Sponsored by: Bayer Hispania S.L. Signed date: 06/03/2018

Ares Segura S. Estudio de dosis ascendente únicas, aleatorizado, doble ciego y controlado con placebo para evaluar la seguridad, la tolerabilidad y la farmacocinética de MK-1654 en neonatos prematuros y a término. Type: Clinical Trial, phase II.

HULP code: Anexo-I 5068. Sponsored's protocol code: MK-1654.

Sponsored by: Merck Sharp & Dhome Corp. Signed date: 14/09/2018

Ares Segura S. Estudio de dosis ascendente únicas, aleatorizado, doble ciego y controlado con placebo para evaluar la seguridad, la tolerabilidad y la farmacocinética de MK-1654 en neonatos prematuros y a término. Type: Clinical Trial, phase II.

HULP code: 5068. Sponsored's protocol code: MK-1654.

Sponsored by: Merck Sharp & Dhome Corp. Signed date: 25/04/2018

Ares Segura S. Estudio de fase III, abierto y aleatorizado para evaluar la eficacia y seguridad de Alectinib adyuvante frente a la quimioterapia adyuvante con un derivado del Platino en pacientes con carcinoma de pulmón no microcítico positivo para la cinasa del linfoma anaplásico en estadio IB (tumores \geq 4 CM) A IIIA completamente extirpado. Type: Clinical Trial, phase III.

HULP code: 5014. Sponsored's protocol code: 5014 BO40336.

Sponsored by: F. Hoffmann-La Roche Ltd. Signed date: 15/06/2018

Armada Maresca F. Influencia de factores clínicos y genéticos en la evolución funcional y anatómica a largo plazo en una cohorte de pacientes con DMAE húmeda tratados según práctica clínica habitual. Type: EPA-AS.

HULP code: PI-2825. Sponsored's protocol code: CUN-RAN-2016-01.

Sponsored by: Universidad de Navarra-Clinica Universidad de Navarra. Signed date: 25/01/2018

Arribas López JR. Estudio de fase 2B aleatorizado, doble ciego, controlado con placebo para evaluar la actividad antiviral, los resultados clínicos, la seguridad, la tolerabili-



2.6 Clinical Trials



Introduction 1

Executive summary 2

- 2.1 Global Analysis
- 2.2 Research Structure
- 2.3 Training Report and Teaching
- 2.4 Innovation and Transfer Activities
- 2.5 Quality Commitment
- 2.6 Clinical Trials**
- 2.7 Platforms
- 2.8 Scientific Production
- 2.9 CIBERs and RETICs
- 2.10 Institutional Projects
- 2.11 Internationalization
- 2.12 Communication

Information Groups by Area 3

Associated Clinicians 4

Scientific Report

2016
2017
2018

dad y farmacocinética de los tratamientos administrados por vía oral de Lumicitabina (JNJ-6404157). Type: Clinical Trial, phase II.

HULP code: 5035. Sponsored's protocol code: 64041575MPN2001.
Sponsored by: Janssen Cilag International NV. Signed date: 20/04/2018

Arribas López JR. Estudio de fase III, aleatorizado, multicéntrico, con grupos paralelos y de ausencia de inferioridad para evaluar la eficacia, la seguridad y la tolerabilidad del cambio a Dolutegravir más Lamivudina en adultos infectados por el VIH I con supresión virológica. Type: Clinical Trial, phase III.

HULP code: Anexo-II 4885. Sponsored's protocol code: 204862.
Sponsored by: VIIV Healthcare Uk Limited. Signed date: 21/11/2018

Arribas López JR. Estudio de fase III, aleatorizado, multicéntrico, con grupos paralelos y de ausencia de inferioridad para evaluar la eficacia, la seguridad y la tolerabilidad del cambio a Dolutegravir más Lamivudina en adultos infectados por el VIH I con supresión virológica. Type: Clinical Trial, phase III.

HULP code: Anexo-I 4885. Sponsored's protocol code: 204862.
Sponsored by: VIIV Healthcare Uk Limited. Signed date: 10/01/2018

Arribas López JR. Estudio fase 3B, aleatorizado, doble ciego, para evaluar el cambio de un tratamiento con una combinación a dosis fija (CDF) de Efavirenz/Emtricitabina/Tenofovir Disoproxil Fumarato (EFV/FTC/TDF) a una CDF de Emtricitabina/Rilpivirina/Tenofovir Alafenamida. Type: Clinical Trial, phase IIIb.

HULP code: Anexo-II 4375. Sponsored's protocol code: GS-US-366-1160.
Sponsored by: Gilead Sciences Inc. Signed date: 11/07/2018

Arribas López JR. Estudio fase III, multicéntrico, abierto, randomizado, para evaluar el cambio a MK 1439a en pacientes con supresión virológica infectados por el VIH-I en un régimen de un inhibidor de proteasa potenciado con Ritonavir y dos inhibidores de la transcriptasa. Type: Clinical Trial, phase III.

HULP code: Anexo-II 4441. Sponsored's protocol code: 1439A-024.
Sponsored by: Merck Sharp & Dhome Corp. Signed date: 20/03/2018

Asencio Durán M. Estudio de fase III multicéntrico, randomizado, con doble enmascaramiento, controlado, con comparador activo para evaluar la eficacia y seguridad de RO6867461 en pacientes con edema macular diabético (Rhine). Type: Clinical Trial, phase III.

HULP code: 5116. Sponsored's protocol code: GR40398.
Sponsored by: F. Hoffmann-La Roche Ltd. Signed date: 16/10/2018

Balsa Criado A. Ensayo fase 3B, aleatorizado, doble ciego para evaluar la eficacia y seguridad de Abatacept sc en combinación con Metotrexato comparado con Metotrexato en monoterapia para conseguir la remisión clínica en adultos con artritis reumatoide temprana sin tratamiento previo con Metotrexato. Type: Clinical Trial, phase IIIb.

HULP code: Anexo-III 4470. Sponsored's protocol code: IM101-550.
Sponsored by: Bristol Myers Squibb International Corporation. Signed date: 21/03/2018

Balsa Criado A. Estudio abierto, de 8 semanas, para comparar la comodidad y facilidad de uso de cinco pautas de tratamiento distintas de inyecciones intraarticulares de

CNTX5 4975-05 en sujetos con dolor crónico de rodilla por artrosis moderada a grave. Type: Clinical Trial, phase III.

HULP code: 5179. Sponsored's protocol code: CNTX-4975I-OA-303.
Sponsored by: Centrexion Therapeutics Corp. Signed date: 13/12/2018

Balsa Criado A. Estudio aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de Sarilumab en pacientes con arteritis de células gigantes. Type: Clinical Trial, phase III.

HULP code: 5137. Sponsored's protocol code: EFC15068.
Sponsored by: Sanofi Aventis S.A. Signed date: 14/11/2018

Balsa Criado A. Estudio en fase/III aleatorizado y de grupos paralelos para evaluar la eficacia, la farmacocinética y la seguridad de CT-P13 subcutáneo y CT-P13 intravenoso en pacientes con artritis reumatoide activa. Type: Clinical Trial, phase I.

HULP code: Anexo-I 4825. Sponsored's protocol code: CT-P13 3.5.
Sponsored by: Celltrion Inc. Signed date: 03/04/2018

Balsa Criado A. Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo para evaluar la seguridad, tolerabilidad y eficacia de Secukinumab en pacientes con spondiloartritis axial no radiográfica activa durante un periodo de 2 años. Type: Clinical Trial, phase III.

HULP code: Anexo-I 4596. Sponsored's protocol code: CAIN457H2315.
Sponsored by: Novartis Farmacéutica SA. Signed date: 08/12/2018

Balsa Criado A. Estudio multicéntrico, internacional, aleatorizado, doble ciego, controlado con alendronato para determinar la eficacia y seguridad de AMG 785 en el tratamiento de mujeres con osteoporosis postmenopáusica. Type: Clinical Trial, phase III.

HULP code: Anexo-V 3576. Sponsored's protocol code: 20110142.
Sponsored by: Amgen S.A. Signed date: 17/01/2018

Baltasar Tello P. Estudio observacional retrospectivo del tratamiento de la leucemia linfocítica crónica (LLC) con Ibrutinib en la práctica clínica habitual (IBRORS LLC). Type: EPA-OD.

HULP code: PI-3319. Sponsored's protocol code: JAN-IBR-2018-01.
Sponsored by: Janssen-Cilag España S.A. Signed date: 13/07/2018

Baltasar Tello P. Evaluación retrospectiva no intervencional posterior a la autorización del uso de Idelalisib en pacientes con leucemia linfocítica crónica (LLC) en recaída/refractaria (R/R) en España. Type: EPA-OD.

HULP code: PI-3477. Sponsored's protocol code: GS-ES-312-4397.
Sponsored by: Gilead Sciences Inc. Signed date: 12/12/2018

Barranco Sanz MPE. Estudio observacional prospectivo para evaluar la carga médica y su asociación al uso de corticosteroides orales en pacientes con asma grave en España. Estudio Levante. Type: EPA-SP.

HULP code: PI-3046. Sponsored's protocol code: PI-3046 EPA-SPAST-COR-2017-02Y D3250R00031.
Sponsored by: Astrazeneca Farmacéutica Spain S.A. Signed date: 08/02/2018

Barrio Gómez de Agüero I. Estudio de extensión, fase III, abierto para evaluar la seguridad y la eficacia del tratamiento a largo plazo con VX 661 en combinación con

Introduction 1

Executive summary 2

- 2.1 Global Analysis
- 2.2 Research Structure
- 2.3 Training Report and Teaching
- 2.4 Innovation and Transfer Activities
- 2.5 Quality Committee
- 2.6 Clinical Trials
- 2.7 Platforms
- 2.8 Scientific Production
- 2.9 CIBERs and RETICs
- 2.10 Institutional Projects
- 2.11 Internationalization
- 2.12 Communication

Information Groups by Area 3

Associated Clinicians 4

Scientific Report



2.6 Clinical Trials

Ivacaftor en sujetos a partir de 12 años con fibrosis quística, homocigóticos o heterocigóticos para la mutación F5. Type: Clinical Trial, phase III.

HULP code: Anexo-I 4529. Sponsored's protocol code: VX14-661-110.

Sponsored by: Vertex Pharmaceuticals Incorporated. Signed date: 26/04/2018

Bartha Rasero JL. Estudio aleatorizado, multicéntrico, doble ciego, controlado con placebo y grupos paralelos para evaluar la efectividad de la cepa *Lactobacillus Salivarius V4II-90* en la reducción de la colonización por estreptococos del grupo B (GBS) de mujeres embarazadas. Type: Producto Alimentario.

HULP code: 5120. Sponsored's protocol code: STB/17.02.

Sponsored by: Recordati España S.L. Signed date: 26/10/2018

Bartha Rasero JL. Un estudio de prueba de concepto de fase 2A, doble ciego, de grupo paralelo, aleatorizado y controlado con placebo que evalúa la eficacia, la seguridad y la farmacocinética de OBE022 combinado con Atosiban tras su administración por vía oral a mujeres EMB. Type: Clinical Trial, phase II.

HULP code: 4942. Sponsored's protocol code: 4942 17-OBE022-003.

Sponsored by: Obseva S.A. Signed date: 24/01/2018

Bartha Rasero JR. Estudio piloto para evaluar el efecto de la cepa *Lactobacillus Salivarius PSI 1610* sobre la microbiota del tracto genital femenino y masculino en parejas con problemas de fecundidad. Type: Producto Alimentario.

HULP code: pi-3245. Sponsored's protocol code: FEC/18.01.

Sponsored by: ProbiSearch S.L. Signed date: 12/09/2018

Beato Merino MJ. Estudio observacional y retrospectivo de las características clínicas y patológicas del carcinoma de células de Merkel (CCM) entre 2012 y 2016 en España. Type: EPA-OD.

HULP code: PI-3459. Sponsored's protocol code: MECCAS GET-QUI-2018-01.

Sponsored by: Grupo Español de Tumores Huérfanos e Infrecuentes. Signed date: 27/11/2018

Bernardino de La Serna JI. estudio en fase III para evaluar el efecto de la Pitavastatina para prevenir los acontecimientos vasculares en personas con infección por VIH -I. Type: Clinical Trial, phase III.

HULP code: 5170. Sponsored's protocol code: EU5332.

Sponsored by: Research Organisation Kc Ltd. Signed date: 05/12/2018

Bernardino de La Serna JI. Estudio en fase IIIB, multicéntrico, abierto, para evaluar el cambio desde una pauta combinada de dosis fija de Elvitegravir/Cobicistat/Emcitribina/Tenofovir Alafenamida o una pauta que contenga Tenofovir Disoproxil Fumarato a una combinación de dosis fijas de Bictegravir/Emtricitabina/Tenofovir Alafenamida en sujetos de edad avanzada, de ≥ 65 años de edad, infectados por VIH-I con supresión virológica. Type: Clinical Trial, phase IIIB.

HULP code: 4974. Sponsored's protocol code: 4974 GS-US-380-4449.

Sponsored by: Gilead Sciences Inc. Signed date: 09/01/2018

Blanco Bañares MJ. Estudio de vida real en pacientes con acontecimientos trombóticos o hemorrágicos graves siendo tratados con antagonistas de la vitamina K (AVK) en hematología. Estudio Eventho. Type: EPA-OD.

HULP code: PI-2999. Sponsored's protocol code: PI-2999 EPA-OD.

Sponsored by: Pfizer Inc. Signed date: 05/02/2018

Borobia Pérez A. Ensayo clínico, piloto, doble ciego, aleatorizado, controlado con placebo para evaluar la eficacia comparada de Ibuprofeno combinado con diferentes dosis de Tramadol y Tramadol 100 mg por vía intravenosa en pacientes con dolor moderado a intenso tras cirugía. Type: Clinical Trial, phase III.

HULP code: 5080. Sponsored's protocol code: FMLD-FEBETRAPI-PILOT-43.

Sponsored by: Farmalider S.A. Signed date: 01/08/2018

Burgos García A. Colorectal cancer omics collection. Type: Producto Sanitario.

HULP code: Anexo-I PI-3334. Sponsored's protocol code: CRC-OC-001.

Sponsored by: Universal Diagnostics. Signed date: 15/11/2018

Burgos García A. Colorectal cancer omics collection. Type: Producto Sanitario.

HULP code: PI-3334. Sponsored's protocol code: CRC-OC-001.

Sponsored by: Universal Diagnostics. Signed date: 11/09/2018

Burgueño García M. Ensayo clínico, piloto, doble ciego, aleatorizado, controlado con placebo para evaluar la eficacia comparada de Ibuprofeno combinado con diferentes dosis de Tramadol y Tramadol 100 mg por vía intravenosa en pacientes con dolor moderado a intenso tras cirugía. Type: Clinical Trial, phase III.

HULP code: 5080. Sponsored's protocol code: FMLD-FEBETRAPI-PILOT-43.

Sponsored by: Farmalider S.A. Signed date: 01/08/2018

Caballero Molina MT. BCX7353-204: estudio abierto para evaluar la seguridad a largo plazo de BCX7353 oral diario en pacientes con angioedema hereditario tiposl y II. Type: Clinical Trial, phase II.

HULP code: 4993. Sponsored's protocol code: BCX7353-204.

Sponsored by: Biocryst Pharmaceuticals Inc. Signed date: 05/02/2018

Caballero Molina MT. BCX7353-302: un estudio fase 3, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos para evaluar la eficacia y seguridad de dos dosis diferentes de BCXS7353 como tratamiento oral para la prevención de ataques en pacientes con angioedema. Type: Clinical Trial, phase III.

HULP code: 4984. Sponsored's protocol code: BCX7353-302.

Sponsored by: Biocryst Pharmaceuticals Inc. Signed date: 16/05/2018

Caballero Molina MT. Registro de pacientes de Firazyr-IOS (Icatibant Outcome Survey). Type: EPA-LA.

HULP code: Anexo-III 3080. Sponsored's protocol code: IOS.


Sponsored by: Shire Pharmaceuticals Iberica S.L. Signed date: 20/09/2018

Calvo Rey C. Desarrollo neurológico en niños con infección del SNC por parechovi-rus humano. Type: NO-EPA.

HULP code: PI-2440. Sponsored's protocol code: PI-2440 BOLSA.


Sponsored by: Cristina Calvo Rey. Signed date: 19/07/2018

Calvo Rey C. Estudio de fase IIA sin enmascaramiento en lactantes con infección de las vías respiratorias bajas por el virus sincitial respiratorio, seguido de una parte con doble enmascaramiento controlada con placebo, para evaluar la seguridad, la tolerabilidad, la farmacocinética y el efecto antivírico de RV521 (REVIRAL I). Type: Clinical Trial, phase II.





2.6 Clinical Trials



Introduction

1

Executive summary

2

2.1 Global Analysis

2.2 Research Structure

2.3 Training Report and Teaching

2.4 Innovation and Transfer Activities

2.5 Quality Commitment

2.6 Clinical Trials

2.7 Platforms

2.8 Scientific Production

2.9 CIBERs and RETICs

2.10 Institutional Projects

2.11 Internationalization

2.12 Communication

Information Groups by Area

3

Associated Clinicians

4

Scientific Report

2016
2017
2018

HULP code: 5196. Sponsored's protocol code: REVC003.

Sponsored by: Reviral Ltd. Signed date: 30/10/2018

Calvo Rey C. Estudio en fase II, doble ciego y controlado con placebo para evaluar la actividad antiviral, los resultados clínicos, la seguridad, la tolerabilidad y las relaciones entre farmacocinética y farmacodinámica de dosis diferentes de JNJ-53718678 en niños ≥ 28 días y ≤ 3 años de edad con infección respiratoria aguda debido a la infección por el virus respiratorio sincitial. Type: Clinical Trial, phase II.

HULP code: 5152. Sponsored's protocol code: 53718678RSV2002.

Sponsored by: Janssen-Cilag España S.A. Signed date: 05/10/2018

Calvo Rey C. Estudio en fase III, multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de Pimodivir en combinación con la práctica clínica habitual en pacientes adolescentes, adultos y ancianos con gripe A no hospitalizados. Type: Clinical Trial, phase III.

HULP code: 4998. Sponsored's protocol code: 63623872FLZ3002.

Sponsored by: Janssen Pharmaceutica NV. Signed date: 04/07/2018

Calvo Rey C. Estudio en fase III, multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de Pimodivir en combinación con la práctica clínica habitual en pacientes adolescentes, adultos y ancianos hospitalizados con gripe A. Type: Clinical Trial, phase III.

HULP code: 4997. Sponsored's protocol code: 63623872FLZ3001.

Sponsored by: Janssen Pharmaceutica NV. Signed date: 03/07/2018

Canales Albendea MA. (R-CHP) en comparación con Rituximab y chop (R-CHOP) en pacientes con linfoma difuso de células grandes tipo B no tratado anteriormente. Type: Clinical Trial, phase III.

HULP code: Anexo-I 4956. Sponsored's protocol code: GO39942.

Sponsored by: F. Hoffmann-La Roche Ltd. Signed date: 21/06/2018

Canales Albendea MA. (R-CHP) en comparación con Rituximab y Chop (R-Chop) en pacientes con linfoma difuso de células grandes tipo B no tratado anteriormente. Type: Clinical Trial, phase III.

HULP code: 4956. Sponsored's protocol code: GO39942.

Sponsored by: F. Hoffmann-La Roche Ltd. Signed date: 01/03/2018

Canales Albendea MA. Ensayo de fase I/II, multicéntrico, sin enmascaramiento para evaluar la seguridad y la farmacocinética de dosis crecientes de BTCT4465A en monoterapia y en combinación con Atezolizumab en pacientes con linfoma no Hodgkiniano de linfocitos B y leucemia linfocítica crónica recidivantes o resistentes. Type: Clinical Trial, phase I.

HULP code: 5151. Sponsored's protocol code: GO29781.

Sponsored by: Genentech Inc. Signed date: 05/12/2018

Canales Albendea MA. Estudio de fase 2B aleatorizado, abierto y de dos grupos, de Selinexor (KPT-330) en asociación con Dexametasona (SEL-DEX) a dosis bajas en pacientes con linfoma difuso de células B grandes (LDCBG). Type: Clinical Trial, phase II.

HULP code: Anexo-I 4305. Sponsored's protocol code: KCP-330-009.

Sponsored by: Karyopharm Therapeutics Inc. Signed date: 26/07/2018

Canales Albendea MA. Estudio de fase IB/II, abierto para evaluar la seguridad y la farmacocinética de GDC-0199 (ABT-199) en combinación con Rituximab (R) o Obinutuzumab (G) más Ciclofosfamida, Doxorubicina, Vincristina y Prednisona (CHOP) en pacientes con linfoma no Hodgkin. Type: Clinical Trial, phase Ib.

HULP code: Anexo-II 4354. Sponsored's protocol code: GO27878.

Sponsored by: Kite Pharma Inc. Signed date: 26/10/2018

Canales Albendea MA. Estudio de fase IB/II para evaluar la seguridad, tolerancia y actividad antitumoral de Polatuzumab Vedotin (DCDS4501A) en combinación con Rituximab (R) u Obinutuzumab (G) más Bendamustina (B), en pacientes con linfoma folicular o linfoma difuso de células. Type: Clinical Trial, phase I.

HULP code: Anexo-I 4456. Sponsored's protocol code: GO29365.

Sponsored by: F. Hoffmann-La Roche Ltd. Signed date: 19/02/2018

Canales Albendea MA. Estudio de fase II, abierto, de 2 cohortes y multicéntrico de INCB050465, un inhibidor de PI3K δ , en linfoma de células del manto en recidiva o resistente al tratamiento, previamente tratado con o sin un inhibidor de la BTK (Citaldel-205). Type: Clinical Trial, phase II.

HULP code: Anexo-I 4949. Sponsored's protocol code: INCB 50465-205.

Sponsored by: Incyte Corporation. Signed date: 16/10/2018

Canales Albendea MA. Estudio de fase II, abierto, de 2 Cohortes y multicéntrico de INCB050465, un inhibidor de PI3K δ , en linfoma de células del manto en recidiva o resistente al tratamiento, previamente tratado con o sin un inhibidor de la BTK (Citaldel-205). Type: Clinical Trial, phase II.

HULP code: 4949. Sponsored's protocol code: INCB 50465-205.

Sponsored by: Incyte Corporation. Signed date: 05/03/2018

Canales Albendea MA. Estudio en fase II de TAK-659 en pacientes con linfoma difuso de células B grandes recidivante o resistente después de dos o más líneas previas de quimioterapia. Type: Clinical Trial, phase II.

HULP code: Anexo-I 4928. Sponsored's protocol code: C34004.

Sponsored by: Millennium Pharmaceuticals Inc. Signed date: 10/04/2018

Canales Albendea MA. Estudio en fase II multicéntrico, estudio abierto de INCB050465, un inhibidor PI3K δ , en el tratamiento del linfoma folicular recidivante o resistente (CITADEL-203). Type: Clinical Trial, phase II.

HULP code: 4939. Sponsored's protocol code: INCB 50465-203.

Sponsored by: Incyte Corporation. Signed date: 01/03/2018

Carballo Cardona C. Ensayo clínico fase IIIB, aleatorizado, abierto, para evaluar el alivio del dolor con Metoxiflurano inhalado, en comparación con el protocolo actual para el tratamiento del dolor de origen traumático, en adultos atendidos en unidades de urgencias españolas. Type: Clinical Trial, phase IIIB.

HULP code: Anexo-I 4803. Sponsored's protocol code: InMEDIATE.

Sponsored by: Mundipharma Pharmaceuticals S.L. Signed date: 19/02/2018

Castelo Fernández B. Estudio en fase 3, aleatorizado, doble ciego sobre Avelumab combinado con la quimiorradioterapia de referencia (Cisplatino más radioterapia definitiva) en comparación con la quimiorradioterapia de referencia en el tratamiento de primera línea de pacientes. Type: Clinical Trial, phase III.

Introduction 1

Executive summary 2

- 2.1 Global Analysis
- 2.2 Research Structure
- 2.3 Training Report and Teaching
- 2.4 Innovation and Transfer Activities
- 2.5 Quality Committee

Information Groups by Area 3

Associated Clinicians 4

Scientific Report 2016 2017 2018



2.6 Clinical Trials

HULP code: Anexo-I 4861. Sponsored's protocol code: 4861 B9991016.
Sponsored by: Pfizer S.L.U. Signed date: 15/06/2018

Castelo Fernández B. A phase II study of Durvalumab (MEDI4736) plus Tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma-the duty trial. Type: Clinical Trial, phase II.

HULP code: 5202. Sponsored's protocol code: GETNE-T1812.
Sponsored by: Grupo Español de Tumores Neuroendocrinos (Getne). Signed date: 17/12/2018

Castelo Fernández B. Ensayo aleatorizado, global, en fase III de Nivolumab con Epacadostat en combinación con quimioterapia (Platino + 5-Fluorouracilo) en comparación con la pauta posológica extreme (Cetuximab + Platino + 5-Fluorouracilo) como tratamiento de primera línea en pacientes con carcinoma de células escamosas de cabeza y cuello (CCECC) recurrente o metastásico. Type: Clinical Trial, phase III.

HULP code: 4987. Sponsored's protocol code: CA209-9NA.
Sponsored by: Incyte Corporation. Signed date: 09/04/2018

Castelo Fernández B. Estudio de calidad de vida en pacientes con dolor irruptivo oncológico atendidos en los servicios de oncología médica. Type: EPA-SP.

HULP code: PI-3018. Sponsored's protocol code: ANG-ANA-2017-01.
Sponsored by: Angelini Farmacéutica S.A. Signed date: 29/01/2018

Castelo Fernández B. Estudio de fase II, aleatorizado, con doble enmascaramiento y controlado con placebo de Cemiplimab en comparación con la combinación de Cemiplimab más ISA101B en el tratamiento de sujetos con cáncer orofaríngeo (COF) VPH-16 positivo resistente al platino. Type: Clinical Trial, phase II.

HULP code: 5124. Sponsored's protocol code: ISA101B-HN-01-17.
Sponsored by: Isa Therapeutics B.U. Signed date: 12/11/2018

Castelo Fernández B. Estudio de fase III, aleatorizado y abierto para evaluar Pembrolizumab como tratamiento neoadyuvante y en combinación con la asistencia habitual como tratamiento adyuvante en el carcinoma epidermoide de cabeza y cuello locorregionalmente avanzado (CECC LA), extirpable, en estadio III-IVA. Type: Clinical Trial, phase III.

HULP code: Anexo-I 4953. Sponsored's protocol code: MK-3475-689.
Sponsored by: Merck Sharp & Dhome Corp. Signed date: 12/03/2018

Castelo Fernández B. Estudio en fase 3, aleatorizado, doble ciego sobre Avelumab combinado con la quimiorradioterapia de referencia (cisplatino más radioterapia definitiva) en comparación con la quimiorradioterapia de referencia en el tratamiento de primera línea de pacientes con carcinoma epidermoide localmente avanzado de cabeza y cuello. Type: Clinical Trial, phase III.

HULP code: 4861. Sponsored's protocol code: 4861 B9991016.
Sponsored by: Pfizer S.L.U. Signed date: 07/02/2018

Castelo Fernández B. Estudio en fase III, aleatorizado, con doble enmascaramiento y controlado con placebo, de Nivolumab o Nivolumab con Cisplatino, en combinación con radioterapia en participantes con carcinoma de células escamosas de cabeza y cuello (CCEC) localmente avanzado elegibles o no para recibir tratamiento con cisplatino. Type: Clinical Trial, phase III.

HULP code: 4975. Sponsored's protocol code: CA209-9TM.
Sponsored by: Bristol Myers Squibb International Corporation. Signed date: 26/03/2018

Castelo Fernández B. Estudio sin enmascaramiento de fase II sobre Tipifarnib en neoplasias malignas no hematológicas avanzadas con mutaciones hras. Type: Clinical Trial, phase II.

HULP code: 4992. Sponsored's protocol code: KO-TIP-001.
Sponsored by: Karma Oncology Ltd. Signed date: 05/10/2018

Castillo Grau P. Estudio de fase 3, aleatorizado, controlado con placebo, de 52 semanas de duración, para evaluar la seguridad y la eficacia de Seladelpar en sujetos con colangitis biliar primaria (CBP) y una respuesta insuficiente o intolerancia al ácido ursodesoxicólico. Type: Clinical Trial, phase III.

HULP code: 5148. Sponsored's protocol code: CB8025-31735.
Sponsored by: Cymabay Therapeutics Inc. Signed date: 16/11/2018

Castillo Grau P. Recogida de muestras de sangre para la evaluación de biomarcadores en el carcinoma hepatocelular. Type: NO-EPA.

HULP code: pi-3289. Sponsored's protocol code: 2017-01.
Sponsored by: Exact Sciences Corporation. Signed date: 13/12/2018

Castro Conde A. Estudio multicéntrico español sobre la prevalencia e incidencia de la insuficiencia cardiaca en pacientes con diabetes tipo 2 en consultas hospitalarias del ámbito nacional. Type: NO-EPA.

HULP code: PI-3231. Sponsored's protocol code: DIABET-IC.
Sponsored by: Sociedad Española de Cardiología (SEC). Signed date: 30/05/2018

Castro Conde A. Estudio multicéntrico, aleatorizado, abierto, de grupos paralelos para estudiar la seguridad y no inferioridad de una nueva estrategia terapéutica (polipíldora cardiovascular de FUSTER-CNIC-FERRER) versus tratamiento habitual en la reducción del LDL y la presión arterial en pacientes con enfermedad cardiovascular aterotrombótica. Ensayo Apolo. Type: Clinical Trial, phase III.

HULP code: 4977. Sponsored's protocol code: FMD-TRI-2017-01.
Sponsored by: Ferrer Internacional S.A. Signed date: 04/07/2018

Chaverri Rada D. Ensayo en fase III, aleatorizado y controlado con placebo de Arimoclomol en esclerosis lateral amiotrófica. Type: Clinical Trial, phase III.

HULP code: 5181. Sponsored's protocol code: ORARIALS-01.
Sponsored by: Worldwide Clinical Trials. Signed date: 11/10/2018

Climent Alcalá FJ. Estudio abierto y comparativo con tratamiento activo, de la seguridad y la eficacia extrapolada en pacientes pediátricos que requieren anticoagulación para el tratamiento de un acontecimiento tromboembólico venoso. Type: Clinical Trial, phase III.

HULP code: 4852. Sponsored's protocol code: B06610137.
Sponsored by: Pfizer Inc. Signed date: 12/01/2018

Cruz Castellanos P. Investigación de la mutación T790M en sangre mediante diferentes metodologías. Type: NO-EPA.

HULP code: PI-3106. Sponsored's protocol code: RING (GCEP 17/03).





2.6 Clinical Trials



Introduction

1

Executive summary

2

2.1 Global Analysis

2.2 Research Structure

2.3 Training Report and Teaching

2.4 Innovation and Transfer Activities

2.5 Quality Commitment

2.6 Clinical Trials

2.7 Platforms

2.8 Scientific Production

2.9 CIBERs and RETICs

2.10 Institutional Projects

2.11 Internationalization

2.12 Communication

Information Groups by Area

3

Associated Clinicians

4

Scientific Report

2016
2017
2018

Sponsored by: Grupo Español Cáncer Pulmón. Signed date: 09/04/2018

Custodio Carretero AB. Ensayo clínico de fase III, aleatorizado, controlado con tratamiento activo, con enmascaramiento parcial y con detección de biomarcadores, de Pembrolizumab en monoterapia y en combinación con Cisplatino + 5-Fluorouracilo frente a placebo + Cisplatino + 5-Fluorouracilo como tratamiento de primera línea en sujetos con adenocarcinoma gástrico o de la unión gastroesofágica (UGE) avanzado. Type: Clinical Trial, phase III.

HULP code: Anexo-I 4689. Sponsored's protocol code: MK-3475-062.

Sponsored by: Merck Sharp & Dhome Corp. Signed date: 08/11/2018

Custodio Carretero AB. Ensayo clínico de fase III, aleatorizado, doble ciego y controlado con placebo, de Pembrolizumab (MK-3475) en combinación con Cisplatino y 5-Fluorouracilo frente a un placebo en combinación con Cisplatino y 5-Fluorouracilo como tratamiento. Type: Clinical Trial, phase III.

HULP code: Anexo-I 4823. Sponsored's protocol code: MK3475-590.

Sponsored by: Merck Sharp & Dhome Corp. Signed date: 12/03/2018

Custodio Carretero AB. Ensayo clínico fase 2, aleatorizado, abierto, de Relatlimab (ANTI-LAG-3) más Nivolumab en combinación con quimioterapia frente a Nivolumab en combinación con quimioterapia como tratamiento de primera línea en pacientes con adenocarcinoma gástrico o de la unión gastroesofágica. Type: Clinical Trial, phase II.

HULP code: 5140. Sponsored's protocol code: CA224-060.

Sponsored by: Bristol Myers Squibb International Corporation. Signed date: 03/10/2018

Custodio Carretero AB. Estudio fase 3 internacional, multicéntrico, doble ciego y aleatorizado, de la eficacia de Zolbetuximab (IMAB362) más Capox, en comparación con placebo más Capox, como tratamiento de primera línea en sujetos con adenocarcinoma gástrico o de la unión gastroesofágica localmente avanzado irresecable o metastásico, Claudin (CLDN)18.2 positivo y HER2 negativo. Type: Clinical Trial, phase III.

HULP code: 5143. Sponsored's protocol code: 8951-CL-0302.

Sponsored by: Astellas Pharma Global Development Inc. Signed date: 13/11/2018

de Andrés Ares J. Ensayo clínico en fase III multicéntrico, aleatorizado, doble ciego, controlado por placebo, con grupos paralelos para investigar la eficacia, seguridad y tolerabilidad de Naloxona HCL LP comprimidos en pacientes con estreñimiento inducido por opioides. Type: Clinical Trial, phase III.

HULP code: 4957. Sponsored's protocol code: 0217/DEV.

Sponsored by: Develco Pharma Schweiz AG. Signed date: 15/01/2018

de Castro Carpeño J. Brigatinib en pacientes con cáncer de pulmón de células no pequeñas avanzado con linfoma anaplásico cinásico positivo (ALK+) cuyo cáncer ha progresado durante el tratamiento con Alectinib o Ceritinib. Type: Clinical Trial, phase II.

HULP code: 5111. Sponsored's protocol code: 2002.

Sponsored by: Pharmaceuticals Inc. Signed date: 17/09/2018

de Castro Carpeño J. Ensayo clínico de grupos paralelos, aleatorizado, de fase III de OSE2101 como tratamiento de segunda línea o tercera línea en comparación con el tratamiento estándar (Docetaxel o Pemetrexed) en pacientes con HLA-A2 positivo

y carcinoma broncopulmonar no microcítico metastásico (IV) o localmente avanzado (IIIB) no apto para radioterapia. Type: Clinical Trial, phase III.

HULP code: Anexo-I 4593. Sponsored's protocol code: OSE2101C301.

Sponsored by: Ose Immunotherapeutics. Signed date: 23/05/2018

de Castro Carpeño J. Ensayo clínico fase II, no randomizado en primera línea de Atezolizumab en combinación con Carboplatino y Pemetrexed en pacientes con cáncer de pulmón no microcítico estadio IV con megástasis cerebrales asintomáticas. Type: Clinical Trial, phase II.

HULP code: 5073. Sponsored's protocol code: 5073 GECP 17/05 (ML40238).

Sponsored by: Fundación GECP. Signed date: 05/06/2018

de Castro Carpeño J. Ensayo de fase II de un único grupo para investigar Tepotinib en el adenocarcinoma pulmonar en estadio IIIB/IV con alteraciones por omisión del exón 14 de Met (METEX14) tras fallar, como mínimo, un tratamiento activo anterior, incluido uno con doblete de platino. Type: Clinical Trial, phase II.

HULP code: Anexo-I 4657. Sponsored's protocol code: MS200095-022.

Sponsored by: Merck KGAA. Signed date: 10/01/2018

de Castro Carpeño J. Ensayo fase III, randomizado, doble ciego, controlado con placebo, multicéntrico, internacional con Osimertinib como tratamiento de mantenimiento en pacientes con cáncer de pulmón no microcítico (estadio III) localmente avanzado e irresecable, con mutación. Type: Clinical Trial, phase III.

HULP code: 5104. Sponsored's protocol code: D516C00048.

Sponsored by: Astrazeneca Farmacéutica Spain S.A. Signed date: 30/07/2018

de Castro Carpeño J. Estudio abierto y aleatorizado de combinaciones de REGN2810 a dosis estándar y alta (Cemiplimab; anticuerpo ANTI-PD-1) e Ipilimumab (anticuerpo ANTI-CTLA-4) en el tratamiento de segunda línea de pacientes con cáncer de pulmón no microcítico metastásico con tumores que expresan <50 % de PDL1. Type: Clinical Trial, phase II.

HULP code: 5059. Sponsored's protocol code: R2810-ONC-1763.

Sponsored by: Regeneron Pharmaceuticals Inc. Signed date: 12/07/2018

de Castro Carpeño J. Estudio ceco, abierto, multicéntrico, global, en fase II con Entrectinib para el tratamiento de pacientes con tumores sólidos localmente avanzados o metastásicos que albergan reordenaciones en los genes NTRK1/2/3, ROS1 o ALK. Type: Clinical Trial, phase II.

HULP code: Anexo-II 4648. Sponsored's protocol code: RXDX-101-02.

Sponsored by: Ignyta Inc. Signed date: 21/12/2018

de Castro Carpeño J. Estudio de extensión y observacional a largo plazo multicéntrico, abierto en pacientes incluidos previamente en un estudio clínico de Atezolizumab promocionado por Genentech y/o F. Hoffmann-la roche LTD. Type: Clinical Trial, phase III.

HULP code: 5032. Sponsored's protocol code: BO39633.

Sponsored by: F. Hoffmann-La Roche Ltd. Signed date: 31/05/2018

de Castro Carpeño J. Estudio de fase 3, aleatorizado y controlado con placebo para evaluar la seguridad y la eficacia de Pemetrexed + quimioterapia a base de platino + Pembrolizumab (MK-3475) con o sin Lenvatinib (E7080/MK-7902) como intervención



2.6 Clinical Trials



Introduction 1

Executive summary 2

- 2.1 Global Analysis
- 2.2 Research Structure
- 2.3 Training Report and Teaching
- 2.4 Innovation and Transfer Activities
- 2.5 Quality Commitment
- 2.6 Clinical Trials**
- 2.7 Platforms
- 2.8 Scientific Production
- 2.9 CIBERs and RETICs
- 2.10 Institutional Projects
- 2.11 Internationalization
- 2.12 Communication

Information Groups by Area 3

Associated Clinicians 4

Scientific Report 2016 2017 2018

de primera línea en participantes con cáncer de pulmón no microcítico, no epidermoide, metastásico (LEAP-006). Type: Clinical Trial, phase III.

HULP code: 5220. Sponsored's protocol code: MK-7902-006.
Sponsored by: Merck Sharp & Dhome Corp. Signed date: 29/12/2018

de Castro Carpeño J. Estudio de fase II/III, aleatorizado, abierto y de dos partes, de Dinutuximab e Irinotecán versus Irinotecán como tratamiento de segunda línea en sujetos con cáncer de pulmón microcítico en recidiva o resistente. Type: Clinical Trial, phase II.

HULP code: Anexo-I 4832. Sponsored's protocol code: DIV-SCLC-301.
Sponsored by: United Therapeutics Corporation. Signed date: 19/03/2018

de Castro Carpeño J. Estudio de fase III, multicéntrico, aleatorizado, abierto de LDK378 oral frente a quimioterapia estándar en pacientes adultos con cancer de pulmon de celulas no pequeñas avanzado con reordenamiento de ALK (ALK-positivo) que han sido tratados previamente con quimioterapia. Type: Clinical Trial, phase III.

HULP code: Anexo-I 4022. Sponsored's protocol code: CLDK378A2303.
Sponsored by: Novartis Farmacéutica S.A. Signed date: 08/01/2018

de Castro Carpeño J. Estudio de fase III, multicéntrico, aleatorizado, abierto de LDK378 oral frente a quimioterapia estándar en pacientes adultos con cáncer de pulmón de células no pequeñas avanzado con reordenamiento de ALK (ALK-positivo) que han sido tratados previamente con quimioterapia. Type: Clinical Trial, phase III.

HULP code: Anexo-II 4022. Sponsored's protocol code: CLDK378A2303.
Sponsored by: Novartis Farmacéutica S.A. Signed date: 23/11/2018

de Castro Carpeño J. Estudio de práctica clínica en condiciones reales para evaluar la toma de decisiones en el tratamiento de segunda línea conforme a las normas asistenciales y basado en los perfiles de Foundation Medicine® en pacientes con cáncer de pulmón no microcítico. Type: NO-EPA.

HULP code: PI-3376. Sponsored's protocol code: ML40221.
Sponsored by: Roche Farma S.A. Signed date: 17/09/2018

de Castro Carpeño J. Estudio en fase I, abierto y no aleatorizado para evaluar el efecto de una o varias dosis orales de Osimertinib (Tagrisso™) en la farmacocinética de un fármaco sonda de Glicoproteína P (Fexofenadina) en pacientes con CPNM con EGFR avanzado que haya progresado en un tratamiento previo con TKI del EGFR. Type: Clinical Trial, phase I.

HULP code: Anexo-I 4774. Sponsored's protocol code: D5160C00036.
Sponsored by: Astrazeneca AB. Signed date: 07/11/2018

de Castro Carpeño J. Estudio en fase I, abierto, no aleatorizado y multicéntrico para evaluar la farmacocinética, la seguridad y la tolerabilidad de Osimertinib tras la administración de una dosis oral única de 80 mg a pacientes con tumores sólidos avanzados y función renal normal o disfunción renal grave. Type: Clinical Trial, phase I.

HULP code: Anexo-I 4775. Sponsored's protocol code: D5160C00035.
Sponsored by: Astrazeneca AB. Signed date: 07/11/2018

de Castro Carpeño J. Estudio en fase III abierto, multicéntrico de Brigatinib (AP26113)

frente a Crizotinib en pacientes con cáncer de pulmón avanzado positivo para ALK positiva. Type: Clinical Trial, phase III.

HULP code: Anexo-II 4698. Sponsored's protocol code: AP26113-13-301.
Sponsored by: Ariad Pharmaceutical Inc. Signed date: 19/07/2018

de Castro Carpeño J. Estudio en fase III, aleatorizado y abierto de Brigatinib (Alunbrigtm) en comparación con Alectinib (Alecensa®) en pacientes con cáncer de pulmón no microcítico avanzado positivo para cinasa de linfoma anaplásico que han progresado con Crizotinib (XALKORI®). Type: Clinical Trial, phase III.

HULP code: 5149. Sponsored's protocol code: BRIGATINIB-3001.
Sponsored by: Ariad Pharmaceutical Inc. Signed date: 22/11/2018

de Castro Carpeño J. Estudio exploratorio de los efectos biológicos y los biomarcadores de Nivolumab en combinación con Ipilimumab en pacientes con cáncer de pulmón no microcítico (CPNM) en estadio IV o recurrente sin tratamiento previo (Checkmate 592: evaluación de la vía del punto de control y de Nivolumab en ensayos clínicos 592. Type: Clinical Trial, phase IV.

HULP code: 5107. Sponsored's protocol code: CA209-592.
Sponsored by: Bristol Myers Squibb International Corporation. Signed date: 15/06/2018

de Castro Carpeño J. Estudio fase III, aleatorizado, abierto, de Nartinitinib en monoterapia frente a fármaco a elección del investigador (Erlotinib o Gefitinib) como tratamiento de primera línea en pacientes con cáncer de pulmón de células no pequeñas localmente avanzado o metastásico con mutaciones activadoras de EGFR. Type: Clinical Trial, phase III.

HULP code: 5066. Sponsored's protocol code: CEGF816A2302.
Sponsored by: Novartis Farmacéutica S.A. Signed date: 05/06/2018

de Castro Carpeño J. Estudio internacional multicéntrico de fase III, aleatorizado, doble ciego, controlado con placebo, de MEDI4736 como tratamiento secuencial en pacientes con cáncer pulmonar de células no pequeñas, localmente avanzado, no reseccable (estadio III) que no han progresado después de la terapia de quimiorradiación concurrente definitiva con base de platino (Pacific). Type: Clinical Trial, phase III.

HULP code: Anexo-I 4235. Sponsored's protocol code: D4191C00001.
Sponsored by: Astrazeneca AB. Signed date: 26/11/2018

de Castro Carpeño J. Estudio multicéntrico, abierto y de un solo grupo, del perfil molecular de pacientes con cáncer de pulmón no microcítico con mutación del EGFR localmente avanzado o metastásico, tratados con Osimertinib. Type: Clinical Trial, phase II.

HULP code: 4929. Sponsored's protocol code: D5161C00003.
Sponsored by: Astrazeneca AB. Signed date: 24/04/2018

de La Oliva Senovilla P. Estudio aleatorizado, controlado con placebo, doble ciego y multicéntrico de la eficacia y la seguridad de LJPC-501 en pacientes pediátricos de > 2 a 17 años de edad con hipotensión resistente a la catecolamina asociada a choque distributivo. Type: Clinical Trial, phase II.

HULP code: 5129. Sponsored's protocol code: LJ501-CRH04.
Sponsored by: La Jolla Pharmaceutical Company. Signed date: 21/08/2018



2.6 Clinical Trials



Introduction 1

Executive summary 2

- 2.1 Global Analysis
- 2.2 Research Structure
- 2.3 Training Report and Teaching
- 2.4 Innovation and Transfer Activities
- 2.5 Quality Committe
- 2.6 Clinical Trials
- 2.7 Platforms
- 2.8 Scientific Production
- 2.9 CIBERs and RETICs
- 2.10 Institutional Projects
- 2.11 Internationalization
- 2.12 Comunication

Information Groups by Area 3

Associated Clinicians 4

Scientific Report

2016
2017
2018

de La Quintana Jiménez P. Estudio clínico observacional postcomercialización, prospectivo e internacional del producto para Ostomía Flexima®/Softima 3s®. Type: NO-EPA.

HULP code: PI-3253. Sponsored's protocol code: KISSS.
Sponsored by: B.Braun Medical S.A. Signed date: 19/11/2018

de Lucas Laguna R. Ensayo aleatorizado, abierto, multicéntrico para evaluar la eficacia de Secukinumab subcutáneo después de doce semanas de tratamiento y evaluar la seguridad, tolerabilidad y eficacia a largo plazo en pacientes de 6 a menos de 18 años de edad con psoriasis. Type: Clinical Trial, phase III.

HULP code: 5043. Sponsored's protocol code: CAIN457A2311.
Sponsored by: Novartis Farmacéutica S.A. Signed date: 27/04/2018

de Lucas Laguna R. Estudio de fase 3, multicéntrico, aleatorizado, comparativo con placebo, con enmascaramiento doble y grupos paralelos, en el que se evalúa la farmacocinética, la eficacia y la seguridad de Baricitinib en niños enfermos ambulatorios con dermatitis atópica. Type: Clinical Trial, phase III.

HULP code: 5215. Sponsored's protocol code: I4V-MC-JAIP.
Sponsored by: Lilly S.A. Signed date: 05/12/2018

de Lucas Laguna R. Estudio de fase III, multicéntrico, aleatorizado, doble ciego, controlado con placebo y un comparador activo para evaluar la eficacia y seguridad de BMS-986165 en pacientes con psoriasis en placas de moderada a grave. Type: Clinical Trial, phase III.

HULP code: 5195. Sponsored's protocol code: IM011046.
Sponsored by: Bristol-Myers Squibb Emea Sarl. Signed date: 27/11/2018

de Lucas Laguna R. Estudio de seguridad y eficacia preliminar de la infusión de células madre mesenquimales haploidénticas derivadas de médula ósea para el tratamiento de la epidermolisis bullosa distrófica recesiva. Type: Clinical Trial, phase I.

HULP code: 4923. Sponsored's protocol code: MESENSISTEM-EB.
Sponsored by: Fundación para la Investigación Biomédica Hospital Universitario La Paz. Signed date: 09/01/2018

de Lucas Laguna R. Estudio fase 2B de búsqueda de dosis, multicéntrico, aleatorizado, doble ciego, controlado con placebo para investigar la eficacia y la seguridad de Ligelizumab (QGE031) en pacientes adolescentes con urticaria crónica espontánea (UCE). Type: Clinical Trial, phase II.

HULP code: 5031. Sponsored's protocol code: CQGE031C2202.
Sponsored by: Novartis Farmacéutica S.A. Signed date: 18/05/2018

De Paz Arias R. Estudio clínico de fase 2, aleatorizado, controlado y abierto para comparar la eficacia y la seguridad de Pevonedistat más Azacitidina frente a Azacitidina en monoterapia en pacientes con síndromes mielodisplásicos de alto riesgo, leucemia mielomonocítica crónica y leucemia mielógena aguda pobre en blastos. Type: Clinical Trial, phase II.

HULP code: Anexo-I 4571. Sponsored's protocol code: Pevonedistat-2001.
Sponsored by: Millennium Pharmaceuticals Inc. Signed date: 14/03/2018

De Paz Arias R. Estudio clínico de fase 3, abierto, aleatorizado y controlado de Pevonedistat más Azacitidina frente a Azacitidina en monoterapia como tratamiento de

primera línea en pacientes con síndromes mielodisplásicos de alto riesgo, leucemia mielomonocítica crónica. Type: Clinical Trial, phase III.

HULP code: 4950. Sponsored's protocol code: PEVONEDISTAT-3001.
Sponsored by: Millennium Pharmaceuticals Inc. Signed date: 22/02/2018

De Paz Arias R. Estudio de extensión abierto del tratamiento de Bosutinib para pacientes con leucemia mieloide crónica (LMC) que han participado previamente en los Estudios de Bosutinib B1871006 o B1871008. Type: Clinical Trial, phase III.

HULP code: Anexo-I 3925. Sponsored's protocol code: B1871040.
Sponsored by: Pfizer Inc. Signed date: 19/03/2018

De Paz Arias R. Estudio fase III, prospectivo, aleatorizado, abierto, con dos brazos de tratamiento, para evaluar la tasa de remisión libre de tratamiento (RLT) en pacientes con LMC cromosoma filadelfia positivo, después de dos duraciones distintas de tratamiento de consolidación con Nilotinib 300 mg BID. Type: Clinical Trial, phase III.

HULP code: Anexo-I 3831. Sponsored's protocol code: CAMN107AIC05.
Sponsored by: Novartis Farmacéutica S.A. Signed date: 23/04/2018

De Paz Arias R. Estudio multicéntrico, de un único brazo, de remisión libre de tratamiento de Nilotinib, en pacientes con leucemia mieloide crónica en fase crónica con BCR-ABL1 positivo, que han alcanzado un estado de enfermedad residual mínima (ERM) duradera con tratamiento. Type: Clinical Trial, phase II.

HULP code: Anexo-II 3807. Sponsored's protocol code: CAMN107I2201.
Sponsored by: Novartis Farmacéutica S.A. Signed date: 12/01/2018

Díaz-Agero Álvarez P. Estudio aleatorizado, comparativo, de no inferioridad, para evaluar la eficacia y la seguridad de Hemopatch comparado con Tachosil en la prevención o reducción de las fugas de aire posquirúrgicas tras la resección pulmonar. Type: Clinical Trial, phase IV.

HULP code: 5010. Sponsored's protocol code: BXU513667.
Sponsored by: Baxter Healthcare Corporation. Signed date: 22/06/2018

Domínguez Ortega FJ. Estudio piloto sobre el control del asma en pacientes con rinitis alérgica a polen de gramíneas tratados con inmunoterapia sublingual de 5 gramíneas (Staloral®) vs placebo. 5 graps. Type: Clinical Trial, phase III.

HULP code: Anexo-I 4284. Sponsored's protocol code: DOM-STA-2014-01.
Sponsored by: Stallergenes Iberica S.A. Signed date: 10/01/2018

Elorza Fernández MD. Ensayo clínico multicéntrico, aleatorizado, abierto, controlado con comparador activo, para evaluar la eficacia y la seguridad de Rivaroxaban a un régimen de dosis ajustado según la edad y el peso, en niños con tromboembolismo venoso agudo. Type: Clinical Trial, phase III.


HULP code: 4180B. Sponsored's protocol code: 59-7939/14372.
Sponsored by: Bayer AG. Signed date: 23/02/2018

Escobar Cervantes C. Patrones de prescripción de Edoxabán en Europa: un estudio de utilización del medicamento mediante la revisión retrospectiva de historias clínicas. Type: EPA-OD.

HULP code: PI-3107. Sponsored's protocol code: DSE-EDO-01-14-EU.



2.6 Clinical Trials



Introduction

1

Executive summary

2

2.1 Global Analysis

2.2 Research Structure

2.3 Training Report and Teaching

2.4 Innovation and Transfer Activities

2.5 Quality Commitment

2.6 Clinical Trials

2.7 Platforms

2.8 Scientific Production

2.9 CIBERs and RETICs

2.10 Institutional Projects

2.11 Internationalization

2.12 Communication

Information Groups by Area

3

Associated Clinicians

4

Scientific Report

2016
2017
2018

Sponsored by: Daiichi-Sankyo Europe GMBH. Signed date: 14/02/2018

Espinosa Arranz E. Ensayo clínico abierto, multicéntrico, de un solo grupo, de Nivolumab (BMS 936558) en sujetos con melanoma en estadio III (Irreseccable) o IV confirmado mediante histología, en progresión después de un tratamiento previo con un anticuerpo monoclonal ANTICTLA4. Type: Clinical Trial, phase II.

HULP code: Anexo-II 4239. Sponsored's protocol code: CA209-172.

Sponsored by: Bristol Myers Squibb S.L. Signed date: 30/08/2018

Espinosa Arranz E. Ensayo de extensión de fase III, abierto y multicéntrico para estudiar la seguridad y eficacia a largo plazo en participantes con tumores avanzados que actualmente están en tratamiento o en seguimiento en un ensayo de Pembrolizumab. Type: Clinical Trial, phase III.

HULP code: 5076. Sponsored's protocol code: MK-3475-587.

Sponsored by: Merck Sharp and Dohme de España S.A. Signed date: 03/05/2018

Espinosa Arranz E. Ensayo de fase 3, aleatorizado y controlado con placebo para evaluar la seguridad y la eficacia de Pembrolizumab (MK-3475) y Lenvatinib (E7080/MK-7902) en comparación con Pembrolizumab en monoterapia como intervención de primera línea en participantes con melanoma avanzado (LEAP-003). Type: Clinical Trial, phase III.

HULP code: 5198. Sponsored's protocol code: MK-7902-003 (E7080-G000-312).

Sponsored by: Merck Sharp & Dhome Corp. Signed date: 14/11/2018

Espinosa Arranz E. Estudio abierto y multicéntrico en fase II de DS-8201A, un Anti-HER2 conjugado anticuerpo-fármaco (CAF) para sujetos con cáncer de mama HER2 positivo irreseccable y/o metastásico que son resistentes o refractarios a T-DMI. Type: Clinical Trial, phase II.

HULP code: Anexo-I 4934. Sponsored's protocol code: DS8201-A-U201.

Sponsored by: Daiichi Sankyo Inc. Signed date: 09/10/2018

Espinosa Arranz E. Estudio abierto y multicéntrico en fase II de DS-8201A, un ANTI-HER2 conjugado anticuerpo-fármaco (CAF) para sujetos con cáncer de mama HER2 positivo irreseccable y/o metastásico que son resistentes o refractarios a T-DMI. Type: Clinical Trial, phase II.

HULP code: 4934. Sponsored's protocol code: DS8201-A-U201.

Sponsored by: Daiichi Sankyo Inc. Signed date: 09/03/2018

Espinosa Arranz E. Estudio aleatorizado de fase II, abierto y multicéntrico para evaluar la seguridad y la eficacia de IMCGP100 en comparación con la elección del investigador en pacientes con HLA-A*0201 positivo y que no hayan recibido tratamiento previo para el melanoma maligno uveal avanzado. Type: Clinical Trial, phase II.

HULP code: 5090. Sponsored's protocol code: IMCgp100-202.

Sponsored by: Immunocore Ltd. Signed date: 09/10/2018

Espinosa Arranz E. Estudio de fase 3, abierto y de un solo grupo para evaluar la seguridad y la eficacia de Pembrolizumab (MK-3475) como tratamiento de primera línea en participantes con carcinoma de células de Merkel avanzado (Keynote-913). Type: Clinical Trial, phase III.

HULP code: 5190. Sponsored's protocol code: MK-3475-913.

Sponsored by: Merck Sharp & Dhome Corp. Signed date: 06/11/2018

Espinosa Arranz E. Estudio de fase IB multicéntrico, sin enmascaramiento para evaluar la seguridad y la eficacia de Ipatasertib en combinación con Atezolizumab y Paclitaxel o Nab-Paclitaxel en pacientes con cáncer de mama triple negativo localmente avanzado o metastásico. Type: Clinical Trial, phase I.

HULP code: 5012. Sponsored's protocol code: CO40151.

Sponsored by: F. Hoffmann-La Roche Ltd. Signed date: 26/01/2018

Espinosa Arranz E. Estudio de fase IB multicéntrico, sin enmascaramiento para evaluar la seguridad y la eficacia de Ipatasertib en combinación con Atezolizumab y Paclitaxel o Nab-Paclitaxel en pacientes con cáncer de mama triple negativo localmente avanzado o metastásico. Type: Clinical Trial, phase I.

HULP code: Anexo-I 5012. Sponsored's protocol code: CO40151.

Sponsored by: F. Hoffmann-La Roche Ltd. Signed date: 26/10/2018

Espinosa Arranz E. Estudio en fase I/II, abierto, multicéntrico, de la seguridad y la eficacia de IMCGP100 usando la pauta posológica con aumento intrapaciente en pacientes con melanoma uveal avanzado. Type: Clinical Trial, phase I.

HULP code: 5074. Sponsored's protocol code: IMCGP100-102.

Sponsored by: Immunocore Ltd. Signed date: 11/07/2018

Espinosa Arranz E. Estudio observacional descriptivo sobre las características y evolución del melanoma avanzado y metastásico en España. Type: EPA-SP.

HULP code: PI-3208. Sponsored's protocol code: GEM-IP1-2018-01.

Sponsored by: Grupo Español Multidisciplinar de Melanoma Gem Gem. Signed date: 25/06/2018

Espinosa Arranz E. Un estudio de fase IB para evaluar el uso de Cobimetinib más Atezolizumab en pacientes con melanoma con BRAFV600 de tipo salvaje avanzado que hayan experimentado progresión. Type: Clinical Trial, phase I.

HULP code: 5040. Sponsored's protocol code: CO39721.

Sponsored by: F. Hoffmann-La Roche Ltd. Signed date: 08/06/2018

Espinosa Román L. Carga de la enfermedad de la hipofosfatemia ligada al cromosoma X (XLH-QOL en adelante). Type: NO-EPA.

HULP code: PI-3004. Sponsored's protocol code: XLH-QoL-2017-02.

Sponsored by: Kyowa Kirin Farmacéutica S.L.U. Signed date: 18/01/2018

Feliu Batlle J. Estudio aleatorizado, multicéntrico, doble ciego, controlado con placebo, de fase 2/3 del inhibidor de la tirosina quinasa de Bruton, Ibrutinib, en combinación con Nab-Paclitaxel y Gemcitabina frente a placebo en combinación con Nab-Paclitaxel y Gemcitabina. Type: Clinical Trial, phase II.

HULP code: Anexo-II 4502. Sponsored's protocol code: PCYC-I137-CA.

Sponsored by: Pharmacyclis Llc. Signed date: 22/02/2018

Feliu Batlle J. Estudio de fase 3 aleatorizado para evaluar el uso de Eryaspase en combinación con quimioterapia, comparada con quimioterapia sola como tratamiento de segunda línea en pacientes con adenocarcinoma pancreático. Type: Clinical Trial, phase III.

Introduction

1

Executive summary

2

2.1 Global Analysis

2.2 Research Structure

2.3 Training Report and Teaching

2.4 Innovation and Transfer Activities

2.5 Quality Commitment

2.6 Clinical Trials

2.7 Platforms

2.8 Scientific Production

2.9 CIBERs and RETICs

2.10 Institutional Projects

2.11 Internationalization

2.12 Communication

Information Groups by Area

3

Associated Clinicians

4

Scientific Report

2016
2017
2018



2.6 Clinical Trials

HULP code: 5105. Sponsored's protocol code: GRASPANC 2018-01.
Sponsored by: Erytech Pharma. Signed date: 05/06/2018

Feliu Batlle J. Estudio de fase III, abierto y aleatorizado de Atezolizumab en combinación con Bevacizumab en comparación con Sorafenib en pacientes con carcinoma hepatocelular localmente avanzado o metastásico no tratado. Type: Clinical Trial, phase III.

HULP code: 4973. Sponsored's protocol code: YO40245.
Sponsored by: F. Hoffmann-La Roche Ltd. Signed date: 13/02/2018

Feliu Batlle J. Estudio en fase II, multicéntrico y abierto, para investigar la eficacia, la seguridad y la farmacocinética del anticuerpo monoclonal ANTI-PD-1, BGB-A317, en pacientes con carcinoma hepatocelular irreseccable tratado anteriormente. Type: Clinical Trial, phase II.

HULP code: 4996. Sponsored's protocol code: BGB-A317-208.
Sponsored by: Beigene Ltd. Signed date: 09/05/2018

Feliu Batlle J. Estudio en fase III, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y seguridad de GS-5745 en combinación con mFOLFOX6 como tratamiento de primera línea en pacientes con adenocarcinoma gástrico avanzado o de la unión gastroesofágica. Type: Clinical Trial, phase III.

HULP code: Anexo-III 4569. Sponsored's protocol code: GS-US-296-1080.
Sponsored by: Gilead Sciences Inc. Signed date: 13/02/2018

Feliu Batlle J. Estudio fase Ib/2 de BMS-813160 en combinación con quimioterapia o Nivolumab en pacientes con tumores sólidos avanzados. Type: Clinical Trial, phase I.

HULP code: 5169. Sponsored's protocol code: CV202-103.
Sponsored by: Bristol Myers Squibb International Corporation. Signed date: 31/10/2018

Feliu Batlle J. Estudio multicéntrico en adenocarcinoma de páncreas reseccable con factores de mal pronóstico sobre la definición de nuevos marcadores de metilación predictivos de respuesta radiológica al tratamiento con Nab-Paclitaxel-Gemcitabina. Correlación Farmacoprot. Type: EPA-AS.

HULP code: PI-3128. Sponsored's protocol code: AVB-NAB-2018-01.
Sponsored by: Complejo Hospitalario de Navarra. Signed date: 12/03/2018

Feliu Batlle J. Refine: estudio observacional de Regorafenib en carcinoma hepatocelular. Type: EPA-LA.

HULP code: PI-3112. Sponsored's protocol code: BAY-REG-2018-01.
Sponsored by: Bayer Hispania S.L. Signed date: 23/05/2018

Frank García A. Estudio de extensión en fase III, multicéntrico, a largo plazo sobre la seguridad y eficacia de AVP-786 (Bromhidrato de [D6]-Dextrometorfano Deuterado [D6-DM]/Sulfato de Quinidina [Q]) para el tratamiento de la agitación en pacientes con demencia de tipo Alzheimer. Type: Clinical Trial, phase III.

HULP code: 5155. Sponsored's protocol code: 15-AVP-786-303.
Sponsored by: Pharmaceuticals Inc. Signed date: 20/09/2018

Frank García A. Estudio de fase IIB/III, multicéntrico, aleatorizado, con doble ciego, controlado con placebo y de grupos paralelos para investigar la eficacia y la seguridad de JNJ-54861911 en sujetos asintomáticos con riesgo de desarrollar demencia de alzheimer. Type: Clinical Trial, phase II.

HULP code: Anexo-I 4448. Sponsored's protocol code: 54861911ALZ2003.
Sponsored by: Janssen Cilag International NV. Signed date: 16/03/2018

Frank García A. Estudio de fase III multicéntrico, aleatorizado, doble ciego, controlado con placebo, con diseño de grupos paralelos, para evaluar la eficacia, la seguridad y la tolerabilidad de AVP-786 (Bromhidrato de Deudextrometorfano [D6-DM]/Sulfato de Quinidina [Q]). Type: Clinical Trial, phase III.

HULP code: 4976. Sponsored's protocol code: 4976 17-AVP-786-305.
Sponsored by: Ph Research S.L. Signed date: 30/01/2018

Gaebelt NE. Ensayo de inmunogenicidad y seguridad de una vacuna conjugada anti-meningocócica tetravalente en investigación administrada de forma concomitante con las vacunas pediátricas de rutina a niños pequeños y lactantes sanos en Europa. Type: Clinical Trial, phase III.

HULP code: 5164. Sponsored's protocol code: MET58.
Sponsored by: Sanofi Pasteur Inc. Signed date: 25/09/2018

Gallego Martínez A. Estudio observacional retrospectivo para evaluar las estrategias de tratamiento en práctica clínica y la evolución clínica de los pacientes con cáncer de ovario avanzado en España: Estudio Ovoc (evaluación objetiva del cáncer de ovario). Type: EPA-OD.

HULP code: PI-3330. Sponsored's protocol code: ML40141.
Sponsored by: Roche Farma S.A. Signed date: 24/09/2018

García García S. Ensayo clínico de fase II de demostración de viabilidad para evaluar la eficacia y la seguridad de MEDI3902 en la prevención de la neumonía nosocomial causada por pseudomonas aeruginosa en pacientes sujetos a ventilación mecánica. Type: Clinical Trial, phase III.

HULP code: Anexo-I 4540. Sponsored's protocol code: HELIOS-AP.
Sponsored by: Sociedad Española de Carburos Metálicos. Signed date: 16/11/2018

García Rio FJ. Caracterización de la variable "minutos diarios de marcha" como una medida útil de actividad física en pacientes con EPOC. Type: NO-EPA.

HULP code: PI-3342. Sponsored's protocol code: FUC-EPO-2018-01.
Sponsored by: Coordinadora Catalana de Fundaciones. Signed date: 25/09/2018

García Rio FJ. Estudio observacional para la validación de un cuestionario para la actividad física de pacientes con EPOC en la práctica clínica: cuestionario saq-copd (spanish activity questionnaire in copd). Type: NO-EPA.

HULP code: PI-3011. Sponsored's protocol code: AST-SAQ-2017-01.
Sponsored by: Astrazeneca Farmacéutica Spain S.A. Signed date: 28/03/2018

García Rio FJ. Importancia de la evaluación de la respuesta y la estandarización con proteómica en la obstrucción buscando desenlaces novedosos y significativos. Type: EPA-SP.

HULP code: PI-3340. Sponsored's protocol code: SEP-ICS-2017-01.
Sponsored by: Fundación Española del Pulmón. SEPAR. Signed date: 02/08/2018

García Sánchez A. Estudio clínico de fase 3, multicéntrico, aleatorizado, doble ciego y controlado con tratamiento activo para evaluar la seguridad y la eficacia de Lenvatinib



Introduction

1

Executive summary

2

2.1 Global Analysis

2.2 Research Structure

2.3 Training Report and Teaching

2.4 Innovation and Transfer Activities

2.5 Quality Committe

2.6 Clinical Trials

2.7 Platforms

2.8 Scientific Production

2.9 CIBERs and RETICs

2.10 Institutional Projects

2.11 Internationalization

2.12 Comunication

Information Groups by Area

3

Associated Clinicians

4

Scientific Report

2016
2017
2018



2.6 Clinical Trials

(E7080/MK-7902) en combinación con Pembrolizumab (MK-3475) frente a Lenvatinib en el tratamiento. Type: Clinical Trial, phase III.

HULP code: 5194. Sponsored's protocol code: MK7902-002.
Sponsored by: Merck Sharp & Dhome Corp. Signed date: 06/11/2018

García-Samaniego Rey J. Estudio clínico de fase III, aleatorizado, doble ciego, controlado con placebo para evaluar la seguridad y eficacia de Selonsertib en pacientes con esteatohepatitis no alcohólica (EHNA) y fibrosis en puentes (F3). Type: Clinical Trial, phase III.

HULP code: Anexo-II 4785. Sponsored's protocol code: GS-US-384-1943.
Sponsored by: Gilead Sciences Inc. Signed date: 27/08/2018

García-Samaniego Rey J. Estudio en fase III, aleatorizado, doble ciego y controlado con placebo para evaluar la seguridad y la eficacia de Selonsertib en pacientes con cirrosis compensada debida a esteatohepatitis no alcohólica (EHNA). Type: Clinical Trial, phase III.

HULP code: Anexo-II 4786. Sponsored's protocol code: GS-US-384-1944.
Sponsored by: Gilead Sciences Inc. Signed date: 27/08/2018

Gasior Kabat M. Estudio de fase 2 de LY2784544 en pacientes con neoplasias mieloproliferativas. Type: Clinical Trial, phase II.

HULP code: Anexo-V 3558. Sponsored's protocol code: I3X-MC-JHTB.
Sponsored by: Lilly S.A. Signed date: 20/07/2018

Gil Garay E. Artroplastia total de cadera con el vástago femoral alteen™ Tapered Wedge de Exactech®. Type: EPA-SP.

HULP code: PI-2913. Sponsored's protocol code: CR14-001.
Sponsored by: Exactech International Operation AG. Signed date: 09/02/2018

Gómez Barrena E. A post-market domestic (US) and international data collection to assess the Optetrak® knee system. Type: EPA-SP.

HULP code: PI-3335. Sponsored's protocol code: CR5-007.
Sponsored by: Exactech International Operation AG. Signed date: 30/10/2018

Gómez Barrena E. Ensayo clínico fase II para evaluar el efecto del HC-SVT-1001 (células mesenquimales troncales adultas autólogas de tejido adiposo expandidas e incluidas en biomaterial de fosfato tricálcico) en el tratamiento quirúrgico de pseudoartrosis atróficas de huesos largos. Type: Clinical Trial, phase II.

HULP code: Anexo-III 4278. Sponsored's protocol code: STEMQUIR/12ES01.
Sponsored by: Salvat S.A. Signed date: 22/06/2018

Gómez Barrena E. Estudio prospectivo, multicéntrico para evaluar la eficacia y la seguridad de una inyección única de Hialuronato Sódico en pacientes con artrosis de rodilla. Type: Producto Sanitario.

HULP code: 5175. Sponsored's protocol code: TM-SH2%/301.
Sponsored by: Tedec-Meiji Farma, S.A. Signed date: 24/09/2018

Gómez Barrena E. Evaluation of safety, feasibility and preliminary efficacy of MSCS from third party donors in the treatment of patients with osteonecrosis of the femoral head after allogeneic stem cell transplantation. Type: Clinical Trial, phase II.

HULP code: 5016. Sponsored's protocol code: ALOFEM.
Sponsored by: Fundación para la Investigación Biomédica Hospital Universitario La Paz.
Signed date: 19/12/2018

Gómez Candela C. Estudio cínico nutricional en agudo para evaluar el efecto sobre la saciedad de una goma con aroma encapsulado en un colectivo de personas sanas. Type: Producto Alimentario.

HULP code: 5003. Sponsored's protocol code: GOMINOLA.
Sponsored by: Creaciones Aromáticas Industriales S.A. Signed date: 03/04/2018

Gómez Candela C. Estudio clínico nutricional para evaluar el efecto sobre la saciedad y el perfil lipídico del consumo habitual de un preparado de miel rico en fibra y Polifenoles en un colectivo de personas con sobrepeso/obesidad. Type: Producto Alimentario.

HULP code: 5049.
Sponsored by: Primo Mendoza S.L. Signed date: 09/08/2018

Gómez Candela C. Estudio clínico-nutricional cruzado y aleatorizado con 3 brazos de estudio (yogur rico en fibra (dextrina, harina de avena integral y salvado de trigo); yogur rico en proteína (proteína de guisante); yogur control), para evaluar las propiedades saciantes. Type: Producto Alimentario.

HULP code: 5007. Sponsored's protocol code: 5007.
Sponsored by: Go Fruselva. Signed date: 01/06/2018

Gómez Candela C. Estudio de intervención nutricional para evaluar el efecto sobre la saciedad de una conserva de bonito en aceite de oliva enriquecida en fibra o polifenoles de un colectivo de personas sanas con sobrepeso. Type: Producto Alimentario.

HULP code: 5048. Sponsored's protocol code: 5048.
Sponsored by: Friobas Basilio S.L. Signed date: 13/06/2018

Gómez Candela C. Estudio prospectivo, observacional de una alimentación por sonda con alto contenido calórico y proteico, con carbohidratos de liberación lenta y ácidos grasos monoinsaturados (AGMI) en una población malnutrida con diabetes. Type: NO-EPA.


HULP code: PI-3167. Sponsored's protocol code: DA14.
Sponsored by: Abbott Laboratories S.A. Signed date: 05/06/2018

Gómez Candela C. Tolerancia y eficacia de una fórmula de nutrición enteral polimérica hiperproteica/hipercalórica, enriquecida en fibra, aceite de oliva virgen extra y omega 3 en pacientes hospitalizados. Type: Producto Alimentario.

HULP code: 5005. Sponsored's protocol code: 5005.
Sponsored by: Adventia Pharma S.L. Signed date: 20/03/2018

Gómez Prieto P. A phase IB/II trial of combined SGN-35 (Brentuximabvedotin) therapy with Cyclophosphamide, Procarbazine, Prednisone, Etoposide and Mitoxantrone (BREP/EM) for older patients with untreated Hodgkin lymphoma (HL). Type: Clinical Trial, phase I.

HULP code: 5009. Sponsored's protocol code: BrEPEM-LH-22017.
Sponsored by: Gel-Tamo. Signed date: 01/06/2018





2.6 Clinical Trials

Gómez Senent S. Estudio postcomercialización observacional de cohortes en pacientes con enfermedad inflamatoria intestinal (EII) tratados con Inflectra (Infliximab) en la práctica clínica habitual (Connect-IBD). Type: EPA-SP.

HULP code: Anexo-I PI-2082. Sponsored's protocol code: ZOB INF I402.

Sponsored by: Hospira Productos Farmacéuticos Y Hospitalarios S.L. Signed date: 16/07/2018

Gómez Traseira C. Efecto de la intervención 'Escalera de la leche' en el desarrollo de tolerancia y en el reconocimiento de epítomos de células B en niños alérgicos a proteínas de leche de vaca. Type: Producto Alimentario.

HULP code: PI-3274. Sponsored's protocol code: PI-3274.

Sponsored by: Fundación para la Investigación Biomédica del Hospital Clínico San Carlos. Signed date: 21/06/2018

González García JJ. Ensayo clínico abierto, aleatorizado y multicéntrico para comparar la eficacia, seguridad y tolerabilidad de una pauta de tratamiento TAF/FTC/DRV/COBI cs. ABC/3TC/DTG en pacientes infectados por el VIH-I naïve de tratamiento antirretroviral. Type: Clinical Trial, phase IV.

HULP code: 5184. Sponsored's protocol code: SYMTRI.

Sponsored by: Asociación RIS (Red de Investigación en SIDA). Signed date: 27/12/2018

González García JJ. Estudio adaptativo, aleatorizado, doble ciego (abierto para el promotor), controlado con placebo para investigar el efecto antiviral, la seguridad, la tolerabilidad y la farmacocinética de GSK3640254 en adultos con infección por VIH-I sin tratamiento previo. Type: Clinical Trial, phase II.

HULP code: 5200. Sponsored's protocol code: 208132.

Sponsored by: Laboratorios ViiV Healthcare S.L. Signed date: 30/11/2018

González Martínez B. Estudio intergrupo para niños o adolescentes con linfoma no-Hodkin B o leucemia linfoblástica de células B; evaluación de eficacia y seguridad de Rituximab en pacientes de alto riesgo. Type: Clinical Trial, phase II.

HULP code: Anexo-II 3546. Sponsored's protocol code: IGR2009/1593.

Sponsored by: Sociedad Española de Oncología y Hematología Pediátricas. Signed date: 20/11/2018

González Pérez de Villar N. Registro nacional de pacientes con diabetes tipo I. Type: EPA-OD.

HULP code: PI-2912. Sponsored's protocol code: SED I.

Sponsored by: Sociedad Española de Diabetes (SED). Signed date: 07/06/2018

Gracia Rio FJ. Caracterización de la variable minutos diarios de marcha como una medida útil de actividad física en pacientes con EPOC. Type: NO-EPA.

HULP code: Anexo-I PI-3342. Sponsored's protocol code: FUC-EPO-2018-01.

Sponsored by: Coordinadora Catalana de Fundacions. Signed date: 26/11/2018

Hardisson Hernández D. Ensayo en fase III, aleatorizado y doble ciego para evaluar la eficacia y la seguridad de una dosis diaria de 10 mg de Empagliflozina en comparación con el placebo en pacientes con insuficiencia cardíaca crónica con fracción de eyección reducida (ICC-FER). Type: NO-EPA.

HULP code: pi-3051. Sponsored's protocol code: SYS-OR2-2017-01.

Sponsored by: Sysmex Europe GMBH. Signed date: 12/04/2018

Hernández Gutiérrez A. Seguridad y beneficios del dispositivo de captura de células tumorales metastásicas en pacientes con cáncer de ovario avanzado. Type: Producto Sanitario.

HULP code: Anexo-I 4723. Sponsored's protocol code: MTRAP-2016-01.

Sponsored by: Mtrap Inc. Signed date: 20/12/2018

Herranz Pinto P. Ensayo aleatorizado, doble ciego, controlado con placebo, de grupos paralelos, multicéntrico, de fase 3 que investiga la eficacia, la seguridad y la tolerabilidad de Tralokinumab administrado en combinación con corticosteroides tópicos a pacientes adultos. Type: Clinical Trial, phase III.

HULP code: 5159. Sponsored's protocol code: LP0162-1346.

Sponsored by: Leo Pharma A/S. Signed date: 05/11/2018

Herranz Pinto P. Ensayo de extensión a largo plazo, multicéntrico, abierto y de un solo brazo, para evaluar la seguridad y eficacia de Tralokinumab en pacientes con dermatitis atópica que participaron previamente en ensayos clínicos con Tralokinumab - Ectend. Type: Clinical Trial, phase III.

HULP code: 5158. Sponsored's protocol code: LP0162-1337.

Sponsored by: Leo Pharma A/S. Signed date: 13/12/2018

Herranz Pinto P. Estudio de fase 3, multicéntrico, aleatorizado, doble ciego y comparado con placebo, para evaluar la eficacia y la seguridad de Baricitinib en pacientes con dermatitis atópica de moderada a grave. Type: Clinical Trial, phase III.

HULP code: Anexo-I 4951. Sponsored's protocol code: I4V-MC-JAHM.

Sponsored by: Lilly S.A. Signed date: 20/06/2018

Herranz Pinto P. Estudio de fase 3, multicéntrico, doble ciego, en el que se evalúan la seguridad y la eficacia a largo plazo de Baricitinib en pacientes adultos con dermatitis atópica. Type: Clinical Trial, phase III.

HULP code: Anexo-I 4958. Sponsored's protocol code: I4V-MC-JAHN.

Sponsored by: Lilly S.A. Signed date: 19/09/2018

Herranz Pinto P. Estudio de fase 3, multicéntrico, doble ciego, en el que se evalúan la seguridad y la eficacia a largo plazo de Baricitinib en pacientes adultos con dermatitis atópica. Type: Clinical Trial, phase III.

HULP code: 4958. Sponsored's protocol code: I4V-MC-JAHN.

Sponsored by: Lilly S.A. Signed date: 09/02/2018

Herranz Pinto P. Estudio de fase 3B, multicéntrico, aleatorizado, en doble ciego, controlado con principio activo de comparación (Secukinumab) y de grupos paralelos, para evaluar la eficacia y la seguridad de Bimekizumab en adultos con psoriasis (PSO) en placas crónica de grado moderado o severo. Type: Clinical Trial, phase III.

HULP code: 5109. Sponsored's protocol code: PS0015.

Sponsored by: UCB Biosciencias GMBH. Signed date: 04/12/2018


Herranz Pinto P. Estudio en fase 3, aleatorizado y abierto que evalúa la eficacia de Axicabtagene Ciloleucel en comparación con el tratamiento estándar en pacientes con linfoma difuso de células B grandes recidivante/resistente (ZUMA-7). Type: Clinical Trial, phase III.

HULP code: 5133. Sponsored's protocol code: KTE-C19-107 (ZUMA-7).





2.6 Clinical Trials



Introduction

1

Executive summary

2

2.1 Global Analysis

2.2 Research Structure

2.3 Training Report and Teaching

2.4 Innovation and Transfer Activities

2.5 Quality Commitment

2.6 Clinical Trials

2.7 Platforms

2.8 Scientific Production

2.9 CIBERs and RETICs

2.10 Institutional Projects

2.11 Internationalization

2.12 Communication

Information Groups by Area

3

Associated Clinicians

4

Scientific Report

2016
2017
2018

Sponsored by: Kite Pharma Inc. Signed date: 02/11/2018

Herranz Pinto P. Estudio en fase III de retirada aleatorizada, doble ciego, controlado con placebo y multicéntrico para investigar la eficacia y la seguridad de PF-04965842 en pacientes de 12 o más años de edad con dermatitis atópica moderada o grave con la opción de un tratamiento de rescate para aquellos pacientes que presenten un empeoramiento de la enfermedad. Type: Clinical Trial, phase III.

HULP code: 5141. Sponsored's protocol code: B7451015.

Sponsored by: Pfizer Inc. Signed date: 03/12/2018

Herranz Pinto P. Estudio en fase III de retirada aleatorizada, doble ciego, controlado con placebo y multicéntrico para investigar la eficacia y la seguridad de PF-04965842 en pacientes de 12 o más años de edad con dermatitis atópica moderada o grave con la opción de un tratamiento de rescate para aquellos pacientes que presenten un empeoramiento de la enfermedad. Type: Clinical Trial, phase III.

HULP code: 5089. Sponsored's protocol code: B7451014.

Sponsored by: Pfizer Inc. Signed date: 20/11/2018

Herranz Pinto P. Estudio multicéntrico, aleatorizado, con doble enmascaramiento y controlado con placebo, para evaluar la eficacia y seguridad de Mirikizumab con Secukinumab y placebo en pacientes con psoriasis en placas moderada a grave - Oasis. Type: Clinical Trial, phase III.

HULP code: 5056. Sponsored's protocol code: I6T-MC-AMAJ.

Sponsored by: Lilly S.A. Signed date: 07/05/2018

Hierro Llanillo L. Ensayo abierto y con un solo grupo para evaluar la farmacocinética, la seguridad y la eficacia de Daclatasvir (DCV) en combinación con Sofosbuvir (SOF) en niños de entre 3 y menos de 18 años con infección por los genotipos del 1 al 6 del virus de la hepatitis crónica (HCC). Type: Clinical Trial, phase II.

HULP code: 5118. Sponsored's protocol code: AI44423.

Sponsored by: Bristol Myers Squibb International Corporation. Signed date: 07/08/2018

Hierro Llanillo L. Estudio abierto de extensión para evaluar la eficacia y la seguridad a largo plazo de A4250 en niños con colestasis intrahepática familiar progresiva de tipo 1 y 2 (PEDFIC 2). Type: Clinical Trial, phase III.

HULP code: 4970. Sponsored's protocol code: A4250-008.

Sponsored by: Albireo AB. Signed date: 01/10/2018

Hierro Llanillo L. Estudio de fase 3 aleatorizado, con doble enmascaramiento, controlado con placebo, para demostrar la eficacia y la seguridad de A4250 en niños con colestasis intrahepática familiar progresiva de tipos 1 y 2 (PEDFIC 1). Type: Clinical Trial, phase III.

HULP code: 4969. Sponsored's protocol code: A4250-005.

Sponsored by: Albireo AB. Signed date: 17/04/2018

Hierro Llanillo L. Estudio de fase 3 aleatorizado, con doble enmascaramiento, controlado con placebo, para demostrar la eficacia y la seguridad de A4250 en niños con colestasis intrahepática familiar progresiva de tipos 1 y 2 (PEDFIC 1). Type: Clinical Trial, phase III.

HULP code: Anexo-I 4969. Sponsored's protocol code: A4250-005.

Sponsored by: Albireo AB. Signed date: 17/09/2018

Higuera Gómez O. Evaluación de la calidad de vida de pacientes con estreñimiento inducido por opioides en tratamiento con Naloxegol. Estudio de un año de seguimiento. Type: EPA-SP.

HULP code: PI-2874. Sponsored's protocol code: KYO-NAL-2017-01.

Sponsored by: Kyowa Kirin Farmacéutica S.L.U. Signed date: 10/01/2018

Higuera Gómez O. Paciente frágil con dolor irruptivo: análisis de la práctica clínica. Type: EPA-OD.

HULP code: PI-3343. Sponsored's protocol code: KYO-FRA-2018-01.

Sponsored by: Kyowa Kirin Farmacéutica S.L.U. Signed date: 22/08/2018

Humala Barbier KK. Estudio de fase III, aleatorizado, doble ciego, multicéntrico y controlado con placebo, de Pracinostat en combinación con Azacitidina en pacientes \geq 18 años con leucemia mieloide aguda (LMA) de diagnóstico reciente no aptos para la quimioterapia de inducción habitual. Type: Clinical Trial, phase III.

HULP code: Anexo-I 4853. Sponsored's protocol code: FRAN-16-52.

Sponsored by: Helsinn Healthcare S.A. Signed date: 17/04/2018

Humala Barbier KK. Estudio en fase 3, multicéntrico, doble ciego, aleatorizado y controlado con placebo para evaluar AG-120 en combinación con Azacitidina en sujetos de 18 años de edad o más con leucemia mieloide aguda con una mutación de IDH1 sin tratamiento previo. Type: Clinical Trial, phase III.

HULP code: 4866. Sponsored's protocol code: AG120-C-009.

Sponsored by: Agios Pharmaceuticals Inc. Signed date: 11/01/2018

Humala Barbier KK. Estudio observacional prospectivo sobre la supervivencia global y la calidad de vida en pacientes mayores de 60 años diagnosticados de leucemia mieloide aguda en España, tratados según la práctica clínica habitual. Estudio SVLMA. Type: EPA-SP.

HULP code: PI-3081. Sponsored's protocol code: CEL-LMA-2017-01.

Sponsored by: Celgene S.L. Signed date: 10/09/2018

Iñiesta Pérez S. Ensayo multicéntrico, aleatorizado, doble ciego, controlado con placebo para investigar la eficacia y seguridad de dos concentraciones de PKB171 frente a placebo en parejas con astenozoospermia que desean concebir. Type: Clinical Trial, phase II.

HULP code: 5092. Sponsored's protocol code: PKB171-02.

Sponsored by: Scope International AG. Signed date: 23/08/2018

Ivñez Mora V. Estudio aleatorizado, doble ciego, controlado con placebo, de búsqueda de dosis para evaluar la eficacia y la seguridad de Padsevoniil como tratamiento adyuvante de crisis focales en sujetos adultos con epilepsia fármacorresistente. Type: Clinical Trial, phase II.

HULP code: 5026. Sponsored's protocol code: EP0091.

Sponsored by: UCB Biosciencias GMBH. Signed date: 26/09/2018

Jiménez Martín C. Evaluación de la consistencia clínica y la solidez analítica de Immunobigram® como herramienta biotecnológica de diagnóstico in vitro para ayudar a la

Introduction

1

Executive summary

2

2.1 Global Analysis

2.2 Research Structure

2.3 Training Report and Teaching

2.4 Innovation and Transfer Activities

2.5 Quality Commitment

2.6 Clinical Trials

2.7 Platforms

2.8 Scientific Production

2.9 CIBERs and RETICs

2.10 Institutional Projects

2.11 Internationalization

2.12 Communication

Information Groups by Area

3

Associated Clinicians

4

Scientific Report

2016
2017
2018



2.6 Clinical Trials



toma de decisiones en el ajuste del tratamiento inmunodepresor del trasplante renal”. Estudio Transbio. Type: NO-EPA.

HULP code: PI-3105. Sponsored's protocol code: BHP-IBG-2017-01.
Sponsored by: Biohope Scientific Solutions For Human Health S.L. Signed date: 13/02/2018

Jiménez Martín C. Impacto de los niveles de Tacrólimus en la prevención del rechazo en pacientes de edad avanzada receptores de trasplante renal de novo: estudio observacional prospectivo en las condiciones de la práctica clínica habitual. Estudio Bitácora. Type: EPA-SP.

HULP code: PI-3314. Sponsored's protocol code: CHI-TAC-2018-01.
Sponsored by: Chiesi Farmaceutici S.P.A. Signed date: 01/10/2018

Jiménez yuste VM. Atlas-A/B: estudio de fase 3 para evaluar la eficacia y la seguridad de Fitusirán en pacientes con hemofilia A o B sin anticuerpos inhibidores de los factores VIII o IX. Type: Clinical Trial, phase III.

HULP code: Anexo-I 4919. Sponsored's protocol code: ALN-AT3SC-004.
Sponsored by: Sanofi-Aventis Recherche & Developpement. Signed date: 19/12/2018

Jiménez Yuste VM. Atlas-A/B: estudio de fase 3 para evaluar la eficacia y la seguridad de Fitusirán en pacientes con hemofilia A o B sin anticuerpos inhibidores de los factores VIII o IX. Type: Clinical Trial, phase III.

HULP code: 4919. Sponsored's protocol code: ALN-AT3SC-004.
Sponsored by: Sanofi-Aventis Recherche & Developpement. Signed date: 19/02/2018

Jiménez Yuste VM. Atlas-INH: estudio en fase 3 para evaluar la eficacia y la seguridad de Fitusirán en pacientes con hemofilia A o B y anticuerpos inhibidores de los factores VIII o IX. Type: Clinical Trial, phase III.

HULP code: Anexo-I 4918. Sponsored's protocol code: ALN-AT3SC-003.
Sponsored by: Sanofi-Aventis Recherche & Developpement. Signed date: 19/12/2018

Jiménez Yuste VM. ATLAS-INH: estudio en fase 3 para evaluar la eficacia y la seguridad de Fitusirán en pacientes con hemofilia A o B y anticuerpos inhibidores de los factores VIII o IX. Type: Clinical Trial, phase III.

HULP code: 4918. Sponsored's protocol code: ALN-AT3SC-003.
Sponsored by: Sanofi-Aventis Recherche & Developpement. Signed date: 19/02/2018

Jiménez Yuste VM. ATLAS-PPX: estudio abierto, internacional, de cambio de tratamiento para evaluar la eficacia y la seguridad de la Profilaxis con Fitusiran en pacientes con hemofilia A y B que recibían previamente Profilaxis con factores o agentes de puenteo. Type: Clinical Trial, phase III.

HULP code: 4900. Sponsored's protocol code: ALN-AT3SC-009/EFC15110.
Sponsored by: Sanofi-Aventis Recherche & Developpement. Signed date: 19/12/2018

Jiménez Yuste VM. Estudio abierto, multicéntrico y no controlado de la eficacia de RFVIIIIFCrfviiiifc para la inducción de tolerancia inmune (ITI) en sujetos con hemofilia a grave con inhibidores que se someten al primer tratamiento de ITI. Type: Clinical Trial, phase IV.

HULP code: Anexo-I 4899. Sponsored's protocol code: 997HA402.
Sponsored by: Bioerativ Therapeutics Inc. Signed date: 31/01/2018

Jiménez Yuste VM. Estudio no intervencionista, prospectivo, en el que se evalúan las hemorragias, las infusiones de factor VIII y los resultados percibidos por el paciente, en personas con hemofilia a grave. Type: EPA-SP.

HULP code: PI-3377. Sponsored's protocol code: 270-902.
Sponsored by: Biomarin Pharmaceutical Inc. Signed date: 24/10/2018

Jiménez Yuste VM. Explorer™5- ensayo multicéntrico para evaluar la eficacia y seguridad de la administración de Concizumab en profilaxis en pacientes con hemofilia a grave sin inhibidores. Type: Clinical Trial, phase II.

HULP code: Anexo-I 4821. Sponsored's protocol code: NN7415-4255.
Sponsored by: Novo Nordisk A/S. Signed date: 04/06/2018

Jiménez Yuste VM. Safety and efficacy of turoctocog Alfa pegol (n8-gp) in prophylaxis and treatment of bleeds in previously N8-GP treated patients with severe haemophilia a ” (Pathfinder 8. Type: Clinical Trial, phase III.

HULP code: 5061. Sponsored's protocol code: NN7088-4410.
Sponsored by: Novo Nordisk A/S. Signed date: 13/06/2018

Lisbona Catalán A. Estudio multicéntrico español sobre la prevalencia e incidencia de la insuficiencia cardiaca en pacientes con diabetes tipo 2 en consultas hospitalarias del ámbito nacional. Type: NO-EPA.

HULP code: PI-3231. Sponsored's protocol code: DIABET-IC.
Sponsored by: Sociedad Española de Cardiología (SEC). Signed date: 30/05/2018

Loeches Yague B. Estudio aleatorizado, multicéntrico, doble ciego, para comparar la eficacia y la seguridad de Ceftobiprol Medocaril con las de la Daptomicina en el tratamiento de la bacteriemia por Staphylococcus Aureus, incluida la endocarditis infecciosa. Type: Clinical Trial, phase III.

HULP code: 5171. Sponsored's protocol code: BPR-CS-009.
Sponsored by: Basilea Farmacéutica Ltd. Signed date: 14/11/2018

López Arrieta JM. Estudio en fase II, multicéntrico, aleatorizado, doble ciego y controlado con placebo, en grupos paralelos, que evalúa la eficacia y seguridad de MTAU9937A en pacientes con enfermedad de Alzheimer de fase prodrómica a leve. Type: Clinical Trial, phase II.

HULP code: 4924. Sponsored's protocol code: GN39763.
Sponsored by: Genentech Inc. Signed date: 18/05/2018

López Arrieta JM. Estudio en fase II, multicéntrico, aleatorizado, doble ciego y controlado con placebo, en grupos paralelos, que evalúa la eficacia y seguridad de MTAU9937a en pacientes con enfermedad de Alzheimer de fase prodrómica a leve. Type: Clinical Trial, phase II.

HULP code: Anexo-I 4924. Sponsored's protocol code: GN39763.
Sponsored by: Genentech Inc. Signed date: 01/08/2018

López Carrasco A. Estudio aleatorizado, controlado con placebo, doble ciego, de grupos paralelos, multicéntrico, de dosis-respuesta para evaluar la eficacia y seguridad de diferentes dosis orales de BAY 1128688 en mujeres con endometriosis sintomática durante un tratamiento. Type: Clinical Trial, phase II.

HULP code: Anexo-I 4904. Sponsored's protocol code: BAY 1128688/17472.

Introduction

1

Executive summary

2

2.1 Global Analysis

2.2 Research Structure

2.3 Training Report and Teaching

2.4 Innovation and Transfer Activities

2.5 Quality Committee

2.6 Clinical Trials

2.7 Platforms

2.8 Scientific Production

2.9 CIBERs and RETICs

2.10 Institutional Projects

2.11 Internationalization

2.12 Communication

Information Groups by Area

3

Associated Clinicians

4

Scientific Report

2016
2017
2018



2.6 Clinical Trials

Sponsored by: Bayer AG. Signed date: 18/09/2018

López Carrasco A. Estudio aleatorizado, doble ciego, de grupos paralelos, multicéntrico y de fase IIB para evaluar la eficacia y seguridad de dos dosis diferentes de Vilaprisán (BAY 1002670) frente a placebo en mujeres con endometriosis sintomática. Type: Clinical Trial, phase II.

HULP code: 5079. Sponsored's protocol code: BAY1002670/15792.

Sponsored by: Bayer AG. Signed date: 25/09/2018

López de La Guía A. Estudio en fase 2, multicéntrico, abierto y de incremento escalonado y ampliación de la dosis de Venetoclax en combinación con Pomalidomida y Dexametasona en pacientes con Mieloma múltiple recidivante o resistente. Type: Clinical Trial, phase II.

HULP code: 5082. Sponsored's protocol code: M16-085.

Sponsored by: Abbvie Deutschland GMBH. Signed date: 24/10/2018

López de La Guía A. Estudio observacional para describir el impacto de las combinaciones de tratamiento con Daratumumab frente a otros tratamientos alternativos en pacientes con mieloma múltiple en recaída /refractario (MMRR). Datos de práctica clínica habitual en España (Géminis). Type: EPA-SP.

HULP code: PI-3315. Sponsored's protocol code: JAN-DAR-2018-01.

Sponsored by: Janssen-Cilag España S.A. Signed date: 14/09/2018

López de Sa Areces E. Ensayo pivotal europeo COOL-AMI: un ensayo multicéntrico, prospectivo, aleatorizado y controlado en el que se evalúan la seguridad y la eficacia del enfriamiento como tratamiento adyuvante en las intervenciones percutáneas de pacientes con infarto agudo. Type: Producto Sanitario.

HULP code: 5113. Sponsored's protocol code: COOL-AMI EU EDC 35.

Sponsored by: Zoll Circulation Inc. Signed date: 05/07/2018

López de Sa Areces E. Estudio clínico unicéntrico de una serie de casos para evaluar la viabilidad de integrar la hipotermia terapéutica con el sistema IVTM de Zoll como adyuvante de la angioplastia coronaria percutánea en pacientes con infarto agudo de miocardio. Type: Producto Sanitario.

HULP code: Anexo-I 4749. Sponsored's protocol code: COOL-AMI.

Sponsored by: Zoll Circulation Inc. Signed date: 19/01/2018

López de Sa Areces E. Estudio de fase IIB, randomizado, controlado con placebo para evaluar la seguridad y la eficacia de MEDI6012 en el infarto de miocardio agudo con elevación del segmento. Type: Clinical Trial, phase II.

HULP code: 5029. Sponsored's protocol code: D5780C00007.

Sponsored by: Medimmune. Signed date: 05/03/2018

López Fernández T. Epiq-affinitit ultrasound system study for cardiology. Type: NO-EPA.

HULP code: PI-2996. Sponsored's protocol code: 253494.

Sponsored by: Philips Ultrasound Inc. Signed date: 04/04/2018

López Oliva MO. Suspensión de la profilaxis con Valganciclovir en trasplantados renales CMV-seropositivo que mantienen la inmunidad celular CD8+ CMV-específica tras recibir Timoglobulina. Type: Clinical Trial, phase III.



HULP code: Anexo-I 4892. Sponsored's protocol code: FCO-TIM-2015-01.

Sponsored by: Fundación Para La Investigación Biomédica de Córdoba (Fibico-Imbic).

Signed date: 22/10/2018

López Ortego P. Ensayo clínico fase I para establecer la seguridad del uso de células mesenquimales alógenicas en pacientes prematuros con displasia broncopulmonar. Type: Clinical Trial, phase I.

HULP code: 4734. Sponsored's protocol code: PULMESCEL-01.

Sponsored by: Fundación Hospital Ramón y Cajal. Signed date: 12/10/2018

López Ortego P. Retrospective cohort safety study of captopril administered for prevention or treatment of heart failure in paediatric patients from birth to 1 year of age. Type: EPA-OD.

HULP code: pi-3351. Sponsored's protocol code: PRO-CAP-2018-01.

Sponsored by: Proveca Ltd. Signed date: 17/10/2018

López-Sendón Hentsche JL. Estudio de fase III fundamental, multicéntrico, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos y determinado por los episodios para evaluar la eficacia y la seguridad de Vericiguat, un estimulador de la guanilato ciclasa soluble (GCS) por vía oral, en sujetos con insuficiencia cardíaca con fracción de eyección disminuida (ICFED): estudio Victoria (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction). Type: Clinical Trial, phase III.

HULP code: Anexo-I 4685. Sponsored's protocol code: I242-001.

Sponsored by: Merck Sharp and Dohme de España S.A. Signed date: 10/09/2018

López-Sendón Hentschel JL. Ensayo de fase III, aleatorizado y doble ciego para evaluar la eficacia y la seguridad de una dosis diaria de 10 mg de Empagliflozina en comparación con placebo en pacientes con insuficiencia cardíaca crónica con fracción de eyección preservada (ICC-FEP). Type: Clinical Trial, phase III.

HULP code: 4988. Sponsored's protocol code: I245.110.

Sponsored by: Boehringer Ingelheim International GMBH. Signed date: 14/03/2018

López-Sendón Hentschel JL. Ensayo en fase III, aleatorizado y doble ciego para evaluar la eficacia y la seguridad de una dosis diaria de 10 mg de Empagliflozina en comparación con el placebo en pacientes con insuficiencia cardíaca crónica con fracción de eyección reducida (ICC-FER). Type: Clinical Trial, phase III.

HULP code: 5001. Sponsored's protocol code: I245.121.

Sponsored by: Boehringer Ingelheim International GMBH. Signed date: 10/04/2018

López-Sendon Hentschel JL. Estudio aleatorizado, doble ciego, controlado con placebo, de grupos paralelos, multicéntrico, para demostrar los efectos de Sotagliflozina sobre los eventos cardiovasculares y renales en pacientes con diabetes tipo 2, factores de riesgo cardiovascular y función renal moderadamente reducida (SCORED). Type: Clinical Trial, phase III.

HULP code: Anexo-I 4943. Sponsored's protocol code: EFC14875.

Sponsored by: Sanofi-Aventis Recherche & Developpement. Signed date: 13/02/2018

López-Sendón Hentschel JL. Estudio de Colchicina en eventos cardiovasculares. Type: Clinical Trial, phase III.

HULP code: 4946. Sponsored's protocol code: COLCOT.



2.6 Clinical Trials



Introduction

1

Executive summary

2

2.1 Global Analysis

2.2 Research Structure

2.3 Training Report and Teaching

2.4 Innovation and Transfer Activities

2.5 Quality Commitment

2.6 Clinical Trials

2.7 Platforms

2.8 Scientific Production

2.9 CIBERs and RETICs

2.10 Institutional Projects

2.11 Internationalization

2.12 Communication

Information Groups by Area

3

Associated Clinicians

4

Scientific Report

2016
2017
2018

Sponsored by: Montreal Heart Institute. Signed date: 25/01/2018

Martín Arranz E. Eficacia de los bolos intravenosos de corticoides más tratamiento con corticoides orales en comparación con corticoides orales en monoterapia para el tratamiento de la colitis. Type: Clinical Trial, phase IV.

HULP code: 5044. Sponsored's protocol code: CECUM.

Sponsored by: Geteccu (Grupo Español de Trabajo En Enfermedad de Crhon y Colitis Ulcerosa). Signed date: 21/03/2018

Martín Arranz MD. Ensayo abierto y a largo plazo de la seguridad del tratamiento con BI 655130 en pacientes con colitis ulcerosa activa moderada o grave que han finalizado ensayos anteriores de BI 655130. Type: Clinical Trial, phase II.

HULP code: 5142. Sponsored's protocol code: BI655130.

Sponsored by: Boehringer Ingelheim España S.A. Signed date: 13/09/2018

Martín Arranz MD. Estudio abierto de extensión y supervisión de la seguridad de pacientes con colitis ulcerosa de moderada a grave previamente inscritos en Estudios de fase III con Etrolizuma. Type: Clinical Trial, phase III.

HULP code: Anexo-II 4274. Sponsored's protocol code: GA28951.

Sponsored by: F. Hoffmann-La Roche Ltd. Signed date: 20/04/2018

Martín Arranz MD. Estudio de ampliación de fase 3, multicéntrico, sin enmascaramiento en el que se evalúa Ozanimod por vía oral para la enfermedad de Crohn activa de moderada a grave. Type: Clinical Trial, phase III.

HULP code: 5025. Sponsored's protocol code: RPC01-3204.

Sponsored by: Celgene International SARL. Signed date: 19/11/2018

Martín Arranz MD. Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia y la seguridad de SHP647 como tratamiento de inducción en sujetos con enfermedad de Crohn de moderada a grave (Carmen CD 306). Type: Clinical Trial, phase III.

HULP code: 5085. Sponsored's protocol code: SHP647-306.

Sponsored by: Shire Human Genetic Therapies Inc. Signed date: 24/05/2018

Martín Arranz MD. Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia y la seguridad de SHP647 como tratamiento de mantenimiento en sujetos con enfermedad de Crohn de moderada a grave (Carmen CD 307). Type: Clinical Trial, phase III.

HULP code: 5086. Sponsored's protocol code: SHP647-307.

Sponsored by: Shire Human Genetic Therapies Inc. Signed date: 24/05/2018

Martín Arranz MD. Estudio de fase 3, de extensión de seguridad a largo plazo de SHP647 en sujetos con colitis ulcerosa de moderada a grave (AIDA). Type: Clinical Trial, phase III.

HULP code: Anexo-I 4965. Sponsored's protocol code: SHP647-304.

Sponsored by: Shire Human Genetic Therapies Inc. Signed date: 25/05/2018

Martín Arranz MD. Estudio de fase 3, multicéntrico, aleatorizado, con enmascaramiento doble y comparativo con placebo, en el que se evalúa Ozanimod por vía oral como tratamiento de mantenimiento para la enfermedad de Crohn activa de moderada a grave. Type: Clinical Trial, phase III.

HULP code: 5024. Sponsored's protocol code: RPC01-3203.

Sponsored by: Celgene International SARL. Signed date: 19/11/2018

Martín Arranz MD. Estudio de fase III multicéntrico, doble ciego y controlado con placebo de la eficacia y seguridad de Etrolizumab durante la inducción y el mantenimiento en pacientes con colitis ulcerosa activa de moderada a grave resistentes o intolerantes a los inhibidores del FNT. Type: Clinical Trial, phase III.

HULP code: Anexo-II 4188. Sponsored's protocol code: GA28950.

Sponsored by: F. Hoffmann-La Roche Ltd. Signed date: 04/06/2018

Martín Arranz MD. Estudio de fase III, aleatorizado, multicéntrico, doble ciego, con doble simulación, para evaluar la eficacia y seguridad de Etrolizumab comparado con Infliximab en pacientes con colitis ulcerosa activa entre moderada e intensa que no han recibido tratamiento previo con inhibidores del FNT. Type: Clinical Trial, phase III.

HULP code: Anexo-II 4273. Sponsored's protocol code: GA29103.

Sponsored by: F. Hoffmann-La Roche Ltd. Signed date: 24/04/2018

Martín Arranz MD. Estudio de inducción en fase III, multicéntrico, aleatorizado, doble ciego, de grupos paralelos, controlado con placebo, para evaluar Mirikizumab en pacientes con colitis ulcerosa moderada o gravemente activa sin respuesta a los tratamientos convencionales. Type: Clinical Trial, phase III.

HULP code: 5099. Sponsored's protocol code: I6T-MC-AMAN.

Sponsored by: Eli Lilly Co Uk Ltd. Signed date: 16/07/2018

Martín Arranz MD. Estudio de inducción multicéntrico, aleatorizado, doble ciego y comparado con placebo para evaluar la eficacia y la seguridad de Padacitinib (ABT-494) en sujetos con enfermedad de Crohn de moderada a grave que han tenido una respuesta insuficiente o intolerancia a un tratamiento convencional pero no han presentado fracaso terapéutico con fármacos biológicos. Type: Clinical Trial, phase III.

HULP code: 4967. Sponsored's protocol code: M14-431.

Sponsored by: Abbott Laboratories S.A. Signed date: 24/07/2018

Martín Arranz MD. Estudio de inducción multicéntrico, aleatorizado, doble ciego y comparado con placebo para evaluar la eficacia y la seguridad de Upadacitinib (ABT-494) en sujetos con enfermedad de Crohn de moderada a grave que han tenido una respuesta insuficiente o intolerancia a un tratamiento convencional pero no han presentado fracaso terapéutico con fármacos biológicos. Type: Clinical Trial, phase III.

HULP code: 4966. Sponsored's protocol code: M14-433.

Sponsored by: Abbvie Spain S.L.U. Signed date: 16/07/2018

Martín Arranz MD. Estudio de inducción N° 1 - fase 3, multicéntrico, aleatorizado, con enmascaramiento, doble y comparativo con placebo, en el que se evalúa Ozanimod por vía oral como tratamiento de inducción para la enfermedad de Crohn activa de moderada a grave. Type: Clinical Trial, phase III.

HULP code: 5022. Sponsored's protocol code: RPC01-3201.

Sponsored by: Celgene International SARL. Signed date: 13/09/2018

Martín Arranz MD. Estudio de mantenimiento en fase III, multicéntrico, aleatorizado, doble ciego, de grupos paralelos, controlado con placebo sobre Mirikizumab en pacientes con colitis ulcerosa activa de moderada a grave. (LUCENT 2). Type: Clinical Trial, phase III.



2.6 Clinical Trials



Introduction 1

Executive summary 2

- 2.1 Global Analysis
- 2.2 Research Structure
- 2.3 Training Report and Teaching
- 2.4 Innovation and Transfer Activities
- 2.5 Quality Committe

2.6 Clinical Trials

- 2.7 Platforms
- 2.8 Scientific Production
- 2.9 CIBERs and RETICs
- 2.10 Institutional Projects
- 2.11 Internationalization
- 2.12 Comunication

Information Groups by Area 3

Associated Clinicians 4

Scientific Report

2016
2017
2018

HULP code: 5100. Sponsored's protocol code: I6T-MC-AMBG.
Sponsored by: Eli Lilly Co Uk Ltd. Signed date: 16/07/2018

Martín Arranz MD. Estudio en fase I abierto, aleatorizado, de grupos paralelos para evaluar la farmacocinética, la eficacia y la seguridad de CT-PI3 subcutáneo y CT-PI3 intravenoso en pacientes con enfermedad activa de Crohn y pacientes con colitis ulcerosa activa. Type: Clinical Trial, phase I.

HULP code: Anexo-I 4901. Sponsored's protocol code: CT-PI3 1.6.
Sponsored by: Celltrion Inc. Signed date: 16/03/2018

Martín Arranz MD. Estudio multicéntrico aleatorizado, doble ciego y controlado con placebo de mantenimiento y de extensión a largo plazo, para evaluar la eficacia y la seguridad de Upadacitinib (ABT-494) en sujetos con enfermedad de Crohn que han finalizado los Estudios MI. Type: Clinical Trial, phase III.

HULP code: 4968. Sponsored's protocol code: M14-430.
Sponsored by: Abbvie Deutschland GMBH. Signed date: 17/08/2018

Martín Arranz MD. Estudio multicéntrico de fase II/III aleatorizado, doble ciego y controlado con placebo, para evaluar la seguridad y la eficacia del tratamiento de inducción con BI 655130 en pacientes con colitis ulcerosa activa de moderada a grave que no han respondido al tratamiento previo con fármacos biológicos. Type: Clinical Trial, phase II.

HULP code: 5011. Sponsored's protocol code: I368.5.
Sponsored by: Boehringer Ingelheim España S.A. Signed date: 01/06/2018

Martín Arranz MD. Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo, prueba de concepto de Ustekinumab en pacientes con lupus eritematoso sistémico activo. Type: Clinical Trial, phase III.

HULP code: Anexo-II 4765. Sponsored's protocol code: CNTO1275CRD3005.
Sponsored by: Janssen Cilag International NV. Signed date: 14/06/2018

Martín Arranz MD. Estudio paralelo de fase IIA multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de PRV-6527 (JNJ-40346527), un inhibidor del receptor del factor I estimulante de colonias, por vía oral, en pacientes con enfermedad de Crohn activa moderada o grave. Type: Clinical Trial, phase II.

HULP code: 5008. Sponsored's protocol code: PRV-6527-CD2A.
Sponsored by: Provention Bio Inc. Signed date: 02/02/2018

Martín Arranz MD. Exploración de la posible interferencia de la microbiotaintestinal en la respuesta clínica al Vedolizumab en pacientes con colitis ulcerosa. Type: EPA-SP.

HULP code: PI-3276. Sponsored's protocol code: FGA-VDE-2016-01.
Sponsored by: Fundació Hospital Vall D'Hebron. Signed date: 19/09/2018

Martín Arranz MD. Registro de exposición a largo plazo prospectivo y observacional de pacientes adultos con colitis ulcerosa registro de exposición a largo plazo prospectivo y observacional de pacientes adultos con colitis ulcerosa moderada a graverosa moderada a grave. Type: Clinical Trial, phase EPA-SP.

HULP code: PI-2741. Sponsored's protocol code: CNTO148UCO4001.
Sponsored by: Mapi Life Sciences Uk Limited. Signed date: 25/04/2018

Martín Arranz MD. Un estudio de búsqueda de dosis en fase II, multicéntrico, aleatorizado, doble ciego, controlado por placebo para evaluar la eficacia y la seguridad de IMU-838 en terapia de inducción y mantenimiento en colitis ulcerosa de moderada a grave (Caldose-I). Type: Clinical Trial, phase II.

HULP code: 5023. Sponsored's protocol code: PS-IMU-838-UC.
Sponsored by: Immunic AG. Signed date: 05/06/2018

Martín Arranz MD. Un estudio de búsqueda de dosis en fase II, multicéntrico, aleatorizado, doble ciego, controlado por placebo para evaluar la eficacia y la seguridad de IMU-838 en terapia de inducción y mantenimiento en colitis ulcerosa de moderada a grave (Caldose-I). Type: Clinical Trial, phase II.

HULP code: Anexo-I 5023. Sponsored's protocol code: PS-IMU-838-UC.
Sponsored by: Immunic AG. Signed date: 17/09/2018

Martín Carbonero L. Combinación de dosis fija de Bictegravir/Emtricitabina/Tenofovir Alafenamida frente a Dolutegravir + Emtricitabina/Fumarato de Disoproxilo de Tenofovir en adultos no tratados anteriormente coingectados por el VIH-I y el virus de la hepatitis B. Type: Clinical Trial, phase III.

HULP code: 5110. Sponsored's protocol code: GS-US-380-4458.
Sponsored by: Gilead Sciences Inc. Signed date: 12/07/2018

Martín Salces M. Estudio en fase III, prospectivo, abierto, internacional y multicéntrico sobre la eficacia y la seguridad de la Profilaxis con RVVF en la enfermedad grave de Von Willebrand. Type: Clinical Trial, phase III.

HULP code: Anexo-I 4884. Sponsored's protocol code: 071102.
Sponsored by: Baxalta Innovations GMGB. Signed date: 10/04/2018

Martínez Marín V. Apixabán para el tratamiento del tromboembolismo venoso en pacientes con cáncer: un estudio prospectivo aleatorizado abierto y ciego para el evaluador - el estudio Caravaggio. Type: Clinical Trial, phase III.

HULP code: 5034. Sponsored's protocol code: FADOI.03.2016.
Sponsored by: Exom Group SRL. Signed date: 22/05/2018

Martínez Marín V. Apixabán para el tratamiento del tromboembolismo venoso en pacientes con cáncer: un estudio prospectivo aleatorizado abierto y ciego para el evaluador . El estudio Caravaggio. Type: Clinical Trial, phase III.

HULP code: Anexo-I 5034. Sponsored's protocol code: FADOI.03.2016.
Sponsored by: Exom Group SRL. Signed date: 26/11/2018

Martínez Marín V. Estudio en fase III, internacional, multicéntrico, abierto y aleatorizado de BLU 285 en comparación con Regorafenib en pacientes con tumor del estroma gastrointestinal (GIST) metastásico o irresecable localmente avanzado. Type: Clinical Trial, phase III.

HULP code: 5054. Sponsored's protocol code: BLU-285-1303.
Sponsored by: Blueprint Medicines Corporation. Signed date: 30/07/2018

Martínez Marín V. Estudio en fase III, internacional, multicéntrico, abierto y aleatorizado de BLU 285 en comparación con Regorafenib en pacientes con tumor del estroma gastrointestinal (GIST) metastásico o irresecable localmente avanzado. Type: Clinical Trial, phase III.



2.6 Clinical Trials



Introduction

1

Executive summary

2

2.1 Global Analysis

2.2 Research Structure

2.3 Training Report and Teaching

2.4 Innovation and Transfer Activities

2.5 Quality Commitment

2.6 Clinical Trials

2.7 Platforms

2.8 Scientific Production

2.9 CIBERs and RETICs

2.10 Institutional Projects

2.11 Internationalization

2.12 Communication

Information Groups by Area

3

Associated Clinicians

4

Scientific Report

2016
2017
2018

HULP code: Anexo-I 5054. Sponsored's protocol code: BLU-285-1303.
Sponsored by: Blueprint Medicines Corporation. Signed date: 04/12/2018

Martínez Marín V. Observational epidemiological study of cancer-associated thrombosis: registry of thrombosis and neoplasia of SEOM./Estudio epidemiológico observacional descriptivo sobre la trombosis asociada al cáncer: registro de trombosis y neoplasias de la SEOM. Type: EPA-SP.

HULP code: PI-3417. Sponsored's protocol code: SEOM-TESEO-2017-01.
Sponsored by: Fundación Seom. Signed date: 07/11/2018

Martínez Méndez JR. Estudio de recogida de datos internacional, observacional y retrospectivo en el que se evalúa la eficacia de las medidas de minimización de riesgos aplicadas en pacientes quemados tratados con Nexobrid. Type: EPA-OD.

HULP code: PI-2885. Sponsored's protocol code: MW2013-06-0.
Sponsored by: Mediwound Ltd. Signed date: 13/02/2018

Martínez Moreno M. Seguimiento clínico posterior a la comercialización en Europa de Synchromed II bajo la plataforma para el registro de vigilancia de producto (PSR) específico para la terapia neurológica - administración de fármaco selectiva. Type: Producto Sanitario.

HULP code: Anexo-I 4947. Sponsored's protocol code: PSR-TDD PMCF.
Sponsored by: Medtronic Bakkeen Research Center B.V. Signed date: 27/06/2018

Martínez Moreno M. Seguimiento clínico posterior a la comercialización en Europa de Synchromed II bajo la plataforma para el registro de vigilancia de producto (PSR) específico para la terapia neurológica - administración de fármaco selectiva. Type: Producto Sanitario.

HULP code: 4947. Sponsored's protocol code: PSR-TDD PMCF.
Sponsored by: Medtronic Bakkeen Research Center B.V. Signed date: 07/03/2018

Maseda Garrido E. Estudio observacional del tratamiento clínico de ITUC, IIAC y NBIH/NBAV atribuibles a infecciones por bacilos gramnegativos resistentes a carbapenemas (EU-CARE). Type: EPA-OD.

HULP code: PI-3150. Sponsored's protocol code: MER-ANT-2017-01.
Sponsored by: Merck Sharp & Dhome Corp. Signed date: 07/05/2018

Maseda Pedrero R. Un primer estudio en humanos, a doble ciego, aleatorio, intraindividual, controlado por placebo, con dosis múltiples de QR-313 evaluando la seguridad, prueba de mecanismo, la eficacia preliminar y la exposición sistémica en sujetos con epidermolísis bullo. Type: Clinical Trial, phase II.

HULP code: 5072. Sponsored's protocol code: PQ-313-002.
Sponsored by: Proqr Therapeutics VII B.V. Signed date: 03/10/2018

Mellado Peña MJ. Estrategia para el mantenimiento de la supresión del VIH en niños con Elvitegravir+ Darunavir/Ritonavir (PENTA 17). Type: Clinical Trial, phase II.

HULP code: Anexo-I 4492. Sponsored's protocol code: PENTA 17-SMILE.
Sponsored by: Fondazione Penta Onlus. Signed date: 18/01/2018

Mellado Peña MJ. Estudio de fase 2B, multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la seguridad, la tolerabilidad, la eficacia y la

inmunogenicidad de una pauta de 2 y 3 dosis de VI60 (Vacuna Contra el Citomegalovirus (CMV) en mujeres sanas seronegativas de 16 a 35 años de edad. Type: Clinical Trial, phase II.

HULP code: 5093. Sponsored's protocol code: VI60-002.
Sponsored by: Merck Sharp & Dhome Corp. Signed date: 28/05/2018

Merino Llorens JL. Estudio eficaz: "eficacia de choque de cardioversión/defibrilación, un estudio aleatorizado que compara la pendiente fija y la anchura de impulso fija en una población general con desfibrilador automático implantable". Type: Producto Sanitario.

HULP code: 5067. Sponsored's protocol code: CRD-914/SJM-CIP-10221.
Sponsored by: Abbott Medical España S.A. Signed date: 18/04/2018

Miguel Mendieta ED. Estudio multicéntrico, observacional no intervencionista, transversal y retrospectivo, para evaluar el control de la actividad de la enfermedad en condiciones de práctica clínica habitual en pacientes con espondilitis anquilosante y artritis psoriásica tratados en consultas de reumatología de España (Estudio Midas). Type: EPA-OD.

HULP code: PI-3434. Sponsored's protocol code: CAIN457FES03.
Sponsored by: Novartis Farmacéutica S.A. Signed date: 23/11/2018

Montes Ramírez ML. Cohorte española de pacientes con infección por VIH mayores de 50 años para el estudio de fragilidad y la función física (HIV-FUNCFRIL). Type: EPA-SP.

HULP code: PI-3056. Sponsored's protocol code: FSG-TAR-2017-01 GESIDA.
Sponsored by: Fundación SEIMC-GESIDA. Signed date: 07/03/2018

Morado Arias M. Estudio en fase 3, aleatorizado, controlado con placebo y doble ciego para evaluar la eficiencia y la seguridad de AG-348 en sujetos adultos con deficiencia de piruvato cinasa (PK) que no reciben transfusiones periódicamente. Type: Clinical Trial, phase III.

HULP code: 5077. Sponsored's protocol code: AG348-C-006.
Sponsored by: Agios Pharmaceuticals Inc. Signed date: 04/09/2018

Morado Arias M. Registro longitudinal internacional de deficiencia de piruvato cinasa o piruvato quinasa. Type: EPA-SP.

HULP code: PI-3316. Sponsored's protocol code: AG348-C008.
Sponsored by: Agios Pharmaceuticals Inc. Signed date: 24/07/2018

Moreno Gómez JR. Edoxabán frente al tratamiento estándar y sus efectos en los resultados clínicos de los pacientes que se han sometido a una implantación de válvula aórtica transcáteter (en fibrilación auricular). Type: Clinical Trial, phase III.


HULP code: Anexo-I 4843. Sponsored's protocol code: DU176B-C-U4001.
Sponsored by: Daiichi Sankyo Inc. Signed date: 18/04/2018

Moreno Gómez JR. Ensayo Clínico aleatorizado para comparar la eficacia del Stent Angiolite frente a un stent farmacológico de segunda generación como Xience en pacientes con indicación de intervención coronaria percutánea. Type: Producto Sanitario.

HULP code: Anexo-I 4517. Sponsored's protocol code: ANGIOLITE.
Sponsored by: Cardiva2 S.L. Signed date: 19/02/2018



2.6 Clinical Trials



Introduction

1

Executive summary

2

2.1 Global Analysis

2.2 Research Structure

2.3 Training Report and Teaching

2.4 Innovation and Transfer Activities

2.5 Quality Commitment

2.6 Clinical Trials

2.7 Platforms

2.8 Scientific Production

2.9 CIBERs and RETICs

2.10 Institutional Projects

2.11 Internationalization

2.12 Communication

Information Groups by Area

3

Associated Clinicians

4

Scientific Report

2016
2017
2018

Moreno Gómez JR. Ensayo pivotal europeo COOL-AMI: un ensayo multicéntrico, prospectivo, aleatorizado y controlado en el que se evalúan la seguridad y la eficacia del enfriamiento como tratamiento adyuvante en las intervenciones percutáneas de pacientes con infarto agudo. Type: Producto Sanitario.

HULP code: 5113. Sponsored's protocol code: COOL-AMI EU EDC 35.
Sponsored by: Zoll Circulation Inc. Signed date: 05/07/2018

Moreno Gómez JR. Estrategias de revascularización percutánea completa utilizando stents liberadores de Sirolimus recubiertos de polímero biodegradable en pacientes con síndrome coronario agudo y enfermedad coronaria multivaso. Type: Producto Sanitario.

HULP code: 5189. Sponsored's protocol code: BIOVASC.
Sponsored by: Erasmus Mc Holding B.V. Signed date: 18/12/2018

Moreno Gómez JR. estudio clínico unicéntrico de una serie de casos para evaluar la viabilidad de integrar la hipotermia terapéutica con el sistema IVTM de Zoll como adyuvante de la angioplastia coronaria percutánea en pacientes con infarto agudo de miocardio. Type: Producto Sanitario.

HULP code: Anexo-I 4749. Sponsored's protocol code: COOL-AMI.
Sponsored by: Zoll Circulation Inc. Signed date: 19/01/2018

Moreno Gómez JR. Estudio con tomografía de coherencia óptica a 9 meses en stent farmacoactivo de polímero abluminal bioestable y sirolimus. Type: Producto Sanitario.

HULP code: 5094. Sponsored's protocol code: IHT-DES-2018-01.
Sponsored by: Iberhospitex S.A. Signed date: 12/11/2018

Moreno Gómez JR. Estudio Onyx One; un estudio aleatorizado y controlado con el Stent Resolute Onyx y tratamiento de doble antiagregación plaquetaria [dapt] de un mes para pacientes con alto riesgo de sangrado. Type: Producto Sanitario.

HULP code: Anexo-I 4961. Sponsored's protocol code: ONYX ONE.
Sponsored by: Medtronic Bakkeen Research Center B.V. Signed date: 03/10/2018

Moreno Gómez JR. Estudio Onyx One; un estudio aleatorizado y controlado con el Stent Resolute Onyx y tratamiento de doble antiagregación plaquetaria [DAPT] de un mes para pacientes con alto riesgo de sangrado. Type: Producto Sanitario.

HULP code: 4961. Sponsored's protocol code: ONYX ONE.
Sponsored by: Medtronic Bakkeen Research Center B.V. Signed date: 05/01/2018

Moreno Gómez JR. Evaluación de la eficacia (ACC) y la seguridad de la endoprótesis recubierta con Biolimus A9TM Biofreedomtm de COCR en un ensayo aleatorizado en pacientes con coronariopatía (ACC con Biofreedomtm). Type: Producto Sanitario.

HULP code: 5042. Sponsored's protocol code: 17-EU-02.
Sponsored by: Biosensors Europe S.A. Signed date: 09/10/2018

Mozo Del Castillo Y. Estudio de fase III, aleatorizado, abierto y multicéntrico de Ruxolitinib frente a la mejor terapia disponible en pacientes con enfermedad de injerto contra huésped aguda y refractaria a corticosteroides en trasplante alogénico de progenitores hematopoyéticos. Type: Clinical Trial, phase III.

HULP code: 5087. Sponsored's protocol code: CINC424C2301.
Sponsored by: Novartis Farmacéutica S.A. Signed date: 28/05/2018

Murias Loza SM. Registro observacional de Abatacept en pacientes con artritis idiopática juvenil. Type: EPA-LA.

HULP code: Anexo-I PI-2079. Sponsored's protocol code: IM101240.
Sponsored by: Bristol Myers Squibb International Corporation. Signed date: 19/12/2018

Núñez López MC. Estudio observacional para evaluar la fragilidad de los sujetos durante los Estudios Zoster-006 y Zoster-022 y la eficacia frente a Hz, la inmunogenicidad y la seguridad de la vacuna HZ/SU según el estado de fragilidad. Type: EPA-OD.

HULP code: PI-3344. Sponsored's protocol code: 204878 ZOSTER-064.
Sponsored by: Glaxosmithkline S.A. Signed date: 24/08/2018

Olveira Martín A. Estudio en fase III, aleatorizado y doble ciego de Nivolumab adyuvante frente a placebo para participantes con carcinoma hepatocelular que presentan un riesgo alto de recaída después de la resección o la ablación hepática con intención curativa. Type: Clinical Trial, phase III.

HULP code: 4989. Sponsored's protocol code: CA209-9DX.
Sponsored by: Bristol Myers Squibb International Corporation. Signed date: 21/03/2018

Olveira Martín A. Estudio multicéntrico de fase III, doble ciego, aleatorizado, a largo plazo y controlado con placebo para evaluar la seguridad y la eficacia del Ácido Obeticoólico en sujetos con esteatohepatitis no alcohólica. Type: Clinical Trial, phase III.

HULP code: 4999. Sponsored's protocol code: 747-304.
Sponsored by: Intercept Pharmaceuticals Inc. Signed date: 24/08/2018

Ortega Floría AB. Ensayo clínico de fase 4, aleatorizado, doble ciego y controlado con comparador activo para estudiar la eficacia, la seguridad y la farmacocinética de Dugammadex (MK-8616) para neutralizar el bloqueo neuromuscular en participantes pediátricos. Type: Clinical Trial, phase IV.

HULP code: 5161. Sponsored's protocol code: MK-8616-089.
Sponsored by: Merck Sharp and Dohme de España S.A. Signed date: 17/10/2018

Pascual Pascual SI. Estudio de continuación, doble ciego, controlado con placebo, aleatorizado, multicéntrico, dividido en dos partes para investigar la seguridad, tolerabilidad, farmacocinética, farmacodinámica y eficacia de RO7034067 en pacientes con atrofia muscular espinal de tipo 2 y 3. Type: Clinical Trial, phase II.

HULP code: 4664. Sponsored's protocol code: BP39055.
Sponsored by: F. Hoffmann-La Roche Ltd. Signed date: 23/03/2018

Pascual Pascual SI. Estudio de extensión del seguimiento internacional, multicéntrico, doble ciego de 9 meses de duración para evaluar la seguridad y tolerabilidad a largo plazo de PXT3003 en pacientes con enfermedad de Charcot-Marie-Tooth de tipo IA. Type: Clinical Trial, phase III.

HULP code: Anexo-II 4768. Sponsored's protocol code: PXT3003-03.
Sponsored by: Pharnext. Signed date: 21/09/2018

Pascual Pascual SI. Estudio de extensión del seguimiento internacional, multicéntrico, doble ciego de 9 meses de duración para evaluar la seguridad y tolerabilidad a largo plazo de PXT3003 en pacientes con enfermedad de Charcot-Marie-Tooth de tipo IA. Type: Clinical Trial, phase III.

HULP code: Anexo-I 4768. Sponsored's protocol code: PXT3003-03.
Sponsored by: Pharnext. Signed date: 12/04/2018

Introduction

1

Executive summary

2

2.1 Global Analysis

2.2 Research Structure

2.3 Training Report and Teaching

2.4 Innovation and Transfer Activities

2.5 Quality Commitment

2.6 Clinical Trials

2.7 Platforms

2.8 Scientific Production

2.9 CIBERs and RETICs

2.10 Institutional Projects

2.11 Internationalization

2.12 Communication

Information Groups by Area

3

Associated Clinicians

4

Scientific Report

2016
2017
2018



2.6 Clinical Trials



Pascual Pascual SI. Tratamiento de extensión a largo plazo y sin enmascaramiento usando fosfato sódico de dexametasona intraeritrocitaria en pacientes con ataxia telangiectasia que participaron en el estudio IEDAT-02-2015. Type: Clinical Trial, phase III.

HULP code: 5062. Sponsored's protocol code: IEDAT-03-2018.
Sponsored by: Erydel S.P.A. Signed date: 08/06/2018

Paz Solís JF. PRO(Precision Retrospective Outcomes) study A7005. Type: EPA-SP.

HULP code: PI-3250. Sponsored's protocol code: A7005.
Sponsored by: Boston Scientific Corporation. Signed date: 27/07/2018

Peces Serrano R. Estudio posautorización de seguridad multicéntrico y no intervencionista de 6 años de duración realizado en pacientes a los que se ha recetado Jinarc® debido a poliquistosis renal autosómica dominante. Type: EPA-LA.

HULP code: PI-2881. Sponsored's protocol code: 156-12-299.
Sponsored by: Otsuka Pharmaceutical Development & Commercialization Inc.
Signed date: 09/02/2018

Peinado Peinado R. Appraise ATP: evaluación de pacientes en prevención primaria previa implantación de un DCI – evaluación sistemática de la electroestimulación anti-taquicárdica. Type: Producto Sanitario.

HULP code: PI-3142. Sponsored's protocol code: C1924.
Sponsored by: Boston Scientific Corporation. Signed date: 10/05/2018

Peinado Peinado R. Estudio eficaz: Eficacia de choque de cardioversión/desfibrilación, un estudio aleatorizado que compara la pendiente fija y la anchura de impulso fija en una población general con desfibrilador automático implantable. Type: Clinical Trial, phase Producto Sanitario.

HULP code: 5067. Sponsored's protocol code: CRD-914/SJM-CIP-10221.
Sponsored by: Abbott Medical España S.A. Signed date: 18/04/2018

Pérez Martínez A. Ensayo en fase IB para evaluar Idelalisib en niños y adolescentes con linfoma difuso de células B grandes o linfoma mediastínico de células B recidivante o resistente en combinación con rice. Type: Clinical Trial, phase I.

HULP code: 4962. Sponsored's protocol code: GS-US-313-1090.
Sponsored by: Gilead Sciences Inc. Signed date: 12/07/2018

Pérez Martínez A. Estudio aleatorizado, abierto, de seguridad y eficacia de Ibrutinib en pacientes pediátricos y adultos jóvenes con linfoma no Hodgkin de células maduras B en recaída o refractario. Type: Clinical Trial, phase III.

HULP code: Anexo-I 4644. Sponsored's protocol code: 54179060LYM3003.
Sponsored by: Janssen Cilag International NV. Signed date: 30/11/2018

Pérez Martínez A. Estudio de fase 2B, abierto y de un solo grupo para evaluar la farmacocinética, la eficacia, la seguridad y la tolerabilidad de Letemovir en participantes pediátricos desde el nacimiento hasta menos de 18 años con riesgo de sufrir infección y/o enfermedad por CMV después de un trasplante alogénico de células madre hematopoyéticas (TCMH). Type: Clinical Trial, phase II.

HULP code: 5199. Sponsored's protocol code: MK-8228-030.
Sponsored by: Merck Sharp & Dhome Corp. Signed date: 11/12/2018

Pérez Martínez A. Estudio multicéntrico de fase I/2, de aumento escalonado de la dosis, para evaluar la seguridad, la farmacocinética, la farmacodinámica y la eficacia de Quizartinib, en combinación con quimioterapia de reinducción y como tratamiento de mantenimiento con un solo agente. En pacientes pediátricos con MLA refractaria o en recaída de entre 1 mes y 18 años (y adultos jóvenes de hasta 21 años) con mutaciones de FLT3-ITD. Type: Clinical Trial, phase I.

HULP code: 5045. Sponsored's protocol code: AC220-A-U202.
Sponsored by: Daiichi Sankyo Inc. Signed date: 05/09/2018

Pérez Valero I. Ensayo clínico fase IV abierto, aleatorizado diseñado para evaluar la reversibilidad de la neurotoxicidad asociada al uso de Abacavir/ Lamivudina /Dolutegravir en el sistema nervioso central tras el cambio a una pauta de tratamiento anti-retroviral basada en Alafenamida/Emtricitabina/Darunavir/Cobicistat. Estudio Detox. Type: Clinical Trial, phase IV.

HULP code: 5135. Sponsored's protocol code: GESIDA 10418.
Sponsored by: Fundación SEIMC-GESIDA. Signed date: 05/11/2018

Pinto Marín A. Análisis retrospectivo de factores clínicos asociados a un mayor beneficio con Axitinib en cáncer renal metastásico. Estudio Axilong. Type: EPA-OD.

HULP code: PI-2983. Sponsored's protocol code: PI-2983 EPA-OD.
Sponsored by: Pfizer S.L.U. Signed date: 30/01/2018

Pinto Marín A. Estudio de fase II para la evaluación del tratamiento neoadyuvante con Cabozantinib previo a la nefrectomía citorreductora en pacientes con cáncer de células renales localmente avanzado o metastásico. Type: Clinical Trial, phase II.

HULP code: 5136. Sponsored's protocol code: CABOPRE.
Sponsored by: Fundación Oncosur. Signed date: 01/10/2018

Pinto Marín A. Estudio de fase II, multicéntrico, aleatorizado y abierto para evaluar la seguridad y la eficacia de Avelumab con Gemcitabina/Carboplatino frente a quimioterapia con Gemcitabina/Carboplatino sola, en pacientes con carcinoma urotelial no resecable o metastásico que no hayan recibido terapia sistémica previa y que no sean aptos para la quimioterapia con cisplatino. Type: Clinical Trial, phase II.

HULP code: 4960. Sponsored's protocol code: MS100070-0160.
Sponsored by: Associació Catalana per a la Reserca Oncològica i les Seves Inpplicacions Sanitàries i Socials. Signed date: 12/03/2018


Pinto Marín A. Estudio en fase III sobre Erdafitinib en comparación con Vinflunina, Docetaxel o Pembrolizumab en sujetos con carcinoma urotelial avanzado y anomalías genéticas seleccionadas en FGFR. Type: Clinical Trial, phase III.

HULP code: 4986. Sponsored's protocol code: 42756493BLC3001.
Sponsored by: Janssen Cilag International NV. Signed date: 13/02/2018

Pinto Marín A. Estudio fase II, internacional, multicéntrico, prospectivo para evaluar la eficacia, la seguridad y la calidad de vida de Pazopanib administrado diariamente por vía oral, en pacientes con carcinoma de células renales avanzado y/o metastásico después de terapia previa con tratamiento con agentes inhibidores del control de la inmunidad (Checkpoint Inhibitors). Type: Clinical Trial, phase II.



2.6 Clinical Trials



Introduction

1

Executive summary

2

2.1 Global Analysis

2.2 Research Structure

2.3 Training Report and Teaching

2.4 Innovation and Transfer Activities

2.5 Quality Commitment

2.6 Clinical Trials

2.7 Platforms

2.8 Scientific Production

2.9 CIBERs and RETICs

2.10 Institutional Projects

2.11 Internationalization

2.12 Communication

Information Groups by Area

3

Associated Clinicians

4

Scientific Report

2016
2017
2018

HULP code: Anexo-I 4877. Sponsored's protocol code: CPZP034A2410.
Sponsored by: Novartis Farmacéutica S.A. Signed date: 25/07/2018

Pinto Marín A. The dutreneo trial: a prospective study to individualize the approach with Durvalumab (MED14736) and Tremelimumab in neoadjuvant bladder cancer patients. Type: Clinical Trial, phase II.

HULP code: 5201. Sponsored's protocol code: DUTRENEO.
Sponsored by: Fundación CRIS contra el Cáncer. Signed date: 06/11/2018

Pinto Marín A. Tratamiento adyuvante del cáncer renal con Axitinib: estudio en fase III, aleatorizado y doble ciego del tratamiento adyuvante con Axitinib frente al placebo en sujetos con alto riesgo de CCR recurrente. Type: Clinical Trial, phase III.

HULP code: Anexo-II 4046. Sponsored's protocol code: AP311736.
Sponsored by: SFJ Pharma Ltd. LI. Signed date: 06/04/2018

Pinto Marín A. Un ensayo multicéntrico, abierto, fase IB/2 de Lenvatinib (E7080) más Pembrolizumab en sujetos con tumores sólidos seleccionados. Type: Clinical Trial, phase I.

HULP code: Anexo-I 5046. Sponsored's protocol code: E7080-A001-111.
Sponsored by: EISAI Europe Limited. Signed date: 24/09/2018

Pinto Marín A. Un ensayo multicéntrico, abierto, fase IB/2 de Lenvatinib (E7080) más Pembrolizumab en sujetos con tumores sólidos seleccionados. Type: Clinical Trial, phase I.

HULP code: 5046. Sponsored's protocol code: E7080-A001-111.
Sponsored by: EISAI Europe Limited. Signed date: 30/04/2018

Plaza López de Sabando D. Paediatric hepatic international tumour trial. Type: Clinical Trial, phase III.

HULP code: 5052. Sponsored's protocol code: PHITT.
Sponsored by: University of Birmingham. Signed date: 05/11/2018

Prados Sánchez C. Estudio abierto en fase III para evaluar la seguridad a largo plazo y la eficacia de la Politerapia con VX-659 en pacientes con fibrosis quística, homocigotos o heterocigotos para la mutación F508DEL. Type: Clinical Trial, phase III.

HULP code: 5047. Sponsored's protocol code: VX17-569-105.
Sponsored by: Vertex Pharmaceuticals Incorporated. Signed date: 18/07/2018

Prados Sánchez C. Estudio en fase III, aleatorizado, doble ciego y controlado para evaluar la eficacia y la seguridad de la politerapia con VX-659 en pacientes con fibrosis quística, heterocigotos para la mutación F508DEL y una mutación de la función mínima (F/MF). Type: Clinical Trial, phase III.

HULP code: 5036. Sponsored's protocol code: VX17-569-102.
Sponsored by: Vertex Pharmaceuticals Incorporated. Signed date: 14/06/2018

Prieto Nieto MI. Ensayo clínico multicéntrico, randomizado, para evaluar la eficacia y seguridad de la quimioterapia intraperitoneal hipertérmica (HIPEC) con Mitomicina C asociada a cirugía en el tratamiento del carcinoma colorrectal localmente avanzado. Type: Clinical Trial, phase III.

HULP code: 5055. Sponsored's protocol code: FCO-HIP-2015-01.
Sponsored by: Fundación para la Investigación Biomédica de Córdoba (FIBICO-IMIBIC). Signed date: 27/07/2018

Quesadas Simón A. Revisión observacional en serie de historias clínicas del uso de Repatha® en sujetos europeos con hiperlipidemia. Type: EPA-SP.

HULP code: Anexo-I PI-2828. Sponsored's protocol code: AMG-EVO-2016-01.
Sponsored by: Amgen S.A. Signed date: 29/05/2018

Quirce Gancedo SE. Registro de pacientes con asma grave no controlada (Gema-Data). Type: EPA-SP.

HULP code: PI-3232. Sponsored's protocol code: VPM-SAL-2017-01.
Sponsored by: Fundación Española del Pulmón. SEPAR. Signed date: 18/05/2018

Ramos Boluda ME. Registro multicéntrico prospectivo para pacientes con síndrome del intestino corto. Type: EPA-LA.

HULP code: PI-3299. Sponsored's protocol code: TED-R13-002.
Sponsored by: Shire International GMBH. Signed date: 29/10/2018

Ramos Ramos JC. Estudio clínico multicéntrico, aleatorizado y abierto de S-649266 o mejor tratamiento disponible para infecciones graves provocadas por patógenos Gram negativos resistentes a carbapenemos. Type: Clinical Trial, phase IV.

HULP code: Anexo-I 4640. Sponsored's protocol code: 1424R2131.
Sponsored by: Shinogi Ltd. Signed date: 16/05/2018

Ramos Ramos JC. Estudio en fase II, multicéntrico, aleatorizado, doble ciego, para evaluar la seguridad, tolerabilidad y eficacia de CD101 inyectable frente a Caspofungina intravenosa seguido de desescalado a Fluconazol oral, en el tratamiento de pacientes con candidemia. Type: Clinical Trial, phase II.

HULP code: Anexo-II 4715. Sponsored's protocol code: CD101.IV.2.03.
Sponsored by: Cidara Therapeutics Inc. Signed date: 02/02/2018

Redondo Sánchez A. Opinión - Estudio en fase IIIB, abierto, de grupo único y multicéntrico de la monoterapia de mantenimiento con Olaparib en pacientes con cáncer de ovario recidivante sin mutación de BRCA en línea germinal y sensible al platino que están en respuesta parcial o completa tras la quimioterapia con platino. Type: Clinical Trial, phase IIIB.

HULP code: 5101. Sponsored's protocol code: D0816C00020.
Sponsored by: Astrazeneca AB. Signed date: 15/06/2018

Redondo Sánchez A. Ensayo clínico fase II abierto de Enzalutamida en cáncer de la granulosa ovárica avanzado no resecable o metastásico. Estudio Greko III. Type: Clinical Trial, phase II.

HULP code: 4941. Sponsored's protocol code: GETHI 2016-01.
Sponsored by: Grupo Español de Tumores Huérfanos e Infrecuentes. Signed date: 21/02/2018

Redondo Sánchez A. Ensayo de fase I/II, abierto, con varios grupos, para investigar la seguridad, la tolerabilidad, la farmacocinética y la actividad biológica y clínica de AGEN1884 en combinación con AGEN2034 en sujetos con tumores sólidos metastásicos o localmente avanzados. Type: Clinical Trial, phase I.

HULP code: 5060. Sponsored's protocol code: C-550-0.
Sponsored by: Agenus Inc. Signed date: 12/12/2018

Redondo Sánchez A. Ensayo fase II de Olaparib de mantenimiento tras la respuesta a

Introduction

1

Executive summary

2

2.1 Global Analysis

2.2 Research Structure

2.3 Training Report and Teaching

2.4 Innovation and Transfer Activities

2.5 Quality Commitment

2.6 Clinical Trials

2.7 Platforms

2.8 Scientific Production

2.9 CIBERs and RETICs

2.10 Institutional Projects

2.11 Internationalization

2.12 Communication

Information Groups by Area

3

Associated Clinicians

4

Scientific Report

2016
2017
2018



2.6 Clinical Trials



Tabectedina y Doxorubicina Liposomal pegilada en cáncer de ovario recurrente. Type: Clinical Trial, phase II.

HULP code: 5037. Sponsored's protocol code: OLATRA.

Sponsored by: Grupo Español de Investigación Cáncer de Ovario (GEICO).

Signed date: 17/05/2018

Redondo Sánchez A. Ensayo fase III, aleatorizado y doble ciego de quimioterapia basada en platino con o sin Atezolizumab, seguida de mantenimiento con Niraparib con o sin Atezolizumab, en pacientes con cáncer de ovario, de trompa de falopio o peritoneal recidivante e intervalo libre de tratamiento con platino (ILP) >6 meses. Type: Clinical Trial, phase III.

HULP code: 5112. Sponsored's protocol code: ENGOT-OV41/GEICO69-O.

Sponsored by: Grupo Español de Investigación Cáncer de Ovario (GEICO).

Signed date: 13/09/2018

Redondo Sánchez A. Ensayo internacional, multicéntrico y con grupo único de Tisotumab Vedotina (Humax®-TF-ADC) en cáncer de cuello de útero tratado con anterioridad, recurrente o metastásico. Type: Clinical Trial, phase II.

HULP code: 5015. Sponsored's protocol code: GCT1015-04.

Sponsored by: Genmad A/S. Signed date: 22/08/2018

Redondo Sánchez A. Estudio aleatorizado fase III de quimioterapia con Platino y Paclitaxel más Bevacizumab y Atezolizumab frente a quimioterapia con Platino y Paclitaxel más Bevacizumab en el carcinoma de cérvix metastásico (estadio IVB), persistente o recurrente. Type: Clinical Trial, phase III.

HULP code: 5088. Sponsored's protocol code: ENGOT-CX10/GEICO68 C/BEAT.

Sponsored by: Grupo Español de Investigación Cáncer de Ovario (GEICO).

Signed date: 20/07/2018

Redondo Sánchez A. Estudio de combinación en fase IB de Rucaparib (CO-338) y Atezolizumab (MPDL3280A) en pacientes con cánceres avanzados del aparato reproductor femenino y cáncer de mama triple negativo. Type: Clinical Trial, phase I.

HULP code: 4959. Sponsored's protocol code: WO39409.

Sponsored by: F. Hoffmann-La Roche Ltd. Signed date: 01/03/2018

Redondo Sánchez A. Estudio de fase 2 de Prexasertib en cáncer de ovario resistente o recurrente refractario a derivados del platino. Type: Clinical Trial, phase II.

HULP code: Anexo-I 4982. Sponsored's protocol code: I4D-MC-JTJN.

Sponsored by: Lilly S.A. Signed date: 22/08/2018

Redondo Sánchez A. Estudio de fase 2 de Prexasertib en cáncer de ovario resistente o recurrente refractario a derivados del platino. Type: Clinical Trial, phase II.

HULP code: 4982. Sponsored's protocol code: I4D-MC-JTJN.

Sponsored by: Lilly S.A. Signed date: 13/03/2018

Redondo Sánchez A. Estudio en fase III aleatorizado sobre Trabectedina (ET 743) frente a la quimioterapia elegida por el clínico en pacientes con cáncer ovárico, peritoneal primario o tubárico con fenotipo de mutación en BRCA o BRCANESS. Type: Clinical Trial, phase III.

HULP code: 4940. Sponsored's protocol code: MITO-23.

Sponsored by: Grupo Español de Investigación Cáncer de Ovario (GEICO).

Signed date: 16/02/2018

Redondo Sánchez A. Estudio fase 2 aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y la seguridad de Farletuzumab (MORAB-003) en combinación con carboplatino más Paclitaxel o Doxorubicina Liposómica Pegilada (PLD) en pacientes con cáncer de ovario. Type: Clinical Trial, phase II.

HULP code: Anexo-I 4403. Sponsored's protocol code: MORAB-003-01 I.

Sponsored by: EISAI Europe Limited. Signed date: 20/12/2018

Redondo Sánchez A. Phase I dose escalation and cohort expansion study of TSR-042, an ANTI-PD-1 monoclonal antibody, in patients with advanced solid tumors. Type: Clinical Trial, phase I.

HULP code: Anexo-I 4831. Sponsored's protocol code: 4010-01-001.

Sponsored by: Tesaro Inc. Signed date: 06/02/2018

Redondo Sánchez A. Phase II trial of Pembrolizumab in combination with Doxorubicin in advanced, recurrent or metastatic endometrial cancer: (TOPIC). Type: Clinical Trial, phase II.

HULP code: 4922. Sponsored's protocol code: 2017-002824-26.

Sponsored by: Fundación Hospital Vall D'Hebron. Signed date: 27/04/2018

Redondo Sánchez A. Sarcomas de partes blandas localizados de alto riesgo de extremidades y pared de tronco en adultos: un enfoque integrador que incluye quimioterapia estándar vs Histotipo-dirigida neoadyuvante. Type: Clinical Trial, phase III.

HULP code: Anexo-I 3411. Sponsored's protocol code: ISG-GRUPO ESPAÑOL de INVESTIGACION EN SARCOMAS I0-01.

Sponsored by: Grupo Español de Investigación en Sarcomas. Signed date: 27/04/2018

Remesal Camba A. Eficacia, seguridad y tolerabilidad de Tofacitinib para el tratamiento de la artritis idiopática juvenil (AIJ) de curso poliarticular en sujetos niños y adolescentes. Type: Clinical Trial, phase III.

HULP code: Anexo-I 4932. Sponsored's protocol code: A3921104.

Sponsored by: Pfizer S.L.U. Signed date: 07/05/2018

Remesal Camba A. Estudio abierto, secuencial, de búsqueda de dosis ascendentes y repetidas de Sarilumab administrado con inyección subcutánea (S.C.) a niños y adolescentes con edades comprendidas entre 2 y 17 años con artritis idiopática juvenil de curso poliarticular (AIJP), seguido de una fase de extensión. Type: Clinical Trial, phase III.

HULP code: Anexo-I 4604. Sponsored's protocol code: DRI13925.

Sponsored by: Sanofi-Aventis Recherche & Developpement. Signed date: 24/10/2018


Rey Blas JR. Ensayo clínico aleatorizado, multicéntrico, abierto, controlado, fase III, paralelo, para evaluar la eficacia y seguridad de Ivabradina versus Digoxina en el control crónico de la frecuencia cardíaca en pacientes con fibrilación auricular en tratamiento. Type: Clinical Trial, phase III.

HULP code: 5128. Sponsored's protocol code: BRAKE-AF.

Sponsored by: Adolfo Fontela Cerezuola. Signed date: 22/08/2018



2.6 Clinical Trials



Introduction

1

Executive summary

2

2.1 Global Analysis

2.2 Research Structure

2.3 Training Report and Teaching

2.4 Innovation and Transfer Activities

2.5 Quality Commitment

2.6 Clinical Trials

2.7 Platforms

2.8 Scientific Production

2.9 CIBERs and RETICs

2.10 Institutional Projects

2.11 Internationalization

2.12 Communication

Information Groups by Area

3

Associated Clinicians

4

Scientific Report

2016
2017
2018

Robles Marhuenda AJ. Estudio aleatorizado, doble ciego, controlado por placebo, de 52 semanas de duración para evitar los acontecimientos adversos de especial interés en adultos con lupus eritematoso sistémico activo, con anticuerpos positivos, que toman Belimumab. Type: Clinical Trial, phase IV.

HULP code: Anexo-II 4282. Sponsored's protocol code: HGS1006-C1113.
Sponsored by: Human Genome Sciences Inc. Signed date: 28/09/2018

Rodríguez de Bethancourt Codes F. Características y manejo de los pacientes diagnosticados de síntomas del tracto urinario inferior por hiperplasia benigna de próstata atendidos en España. Type: EPA-OD.

HULP code: PI-3190. Sponsored's protocol code: GSK-HBP-2018-01.
Sponsored by: Glaxosmithkline S.A. Signed date: 17/05/2018

Rodríguez Salas N. A single arm phase I-II multicenter trial with avelumab plus autologous dendritic cell vaccine to determine safety and preliminary efficacy of the combination in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients. Type: Clinical Trial, phase I.

HULP code: 4878. Sponsored's protocol code: GEMCAD 1602.
Sponsored by: Grupo GEMCAD. Signed date: 29/01/2018

Rodríguez Salas N. Determinación del estado mutacional de ras en biopsias líquidas de sujetos con cáncer colorrectal metastásico ras no mutado en primera línea: estudio observacional, prospectivo y multicéntrico en España. Estudio Perseida. Type: EPA-SP.

HULP code: PI-3166. Sponsored's protocol code: AMG-RAS-2015-01.
Sponsored by: Amgen S.A. Signed date: 13/04/2018

Rodríguez Salas N. Estudio abierto, aleatorizado, fase 2 que compara S95005 con Bevacizumab frente a Capecitabina con Bevacizumab en pacientes con cáncer colorrectal metastásico no tratado previamente que no son candidatos a terapia intensiva. Type: Clinical Trial, phase II.

HULP code: Anexo-II 4580. Sponsored's protocol code: CL2-95005-002.
Sponsored by: Laboratorios Servier S.L. Signed date: 23/07/2018

Rodríguez Salas N. Estudio aleatorizado de fase II para evaluar la eficacia de Folfiri + Panitumumab en el tratamiento en segunda línea de pacientes con cáncer colorrectal metastásico ras no mutado que han recibido Folfiri + Panitumumab en primera línea de tratamiento. Type: Clinical Trial, phase II.

HULP code: 4991. Sponsored's protocol code: GEMCAD-17-01 (BEYOND).
Sponsored by: Grupo GEMCAD. Signed date: 07/05/2018

Rodríguez Salas N. Estudio de fase III, aleatorizado, secuencial y abierto, para evaluar la eficacia de Folfiri + Panitumumab seguido por Folfiri + Bevacizumab (secuencia 1) frente a Folfiri + Bevacizumab seguido por Folfiri + Panitumumab (secuencia 2) en pacientes con cáncer colorrectal metastásico no resecable, ras nativo, tumor primario en lado izquierdo, no tratado previamente: CR-SEQUENCE. Type: Clinical Trial, phase III.

HULP code: 5095. Sponsored's protocol code: TTD-18-01.
Sponsored by: Grupo Tratamiento Tumores Digestivos (GERCOR). Signed date: 30/07/2018

Romero Ribate D. Estudio multicéntrico, aleatorizado, controlado con placebo, de grupos paralelos en dos periodos de tratamiento para evaluar la seguridad de

QAW039 añadido al tratamiento existente en pacientes con asma no controlada con los pasos 3, 4 y 5 de la gina. Type: Clinical Trial, phase III.

HULP code: 5210. Sponsored's protocol code: CQAW039A2315.
Sponsored by: Novartis Farmacéutica S.A. Signed date: 11/12/2018

Rubio Suárez JC. Fracturas extracapsulares del tercio proximal de fémur con inestabilidad rotacional. Estudio comparativo de la eficiencia de diferentes sistemas para incrementar la estabilidad. Type: Producto Sanitario.

HULP code: PI-3134. Sponsored's protocol code: ICSCYL-HURH-GAMMAUb.
Sponsored by: Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León.
Signed date: 08/05/2018

Sáenz de Pipaón Marcos M. Estudio aleatorizado, doble ciego y controlado con placebo para evaluar el efecto de un probiótico en niños prematuros. Type: Producto Alimentario.

HULP code: 5098. Sponsored's protocol code: PRE/18.02.
Sponsored by: Probisearch S.L. Signed date: 25/09/2018

Santos Simarro F. Ensayo MO-PED: estudio de fase 2, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de Palovaroteno en sujetos con osteocondromas múltiples. Type: Clinical Trial, phase II.

HULP code: 5154. Sponsored's protocol code: PVO-2A-201.
Sponsored by: Clementia Pharmaceuticals Inc. Signed date: 15/10/2018

Sanz Pérez CM. Estudio observacional prospectivo sobre el uso de dos pautas de estimulación ovárica con Folitropina Alfa (FSH) y Gonadotropina Menopáusica Humana (HMG) en técnicas de reproducción asistida en pacientes con potencial baja respuesta (Estudio Life). Type: EPA-SP.

HULP code: PI-3418. Sponsored's protocol code: LFB-FSH-2018-01.
Sponsored by: de la Fuente Botaine Laura. Signed date: 04/12/2018

Sastre Urgüelles A. Ensayo clínico fase I/2 de un brazo para evaluar la seguridad y la eficacia del Mesilato de Eribulina en combinación con Irinotecán en niños con tumores sólidos refractarios o recurrentes. Type: Clinical Trial, phase I.

HULP code: 5125. Sponsored's protocol code: E7389-G000-213.
Sponsored by: EISAI Europe Limited. Signed date: 02/10/2018

Sastre Urgüelles A. Estudio de fase I/II, multicéntrico, abierto, a un solo brazo, de Ruxolitinib añadido a corticosteroides en pacientes pediátricos con enfermedad aguda de injerto contra huésped de grado II-IV tras trasplante alogénico de células madre hematopoyéticas. Type: Clinical Trial, phase I.

HULP code: 5119. Sponsored's protocol code: 5119 CINC424F12201.
Sponsored by: Novartis Farmacéutica S.A. Signed date: 02/07/2018

Sastre Urgüelles A. Programa de registro europeo de Evoltra®: LLA pediátrica. Type: EPA-LA.

HULP code: Anexo-I 3372. Sponsored's protocol code: CLO-08708.
Sponsored by: Genzyme Europe Bv. Signed date: 19/02/2018

Sendagorta Cudos E. Ensayo clínico fase IV, abierto, de brazo único y multicéntrico sobre la inmunogenicidad de la vacuna nonavalente frente al virus del papiloma huma-

Introduction 1

Executive summary 2

- 2.1 Global Analysis
- 2.2 Research Structure
- 2.3 Training Report and Teaching
- 2.4 Innovation and Transfer Activities
- 2.5 Quality Committe
- 2.6 Clinical Trials
- 2.7 Platforms
- 2.8 Scientific Production
- 2.9 CIBERs and RETICs
- 2.10 Institutional Projects
- 2.11 Internationalization
- 2.12 Comunication

Information Groups by Area 3

Associated Clinicians 4

Scientific Report 2016 2017 2018



2.6 Clinical Trials

no en hombres infectados por el VIH que tienen sexo con hombres. Estudio GESIDA 10017. Type: Clinical Trial, phase IV.

HULP code: 5051. Sponsored's protocol code: GESIDA 10017.
Sponsored by: Fundación SEIMC-GESIDA. Signed date: 01/06/2018

Tallón Barranco A. Estudio de extensión multicéntrico, abierto y de un solo grupo para evaluar la efectividad y la seguridad de Ocrelizumab en pacientes con esclerosis múltiple incluidos previamente en un ensayo clínico de fase IIIB/IV de Ocrelizumab patrocinado por F. HOFF. Type: Clinical Trial, phase IIb.

HULP code: 5050. Sponsored's protocol code: MN39158.
Sponsored by: F. Hoffmann-La Roche Ltd. Signed date: 18/06/2018

Trigo Esteban E. Estudio de fase 2, aleatorizado, multicéntrico, doble-ciego, eficacia y seguridad, para la evaluación de esquemas de dosis orales de Fexinidazol para el tratamiento de pacientes adultos con enfermedad de chagas crónica indeterminada. Type: Clinical Trial, phase II.

HULP code: 5013. Sponsored's protocol code: DNDI-CH-FEX-12.
Sponsored by: Drugs for Neglected Diseases Initiative. Signed date: 11/05/2018

Trigo Esteban E. Estudio de fase 2, aleatorizado, multicéntrico, doble-ciego, eficacia y seguridad, para la evaluación de esquemas de dosis orales de Fexinidazol para el tratamiento de pacientes adultos con enfermedad de chagas crónica indeterminada. Type: Clinical Trial, phase II.

HULP code: Anexo-I 5013. Sponsored's protocol code: DNDI-CH-FEX-12.
Sponsored by: Drugs for Neglected Diseases Initiative. Signed date: 13/11/2018

Valverde Núñez E. Efecto del Alopurinol en pacientes con encefalopatía hipóxico-isquémica tratados con hipotermia- albino- ensayo clínico multicéntrico aleatorizado, ciego, controlado con placebo. Type: Clinical Trial, phase III.

HULP code: 4800. Sponsored's protocol code: ALBINO.
Sponsored by: Instituto Investigación Sanitaria H La Fe. Signed date: 17/01/2018

Villanueva Peña R. Estudio de fase II, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia y la seguridad de 4 dosis orales de BI 425809 una vez al día durante un periodo de tratamiento de 12 semanas en pacientes con esquizofrenia. Type: Clinical Trial, phase II.

HULP code: 5078. Sponsored's protocol code: 1346.9.
Sponsored by: Boehringer Ingelheim España S.A. Signed date: 11/05/2018

Villanueva Peña R. Cohorte de depresión resistente al tratamiento en Europa. Type: EPA-SP.

HULP code: PI-3281. Sponsored's protocol code: 54135419DEP4001.
Sponsored by: Janssen Pharmaceutica NV. Signed date: 04/10/2018

Villanueva Peña R. Estudio de fase II, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia y la seguridad de 4 dosis orales de BI 425809 una vez al día durante un periodo de tratamiento de 12 semanas en pacientes con esquizofrenia. Type: Clinical Trial, phase II.

HULP code: Anexo-I 5078. Sponsored's protocol code: 1346.9.
Sponsored by: Boehringer Ingelheim España S.A. Signed date: 23/10/2018

Vivancos Matellano F. Estudio aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de Safinamida 100 mg una vez al día, como tratamiento complementario, en pacientes con enfermedad de Parkinson idiopática (EPI) con fluctuaciones motoras y dolor crónico relacionado con la enfermedad de Parkinson. Type: Clinical Trial, phase IV.

HULP code: 5150. Sponsored's protocol code: Z7219M01.
Sponsored by: Zambon S.A. Signed date: 25/10/2018

York E. Evaluación del resultado de Hemopatch: registro de observación prospectivo. Type: NO-EPA.

HULP code: Anexo-I PI-3057. Sponsored's protocol code: BXU011443.
Sponsored by: Baxter Healthcare Corporation. Signed date: 24/09/2018

York E. Evaluación del resultado de Hemopatch: registro de observación prospectivo. Type: NO-EPA.

HULP code: PI-3057. Sponsored's protocol code: BXU011443.
Sponsored by: Baxter Healthcare Corporation. Signed date: 11/01/2018

Zamora Auñón P. Estudio aleatorizado, doble ciego, controlado con placebo, de LEE011 en combinación con Letrozol para el tratamiento de mujeres postmenopáusicas con cáncer de mama avanzado con receptor hormonal positivo, HER2-negativo que no han recibido terapia previa para la enfermedad avanzada. Type: Clinical Trial, phase III.

HULP code: Anexo-II 4070. Sponsored's protocol code: CLEE011A2301.
Sponsored by: Novartis Farmacéutica S.A. Signed date: 09/04/2018

Zamora Auñón P. Estudio de fase II randomizado, multicéntrico, abierto para evaluar la eficacia y seguridad de Palbociclib en combinación con Fulvestrant o Letrozol en pacientes con cáncer de mama metastásico HER2 negativo, ER+ (Parsifal 1). Type: Clinical Trial, phase II.


HULP code: Anexo-III 4390. Sponsored's protocol code: MEDOPP067.
Sponsored by: Medica Scientia Innovation Research. Signed date: 12/01/2018

Zamora Auñón P. Estudio de fase II, abierto, aleatorizado y multicéntrico, para evaluar la seguridad y la eficacia de agentes dirigidos frente a los mecanismos de reparación del ADN en combinación con Olaparib, en comparación con Olaparib en monoterapia, en el tratamiento de pacientes con cáncer de mama metastásico triple negativo con estratificación en función de sus alteraciones en los genes recombinantes de reparación homóloga (incluido BRCA 1/2) (Violette). Type: Clinical Trial, phase II.


HULP code: 4954. Sponsored's protocol code: D5336C00001.
Sponsored by: Astrazeneca AB. Signed date: 11/05/2018

Zamora Auñón P. Estudio en fase 3 aleatorizado, abierto, de Abemaciclib en combinación con tratamiento endocrino adyuvante estándar frente a monoterapia con tratamiento endocrino adyuvante estándar, en pacientes con cáncer de mama en estadios iniciales, de alto riesgo, con afectación ganglionar, receptores hormonales positivos, HER2 negativo. Type: Clinical Trial, phase III.

HULP code: 5063. Sponsored's protocol code: 13Y-MC-JPCF.
Sponsored by: Lilly S.A. Signed date: 03/05/2018



2.7 Platforms



2.7.1 Biobank

The Hospital La Paz Institute for Health Research Biobank (IdiPAZ Biobank) is a platform of support service to the Institute's research, product of the integration of different pre-existing nodes with a long and fruitful research trajectory within the University Hospital La Paz. The IdiPAZ Biobank works to obtain, store, manage and distribute large collections of human biological samples of diseases of interest for researchers.



This service is created with the collaboration of the University Hospital La Paz, the Foundation for Biomedical Research of the University Hospital La Paz (FIBHULP) and the Carlos III Health Institute, being integrated into the Network of Hospital Biobanks (RetBioH). The Biobank of the University Hospital La Paz - Institute of Health Research of the University Hospital La Paz - IdiPAZ is registered in the National Biobank Network of the Carlos III Health Institute with the code B.0000684



The IdiPAZ Biobank belongs to the National Biobank Network (RNBB) (<http://www.redbiobancos.es>) to support research in science and technologies of the Strategic Health Action 2018-2020 of the Carlos III Health Institute.

OBJETIVES

The main objective of the IdiPAZ Biobank is to promote biomedical research, which will increase and improve the quality of scientific production in Spain. This is a specialized work in the management of human biological samples and their associated data for biomedical research in accordance with the legislation in force in Spain, Law 14/2007 on Biomedical Research and the Royal Decree of Biobanks 1716/2011. This guarantees the confidentiality of the samples and associated data. The IdiPAZ Biobank provides researchers with an agile channel to access sam-



ples, their products and data associated with quality assurances and ethical-legal adaptation.

The obtaining, and if necessary the revocation, of the patient's informed consent is controlled, giving the same all the required information. Special attention is given to guarantee the protection of privacy and the confidential treatment of personal data contained in the IdiPAZ Biobank, clinical data and research results.

Thanks to this, the development of a continuous dynamic of analysis and evaluation of the needs of the users of the Biobank is favored. In addition, the activity of the IdiPAZ Biobank is made known and valued to society and, especially, in the field of patient and affected associations.

The IdiPAZ Biobank will provide benefits at different levels, starting with donors, patients, society in general and the clinicians and researchers involved. It also aims to facilitate communication and cooperation of different groups with common interests both nationally and internationally.

All of this will result in a higher quality of research and an increase in scientific production, without forgetting the strict compliance with the regulations on Data Protection and the Rights to Privacy and Confidentiality of all patients (Organic Law 3/2018 and Regulation General Data Protection 2016/679).



2.7 Platforms

COMPOSITION

Scientific Director:

Paloma Gómez Campelo (PhD)

Coordinator:

Marina Arranz Álvarez

Senior Experts in Pathology and Cytology:

Sandra NietoTorrero

Contact:

biobanco.hulp@salud.madrid.org

biobanco@idipaz.es

Phone: Biobank Laboratory (+34) 91 207 11 91

Scientific Committee:


David Hardisson Hernández (MD, PhD)

Francisco Arnalich Fernández (MD, PhD)

Inmaculada Ibáñez de Cáceres (PhD)

Enrique Espinosa Arranz (MD, PhD)

Eduardo López Granados (MD, PhD)



EQUIPMENT

- Eight -80°C deep freezers equipped with remote alarm temperature control and a CO₂ backup system. Seven of these are equipped with an open door control software
- One tank of liquid nitrogen at its gas phase with an alarm temperature control and a lack of CO₂ detector
- W-2D tube system with a data matrix codification for liquids, with a scanner to read col boxes and reader for the identification and the traceability of the tubes
- Combined refrigerator of 4° C y - 20° C
- Cryostat to cut frozen samples
- Microtome y bath/coating to cut paraffin samples
- Laser Microdissector
- Biological safety cabins IIA
- Centrifuge with capacity to process samples in tubes and Eppendorfs

- Automatic platform to manipulate and trace liquids
- One mini coolers to freeze inclined biological samples below 1°C
- Two containers to freeze and transport Isopentane
- One container for the transport of isopentane samples
- Vortex Mixer /agitator
- Spectrophotometer (Nanodrop®)
- Fungibility: basically kits and the necessary products to process and preserve tissues, blood, and cells.
- Printer/photocopier/scanner
- 3 computers and a management computer system
- Label printing system and a bar code reader connected to the management software

PORTFOLIO OF SERVICES

Technical and scientific assessment:

- Collection and management of new collection
- Work Methodology/ Methods
- Quality control of DNA/ARN sample treatment
- Expert training to use Biobank management system
- Training and advice on the use of Biobank management software (Bio-e-Bank)
- Information to the investigator on the custody, deposit, availability and transfer of samples associated with the biobank
- Training of trainees (FCTs) of training cycles

Sample/collection management:

- Coordinating a collection of samples in multiple study/research centers
- Storage of pre-existing collections under LIB 14/2007
- Storage of preexisting samples in accordance with Spain's Biobank laws LIB 14/2007 and 1716/2011 Royal Decree
- Management and control of Informed Consent (CI) and/or clinic's regarding samples
- Aliquot of blood/salines/plasma/other liquids
- Sample reception and codification

Histology techniques:

- Making paraffin block
- Making frozen tissue blocks





2.7 Platforms

- Paraffin/frozen cuts
- Hematoxylin and eosin stain (H&E)
- Other kinds of stains
- Laser microdissection

Cell techniques:

- Purifying and freezing of mononuclear cells of peripheral blood (PMBCs)

Molecular Techniques:

- DNA and RNA quantification via spectrophotometer (NANODROP)


Researchers who wish to deposit their collections in IdiPAZ' Biobank will have to sign an agreement of sample deposit (in which the terms and conditions under which the Biobank will deposit the samples) and in agreement with the existing legislation on the subject.

2.7.2 UCICEC

La Paz Central Research and Clinical Trials Unit (Unidad Central de Investigación Clínica y Ensayos Clínicos de La Paz, HULP-UCICEC), is one of the IdiPAZ supported research platforms. Its purpose is to promote and support clinical research at La Paz University Hospital and to establish collaboration links with other investigation centres. Presently HULP-UCICEC is integrated in the Spanish Clinical Research Network (SCReN).

Its wide portfolio of services provides support to researchers in design, set-up (including IRBs and Competent Authority approvals), management, data analysis and report writing of clinical trials and research projects. As Trials Managers, assists the Principal Investigators in the preparation of feasibility and financial reports, administrative tasks (i.e., investigators coordination, schedule of visits), as well as projects development and research, particularly in the recruitment and follow-up of patients and data collection, assistance in audit, inspections and adverse drug reactions management according to regulatory procedures, among other tasks. We also perform nursing activities and laboratory management, obtaining, processing and shipping the samples to central laboratories. All operations are GCP compliant as needed.

HULP-UCICEC also runs a Phase I-II Trial Unit; the facilities and equipment allows harbour early phase clinical trials both in healthy volunteers and patients (children and adults).



On the other hand researchers who wish to use our samples will have to sign a Transfer Agreement (Material Transfer Agreement) in which the terms and conditions under which the Biobank will grant the samples.

BIOBANK'S SCIENTIFIC INDICATORS

In the year 2019, Biobank IdiPAZ has worked on 64 research projects funded by Spanish State aid, private foundations, industrial companies or cooperatives. The principal researchers of these projects belonged to IdiPAZ research groups and to external, national and international groups. Of these projects and together with the central node of the biobank, a total of 2,969 new samples have been stored, generating more than 11,549 aliquots so far this year.

During the same period, the Biobank has opened several projects, so it has been dedicated to the recruitment of samples. In addition, 20 sample requests were processed and about 1,000 samples were allocated while maintaining the demand for samples.

COMPOSITION

Head

Jesús Frías Iniesta (MD, PhD)
jesus.frias@salud.madrid.org

UCICEC Manager

Alberto M. Borobia Pérez (MD, PhD)
alberto.borobia@salud.madrid.org
Phone: (+34) 912 071 466

Scientific Coordinator

Antonio J. Carcas Sansuán (MD, PhD)
antonio.carcas@salud.madrid.org

Safety and Pharmacovigilance Coordinators

Antonio J. Carcas Sansuán (MD, PhD)
antonio.carcas@salud.madrid.org
Elena Ramírez García (MD, PhD)
elena.ramirez@salud.madrid.org

Responsible for Pharmacovigilance

Irene García García (MD)
igarciagarcia@salud.madrid.org

Introduction 1

Executive summary 2

- 2.1 Global Analysis
- 2.2 Research Structure
- 2.3 Training Report and Teaching
- 2.4 Innovation and Transfer Activities
- 2.5 Quality Committee
- 2.6 Clinical Trials
- 2.7 Platforms
- 2.8 Scientific Production
- 2.9 CIBERs and RETICs
- 2.10 Institutional Projects
- 2.11 Internationalization
- 2.12 Communication

Information Groups by Area 3

Associated Clinicians 4

Scientific Report 2016 2017 2018



2.7 Platforms

Project Manager / Senior CRA

Paloma Moraga Alapont (MSc)
paloma.moraga@salud.madrid.org
Victoria Hernandez Rubio (MSc)
vherandezr@salud.madrid.org

Project Manager Paediatrics Oncology Trials

Mario Muñoz Builes (MD)
mmunoz.amm@gmail.com

Junior Project Manager Paediatrics Oncology Trials

Paula Valle Simon (MD)
paula.valle.simon@idipaz.es

Senior Clinical Research Associate

Paloma Moraga Alapont (MSc)
paloma.moraga@salud.madrid.org
Victoria Hernandez Rubio (MSc)
vherandezr@salud.madrid.org

Junior Clinical Research Associate

Nuria Álvarez Ortego
nuria.alvarez.ortego@idipaz.es

Bioinformatic

Jose Carlos Martínez Ávila (PhD)
josecarlos.martinez.avila@idipaz.es

Clinical Trials Nurses

Vega Mauleón Martínez
vega.mauleon@idipaz.es
Raquel de Madariaga Castell
raquel.madariaga@idipaz.es
Laura Vitón Vara (MSc)
laura.viton@idipaz.es
Beatriz Segura Díaz
beatriz.segura@salud.madrid.org

Nursing supervisor

Patricia Luna Castaño
patricia.luna@salud.madrid.org

Receptionist /Clinical Trials Assistant

Cristina Miragall Roig
cristina.miragall@salud.madrid.org
Phone: (+34) 912 071 466

FACILITIES

- 3 Work offices (9 work stations)
- 1 Meeting room (with audiovisual and teleconference systems)
- 1 Archive room
- Phase I/II Clinical Trial Unit:





2.7 Platforms

- A hospital ward with eight beds and four chairs (children and adults)
- 1 Doctor's office
- 1 Central point for sample collection
- 1 Sitting room
- Carlos III Satellite Unit
 - 1 Work office and doctor's office
 - 1 Laboratory


EQUIPMENT

- 1 ECG
- 1 Centrifuge (Carlos III Satellite Unit)
- 2 Refrigerated centrifuge
- 1 Refrigerator
- 1 Room temperature chamber (Carlos III Satellite Unit)
- 3 -20°C freezers (1 in Carlos III Satellite Unit)
- 2 -80°C deep freezer
- 4 Vital signs monitors
- Defibrillator
- Temperature recording system
- Digital clocks synchronised by GPS
- 2 medical scales (1 in Carlos III Satellite Unit)
- Digital blood pressure monitors and pulse oximeters
- Digital timers
- Crash trolley
- 2 Cure trolleys

2.7.3 Experimental Surgery

The Experimental Surgery Section is a support unit for research and teaching. In the research field, the Section develops biomedical research projects and fine-tunes procedures for new diagnostic and therapeutic techniques that use laboratory animals.

In the teaching field, the Section organises and supports training courses in surgical, microsurgical, laparoscopic and anaesthetic techniques.



- Video surveillance system
- 11 patient calling devices
- 4 patient surveillance cameras

PORTFOLIO OF SERVICES

The portfolio of services includes more than 80 tasks grouped into:

- Methodologic support
- Clinical trial pre-study activities
- Study development
- Finalization and closure tasks
- Pharmacovigilance
- Statistics and data management
- Medical and nursing tasks

RESEARCH ACTIVITY OF UCICEC

During 2018, the platform has provided assistance and support in start-up, coordination, data-management, laboratory management or nursing tasks in more than 132 commercial clinical trials of 46 Research Groups and more than 40 independent clinical research projects. In this period, 6 audits have been conducted and have been successfully overcome. In 2017 UCICEC was certified to the ISO 9001:2008 standard.

HULP-UCICEC has also provided methodological support in almost 150 clinical independent projects, including advice on study requirements and documentation, protocol development and design and preparation of application reports for competitive projects.

Finally, more than 10 early phase trials have been conducted in our Phase I.

COMPOSITION

Section Head:

Manuel Quintana Díaz

manuel.quintana@salud.madrid.org

Phone: (+34) 91 727 71 54



2.7 Platforms

Veterinarian:

Carlota Largo Aramburu
carlota.largo@salud.madrid.org
Phone: (+34)91 727 71 54

Secretary:

Irene Cuevas Gordo
Irene.cuevas@salud.madrid.org
Phone: (+34) 91 727 71 54

Technicians and assistants:

Javier Rubio Bolívar
Sonsoles Jiménez Mediano
Isabel Rodríguez Marín
Pablo Llorente Fernández
Pedro Gallego Montesano
Daniel Ruiz Pérez
M^a del Mar Barona Garcia

EQUIPMENT

The Section consists of two microsurgery rooms, an operating room and an animal facility. The microsurgery room has surgical loupes and microscopes, as well as inhalers anaesthesia systems for rodents. All experimental procedures with rodents are performed in this room. Its layout, with fixed and mobile posts, allows for the implementation of microsurgical and laparoscopic courses with simulators.

The operating room is equipped with double team surgical tables and anaesthesia stations with monitoring equipment, which allow for two surgeries to be performed simultaneously. It is also equipped with laparoscopic, ultrasound and C-Arm X-ray equipment. All procedures performed on large animals are carried out here, along with training courses on surgical, laparoscopic and anaesthetic techniques. The animal facility has a total of five rooms for conventional accommodation of animals, in both the breeding phase and for experimentation. Two of these rooms have modular enclosures for housing large species such as pigs, sheep and rabbits. The remaining three accommodate rodents (rat, mouse and gerbil). The housing of rodents has controlled ventilation systems (a ventilated rack for mice and another for rats) and conventional systems in shelves. It also has a sealed positive and negative pressure room.

ANIMAL FACILITY

The research and teaching at IdiPAZ involving the use of laboratory animals is managed via the animal platform of IdiPAZ, and is overseen by Dr. Carlota Largo Aramburu. In this department we develop biomedical research projects, training courses specific

to the various specialties as well as procedures for putting in place new diagnostic techniques or therapies that involve the use of experimental animals. In addition, the animal facility works with the Ethics Committee for Animal Wellbeing, whose authorisations is required for all procedures.

The animal facility is located in basement 2 of the IdiPAZ building within the hospital complex. The facility provides a total of 10 rooms for animal housing, in both breeding and experimental phases, two rooms for animal handling and experimental procedures, a room for washing material, which includes a cage washer, an autoclave and a pressurebased washing system, and several storage rooms for clean materials, feed and wood shavings for cages. In addition, for its proper functioning, the animal facility is connected with the rest of the departments of Experimental Surgery where there is a double operating theatre, a microsurgery room and various additional rooms (dressing areas, offices, and store rooms).

The species typically used include: rodents (rats, mice and gerbils), rabbits, pigs, sheep and goats, and occasionally dogs, cats or guinea pigs. Recently, a fish housing unit has been established

(zebra fish). To avoid contamination and permit a good workflow, the rooms for housing of large animals are physically separated from those for the rodents and the rest of the facilities (washing area, store rooms, or the handling room). In addition, all the rooms include an external video camera system to monitor the interior while avoiding the unnecessary entrance of unauthorised personnel.

The cages provide the minimum dimensions required for housing pigs and/or small ruminants. The structure of each cage is includes stainless steel anchored to the wall, with sliding separators that allow the expansion of the space by uniting two cages. The rooms have the slope needed to encourage the elimination of solid residue via a drain located in the rear of the cage. All of the drains are equipped with protection systems to prevent the entrance of rodents or insects. For the cleanliness of the room and the animals, there are hot and cold water connections via a hose.





2.7 Platforms

The rabbit room includes modular mobile crate racks of 3, 6 or 9 cages. The rabbits are kept in individual stainless steel cages with plastic grids. They also have a box structure inside that allows the animal to hide or go up to a higher position. The stainless steel feeders and drinking water are located in the cage door. Faeces and urine are collected in an extractible stainless steel tray. This room has a central drain with similar characteristics as those in the large animal room.

The rodent area is separated from the rest of the facility via a gate system (without locking doors) where staff can dress appropriately before entering (boots, robe, gloves, hat and mask). In this area, 5 rooms are located for the housing of rats and mice in both breeding and experimental phases and a room for fish. There is a storeroom for feed and shavings and a room for handling and the performance of procedures.

In addition to two large areas of animals, the animal facility includes:


- A washroom equipped with a cage washer (Hobart), a stainless steel pool and an autoclave. It also has a pressure wash system for cleaning the cages and/or visits that require it.

2.7.4 Simulation Platform (CEASEC)

OBJECTIVES

The IdiPAZ/FIBHULP Simulation Centre offers professionals from various fields the following possibilities:

- Learning and training on the approach for patients in critical clinical conditions: cardiopulmonary resuscitation, shock of various origins, acute respiratory failure of various aetiologies, multiple trauma, arrhythmias, complicated births, difficult airways, safety, and leadership.
- Ongoing training of teams who treat patients in critical conditions: ICU, anaesthesia, emergency department, surgery.
- Learning and training on managing patients with technology-dependent conditions: mechanical ventilation, extracorporeal membrane oxygenation, dialysis, haemodialysis and haemofiltration and external ventricular assistance.
- Learning and training on managing technology for diagnostic and therapeutic use: echocardiography, abdominal ultrasonography, catheterisation, laparoscopic surgery, bronchoscopy, laryngoscopy, endoscopy and colonoscopy.
- Learning the use of invasive techniques: arterial and central venous cannulation, nasogastric and vesical catheterisation, suturing, thoracentesis, paracentesis, tracheostomy, nerve blocks.



- A room for handling large animals for the performance of procedures with a table and surgical lamp, surgical cart, monitoring equipment and a C-arm X-Ray.
- Store room (clean material).
- Control room with computers for environmental control.

The animal facility complies with all current legislation and is registered with number ES-280790001941.

PORTFOLIO OF SERVICES

- Animals for experimentation (own breeding)
- Housing and maintenance of animals
- Leasing of spaces for conducting courses (microsurgery laboratories and operating room)
- Performance of surgical procedures on large animals (leasing space and anaesthesia, does not include surgery)

- Learning to perform a correct medical history review and physical examination and communicating and contacting patients, using actors and advanced simulators.

COMPOSITION

Governing Council

Dr. Javier Cobas Gamallo
D^o. Ana Coloma Zapatero
Dra. Carlota Largo Aramburu
D^o Elena Martín de Castro
Dr. Juan Vázquez Estévez
D^o. Alicia Portas Martínez
Dr. Manuel Quintana Díaz
Dr. Pedro de la Oliva Senovilla
Dr. Ramón Cantero Cid
Dra. Ana M^o Sánchez Torres
Dra. Emilia Guash Arévalo
Dr. Esteban López de Sá y Areses
Dr. Ignacio Zapadiel Gutierrez

- 2.1 Global Analysis
- 2.2 Research Structure
- 2.3 Training Report and Teaching
- 2.4 Innovation and Transfer Activities
- 2.5 Quality Committee
- 2.6 Clinical Trials
- 2.7 Platforms**
- 2.8 Scientific Production
- 2.9 CIBERs and RETICs
- 2.10 Institutional Projects
- 2.11 Internationalization
- 2.12 Communication



2.7 Platforms

*Dra. Esther Rey Cuevas
Dr. Juan José Ríos Blanco
Dra. Dolores Elorza Fernández*

Chairman Governing Council
*Dr. Juan José Vázquez Estévez
Dr. Manuel Quintana Díaz*

Secretary Governing Council:
*D^o. Ana Coloma Zapatero
D^o. Estela Sánchez Simón*

Contact:
*D^o. Irene Cuevas Gordo
irene.cuevas@salud.madrid.org
Phone: (+34) 91 727 71 54*

Clinical Simulation Technician:
Javier Rubio Bolívar



ACTIVITY OF CEASEC

CEASEC is the Advanced Clinical Training and Simulation Center. During 2018, the CEASEC activity has highly increased by 45 % compared to 2017. The platform has provided assistance and support for research and teaching in more than 50 courses.

School Courses Simulation (Summary)

Course	Director	Date
Curso RCP Básico	Dr. Manuel Quintana Díaz	January, 15 th , 16 th , 17 th
Curso RCP Avanzado Pediátrico	Dr. José Antonio Ruiz Domínguez	January 31 st
SIMUVAD 2018	Dr. Pedro Garrido	February 1 st , 2 nd , 3 rd
Curso RCP Básico	Dr. Manuel Quintana	February 13 th
Módulo politrauma pediátrico	Dr. Juan José Vázquez Estévez	February 15 th
Curso de Colgajos Microvasculares en la rata	Dr. Javier Arias Gamallo Dra. María José Morán	February 19 th , 23 rd
Accesos vasculares periféricos	Dr. Juan José Menéndez Suso	February 28 th
Curso de Asistencia Inicial al Trauma Pediátrico (AITP)	Dr. José Antonio Ruiz Domínguez	March 15 th , 16 th
RCP Básico + DESA	Dr. Manuel Quintana	March 19 th
Simulación en ECMO Neonatal	Dra. M ^a Dolores Elorza	March 21 st

IX Curso de Ecografía en el Paciente Pediátrico Crítico	Dr. Juan José Menéndez Suso	March 20 th , 21 st , 22 nd
RCP Básico + DESA	Dr. Manuel Quintana	March 28 th
Shock 2018	Dr. Emilio Maseda	April 6 th
Curso de Microcirugía Experimental y Colgajos Microvasculares en la Rata	Dr. César Casado Sánchez	April 9 th , 13 th
SIMUMED 2017	Dr. Pedro Garrido	April 19 th , 20 th , 21 st
SopORTE Vital Pediátrico	D ^a . Catalina Fernández Carretero	April 24 th
XXXI Curso Nacional Práctico Multidisciplinario de Microcirugía Vasculo Nervioso y sus Aplicaciones Clínicas	Dr. César Casado Sánchez	May 7 th , 11 th
Simulación en Emergencias Obstétricas	Dr. José Luis Bartha Rasero	May 17 th
Ecografía Pulmonar en Cardiología	Dr. César Carballo	May 21 st , 22 nd , 23 rd
RCP Avanzado	Dr. Manuel Quintana Díaz	May 21 st to 25 th
Técnicas de depuración extracorpórea	Dra. Carlota Largo Aramburu	May 29 th , 30 th
Crisis Resource Management Radiología	Dr. Manuel Quintana Díaz	June 5 th
RCP Avanzado	Dr. César Carballo	June 18 th , 19 th

Introduction 1

Executive summary 2

- 2.1 Global Analysis
- 2.2 Research Structure
- 2.3 Training Report and Teaching
- 2.4 Innovation and Transfer Activities
- 2.5 Quality Committe
- 2.6 Clinical Trials
- 2.7 Platforms
- 2.8 Scientific Production
- 2.9 CIBERs and RETICs
- 2.10 Institutional Projects
- 2.11 Internationalization
- 2.12 Comunication

Information Groups by Area 3

Associated Clinicians 4

Scientific Report 2016 2017 2018



2.7 Platforms

Atención al paciente pediátrico grave en el servicio de urgencias (CRM - Crisis resources)	Dr. José Antonio Ruiz Domínguez	June 19 th
Retos en el manejo y diagnóstico del ictus	Dra. Blanca Fuentes	June 21 st
Caso clínico laringoespasma	Dr. Francisco Reinoso	Junio 21 st , 22 nd
Curso Práctico de Cirugía Laparoscópica	Dr. Ignacio Zapardiel	September 17 th
RCP Básica Neonatal y Pediátrica	Dr. Miguel de Río	September 18 th , 19 th
Simulación en Cuidados Intensivos Pediátricos	Dr. Miguel del Río	September 28 th
Curso de Simulación en Enfermería de Atención al ICTUS	Dra. Blanca Fuentes	October 1 st , 2 nd , 3 rd
Curso de Asistencia Inicial al Trauma Pediátrico (AITP)	Dr. José Antonio Ruiz Domínguez	October 18 th , 19 th
Curso de Ecografía en el Paciente Pediátrico Critico	Dr. Juan José Menéndez Suso	October 8 th , 9 th , 10 th

2.7.5 Cell Culture Unit

The Cell Culture Unit has been established as a core support division integrated into the Hospital La Paz Institute for Health Research (IdiPAZ). This unit facilitates the establishment and management of in vitro model systems and experimental-related techniques for different applications and purposes including the study of biochemical processes in cells, the elucidation of the molecular and cellular mechanisms involved in a biological process, the prediction of the cellular and tissue responses to a specific microenvironment and/or the identification and development of novel drugs, compounds and therapeutic targets. Therefore, this platform provides a fundamental basis for the development of research initiatives in the field of Biomedical and Pharmacological Research and Health Sciences.

The Cell Culture Unit accomplishes its mission by providing users with assistance and support at scientific, technical and instrumental level through access to knowledge, equipment, material and human resources. According to IdiPAZ strategic plan and other institutional guidelines, this division contributes to the translation of biomedical research by fostering the synergies and cooperation between



Curso de Canalización ecoguiada de accesos vasculares periféricos y PICCS	Dr. Juan José Menéndez Suso	October 22 nd
Curso de Instructores en RCP Pediátrica y Neonatal	Dr. Miguel de Río	October 24 th , 25 th , 26 th
Crisis Resource Management en Neonatología	Dra. M ^a Dolores Elorza Dr. Juan José Vázquez Estévez	October 25 th
Soporte Vital Inmediato	D ^a . Catalina Fernández	November 5 th , 6 th ,
Curso de simulación avanzada en el manejo de paciente crítico cardiológico	Dr. Esteban López de Sá	November 12 th , 13 th
Curso Avanzado de Instructores en Simulación Clínica	Dr. Juan José Vázquez Estévez Dr. Manuel Quintana Díaz	November 20 th , 21 st
Simulación en ECMO neonatal	Dra. M ^a Dolores Elorza	November 27 th , 28 th
CRM Anestesiología Pediátrica	Dr. Francisco Reinoso	November 30 th
Curso de Simulación en Emergencias Obstétricas	Dr. José Luis Bartha Rasero	December 5 th
Curso de microcirugía vascular cerebral y By-Pass Extra Intracraneal	Dr. González Llanos	December 13 th , 14 th , 15 th , 16 th , 17 th

clinic- and basic- oriented research groups belonging to IdiPAZ as well as to external institutions. It also provides a dynamic and shared operational environment offering a convenient basis for the exchange and dissemination of the scientific knowledge, innovation and creativity as well as the creation of collaborations and alliances between researchers of various categories and disciplines. Moreover, the association and physical proximity with other core facilities such as the Imaging and Flow Cytometry Units, enable users to develop complementary techniques, to explore and upgrade innovative hypotheses and to extend and/or improve their objectives.

COMPOSITION

Head:
Gema Vallés Pérez (PhD)
 gema.valles@salud.madrid.org
 Phone: (+34) 917277000 (ext. 1576)



2.7 Platforms

Technical Support:

Beatriz Sanz Minguel

Phone: (+34) 91 7277000 (ext. 2142)

Secretary:

Susana García Pérez

investigacion.hulp@salud.madrid.org

Phone: (+34) 912 071 512

EQUIPMENT AND FACILITIES

The Cell Culture Unit consists of an experimentation laboratory, a cryopreservation room and a warehouse. All facilities are located in the IdiPAZ building.

The experimentation laboratory is fitted with the following equipment:

Cabinets:

- 3 Telstar Bio-II-A biological safety cabinets
- 2 Nuair NU-437-400E biological safety cabinets
- 1 Heraeus HS-12 biological safety cabinets
- 1 Faster BH-EN 2004 biological safety cabinet
- 1 Gelaire BSB 4A biological safety cabinet
- 1 Esco Class II BSC biological safety cabinet
- 3 Faster BIO 48 vertical laminar flow cabinets
- 1 Faster TWO 30 vertical laminar flow cabinet

Incubators:

- 3 Thermo Forma Scientific incubators
- 2 HERAcell incubators
- 2 Biotech Galaxy S incubators
- 2 Nuair Autoflow incubators
- 1 Sanyo O2/CO2 incubator

This equipment is complemented with a centralized and alarmed gas system, which guarantees a constant and controlled supply of CO₂ and N₂.

Microscopes:

- 1 Nikon DIAPHOT TMD inverted light microscope connected to a Nikon D80 digital camera.
- 1 Leica DMIL inverted light microscope

connected to a Canon Powershot S70 digital camera.

- 1 Optika inverted light microscope
- 1 Motic AE2000 inverted light microscope connected to an automatic counter Celeromics
- 1 Lan Optics inverted light microscope

Centrifuges:



- 2 Eppendorf 5810R refrigerated centrifuges
- 2 Eppendorf 5804 centrifuge
- 1 Hettich Universal 32R refrigerated centrifuge
- 1 Kubota 2010 centrifuge
- Cell Separation System:
 - 1 Milteny Biotec autoMACS cell separation system

Freezing systems:

- 1 Liebherr refrigerator (4 ° C and -20 ° C)
- 1 Balay refrigerator (4 ° C and -20 ° C)
- 1 Whirlpool refrigerator (4 ° C and -20 ° C)
- 1 Beko refrigerator (4 ° C and -20 ° C)

Other equipment:

- 1 Presoclave 75 P-Selecta autoclave
- 1 Millipore water purification system
- 1 Heidolph Reax 2000 vortex
- 1 Raypa thermostatic waterbath





2.7 Platforms

- 1 Memmert thermostatic waterbath
- 2 Precistern thermostatic waterbath
- 1 Grant JB Aqua 12 Plus thermostatic waterbath
- Vacuum pumps, pipettes, counters, automatic pipettors, freezing containers, cell counting cameras, etc

The cryopreservation room is equipped with:


- 2 Statebourne Biorack 3000 liquid nitrogen tank
- 1 Thermo Locator 6 Plus liquid nitrogen tank
- 1 10 K Taylor Wharton liquid nitrogen tank
- 1 MVE cryosystem 4000 liquid nitrogen tank
- 1 Cryo Diffusion B2016 liquid nitrogen tank
- 1 Cryo diffusion B2048 liquid nitrogen tank
- 1 Cryo Diffusion B2011 liquid nitrogen tank
- 1 SEO GT40 liquid nitrogen tank
- 1 MVE XLC 511 liquid nitrogen tank

The infrastructure for cryopreservation is completed with a liquid nitrogen transfer device and an alarmed Oxygen O2 detector coupled to a mechanical ventilation system.

PLATFORM OPERATING STANDARDS

The Cell Culture Unit provides a joint support structure for biomedical research, including infrastructure and equipment, technical assistance and scientific consultation to researchers who request their services. With regard to facilities and equipment available, staff associated with the Unit will be responsible for their proper maintenance and operational guidelines and will provide support, training and supervision to users in order to obtain optimal utilization and exploitation. The Unit is oriented to specialized training, exchange and dissemination of scientific knowledge and an active collaboration with users to develop cell culture-related procedures and technology. This service aims not only to meet the needs of IdiPAZ researchers but also to provide adequate support to non-IdiPAZ scientists that do not have specific facilities to perform their cell culture experimentation. All users must respect the internal rules of the Service, the established principles of prevention, health and safety, guidelines on handling and management of reagents, materials and waste disposal besides the operating instructions and procedures for instruments and equipment.

Users (from the IdiPAZ or other facility or institution) who request services for the first time or who demand additional information, please contact to the Head of the Platform.



PORTFOLIO OF SERVICES

The Cell Culture Platform activities are focused on providing users with flexible and results-oriented services in a collaborative and translational research framework. In general, this Division offers support for experimental approaches developed by IdiPAZ and non-IdiPAZ scientists on an extensive range of matters including cell experimentation, consumables and reagents, equipment and laboratory area, technical assistance, training and research.

The specific support provided by this Unit includes:


- Scientific and technical advice, personalized support and consultation: guidance in experimental setup and design, study planning, optimization of techniques and protocols, reagents and material acquisition, cells supply, troubleshooting, analysis and interpretation of results...
- Basic training and hands-on experiments (implementation of the self-service mode) according to biosafety, waste disposal and good laboratory practice guidelines
- Access to specific facilities including instrumentation, equipment, materials and reagents
- Preparation and supply of certain materials, reagents and sterile solutions.
- Management and general supervision including good laboratory practices and work habits, cleaning and waste disposal and operation and maintenance of the equipment
- Performance of experimental procedures: cell separation, cell isolation for cultivation, maintenance and propagation of cell lines and primary cultures, cryopreservation and resuscitation, viability and proliferation, etc..
- Control and maintenance of cryopreserved stock cells
- Elaboration and management of protocols and guidelines, operating procedures, reports and other required mandatory documentation
- Detection, identification and treatment of contaminations in cell cultures
- In addition to these standard services, this platform offers collaboration with individual researchers as an effective way to improve and to expand the portfolio of technology and services offered. Furthermore, and as part of its commitment to warrant users the optimal development of their research projects, the contact to other centralised equipment and affiliated facilities, infrastructures and common equipment is also provided

Pricing services available on the web:

<http://www.idipaz.es/PaginaDinamica.aspx?IdPag=191&Lang=EN>



2.7 Platforms





2.7.6 Sanger Sequencing Facility

The main role of the Sanger sequencing laboratory is to provide support for medical research in the field of Molecular Biology. The goal is to support to research groups both inside our Institute and elsewhere that require the infrastructure CE.

Our laboratory is located inside INGEMM. This allows for frequent interactions with the hospital's various research groups, and thus allows for the laboratory members to stay up to date on state-of-the-art techniques in genetics. Therefore, the laboratory is an translational-research model. Nowadays, the Sanger sequencing method is regarded it as the gold standard for validation of Next-Generation Sequencing single nucleotide variants. In order to achieve the goals stated above, our laboratory owns the necessary equipment and infrastructure for performing tasks such as conventional sequencing (Sanger method), marker DNA genotyping, and other molecular biology techniques based on capillary electrophoresis. The equipment can use up to 5 simultaneous colours on the same sample when it migrates into the genetic analysers. Therefore, we are able to detect more than 30 polymorphic markers per sample.

The laboratory is regularly involved in quality control audits on the Sanger sequencing and genotyping, as well as result homologation. Such audits are performed at both national and international levels (e.g., EMQN). In addition, Sanger Sequencing Facility has been adapted to the ISO 9001:2015 Standard during 2018.



COMPOSITION

Lab Manager

María del Rocío Mena de la Cruz (PhD)
mariarocio.mena@salud.madrid.org
Phone: 91 207 10 10 (Ext. 230)

Technician

Inmaculada Rueda Arenas
inma.rueda@salud.madrid.org

EQUIPMENT

- Eppendorf 5415D Centrifuge.
- Veriti Thermocycler (Applied Biosystems).
- Genetics Analyzers 3130xl y 3730xl (Applied Biosystems-Life Technologies).

Software:

- Sequencing Analysis v5.3.1
- Sequence Scanner v1.0
- GeneMapper v4.0
- Peak Scanner v1.0
- Variant report v1.0



PORTFOLIO OF SERVICES

- Nucleic Acid quantitation (Tecan, Nanodrop)
- PCR purification for Sanger sequencing (Exosap)
- Sanger Sequencing
- Fragments Analysis:
 - QF-PCR
 - MLPAs (multiplex ligation-dependent probe amplification).
 - Microsatellite instability (MSI)
 - AZF
 - SnapShot
 - TP-PCR



2.7 Platforms



2.7.7 Image laboratory



Image and Immunohistochemistry Unit, as a part of the network of IdiPAZ core facilities, play an essential role in enabling scientists and clinicians to realise their goals in biomedical research. The laboratory mission is to provide a centralized service dedicated to assisting with the highest quality histology, immunohistochemistry and imaging equipment, as well as scientific and technical support to researchers. The Unit collaborates in creating a link between basic and clinical research to reach the translational research milestones, in addition of Institute training and education plans. Therefore, Image and immunohistochemistry Unit is open to all researchers, including; IdiPaz and their affiliates, commercial and not-for-profit biotechnology companies, and other academic institutions.

Specialized staff provides histological and molecular technical support to the researchers' requirements, which in turn produces high quality data interpretation to support grant applications and national and international scientific publications. Currently a broad range of techniques ranging from classical histology, to molecular techniques as immunohistochemistry, immunofluorescence and image and digital analysis are available at the facility. The general rules of the platform is that trained and authorized users have free access to the platform; IdiPaz staff in a Do-It-yourself manner and in a fee-for-service manner to all the rest. The Unit, located in the IdiPaz building at the La Paz University Hospital, consists of two sections, the Immunohistochemistry and the Microscopy laboratories.

Immunohistochemistry laboratory, housed in the first floor of IdiPaz building, offers protocols and automated high-throughput equipment allowing citospines, fixation techniques (paraffined or frozen), sectioning of tissues (microtomes and cryostats), and classical or advanced immuno-staining (Dako Autostainer). Microscopy Lab is in the -1 floor of IdiPaz building and offers facilities to perform a range of real time and end-point assays, including cell number, proliferation, apoptosis, cell size, and shape and viability measures. The equipment of Microscopy's lab allows to do conventional, fluorescence, confocal and high-content microscopy, includes a Leica TCS SPE inverted confocal, Leica DM6000 inverted fluorescence microscope, a microscope inverted Nikon Eclipse Ti with in vivo incubation system and a microscope Nanosight with

a system of tracking nanoparticles. In addition, the lab offers image analysis programmes (NIS Elements AR, Nanosight 3.1, LASAF, Image ProPlus and ImageJ).

COMPOSITION

Head:
María Teresa Vallejo Cremades (PhD)
tvallejo.hulp@salud.madrid.org
Phone: (+34) 917277526

Technician:
Onys Camps Ortega
Phone: (+34) 917277526

Secretary:
Susana García Pérez
investigacion.hulp@salud.madrid.org
Phone: (+34) 91 207 15 12

RESOURCES, EQUIPMENT AND MANAGEMENT OF THE LABORATORY

The laboratory staff will present the basic rules to new users for good practices and safety in the laboratory. Users should not use the equipment until the laboratory personnel have checked their correct training. Users must schedule the time of work in any equipment and booking reserve it is mandatory in all the facility. Access to the Microscopy requires the magnetic individual. The services of the image core facility are available to all scientists in collaboration, Do-It-Yourself model or in a fee model (in this case, it must be consulted the head of the laboratory, the lab will support the service depending on staff availability).

- Equipment of Image and Immunohistochemistry Unit

Immunohistochemistry Laboratory:

- Tissue processor providing efficient, reliable and timely processing of paraffin wax (Leica TPI020)
- Embedding unit for high quality paraffin blocking (Leica EGI 160)
- Selecta Wax dispenser, paraffin wax dispenser with adjustable temperature from ambient to 100 °C
- 2 microtomes for specimen sectioning Leica RM2255
- 1 microtome for specimen sectioning Shandon AS325

Introduction 1

Executive summary 2

- 2.1 Global Analysis
- 2.2 Research Structure
- 2.3 Training Report and Teaching
- 2.4 Innovation and Transfer Activities
- 2.5 Quality Committe
- 2.6 Clinical Trials
- 2.7 Platforms**
- 2.8 Scientific Production
- 2.9 CIBERs and RETICs
- 2.10 Institutional Projects
- 2.11 Internationalization
- 2.12 Comunication

Information Groups by Area 3

Associated Clinicians 4

Scientific Report 2018



2.7 Platforms

- Leica EG 1150C Cold plate
- 2 thermostatic water Leica HI 1210 baths
- 1 thermostatic water Selecta Thermofn bath
- Automated Immunohistochemistry autostainer (Autostainer Plus DAKO)
- 2 Cryostat for frozen sectioning (Leica CM 3050S and Leica CMI950)
- PTLINK DAKO
- Crison pH meter
- Liebherr upright freezer (-20°C and 4°C)
- Liebherr economy freezer (-20°C)
- Shandon Cytospin 2
- Memmert BE 500 oven
- Memmert UN 30 oven
- Selecta Agimatic-E magnetic stirrer with heating
- Pipetors
- Olympus CH microscope, for practical laboratory applications
- Gilson pipette sets
- NUAIRE laboratory fume hood.

Dissection equipped and staining area with manual options for Do-It-Yourself staining and cover slipping.

The laboratory is equipped with shared facilities from Translational Oncology and Anatomopathology Breast and Gynecological Cancer groups that use them for diagnostic and clinical research purpose (ESCO fume hood and Crison Microtome). Permission to use must be asked to the head of these laboratories.

The Microscopy laboratory equipment includes:


- Leica TCS SPE inverted confocal. Leica DMI4000B inverted microscope; Illumination source, Lasers diode 405, Lasers diode 488, Lasers diode 532 and Lasers diode 635; Dishes, Standard microscope slides.
- NIKON microscope ECIPSE IT to conventional and fluorescence microscopy, in vivo imaging and High Content (equipped with incubation chamber)
 - Camera IMAGING SOURCE
 - Camera Camera ANDOR Neo SCHOS refrigerated.
 - Lauda Ecoline Star incubator edition 003
 - Hotplate (OKO LAB)
 - D gas (Okolab)
 - Microscope culture plates adapter
- Leica DMI6000B inverted microscope. Filter cubes: A4(UV), L5 (green), N3 (red) and Y5 (far red)

- Olympus BX41 (Bright field) upright microscope with an attached Digital camera
- Zeiss Axioplan 2 upright microscope with five objectives from 5x to 100x, phase contrast and fluorescent capabilities
- Zeiss Axio Lab.A1 microscope five objectives from 5x to 100x. ERC5S Axocan camera.
- Nanosight LM10 viewing unit measures nanoparticles, exosomes, vesicles's size based on the scattering of light, includes a microscope, a LM10 viewing unit, a Marlin camera, an objective x20 and is connected to a image analysis software.
- Digital microscopy (photography with a Leica DFC 350 FXR2 digital camera attached)
- Image ProPlus 5.0 image analysis software
- Leica LAS AF image analysis software
- Analysis station with Huygens deconvolution software, Image J, LASAF Lite programme and related image analysis software.
- Nanosight NTA 3.1 analytical software.

The laboratory is equipped with shared facility from Neuroscience group (Leica TCS SPE inverted confocal).

RESEARCH HIGHLIGHTS

In 2018, Image unit maintained their quality standards in order to support and collaborate with the groups belonging to the research areas of IdiPAZ; Neurosciences, Infectious disease and immunity, Cancer and human molecular genetics, Cardiovascular, Organ system pathologies and Surgery, transplant and health technologies. The results of these collaboration are reflected in projects granted (publics or privates, national or international grants), scientific dissemination (thesis) and high impact international publications.





In the last year, we have maintained the number of users inside Hospital La Paz (HULP; clinical and basic researchers), associated IdiPaz groups (UAM), and extended research groups (UCM, CSIC etc). The Operation Time in 2018 (calculated as the total time of use per year of some equipment from Microscopy lab and from immunohistochemistry) has been almost equal than in 2017.

The platform began during 2018 to develop a system of quality management following the ISO9001:2015 STANDARD. In addition, the staff of the unit assist to the SPAOM Spanish-Portuguese Meeting for Advanced Optical Microscopy orga-




2.7 Platforms

nized by the Spanish Network of Advanced Optical Microscopy (REMOA) in Granada with a poster communication. This allows us to implement the collaboration with other image core platforms and the knowledge of recent advances in the field of bioimaging techniques. The platform maintains the training activities as tutor centre trainees of the Community of Madrid, maintaining a collaboration agreement with two institutes for their students perform regulated practices.



PORTFOLIO OF SERVICES

- Collection and processing for fixing and decalcification of samples
- Sample processing in paraffin by hand or automatic
 - Complete paraffin embedding processing
 - Serial cut in microtome and tissue assembly
- Antibodies' validation
- Buffer preparation and distribution of consumables
- Sample processing frozen
 - Preparation of freeze blocks
 - Serial sections of blocks freeze and cuts collected on slides or floating
- Staining
 - Hematoxylin - eosin
 - Masson trichrome
 - Nissl
 - PAS
 - Acetylcholinesterase
- Cytochemical and immunohistochemical techniques
 - Decalcification of samples required
 - Dewaxing cuts, performing staining
 - Immunohistochemical staining automated system Autostainer
 - Immunofluorescence in frozen tissue and paraffin. Protocols
 - Dehydration and slide assembly



- Image acquisition. Viewing and digital format acquisition
 - Light microscopy
 - Light microscopy with phase contrast
 - Epifluorescence
 - Confocal microscopy
 - Advanced Microscopy in living cell
- Fluorescence localization by confocal microscopy
- 3D reconstruction
- *In vivo* image acquisition of biological samples (incubation system for the temperature and CO₂)
- Morphometry in biological samples
- Large images acquisitions (scanning the entire slide) for bright field and fluorescence
- Collaboration for sample processing protocols for microscopy (fastening, staining, marking, etc.) and advice for planning projects that could require the use of microscopy



2.7 Platforms

2.7.8 Flow Cytometry Laboratory

The IdiPAZ Flow Cytometry Laboratory is becoming consolidated as a great tool in the centre's research approach. The laboratory is dedicated to providing all IdiPAZ members Access to affordable and high-quality flow cytometry services, together with the decisive scientific expertise to utilize this technology in research. We Excel at a wide variety of flow cytometry applications:

- Sample processing for extra- and intracellular staining
- Functional assays
- Phenotypic analysis of subpopulations
- Preliminary studies for a posterior clinical application
- Complex multi-color flow cytometry analyses

COMPOSITION

Head:

Victor M. Toledano Real
victor.toledano@idipaz.es
Phone: (+34) 91 727 00 00 (ext. 2484)

Secretary:

Susana García Pérez
investigacion.hulp@salud.madrid.org
Tel: (+34) 912 071 512

EQUIPMENT

The Flow Cytometry Laboratory of IdiPAZ has the following facilities:

- One Beckman Coulter Navios cytometer analyser is a clinical system that delivers analytical excellence by coupling extraordinary sensitivity, resolution and dynamic range with high-speed data collection. With superior detection capabilities, the Navios provides accurate measurements, especially for rare events, which is critical to clinical diagnosis and monitoring. The fully-featured, easy-to-use Navios software provides tools to improve the quality of results as well as optimize workflow efficiencies in a clinical lab.



- This analyser has three lasers; Blue solid state Diode: 488nm, 22mW laser output, Red solid state Diode: 638nm, 25mW laser output and Violet solid state Diode: 405nm, 40mW laser output. The Navios can analyse ten colours simultaneously in samples marked with the following fluorochromes: • FL1: FITC, GFP, Cy2, Alexa 488 • FL2: PE, Cy3 • FL3: PI, ECD,

PE-TEXAS RED, RED RFD • FL4: PE-Cy5, PerCP, Per-CP5.5, TC 7AAD, SPRD • FL5: PE-Cy7 • FL6: APC, Alexa 647 • FL7: APC-Alexa700, Alexa 700 • FL8: APC-Cy7, APC-Alexa750, APC-Alexa780 • FL9: Pacific Blue, eFluor 450 Cyan, Cyan, Violet RFD • FL10: Pacific Orange, AmCyan

- The Navios is connected to computer using the Navios acquisition and analysis programme.

- Two Becton Dickinson FACSCalibur™ cytometer analysers is a platform allows users to perform both cell analysis and cell sorting in a single benchtop system. The system supports a wide variety of research and clinical applications and is complemented by a broad suite of intuitive software solutions to streamline analysis for a wide range of applications including enumeration of lymphocyte subsets, stem cells, residual white blood cells, and reticulocytes.



- Each analyser has two lasers, a 488nm argon laser and a 635nm solid-state red diode laser. The FACSCalibur™ can analyse four colours simultaneously in samples marked with the following fluorochromes: • FL1: FITC, Alexa 488 • FL2: PE, PI • FL3: PE-Cy5, PerCP, Per-CP5.5 • FL4: APC, APCCy7, Alexa 647

- The two cytometers are connected to Macintosh G4 OS.9.2.2 computers using the CellQuest™ acquisition and analysis programme, and Macintosh G5 OSX with CellQuestPro™ acquisition and analysis software

- One cytometer analyser Becton Dickinson FACSCelesta. It is designed to make multicolored flow cytometry more accessible and allow researchers to benefit from technological innovations in equipment and reagents. These parallel advances in optical and reagent technology allow multi-laser equipment to complement the new bright fluorochromes, allowing for a deeper and more powerful insight into cell analysis.

- This analyser has three lasers; BUV12: 4 Blue(488nm) / 2 ultra violet (355nm) / 6 violet (405nm). Can analyse twelve colours simultaneously in samples marked with the following fluorochromes: FITC; PE; Brilliant Blue 515 (BB515); Brilliant Blue 700 (BB700); PERCP; PERCP CY5.5; PE CY5; PE CY7; Brilliant Ultra Violet 395 (BUV 395); Brilliant Ultra Violet 496 (496); Brilliant Ultra Violet 563 (BUV 563); Brilliant Ultra Violet 661 (BUV 661); Brilliant Ultra Violet 737 (BUV 737); Brilliant Violet 421 (BV 421); Brilliant Violet 480



- 2.1 Global Analysis
- 2.2 Research Structure
- 2.3 Training Report and Teaching
- 2.4 Innovation and Transfer Activities
- 2.5 Quality Committee
- 2.6 Clinical Trials
- 2.7 Platforms
- 2.8 Scientific Production
- 2.9 CIBERs and RETICs
- 2.10 Institutional Projects
- 2.11 Internationalization
- 2.12 Communication



2.7 Platforms

(BV 480); Brilliant Violet 510 (BV 510); Brilliant Violet 605 (BV 605); Brilliant Violet 650 (BV 650); Brilliant Violet 711 (BV 711); Brilliant Violet 786 (BV 786); V450; V500; PACIFIC BLUE; PACIFIC ORANGE.

- The FACSCelesta is connected to computer using the DIVA acquisition and analysis programme
- The laboratory also has an additional Mac G5 OSX analysis station with Cell-QuestPro™ acquisition and analysis software

2.7.9 Radioisotope Laboratory

The radioactive facility of IdiPAZ laboratories is authorised by the Nuclear Safety Council (Consejo de Seguridad Nuclear, CSN) to operate with non-encapsulated sources radioisotopes: 14C, 3H, 33P, 32P, 125I, 51Cr. Personnel of the Radiological Protection Department of HULP conduct radiological protection and periodically monitor laboratory contamination levels. They are also responsible for the removal and management of waste products and the management of users' personal dosimeters:

COMPOSITION

Person Responsible

Nuria Vilaboa Díaz
nuria.vilaboa@salud.madrid.org
Phone: (+34) 91 207 10 34


David Vicent López
david.vicent@salud.madrid.org
Phone: (+34) 91 207 10 30

Secretary

Susana García Pérez
investigacion.hulp@salud.madrid.org
Phone: (+34) 91 207 15 12



Activity of the flow cytometry platform distributed by usage hours (%) of each group.



EQUIPMENT

Contains exclusive areas for the use of β and γ isotopes; aliquot withdrawal and storage of radiolabeled compounds; and equipment for exclusive use with radioactive material. The laboratory has the following equipment: • CO₂ incubator • Cell harvester • Beta counter • Hybridisation oven • Gel dryer • SpeedVac® concentrator • Screens and containers specifically for γ and β radiation emitters • High-energy γ and β contamination detectors (Geiger counter).





2.7 Platforms

2.7.10 Biostatistic Section

The Biostatistics Section has the mission of giving methodological support to the professionals of the “La Paz” University Hospital and, in general, to the IdiPAZ professionals, and to provide technical solutions for the optimization of clinical processes by incorporating the necessary technologies for this:

COMPOSITION

Team leader

Clinical Biostatistics

Mariana Díaz Almirón

mariana.diaz@salud.madrid.org

Staff

Clinical Biostatistics

Itsaso Losantos García

itsaso.losantos@salud.madrid.org

Phone: (+34): 912071 791

Bioengineer

Francisco Gayá Moreno

francisco.gaya@salud.madrid.org

Phone: (+34): 912071 791

Clinical Epidemiologist

Jesús Díez Sebastián

jdiezs@salud.madrid.org

Phone: (+34)917277570

COMPUTER TOOLS

Main programs used for data analysis:

- SAS 9.3 (Copyright © 2012, SAS Institute Inc., Cary, NC, USA)
- SAS Enterprise Guide 5.1 (Copyright © 2012, SAS Institute Inc., Cary, NC, USA)
- R version 3.5.0 R Core Team (2018). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL <https://www.R-project.org/>.
- SPSS 9 (Copyright 1999 by SPSS Inc.)
- SYSTAT 11 (Copyright (c) 2004 by SYSTAT Software Inc., Richmon, CA, USA.)
- nQuery Advisor 5.0 (Copyright (c) 1995-2002)




- PEST 4.0 Planning and Evaluation of Sequential Trials (Medical and pharmaceutical Statistics Research Unit. The University of Reading, UK)
- Review Manager (RevMan) Version 5.0. (Meta-análisis) Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
- Joinpoint Regression Program, Version 4.5.0.1. June, 2017; Statistical Research and Applications Branch, National Cancer Institute.

PORTFOLIO OF SERVICES

- Study design
- Creation of data collection systems (such as ms Access)
- Technical support in the development of studies.
- Assistance in the design, analysis and interpretation of validation studies of diagnostic tests in the clinical hospital context
- Development of information processing systems (clinical image, readings of measuring devices, implementation of statistical methods ...) Analysis of results: Multivariate Analysis (Discriminant Analysis, Correspondence Analysis, Factor Analysis, Survival Analysis, Analysis with competitive risks. ..), Generalized Linear Models including Models with Mixed Effects and Generalized Equation Models, development of Risk Models for classification and prediction, construction of scoring systems for risk assessment, Analysis of growth curves, clinical trial methodology, methods of sequential data analysis, analysis of high-dimensional data (Analysis of microarrays). Biclúster analysis. Resampling methods (Bootstrap, Jackknife, ...)
- Presentation and dissemination of results
- Realization of training activities

ACTIVITY CARRIED OUT DURING 2018







2.7 Platforms




Distribution by 'Research Dissemination Objectives'




Distribution by 'Required Support'



Distribution by 'Research Statement'



Pertaining to a research line





2.7 Platforms

2.7.11 Documentalist

IdiPAZ's Documentalist Platform aims to control and analyze the scientific production generated through the activity of the researchers from the Institute. This control is carried out thanks to the use of different tools specifically created for this purpose and whose results are published in the bibliometric reports that appear on our website. In these reports you can observe the scientific production of each one of the research groups that form part of IdiPAZ.

However, the information contained in the reports has not yet been validated by the groups, hence its provisional nature. The information supervised and validated by the directors of each group will be officially published in the Annual Research Report together with the rest of the information from the different committees and platforms that make up our Institute. The Documentation Platform also provides assistance to all IdiPAZ members who need help regarding access and use of databases, bibliographic searches, bibliometric indicators or any other related subject. As an additional service, for some time now, we have also been in charge of printing the posters that our researchers present at congresses around the world:


2.7.12 Pain Platform

The PAIN Platform-Early-Stage Researches Support Platform (Plataforma de Apoyo al Investigador Novel) from IdiPAZ that aims to promote the design and development of research projects in several health areas, with high methodological quality, to enable our professionals in early-stage research. Additionally, the mission of the PAIN Platform is to promote the training and development of early career researchers of IdiPAZ.

COMPOSITION

Head

Paloma Gómez Campelo
pgomez@salud.madrid.org
Phone: (+34) 91 207 15 12



COMPOSITION

Head

Raúl Román Cañizares
documentalista@idipaz.es
Phone: (+34) 91 207 15 12

PORTFOLIO OF SERVICES

- Draw up of IdiPAZ's Annual Research Report
- Support to researchers in their access and use of databases, literature searches, etc.
- Design and creation of tools to control the scientific production
- Development of Bibliometric Reports
- Evaluation of researchers
- Bibliometric assessment of Research Groups
- Advice on literature search tools
- Advice on the use of bibliometric techniques
- Poster printing for congress

PORTFOLIO OF SERVICES

- Methodological and epidemiological support to the study design of the professionals in early-stage research
- Technical and methodological support in developing a research protocol for a study
- Analysis of the grounds for refusal of rejected projects
- Methodological support to write grant proposals to access all available funding programs
- Technical support in writing other scientific documents





2.7 Platforms

2.7.13 Internationalization Platform

The IdiPAZ Internationalisation Platform constitutes a service tool for supporting IdiPAZ researchers who wish either to increase their influence or to keep being reference in the Health Research international arena, with particular focus in the European funding schemes and framework programmes.

The main objective is to promote the different research groups of IdiPAZ at international level. Thus, identifying possible synergies between groups and centres, new partners and funding sources, as well as forging strategic alliances.

COMPOSITION

Team

José Luis Narro Villanueva
institutional.relations@idipaz.es
Phone: +34 91727 75 76

Marisa Tejedor Botello
relacionesinternacionales@idipaz.es
Phone: +34 91727 75 76

Santiago Rello Varona
international.projects@idipaz.es
Phone: +34 91207 17 90

Marta Marín Barba
international.grants@idipaz.es
Phone: +34 91207 17 90

OBJECTIVES

- To conduct active monitoring of international funding programs for Research & Innovation.
- To flag and disseminate relevant opportunities and calls for IdiPAZ research groups.
- To identify and actively participate in international networks of interest for the centre.
- To introduce and disseminate the capabilities of the centre and its research groups.
- To recognise, define, validate and develop project ideas that emerge in the centre.
- To support and encourage participation in information events.



- To organise and host information and training sessions on specific required areas.
- To advise on the proposal preparation and the negotiation phase with the European Commission
- To manage the approved projects.

PROGRAMMES

Horizon 2020

H2020 is the leading European program for funding research and innovation projects in various subject areas. For the period 2014-2020 it accounts with a budget of nearly € 80,000 million.

Most activities are implemented through competitive calls managed by the European Commission's Research Executive Agency. H2020 calls are fundamentally oriented research rooted in priorities established in bi-annual work programs.

The program structure can be seen reflected in the following figure:



2.7 Platforms

Horizon Europe

The future framework programme for R&I will come into force in 2021 and last until the end of 2027. The EC ambitions a budget of € 100,000 million and a drive towards Innovation and societal impact to address the UN's Sustainable Development Goals through the new instrument of Research Missions.



EU Health Programme

The Health Program of the EU is the main instrument available to the European Commission to carry out its Health Strategy for the Union. It is implemented through annual work plans, in which the criteria and funding priorities are established.

The total budget of the third program is 449.4 million euros for the period 2014-2020.

IMI

The Innovative Medicines Initiative (IMI) is the world's biggest public-private partnership in the life sciences. It joins the European Union (represented by the European Commission) and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations). Through its € 3,300 million budget for 2014-2020, IMI facilitates open collaboration in research to advance the development of, and accelerate patient access to, personalised medicines for the health and wellbeing of all, especially in areas of unmet medical need.

COST

COST is the oldest (established in 1971) and widest European intergovernmental framework for transnational Cooperation in Science and Technology.

Its aim is to enable breakthrough scientific developments leading to new concepts and products. Thereby it contributes to strengthen Europe's research and innovation capacities. These networks, COST Actions, represent the main instrument available to the program for its implementation.

The calls are continuously open with two court dates per year.

Other programmes

- INTERREG-SUDOE
- ERA-NETs

DOCUMENTATION

Webs

Funding & Tenders: it is the entry point for electronic administration of EU-funded research and innovation projects.

CORDIS: it is the European Commission's primary public repository and portal to disseminate information on all EU-funded research projects and their results in the broadest sense.

Eshorizonte2020: it is the H2020 Spanish portal.

EURAXESS: it is a unique pan-European initiative providing access to a complete range of information and support services to researchers wishing to pursue their research careers in Europe or stay connected to it.

European IPR Helpdesk: it offers free of charge, first-line support on IP and IPR matters to beneficiaries of EU funded research projects and EU SMEs involved in transnational partnership agreements, especially within the Enterprise Europe Network (EEN).

EATRIS: European Infrastructure for Translational Medicine, it provides a new development pathway, open to researchers and companies in need of support for advancing biomedical innovations.

ECRIN: European Clinical Research Infrastructure Network, it is a public, non-profit organisation that links scientific partners and networks across Europe to facilitate multinational clinical research.

Documents


Guía del participante H2020



Annotated Model Grant Agreement - AMGA December 2018 version



2.7 Platforms









CURRENT ACTIVE PROJECTS

Acronym	Title	Link to project (CORDIS or similar)	Specific web	Logo	Program	IP
COMBACTE-CARE	A New Public-Private Funded Project to Combat Carbapenem Resistance	https://cordis.europa.eu/project/rcn/203671_en.html	https://www.combacte.com/about/about-combacte-care-detail/		IMI	José Ramón Arribas
ENABLE	European Gram-negative Antibacterial Engine	https://cordis.europa.eu/project/rcn/203716_en.html	https://enable-project.eu/		IMI	Jesús Mingorance
EpiAD	Effect of early and adult-life stress on the brain epigenome: relevance for the occurrence of Alzheimer's Disease.	http://www.neurodegenerationresearch.eu/wp-content/uploads/2017/10/JPND-Project-Fact-Sheet_2017_EpiAD.pdf			ERA-NET JPND	Ana Frank
ERN RARE-LIVER	European Reference Network on hepatological diseases		http://www.rare-liver.eu/		H2020	Loreto Hierro
ERN TransplantChild (Coordinado por el HULP)	European Reference Network on transplantation in children		http://www.transplantchild.com/		EU Health Programme	Paloma Jara
	ERN-TransplantChild Support Core Systems for IT Platforms services	https://ec.europa.eu/inea/en/connecting-europe-facility/cef-telecom/2017-es-ia-0102			CEF TELECOM	Paloma Jara
ID-EPTRI	European Paediatric Translational Research Infrastructure	https://cordis.europa.eu/project/rcn/213793_en.html	https://eptri.eu/		H2020	María José Mellado
NICOFA	Nicotinamide for the treatment of Friedreich ataxia	http://www.erare.eu/node/1245			ERA-NET E-Rare	Francisco Javier Rodríguez de Rivera Garrido
	Craniofacial Microsomia: Genetic Causes and Pathway Discovery	http://grantome.com/grant/NIH/U01-DE025862-01A1			NIH-ROI	Pablo Lapunzina
ORTHOUNION	ORTHOpedic randomized clinical trial with expanded bone marrow MSC and bioceramics versus autograft in long bone nonUNIONS	https://cordis.europa.eu/project/rcn/207447_en.html	https://orthounion.eu/		H2020	Enrique Gómez Barrena



2.7 Platforms



qMAR	Quantification of the intestinal load of a targeted set of resistance genes to Monitor Antibiotic Resistance in paediatric transplant patients	https://cordis.europa.eu/project/rcn/215416_en.html	X:\Fundacion\FUNDACIÓN\TODOS LOS PROYECTOS\Proyectos de ADMINISTRACIÓN PÚBLICA\UNIÓN EUROPEA\ACTIVOS\DAHDOUH, ELIAS_qMAR		MSCA-IF-EF	Elias Dahdouh
RESSTORE	REgenerative Stem cell therapy for STroke in Europe	https://cordis.europa.eu/project/rcn/198791_en.html			H2020	Exuperio Diez Tejedor
SAPHeIN	Implementing SAPHetydoc for the wide adoption of eInvoicing	https://ec.europa.eu/inea/en/connecting-europe-facility/cef-telecom/2016-eu-ia-0109			CEF TELECOM	Ana del Prado
VIRUSCAN	Optomechanics for Virology	https://cordis.europa.eu/project/rcn/205930_en.html	https://viruscanproject.eu/		H2020	Jesús Mingorance
WEAKID	Clinical validation of miniature wearable dialysis machine	https://cordis.europa.eu/project/rcn/207629_es.html			H2020	Rafael Selgas
H2020PAZ	Impulso a la participación en H2020 de IdiPAZ				MINECO – Europa Redes y Gestores	José Ramón Arribas

Last November the Ministry of Economy and Competitiveness notified the final resolution approving the project “Promoting the participation in H2020 of IdiPAZ-H2020PAZ” presented in the call “Europa Redes y Gestores 2017”.

The final aim of the project H2020PAZ is to encourage and facilitate the participation of IdiPAZ researchers in European research, technological development and innovation programs, making possible the coordination and leadership of large projects that improve the rates of success and return of the institute.

In this sense, the H2020PAZ project has two main objectives: to consolidate and expand the current structure of the Internationalization Platform of IdiPAZ and to

encourage the participation of the research groups of the institute in international research programs - especially H2020-, technological development and innovation, by the different tasks and activities defined in this proposal.

In order to achieve these main objectives, the project is structured into four task groups with their respective sub-tasks and activities directly related to the specific objectives identified. The task groups are: Awareness raising and training; Participation in proposals; Foreign promotion; and Project Management.

H2020PAZ will have a duration of 2 years, beginning on January 1st, 2017 but the ending date has been extended to December 31st, 2019.



2.7 Platforms

PORTFOLIO OF SERVICES

- Participation in international networks of interest to the centre
- Targeted dissemination of funding and project involvement opportunities
- Organization of information sessions and training courses
- Preparation and dissemination of scientific and technological profiles of the research groups
- Advice on the definition of the project idea and the preparation of proposals

2.7.14 Tissue Engineering and 3D Printing Platform

The Tissue Engineering and 3D Printing Platform purpose is to promote the development of biomedical research and solutions based on tissue engineering and bioprinting and offer different services as 3D printing technologies, computer imaging, virtual planning and computer aided design to the professionals.

Research and activity areas of the platform are:

- Synthetic biology, bioprinting of tissues and organs → development of a skin model
- Establishment of a live organoid biobank from patients' samples
- Lab on a Chip (LOC) and Organ on a Chip (OOC) devices
- Tissue engineering approaches to develop tissue models and organs
- Development of new medical devices (biomodels, surgical guides, prosthesis and implants) based on emerging technologies as 3D printing
- Computer imaging, virtual planning and 3D printing to plan surgeries

COMPOSITION

Director

Ramón Cantero Cid

Scientific advisor


María P. De Miguel González

Lab manager

Daniel Cermeño Pampliega
PITI3D@idipaz.es

Research assistant

Mario Juárez Rodríguez



- Identification of project proposals under preparation in which the centre can be involved
- Identification of partners for projects coordinated or participated by researchers at the centre
- Support in the negotiation phase with the European Commission - EC before the signing of the grant agreement - GA
- Management of funded projects

Entrepreneur

Carlos Biec Amigo
info.piti3d@gmail.com
Phone: (+34) 91 207 15 12 (ext 2484)

EQUIPMENT


- Bioprinter Unit (VI REGEMAT 3D) for thermoplastics, microextrusion, UV curing, temperature control and injection of cell laden biomaterials
- Fused deposition modelling (FDM) 3D printer for prototyping

PORTFOLIO OF SERVICES

- Bioprinting of meshes structures with or without cells
- 3D cell cultures
- Cell viability and proliferation assays to assess biocompatibility of reactives and materials
- Development of biofabrication processes
- Development of Lab on a Chip (LOC) and Organ on a Chip (OOC) devices
- Computer imaging and tissue segmentation from TAC and MRI
- 3D virtual planning
- Computer Aided Design (CAD)
- 3D printing of biomodels, surgical guides, prosthesis and implants in polymers and metals
- Biomaterials processing and manufacturing
- Education and training in the areas of activities



2.7 Platforms



2.7.15 Food, Nutrition and Health Platform

The IdiPAZ Food, Nutrition and Health Platform (NUTRinvest) is a structure created to provide scientific-technical service and support in Human Research and Specialized Advice in Nutrition and Food issues.

The Platform provide service of Specialized Advice in Nutrition and Food at 3 levels: 1. Industries (agro-food or pharmaceutical sector) interesting in the new products development with an improved nutritional profile; 2. Companies interested in creating new technological tools to facilitate the acquisition of guidelines and healthy habits (web, app, etc.) and 3. Individual interested in knowing their nutritional status through a precision and individualized nutritional assessment.

COMPOSITION

Head

Carmen Gómez Candela (PhD, MD)
cgcandela@salud.madrid.org

Project manager

Bricia López Plaza, PhD, MSc
briciaplaza@idipaz.es

Clinical Research Associate

Samara Palma Milla (Endocrinologist) (PhD, MD)
samara.palma@salud.madrid.org

Cristina Santurino Fontecha (PhD)
cristina.santurino@idipaz.es

Edwin Fernández Cruz (PhD)
edwin.fernandez.cruz@idipaz.es

Marlhyn Valero Pérez (Nutricionist)
marlhyn.valero@idipaz.es

Natalia García Vázquez (Pharmacist)
ngarcia.hulp@salud.madrid.org

Marina Morato Martínez (Nutricionist)
marina.morato@salud.madrid.org

OBJECTIVE

To implement clinical trials or epidemiological studies well designed in the area of human nutrition, in order to validate the activity and efficacy of bioactive compounds, nutrients, foods, dietary patterns or artificial nutrition, on different parameters related to the health promotion, the disease prevention or its therapeutic activity.

MAIN SECTORS

- Agri-food/pharmaceutical industries interested in designing or validating the effectiveness of new products.
- Institutions/government agencies with an interest in expanding knowledge in the area of nutrition for the generation/implementation of political measures in Public Health.
- Public or private institutions that want to develop computer applications, or information or communication programs in the field of Nutrition of interest to health professionals, consumers or patients.
- Researchers with interest in the inclusion of nutritional variables in their research projects.
- Individuals interested in obtain information about their nutritional health and who wish to receive precision and individualized nutrition through detailed analysis.

EQUIPMENT

- Dual-energy x-ray absorptiometry (DXA)
- Bioelectric Impedance System (BIA)
- Holtain Skinfold Calipers
- Tanita digital healthcare scales
- Executive Diameter Tape
- Indirect calorimetry
- Accelerometers

PORTFOLIO OF SERVICES

- Scientific advice to improve nutritional profiles of foods or nutritional formulas
- Scientific-technical support in the area of Human Nutrition research
 - Create well designed Project Plan for Clinical Trials and other human studies
 - Management and Submission of applications to the Ethics Committee: The platform prepares and management all the documents required by obtain the approval of the Ethics Committee (Informed consent form, Letters from ethics committees. Study questionnaire (copies of any questionnaires or draft questionnaires), Case Record Forms (CRFs), Budget details, etc.)
 - Field work execution (all activities are carried out by members of the platform team with consolidated qualifications in the area)
 - Dietary studies: through the use of validated tools (Food records (24h, 3-7

Introduction 1

Executive summary 2

- 2.1 Global Analysis
- 2.2 Research Structure
- 2.3 Training Report and Teaching
- 2.4 Innovation and Transfer Activities
- 2.5 Quality Committee
- 2.6 Clinical Trials
- 2.7 Platforms**
- 2.8 Scientific Production
- 2.9 CIBERs and RETICs
- 2.10 Institutional Projects
- 2.11 Internationalization
- 2.12 Communication

Information Groups by Area 3

Associated Clinicians 4


Scientific Report
2016
2017
2018



2.7 Platforms

- days), Food Frequency Questionnaires, Weighted food records, DIAL software, calorimetry...)
- Diagnostic and screening nutritional studies: using validated methodology (Subjective Global Assessment (SGA), Nutritional Status Assessment (NSA), Malnutrition Universal Screening Tool (MUST), Mini Nutrition Assessment (MNA))
- Anthropometric studies: Weight, Height, Circumferences, Folds, Bioelectrical Impedance, DXA...
- Biochemical studies (blood, urine, feces): measurements of health markers related to the area of nutrition (glucose metabolism parameters, curves for calculating the glycemic index, lipid metabolism, inflammation, oxidation and hormonal biomarkers...)
- Physical activity studies: through the use of validated questionnaires (IPAQ, MINNESOTA...)
- Functional capacity studies: through dynamometry and validated questionnaires
- Sensory perception studies: through the use of validated questionnaires
- Satiety control studies: using biochemical markers and handling of validated questionnaires
- Quality of life studies: through the use of validated questionnaires
- Gastrointestinal Tolerance Studies: through the use of validated questionnaires
- Nutrigenetics and Metabolic Studies with our collaborating centers
- Production of scientific and technical report

- Development of computer applications for websites or mobile apps in the nutrition / food area
- Individual nutritional status evaluations and proposals for individualized nutrition intervention programs
- To contribute and design components for nutrition education strategies and programs



Introduction

1

Executive summary

2

2.1 Global Analysis

2.2 Research Structure

2.3 Training Report and Teaching

2.4 Innovation and Transfer Activities

2.5 Quality Committee

2.6 Clinical Trials

2.7 Platforms

2.8 Scientific Production

2.9 CIBERs and RETICs

2.10 Institutional Projects

2.11 Internationalization

2.12 Communication

Information Groups by Area

3


Associated Clinicians

4

Scientific Report

2016
2017
2018

2.8 Scientific Production




2.8.1 Journal Analysis

Journal	ISSN	Total of documents	Impact factor	Quartile
ACS COMBINATORIAL SCIENCE	2156-8952	1	3.2	Q2
ACTA BIOMATERIALIA	1742-7061	1	6.638	Q1
ACTA CLÍNICA BÉLGICA	1784-3286	1	0.96	Q3
ACTA ONCOLÓGICA	0284-186X	1	3.298	Q2
ACTA ORTHOPAEDICA ET TRAUMATOLOGICA TURCICA	1017-995X	1	0.896	Q4
ACTA ORTOPÉDICA MEXICANA	2306-4102	1	Not Indexed	
ACTA PEDIÁTRICA	0803-5253	2	2.265	Q2
ACTAS DERMO-SIFILIOGRÁFICAS	0001-7310	9	Not Indexed	
ACTAS UROLÓGICAS ESPAÑOLAS	0210-4806	5	1.136	Q4
AGE AND AGEING	0002-0729	1	4.511	Q1
AIDS	0269-9370	3	4.499	Q1
AIDS PATIENT CARE AND STDS	1087-2914	1	3.742	Q2
AIDS REVIEWS	1139-6121	9	2.357	Q3
AIMS NEUROSCIENCE	2373-8006	1	Not Indexed	

ALERGIA ASTMA IMMUNOLOGIA	1427-3101	1	Not Indexed	
ALIMENTARY PHARMACOLOGY & THERAPEUTICS	0269-2813	1	7.731	Q1
ALLERGOLOGIA ET IMMUNOPATHOLOGIA	0301-0546	1	1.64	Q4
ALLERGOLOGIE	0344-5062	1	0.15	Q4
ALLERGY	0105-4538	1	6.771	Q1
ALLERGY AND ASTHMA PROCEEDINGS	1088-5412	1	2.124	Q3
ALZHEIMERS & DEMENTIA	1552-5260	1	14.423	Q1
ALZHEIMERS & DEMENTIA	2352-8729	1	Not Indexed	
AMERICAN JOURNAL OF BOTANY	0002-9122	1	2.481	Q1
AMERICAN JOURNAL OF CARDIOLOGY	0002-9149	2	2.843	Q2
AMERICAN JOURNAL OF CLINICAL NUTRITION	0002-9165	3	6.568	Q1
AMERICAN JOURNAL OF DERMATOPATHOLOGY	0193-1091	1	1.106	Q4
AMERICAN JOURNAL OF HEMATOLOGY	0361-8609	1	6.137	Q1
AMERICAN JOURNAL OF HUMAN GENETICS	0002-9297	3	9.924	Q1
AMERICAN JOURNAL OF MEDICAL GENETICS PART A	1552-4825	2	2.197	Q3
AMERICAN JOURNAL OF MEDICINE	0002-9343	2	4.76	Q1



2.8 Scientific Production



Introduction **1**

Executive summary **2**

2.1 Global Analysis

2.2 Research Structure

2.3 Training Report and Teaching

2.4 Innovation and Transfer Activities

2.5 Quality Committee

2.6 Clinical Trials

2.7 Platforms

2.8 Scientific Production

2.9 CIBERs and RETICs

2.10 Institutional Projects

2.11 Internationalization

2.12 Communication

Information Groups by Area **3**

Associated Clinicians **4**

Scientific Report


2016
2017
2018

AMERICAN JOURNAL OF OPHTHALMOLOGY	0002-9394	2	4.483	Q1
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY	1931-857X	1	3.323	Q1
AMERICAN JOURNAL OF PREVENTIVE MEDICINE	0749-3797	1	4.435	Q1
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE	1073-449X	2	16.494	Q1
AMERICAN JOURNAL OF TRANSPLANTATION	1600-6135	1	7.163	Q1
AMERICAN SOCIETY OF NEURORADIOLOGY	1936-959X	1	3.256	Q2
AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION	2167-8421	2	2.883	Q2
ANALES DE PEDIATRIA	1695-9531	26	1.166	Q3
ANALYTICAL CHEMISTRY	0003-2700	2	6.35	Q1
ANDROLOGY	2047-2919	1	3.106	Q1
ANESTHESIA AND ANALGESIA	0003-2999	1	3.489	Q2
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION	1433-7851	1	12.257	Q1
ANGIOLOGIA	0003-3170	2		Not Indexed
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY	1081-1206	3	3.56	Q2
ANNALS OF HEMATOLOGY	0939-5555	2	2.85	Q3
ANNALS OF INTERNAL MEDICINE	0003-4819	1	19.315	Q1
ANNALS OF ONCOLOGY	0923-7534	1	14.196	Q1
ANNALS OF PEDIATRIC CARDIOLOGY	0974-2069	1		Not Indexed
ANNALS OF THE RHEUMATIC DISEASES	0003-4967	3	14.299	Q1
ANTICANCER RESEARCH	0250-7005	2	1.935	Q4
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY	0066-4804	2	4.715	Q1
ANTIOXIDANTS & REDOX SIGNALING	1523-0864	3	5.828	Q1
ANTIVIRAL THERAPY	1359-6535	2	2.305	Q3
APLEY & SOLOMON'S SYSTEM OF ORTHOPAEDICS AND TRAUMA, 10TH EDITION	xxxx-xxxx	1		Not Indexed
APMIS	0903-4641	1	2.225	Q2
APPLIED PHYSICS LETTERS	0003-6951	1	3.521	Q1
APPLIED RADIATION AND ISOTOPES	0969-8043	1	1.343	Q2
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS	0003-9861	1	3.559	Q2
ARCHIVES OF BONE AND JOINT SURGERY-ABJS	2345-4644	4		Not Indexed
ARCHIVES OF GYNECOLOGY AND OBSTETRICS	0932-0067	1	2.199	Q2
ARCHIVES OF OSTEOPOROSIS	1862-3522	1	2.469	Q2
ARCHIVOS ARGENTINOS DE PEDIATRÍA	0325-0075	1	0.506	Q4
ARCHIVOS DE BRONCONEUMOLOGÍA	0300-2896	14	4.214	Q1
ARCHIVOS DE CARDIOLOGÍA DE MÉXICO	1405-9940	1		Not Indexed
ARCHIVOS DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA	1989-7286	1		Not Indexed
ARCHIVOS ESPAÑOLES DE UROLOGÍA	0004-0614	16	0.335	Q4

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY	1079-5642	1	6.618	Q1
ARTHRITIS & RHEUMATOLOGY	2326-5191	1	9.002	Q1
ARTHRITIS RESEARCH & THERAPY	1478-6354	1	4.148	Q2
ASCLEPIO-REVISTA DE HISTORIA DE LA MEDICINA Y DE LA CIENCIA	0210-4466	1		Not Indexed
ASIAN JOURNAL OF ANESTHESIOLOGY	2468-824X	1		Not Indexed
ASIAN JOURNAL OF UROLOGY	2214-3882	1		Not Indexed
ATENCIÓN PRIMARIA	0212-6567	1	1.346	Q3
AUDIOLOGY AND NEURO-OTOLOGY	1420-3030	1	2.053	Q2
AUTOPHAGY	1554-8627	1	11.059	Q1
BENEFICIAL MICROBES	1876-2883	1	2.939	Q2
BIOCHEMICAL GENETICS	0006-2928	1	1.931	Q3
BIOCHEMICAL JOURNAL	0264-6021	1	4.331	Q1
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE	0925-4439	4	4.328	Q1
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH	0167-4889	1	4.739	Q1
BIOCONJUGATE CHEMISTRY	1043-1802	1	4.349	Q1
BIODRUGS	1173-8804	1	4.903	Q1
BIOLAW JOURNAL-RIVISTA DI BIODIRITTO	2284-4503	1		Not Indexed
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION	1083-8791	3	3.599	Q2
BIOMED RESEARCH INTERNATIONAL	2314-6133	1	2.197	Q3
BIOMEDICINES	2227-9059	1		Not Indexed
BIOMOLECULES	2218-273X	1	4.694	Q1
BLADDER CANCER	2352-3727	1		Not Indexed
BLOOD PURIFICATION	0253-5068	1	2.363	Q2
BLOOD REVIEWS	0268-960X	2	6.125	Q1
BMC CANCER	1471-2407	1	2.933	Q3
BMC FAMILY PRACTICE	1471-2296	1	2.431	Q2
BMC GASTROENTEROLOGY	1471-230X	1	2.252	Q3
BMC GENOMICS	1471-2164	1	3.501	Q2
BMC HEALTH SERVICES RESEARCH	1472-6963	1	1.932	Q3
BMC MEDICAL GENETICS	1471-2350	2	1.74	Q3
BMC MEDICINE	1741-7015	1	8.285	Q1
BMC NEPHROLOGY	1471-2369	2	2.088	Q3
BMC PHARMACOLOGY & TOXICOLOGY	2050-6511	1	2.103	Q3
BMC PUBLIC HEALTH	1471-2458	1	2.567	Q2
BMJ case reports	1757-790X	1		Not Indexed
BMJ OPEN	2044-6055	1	2.376	Q2



2.8 Scientific Production



Introduction **1**

Executive summary **2**

2.1 Global Analysis

2.2 Research Structure

2.3 Training Report and Teaching

2.4 Innovation and Transfer Activities

2.5 Quality Committee

2.6 Clinical Trials

2.7 Platforms

2.8 Scientific Production

2.9 CIBERs and RETICs

2.10 Institutional Projects

2.11 Internationalization

2.12 Communication

Information Groups by Area **3**

Associated Clinicians **4**

Scientific Report


2016
2017
2018

BONE & JOINT JOURNAL	2049-4394	1	4.301	Q1
BRAIN INJURY	0269-9052	1	1.665	Q2
BRAIN STRUCTURE & FUNCTION	1863-2653	1	3.622	Q1
BREAST CANCER RESEARCH AND TREATMENT	0167-6806	2	3.471	Q2
BRITISH JOURNAL OF CANCER	0007-0920	1	5.416	Q1
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY	0306-5251	1	3.867	Q1
BRITISH JOURNAL OF DERMATOLOGY	0007-0963	1	6.714	Q1
BRITISH JOURNAL OF HAEMATOLOGY	0007-1048	2	5.206	Q1
BRITISH JOURNAL OF RADIOLOGY	0007-1285	2	1.939	Q3
BURNS	0305-4179	1	2.247	Q2
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY	2291-2789	1	1.714	Q4
CANCER	0008-543X	1	5.238	Q1
CANCER LETTERS	0304-3835	1	6.508	Q1
CANCER TREATMENT REVIEWS	0305-7372	1	8.332	Q1
CARBON	0008-6223	1	7.466	Q1
CARCINOGENESIS	0143-3334	1	4.004	Q2
CARDIOLOGY JOURNAL	1897-5593	1	1.743	Q3
CARDIOVASCULAR & HEMATOLOGICAL AGENTS IN MEDICINAL CHEMISTRY	1875-6182	1		Not Indexed
CARDIOVASCULAR & HEMATOLOGICAL DISORDERS DRUG TARGETS	2212-4063	1		Not Indexed
CARDIOVASCULAR DRUGS AND THERAPY	0920-3206	1	4.181	Q1
CELL DEATH & DISEASE	2041-4889	1	5.959	Q1
CELL DEATH AND DIFFERENTIATION	1350-9047	1	8.086	Q1
CELLS	2073-4409	1	5.656	Q1
CELLULAR IMMUNOLOGY	0008-8749	1	3.291	Q2
CEREBRAL CORTEX	1047-3211	1	5.437	Q1
CIRCULATION	0009-7322	1	23.054	Q1
CIRUGÍA CARDIOVASCULAR	1134-0096	2		Not Indexed
CIRUGÍA ESPAÑOLA	0009-739X	1	0.835	Q4
CIRUGÍA PEDIÁTRICA	0214-1221	11		Not Indexed
CLINICA CHIMICA ACTA	0009-8981	1	2.735	Q2
CLÍNICA E INVESTIGACIÓN EN ARTERIOSCLEROSIS	0214-9168	3		Not Indexed
CLINICAL & TRANSLATIONAL ONCOLOGY	1699-048X	15	2.441	Q3
CLINICAL AND EXPERIMENTAL ALLERGY	0954-7894	3	4.471	Q2
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY	0392-856X	5	3.238	Q2
CLINICAL AND TRANSLATIONAL ALLERGY	2045-7022	2	4.232	Q2
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY	2155-384X	1	4.803	Q1
CLINICAL BREAST CANCER	1526-8209	1	2.762	Q3

CLINICAL CANCER RESEARCH	1078-0432	2	8.911	Q1
CLINICAL CHEMISTRY	0009-9147	3	6.891	Q1
CLINICAL CHEMISTRY AND LABORATORY MEDICINE	1434-6621	3	3.638	Q1
CLINICAL ENDOCRINOLOGY	0300-0664	1	2.897	Q3
CLINICAL EPIGENETICS	1868-7075	1	5.496	Q1
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY	1542-3565	2	7.958	Q1
CLINICAL GENETICS	0009-9163	3	4.104	Q1
CLINICAL INFECTIOUS DISEASES	1058-4838	2	9.055	Q1
CLINICAL JOURNAL OF PAIN	0749-8047	1	2.893	Q2
CLINICAL KIDNEY JOURNAL	2048-8505	1	2.975	Q1
CLINICAL MICROBIOLOGY AND INFECTION	1198-743X	3	6.425	Q1
CLINICAL NEUROPHARMACOLOGY	0362-5664	1	1.272	Q4
CLINICAL NUTRITION	0261-5614	17	6.042	Q1
CLINICAL NUTRITION ESPEN	2405-4577	1		Not Indexed
CLINICAL REHABILITATION	0269-2155	1	2.738	Q1
CLINICAL RESEARCH IN CARDIOLOGY	1861-0684	2	4.907	Q1
CLINICAL RHEUMATOLOGY	0770-3198	1	2.293	Q3
CLINICAL SCIENCE	0143-5221	2	5.237	Q1
COCHLEAR IMPLANTS INTERNATIONAL	1754-7628	1		Not Indexed
COMMUNICATIONS BIOLOGY	2399-3642	1		Not Indexed
CRITICAL CARE	1466-609X	2	6.959	Q1
CRITICAL CARE MEDICINE	0090-3493	2	6.971	Q1
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY	1040-8428	1	5.012	Q1
CTS-CLINICAL AND TRANSLATIONAL SCIENCE	1752-8054	1	3.989	Q2
CUADERNOS DE BIOÉTICA	1132-1989	1		Not Indexed
CURRENT ALLERGY AND ASTHMA REPORTS	1529-7322	1	3.982	Q2
CURRENT CARDIOVASCULAR IMAGING REPORTS	1941-9066	1		Not Indexed
CURRENT GENE THERAPY	1566-5232	1	2.218	Q3
CURRENT HEMATOLOGIC MALIGNANCY REPORTS	1558-8211	1	2.397	Q3
CURRENT HIV/AIDS REPORTS	1548-3568	1	4.382	Q1
CURRENT MEDICAL IMAGING REVIEWS	1573-4056	1	0.533	Q4
CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY	1528-4050	2	3.014	Q3
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY	1040-872X	1	2.411	Q2
CURRENT OPINION IN ORGAN TRANSPLANTATION	1087-2418	1	2.574	Q3
CURRENT PHARMACEUTICAL DESIGN	1381-6128	1	2.412	Q3
CURRENT UROLOGY REPORTS	1527-2737	1	2.079	Q3
CYTOMETRY PART B-CLINICAL CYTOMETRY	1552-4949	1	2.938	Q1
CYTOPATHOLOGY	0956-5507	2	1.473	Q3



2.8 Scientific Production



Introduction 1

Executive summary 2

2.1 Global Analysis

2.2 Research Structure

2.3 Training Report and Teaching

2.4 Innovation and Transfer Activities

2.5 Quality Committee

2.6 Clinical Trials

2.7 Platforms

2.8 Scientific Production

2.9 CIBERs and RETICs

2.10 Institutional Projects

2.11 Internationalization

2.12 Comunication

Information Groups by Area 3

Associated Clinicians 4

Scientific Report


2016
2017
2018

CYTOTHERAPY	1465-3249	I	4.297	Q1
DATA IN BRIEF	2352-3409	I	Not Indexed	
DEPRESSION AND ANXIETY	1091-4269	I	4.86	Q1
DEVELOPMENT	0950-1991	I	5.763	Q1
DIABETES CARE	0149-5992	2	15.27	Q1
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY	1178-7007	I	3.319	Q2
DIABETES RESEARCH AND CLINICAL PRACTICE	0168-8227	I	3.239	Q2
DIAGNOSTIC CYTOPATHOLOGY	8755-1039	2	1.402	Q2
DIGESTIVE AND LIVER DISEASE	1590-8658	I	3.037	Q2
DISABILITY AND REHABILITATION	0963-8288	I	2.054	Q2
DISEASE MODELS & MECHANISMS	1754-8403	I	4.028	Q1
DRUG SAFETY	0114-5916	I	3.526	Q1
DRUGS IN R&D	1174-5886	I	Not Indexed	
EBIOMEDICINE	2352-3964	I	6.68	Q1
EFORT OPEN REVIEWS	2058-5241	4	Not Indexed	
EJSO	0748-7983	I	Not Indexed	
ELIFE	2050-084X	I	7.551	Q1
EMBO MOLECULAR MEDICINE	1757-4676	I	10.624	Q1
EMERGENCIAS	1137-6821	3	3.35	Q1
EMERGING INFECTIOUS DISEASES	1080-6040	2	7.185	Q1
ENDOCRINE RESEARCH	0743-5800	I	1.629	Q4
ENDOCRINOLOGÍA DIABETES Y NUTRICIÓN	2530-0180	5	0.934	Q4
ENDOCRINOLOGY	0013-7227	I	3.8	Q2
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGÍA CLÍNICA	0213-005X	18	1.685	Q4
ENTROPY	1099-4300	I	2.419	Q2
ENVIRONMENTAL POLLUTION	0269-7491	I	5.714	Q1
ENVIRONMENTAL RESEARCH	0013-9351	I	5.026	Q1
EPIDEMIOLOGY AND INFECTION	0950-2688	I	2.047	Q2
EPIGENETICS	1559-2294	I	4.584	Q1
EPIGENOMES	2075-4655	I	Not Indexed	
EPIGENOMICS	1750-1911	3	4.404	Q1
ERJ OPEN RESEARCH	2312-0541	I	Not Indexed	
ESC HEART FAILURE	2055-5822	I	3.407	Q2
EURASIAN JOURNAL OF MEDICINE	1308-8734	2	Not Indexed	
EUROINTERVENTION	1774-024X	2	4.018	Q2
EUROPACE	1099-5129	5	6.1	Q1
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY	0937-4477	I	1.75	Q2

EUROPEAN HEART JOURNAL-ACUTE CARDIOVASCULAR CARE	2048-8726	I	3.734	Q2
EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING	2047-2404	2	5.26	Q1
EUROPEAN JOURNAL OF ANAESTHESIOLOGY	0265-0215	I	4.14	Q1
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION	0014-2972	3	2.784	Q1
EUROPEAN JOURNAL OF CLINICAL NUTRITION	0954-3007	I	3.114	Q2
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY	0954-691X	2	2.198	Q3
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY	0392-2936	I	0.245	Q4
EUROPEAN JOURNAL OF HAEMATOLOGY	0902-4441	2	2.217	Q3
EUROPEAN JOURNAL OF HEART FAILURE	1388-9842	I	13.965	Q1
EUROPEAN JOURNAL OF HUMAN GENETICS	1018-4813	2	3.65	Q2
EUROPEAN JOURNAL OF INTERNAL MEDICINE	0953-6205	3	3.66	Q1
EUROPEAN JOURNAL OF MEDICAL GENETICS	1769-7212	3	2.022	Q3
EUROPEAN JOURNAL OF NUTRITION	1436-6207	I	4.449	Q1
EUROPEAN JOURNAL OF PEDIATRIC SURGERY	0939-7248	5	1.148	Q4
EUROPEAN JOURNAL OF PEDIATRIC SURGERY REPORTS	2194-7619	2	Not Indexed	
EUROPEAN JOURNAL OF PEDIATRICS	0340-6199	3	2.188	Q2
EUROPEAN JOURNAL OF RHEUMATOLOGY	2147-9720	I	Not Indexed	
EUROPEAN JOURNAL OF TRAUMA AND EMERGENCY SURGERY	1863-9933	I	1.781	Q2
EUROPEAN RESPIRATORY JOURNAL	0903-1936	2	11.807	Q1
EUROPEAN SPINE JOURNAL	0940-6719	4	2.513	Q2
EUROPEAN STROKE JOURNAL	2396-9873	I	Not Indexed	
EUROSURVEILLANCE	1560-7917	4	7.421	Q1
EXPERIMENTAL EYE RESEARCH	0014-4835	I	2.998	Q1
EXPERT OPINION ON BIOLOGICAL THERAPY	1471-2598	I	3.585	Q2
EXPERT OPINION ON DRUG SAFETY	1474-0338	2	3.22	Q2
EXPERT OPINION ON ORPHAN DRUGS	2167-8707	I	0.763	Q4
EXPERT REVIEW OF CLINICAL PHARMACOLOGY	1751-2433	2	2.776	Q2
EXPERT REVIEW OF HEMATOLOGY	1747-4086	3	2.505	Q3
FARMACIA HOSPITALARIA	1130-6343	I	Not Indexed	
FASEB JOURNAL	0892-6638	I	5.391	Q1
FOOD & FUNCTION	2042-6496	3	3.241	Q1
FOOD AND CHEMICAL TOXICOLOGY	0278-6915	I	3.775	Q1
FOOD CONTROL	0956-7135	2	4.248	Q1
FRONTIERS IN AGING NEUROSCIENCE	1663-4365	2	3.633	Q2
FRONTIERS IN IMMUNOLOGY	1664-3224	13	4.716	Q2
FRONTIERS IN MOLECULAR NEUROSCIENCE	1662-5099	I	3.72	Q2



2.8 Scientific Production



Introduction **1**

Executive summary **2**

2.1 Global Analysis

2.2 Research Structure

2.3 Training Report and Teaching

2.4 Innovation and Transfer Activities

2.5 Quality Committee

2.6 Clinical Trials

2.7 Platforms

2.8 Scientific Production

2.9 CIBERs and RETICs

2.10 Institutional Projects

2.11 Internationalization

2.12 Communication

Information Groups by Area **3**

Associated Clinicians **4**

Scientific Report


2016
2017
2018

FRONTIERS IN ONCOLOGY	2234-943X	1	4.137	Q2
FRONTIERS IN PEDIATRICS	2296-2360	1	2.349	Q2
FRONTIERS IN PHARMACOLOGY	1663-9812	2	3.845	Q1
FRONTIERS IN PHYSIOLOGY	1664-042X	4	3.201	Q2
FRONTIERS IN SURGERY	2296-875X	1	Not Indexed	
FUTURE CARDIOLOGY	1479-6678	1	Not Indexed	
FUTURE ONCOLOGY	1479-6694	1	2.279	Q3
GACETA SANITARIA	0213-9111	1	1.653	Q3
GASTRIC CANCER	1436-3291	1	5.554	Q1
GASTROENTEROLOGÍA Y HEPATOLOGÍA	0210-5705	4	1.126	Q4
GENE	0378-1119	1	2.638	Q2
GENE REPORTS	2452-0144	1	Not Indexed	
GENETICS IN MEDICINE	1098-3600	4	8.683	Q1
GLIA	0894-1491	3	5.829	Q1
GLOBAL SPINE JOURNAL	2192-5682	1	Not Indexed	
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY	0721-832X	1	2.25	Q2
GUT	0017-5749	1	17.943	Q1
HAEMATOLÓGICA	0390-6078	3	7.57	Q1
HAEMOPHILIA	1351-8216	4	3.59	Q2
HEARING RESEARCH	0378-5955	1	2.952	Q1
HEART	1355-6037	1	5.082	Q1
HEPATOLOGY	0270-9139	1	14.971	Q1
HISTOPATHOLOGY	0309-0167	1	3.294	Q2
HISTORIA Y MEMORIA DE LA EDUCACIÓN	2444-0043	1	Not Indexed	
HIV MEDICINE	1464-2662	3	3.734	Q2
HLA	2059-2302	1	2.785	Q2
HORMONE RESEARCH IN PAEDIATRICS	1663-2818	1	2.324	Q2
HOSPITAL PRACTICE (1995)	2154-8331	2	Not Indexed	
HSS JOURNAL	1556-3316	2	Not Indexed	
HUMAN GENETICS	0340-6717	1	5.207	Q1
HUMAN MOLECULAR GENETICS	0964-6906	1	4.544	Q1
HUMAN MOVEMENT SCIENCE	0167-9457	1	1.928	Q2
HUMAN MUTATION	1059-7794	4	4.453	Q1
HYPERTENSION	0194-911X	3	7.017	Q1
INDIAN JOURNAL OF SURGERY	0972-2068	1	0.55	Q4
INFECTION	0300-8126	1	2.927	Q2
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY	0899-823X	1	2.856	Q2
INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED	0020-1383	3	1.834	Q2

INTENSIVE CARE MEDICINE	0342-4642	5	18.967	Q1
INTENSIVE CARE MEDICINE EXPERIMENTAL	2197-425X	1	Not Indexed	
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS	0924-8579	3	4.615	Q1
INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS	0391-3988	1	1.232	Q4
INTERNATIONAL JOURNAL OF CANCER	0020-7136	3	4.982	Q1
INTERNATIONAL JOURNAL OF CARDIOLOGY	0167-5273	1	3.471	Q2
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE	1178-2005	1	3.274	Q2
INTERNATIONAL JOURNAL OF CLINICAL AND HEALTH PSYCHOLOGY	1697-2600	1	3.317	Q1
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY	2210-7703	1	1.692	Q4
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE	1368-5031	1	2.613	Q2
INTERNATIONAL JOURNAL OF DERMATOLOGY	0011-9059	2	1.794	Q3
INTERNATIONAL JOURNAL OF EMERGENCY SERVICES	2047-0894	1	Not Indexed	
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY	0300-5771	3	7.339	Q1
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER	1048-891X	2	1.746	Q3
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES	1422-0067	5	4.183	Q2
INTERNATIONAL JOURNAL OF OBESITY	0307-0565	1	4.514	Q1
INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY	0165-5876	1	1.225	Q3
INTERNATIONAL JOURNAL OF PUBLIC HEALTH	1661-8556	1	2.373	Q2
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES	1756-1841	2	1.938	Q4
INTERNATIONAL JOURNAL OF SURGERY	1743-9191	1	3.158	Q1
INTERNATIONAL JOURNAL OF SYSTEMATIC AND EVOLUTIONARY MICROBIOLOGY	1466-5026	2	2.166	Q3
ISCIENCE	2589-0042	1	Not Indexed	
JAAD CASE REPORTS	2352-5126	1	Not Indexed	
JACC-CARDIOVASCULAR INTERVENTIONS	1936-8798	3	9.544	Q1
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES	1525-4135	2	3.863	Q1
JAMA DERMATOLOGY	2168-6068	1	7.995	Q1
JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY	2168-6181	1	3.502	Q1
JAMA PSYCHIATRY	2168-622X	1	15.916	Q1
JIMD REPORTS	2192-8304	2	Not Indexed	
JMIR SERIOUS GAMES	2291-9279	1	3.351	Q2
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE	0027-8874	2	13.757	Q1



2.8 Scientific Production



Introduction **1**

Executive summary **2**

2.1 Global Analysis

2.2 Research Structure

2.3 Training Report and Teaching

2.4 Innovation and Transfer Activities

2.5 Quality Committee

2.6 Clinical Trials

2.7 Platforms

2.8 Scientific Production

2.9 CIBERs and RETICs

2.10 Institutional Projects

2.11 Internationalization

2.12 Communication

Information Groups by Area **3**

Associated Clinicians **4**

Scientific Report

2016
2017
2018

JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY	0021-8561	1	3.571	Q1
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY	0091-6749	4	14.11	Q1
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE	2213-2198	1	7.55	Q1
JOURNAL OF ALZHEIMERS DISEASE	1387-2877	1	3.517	Q2
JOURNAL OF ANATOMY	0021-8782	1	2.638	Q1
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY	0305-7453	2	5.113	Q1
JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS	1526-9914	1	1.544	Q3
JOURNAL OF ARTHROPLASTY	0883-5403	2	3.524	Q1
JOURNAL OF ASTHMA AND ALLERGY	1178-6965	1	4.694	Q1
JOURNAL OF BIOLOGICAL CHEMISTRY	0021-9258	1	4.106	Q2
JOURNAL OF BODYWORK AND MOVEMENT THERAPIES	1360-8592	2	Not Indexed	
JOURNAL OF CARDIOVASCULAR MAGNETIC RESONANCE	1097-6647	1	5.07	Q1
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY	0160-2446	1	2.371	Q3
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE	1582-4934	1	4.658	Q1
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM	0271-678X	1	6.04	Q1
JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY	1380-3395	1	1.994	Q3
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM	0021-972X	2	5.605	Q1
JOURNAL OF CLINICAL HYPERTENSION	1524-6175	2	2.444	Q3
JOURNAL OF CLINICAL IMMUNOLOGY	0271-9142	3	4.128	Q2
JOURNAL OF CLINICAL INVESTIGATION	0021-9738	2	12.282	Q1
JOURNAL OF CLINICAL LIPIDOLOGY	1933-2874	1	3.581	Q2
JOURNAL OF CLINICAL ONCOLOGY	0732-183X	3	28.245	Q1
JOURNAL OF CLINICAL VIROLOGY	1386-6532	1	3.02	Q2
JOURNAL OF COMPARATIVE NEUROLOGY	0021-9967	1	3.239	Q1
JOURNAL OF CRITICAL CARE	0883-9441	1	2.783	Q2
JOURNAL OF CROHNS & COLITIS	1873-9946	1	7.827	Q1
JOURNAL OF DERMATOLOGY	0385-2407	1	3.377	Q1
JOURNAL OF ENDOCRINOLOGY	0022-0795	1	4.381	Q1
JOURNAL OF EXPERIMENTAL ORTHOPAEDICS	2197-1153	1	Not Indexed	
JOURNAL OF GENETIC COUNSELING	1059-7700	2	2.446	Q3
JOURNAL OF GERIATRIC ONCOLOGY	1879-4068	2	3.164	Q2
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE	2213-7165	1	2.469	Q3
JOURNAL OF GYNECOLOGIC ONCOLOGY	2005-0380	1	2.914	Q1
JOURNAL OF HEAD TRAUMA REHABILITATION	0885-9701	1	2.667	Q1

JOURNAL OF HEALTHCARE QUALITY RESEARCH	2603-6479	2	Not Indexed	
JOURNAL OF HOSPITAL INFECTION	0195-6701	2	3.704	Q1
JOURNAL OF HYPERTENSION	0263-6352	4	4.209	Q1
JOURNAL OF INFECTIOUS DISEASES	0022-1899	6	5.045	Q1
JOURNAL OF INORGANIC BIOCHEMISTRY	0162-0134	1	3.224	Q1
JOURNAL OF INTENSIVE CARE	2052-0492	1	Not Indexed	
JOURNAL OF INTERNAL MEDICINE	0954-6820	1	6.051	Q1
JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY	1383-875X	1	1.534	Q4
JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY	1018-9068	11	3.802	Q2
JOURNAL OF LAPAROENDOSCOPIC & ADVANCED SURGICAL TECHNIQUES	1092-6429	1	1.322	Q3
JOURNAL OF LIPID RESEARCH	0022-2275	1	4.743	Q1
JOURNAL OF MANIPULATIVE AND PHYSIOLOGICAL THERAPEUTICS	0161-4754	1	1.274	Q3
JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE	1476-7058	4	1.569	Q3
JOURNAL OF MEDICAL ENTOMOLOGY	0022-2585	1	1.907	Q1
JOURNAL OF MEDICAL GENETICS	0022-2593	1	5.899	Q1
JOURNAL OF MICROBIOLOGICAL METHODS	0167-7012	1	1.801	Q3
JOURNAL OF MINIMALLY INVASIVE GYNECOLOGY	1553-4650	1	2.414	Q2
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY	0022-2828	2	5.056	Q1
JOURNAL OF NANOBIO TECHNOLOGY	1477-3155	1	5.345	Q1
JOURNAL OF NEUROINTERVENTIONAL SURGERY	1759-8478	1	3.925	Q1
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY	0022-3050	1	8.272	Q1
JOURNAL OF NEURO-OPHTHALMOLOGY	1070-8022	1	2.509	Q2
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY	0022-3069	1	3.46	Q1
JOURNAL OF NEUROSURGERY-SPINE	1547-5654	1	2.998	Q1
JOURNAL OF NUTRITIONAL BIOCHEMISTRY	0955-2863	1	4.49	Q1
JOURNAL OF OBSTETRICS AND GYNAECOLOGY	0144-3615	2	0.588	Q4
JOURNAL OF ORAL & FACIAL PAIN AND HEADACHE	2333-0384	2	1.443	Q3
JOURNAL OF PAIN	1526-5900	1	5.424	Q1
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT	0885-3924	1	3.378	Q1
JOURNAL OF PAIN RESEARCH	1178-7090	2	2.236	Q3
JOURNAL OF PARENTERAL AND ENTERAL NUTRITION	0148-6071	1	3.612	Q1
JOURNAL OF PATHOLOGY	0022-3417	2	5.942	Q1
JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM	0334-018X	1	1.239	Q3



2.8 Scientific Production



Introduction

1

Executive summary

2

2.1 Global Analysis

2.2 Research Structure

2.3 Training Report and Teaching

2.4 Innovation and Transfer Activities

2.5 Quality Committee

2.6 Clinical Trials

2.7 Platforms

2.8 Scientific Production

2.9 CIBERs and RETICs

2.10 Institutional Projects

2.11 Internationalization

2.12 Communication

Information Groups by Area

3

Associated Clinicians

4

Scientific Report

2016
2017
2018

JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION	0277-2116	4	3.015	Q1
JOURNAL OF PEDIATRIC INFECTIOUS DISEASES	1305-7707	1	0.197	Q4
JOURNAL OF PEDIATRIC NEUROLOGY	1304-2580	4	Not Indexed	
JOURNAL OF PEDIATRIC SURGERY	0022-3468	6	2.092	Q2
JOURNAL OF PINEAL RESEARCH	0742-3098	1	15.221	Q1
JOURNAL OF PSYCHOPHARMACOLOGY	0269-8811	1	4.221	Q1
JOURNAL OF PUBLIC HEALTH	1741-3842	1	Not Indexed	
JOURNAL OF RHEUMATOLOGY	0315-162X	2	3.634	Q2
JOURNAL OF SHOULDER AND ELBOW SURGERY	1058-2746	1	2.865	Q1
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY	0735-1097	6	18.639	Q1
JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION	0731-5724	1	2.08	Q3
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY	0002-8614	1	4.113	Q1
JOURNAL OF THE AMERICAN HEART ASSOCIATION	2047-9980	4	4.66	Q1
JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION	1525-8610	3	4.899	Q1
JOURNAL OF THE ASSOCIATION OF PHYSICIANS OF INDIA	0004-5772	1	Not Indexed	
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY	0926-9959	3	5.113	Q1
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY	0022-5223	1	5.261	Q1
JOURNAL OF THROMBOSIS AND HAEMOSTASIS	1538-7933	1	4.662	Q1
JOURNAL OF TRAUMA AND ACUTE CARE SURGERY	2163-0755	1	3.377	Q1
JOURNAL OF TRAVEL MEDICINE	1195-1982	1	4.155	Q1
JOURNAL OF UROLOGY	0022-5347	1	5.647	Q1
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY	1051-0443	2	2.828	Q2
JOURNAL OF VASCULAR SURGERY-VENOUS AND LYMPHATIC DISORDERS	2213-333X	1	2.696	Q2
JOURNAL OF VIRAL HEPATITIS	1352-0504	1	4.016	Q1
JOURNAL OF VIROLOGY	0022-538X	1	4.324	Q1
JOURNAL OF VIRUS ERADICATION	2055-6640	1	Not Indexed	
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES	1079-5006	2	4.711	Q1
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS	1940-087X	1	1.108	Q3
KIDNEY & BLOOD PRESSURE RESEARCH	1420-4096	1	2.123	Q2
LANCET	0140-6736	7	59.102	Q1
LANCET CHILD & ADOLESCENT HEALTH	2352-4642	1	Not Indexed	
LANCET GASTROENTEROLOGY & HEPATOLOGY	2468-1253	1	12.856	Q1
LANCET HIV	2352-3018	2	14.753	Q1

LANCET INFECTIOUS DISEASES	1473-3099	2	27.516	Q1
LANCET NEUROLOGY	1474-4422	1	28.755	Q1
LANCET PUBLIC HEALTH	2468-2667	1	11.6	Q1
LEUKEMIA	0887-6924	1	9.944	Q1
LIVER TRANSPLANTATION	1527-6465	1	4.159	Q1
MALARIA JOURNAL	1475-2875	1	2.798	Q1
MARINE DRUGS	1660-3397	1	3.772	Q1
MATERNAL AND CHILD HEALTH JOURNAL	1092-7875	1	1.736	Q2
MATURITAS	0378-5122	2	3.654	Q1
MAYO CLINIC PROCEEDINGS. INNOVATIONS, QUALITY & OUTCOMES	2542-4548	1	Not Indexed	
MEDIATORS OF INFLAMMATION	0962-9351	3	3.545	Q2
MEDICAL HYPOTHESES	0306-9877	1	1.322	Q4
MEDICAL MYCOLOGY	1369-3786	3	2.851	Q1
MEDICAL MYCOLOGY CASE REPORTS	2211-7539	1	Not Indexed	
MEDICINA CLÍNICA	0025-7753	16	1.277	Q3
MEDICINA INTENSIVA	0210-5691	5	1.982	Q3
MEDICINA ORAL PATOLOGÍA ORAL Y CIRUGÍA BUCAL	1698-6946	1	1.284	Q3
MEDICINE	0025-7974	5	1.87	Q2
METABOLOMICS	1573-3882	1	3.167	Q2
MINERVA ANESTESIOLOGICA	0375-9393	2	2.84	Q2
MINERVA GINECOLÓGICA	0026-4784	1	Not Indexed	
MINERVA UROLÓGICA E NEFROLÓGICA	0393-2249	1	2.477	Q2
MOLECULAR AND CELLULAR BIOLOGY	0270-7306	1	3.735	Q2
MOLECULAR CANCER	1476-4598	1	10.679	Q1
MOLECULAR CANCER THERAPEUTICS	1535-7163	1	4.856	Q1
MOLECULAR CARCINOGENESIS	0899-1987	1	3.411	Q2
MOLECULAR CELL	1097-2765	1	14.548	Q1
MOLECULAR GENETICS AND METABOLISM	1096-7192	1	3.61	Q2
MOLECULAR IMMUNOLOGY	0161-5890	1	3.064	Q2
MOLECULAR METABOLISM	2212-8778	2	6.181	Q1
MOLECULAR NEUROBIOLOGY	0893-7648	1	4.586	Q1
MOLECULAR ONCOLOGY	1878-0261	1	5.962	Q1
MUSCULOSKELETAL SCIENCE AND PRACTICE	2468-7812	1	1.125	Q2
MYCOSES	0933-7407	1	1.278	Q2
NATURE	0028-0836	2	43.07	Q1
NATURE COMMUNICATIONS	2041-1723	4	11.878	Q1
NATURE MEDICINE	1078-8956	1	30.641	Q1
NATURE REVIEWS CARDIOLOGY	1759-5002	1	17.42	Q1



2.8 Scientific Production



Introduction

1

Executive summary

2

2.1 Global Analysis

2.2 Research Structure

2.3 Training Report and Teaching

2.4 Innovation and Transfer Activities

2.5 Quality Committee

2.6 Clinical Trials

2.7 Platforms

2.8 Scientific Production

2.9 CIBERs and RETICs

2.10 Institutional Projects

2.11 Internationalization

2.12 Communication

Information Groups by Area

3

Associated Clinicians

4

Scientific Report


2016
2017
2018

NATURE REVIEWS ENDOCRINOLOGY	1759-5029	2	24.646	Q1
NEFROLOGÍA	0211-6995	7	1.439	Q4
NEONATOLOGY	1661-7800	1	2.544	Q1
NEOPLASIA	1476-5586	1	3.837	Q2
NEPHROLOGY DIALYSIS TRANSPLANTATION	0931-0509	3	4.198	Q1
NEUROBIOLOGY OF AGING	0197-4580	1	4.398	Q1
NEUROCIURGÍA	1130-1473	3	0.519	Q4
NEUROLOGÍA	0213-4853	6	2.038	Q3
NEUROLOGY	0028-3878	2	8.689	Q1
NEUROPEDIATRICS	0174-304X	1	1.654	Q3
NEUROSURGICAL FOCUS	1092-0684	1	2.891	Q2
NEW ENGLAND JOURNAL OF MEDICINE	0028-4793	7	70.67	Q1
NUCLEIC ACIDS RESEARCH	0305-1048	1	11.147	Q1
NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS	1525-7770	1	1.167	Q4
NUTRICIÓN CLÍNICA Y DIETÉTICA HOSPITALARIA	0211-6057	1	Not Indexed	
NUTRICIÓN HOSPITALARIA	0212-1611	11	0.759	Q4
NUTRIENTS	2072-6643	6	4.171	Q1
ONCOGÉNESIS	2157-9024	1	5.995	Q1
ONCOIMMUNOLOGY	2162-402X	2	5.333	Q1
ONCOLOGIST	1083-7159	2	5.252	Q1
ONCOTARGET	1949-2553	10	5.168	Q1
ONCOTARGETS AND THERAPY	1178-6930	1	3.046	Q2
OPEN FORUM INFECTIOUS DISEASES	2328-8957	2	3.371	Q2
OPEN ORTHOPAEDICS JOURNAL	1874-3250	1	Not Indexed	
OPHTHALMOLOGICA	0030-3755	1	1.781	Q3
OPHTHALMOLOGY. RETINA	2468-7219	1	Not Indexed	
ORPHANET JOURNAL OF RARE DISEASES	1750-1172	2	3.687	Q2
OSTEOPOROSIS INTERNATIONAL	0937-941X	1	3.819	Q2
OTOLARYNGOLOGY-HEAD AND NECK SURGERY	0194-5998	1	2.31	Q2
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY	1942-0900	2	4.868	Q2
PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY	0147-8389	1	1.34	Q4
PAIN PRACTICE	1530-7085	1	2.486	Q3
PAIN RESEARCH & MANAGEMENT	1203-6765	1	1.701	Q4
PARASITOLOGY RESEARCH	0932-0113	1	2.067	Q2
PATHOBIOLOGY	1015-2008	1	1.831	Q3
PATIENT PREFERENCE AND ADHERENCE	1177-889X	1	2.097	Q2
PEDIATRIC ALLERGY AND IMMUNOLOGY	0905-6157	1	4.654	Q1
PEDIATRIC DERMATOLOGY	0736-8046	10	1.178	Q3
PEDIATRIC EMERGENCY CARE	0749-5161	1	1.119	Q3
PEDIATRIC INFECTIOUS DISEASE JOURNAL	0891-3668	4	2.317	Q2

PEDIATRIC RADIOLOGY	0301-0449	1	2.022	Q2
PEDIATRIC RESEARCH	0031-3998	10	2.88	Q1
PEDIATRIC SURGERY INTERNATIONAL	0179-0358	1	1.397	Q3
PEDIATRICS	0031-4005	3	5.401	Q1
PEERJ	2167-8359	1	2.353	Q2
PERCEPTUAL AND MOTOR SKILLS	0031-5125	1	1.049	Q4
PHARMACOEPIDEMOLOGY AND DRUG SAFETY	1053-8569	1	2.87	Q1
PHARMACOGENOMICS	1462-2416	1	2.265	Q3
PHARMACOGENOMICS JOURNAL	1470-269X	2	3.503	Q2
PHARMACOLOGICAL RESEARCH	1043-6618	2	5.574	Q1
PHARMACOLOGICAL REVIEWS	0031-6997	1	18.84	Q1
PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY	1572-1000	1	2.589	Q3
PHYSICA MEDICA-EUROPEAN JOURNAL OF MEDICAL PHYSICS	1120-1797	1	2.532	Q2
PHYSICAL THERAPY IN SPORT	1466-853X	1	2	Q2
PHYSIOTHERAPY THEORY AND PRACTICE	1532-5040	2	1.158	Q4
PLOS GENETICS	1553-7404	1	5.224	Q1
PLOS MEDICINE	1549-1676	2	11.048	Q1
PLOS NEGLECTED TROPICAL DISEASES	1935-2735	1	4.487	Q1
PLOS ONE	1932-6203	18	2.776	Q2
PM&R	1934-1482	1	1.902	Q2
POSTGRADUATE MEDICINE	0032-5481	2	2.237	Q2
PRECLINICAL MRI: METHODS AND PROTOCOLS	1064-3745	1	Not Indexed	
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA	0027-8424	2	9.58	Q1
PROGRESS IN TRANSPLANTATION	1526-9248	1	0.958	Q4
PULMONARY PHARMACOLOGY & THERAPEUTICS	1094-5539	1	2.669	Q1
QUALITY OF LIFE RESEARCH	0962-9343	1	2.488	Q2
RADIOLOGÍA	0033-8338	1	Not Indexed	
REDOX BIOLOGY	2213-2317	5	7.793	Q1
REPRODUCTIVE SCIENCES	1933-7191	1	2.559	Q2
RESPIRATION	0025-7931	2	2.935	Q2
RESPIRATORY MEDICINE	0954-6111	2	3.237	Q2
RESPIRATORY RESEARCH	1465-993X	1	3.829	Q2
RESUSCITATION	0300-9572	1	4.572	Q1
REUMATOLOGÍA CLÍNICA	1699-258X	8	Not Indexed	
REVISTA ALERGIA MÉXICO (TECAMACHALCO, PUEBLA, MÉXICO: 1993)	0002-5151	1	Not Indexed	
REVISTA CLÍNICA ESPAÑOLA	0014-2565	7	1.043	Q3
REVISTA DA ASSOCIACAO MEDICA BRASILEIRA	0104-4230	1	0.801	Q4
REVISTA DE GASTROENTEROLOGÍA DE MÉXICO	0375-0906	1	Not Indexed	



2.8 Scientific Production



Introduction

1

Executive summary

2

2.1 Global Analysis

2.2 Research Structure

2.3 Training Report and Teaching

2.4 Innovation and Transfer Activities

2.5 Quality Committee

2.6 Clinical Trials

2.7 Platforms

2.8 Scientific Production

2.9 CIBERs and RETICs

2.10 Institutional Projects

2.11 Internationalization

2.12 Communication

Information Groups by Area

3

Associated Clinicians

4

Scientific Report

2016
2017
2018

REVISTA DE NEUROLOGÍA	0210-0010	5	0.485	Q4
REVISTA DE PSIQUIATRÍA Y SALUD MENTAL	1888-9891	1	2.927	Q2
REVISTA ESPAÑOLA DE ANESTESIOLOGÍA Y REANIMACIÓN	0034-9356	7	Not Indexed	
REVISTA ESPAÑOLA DE CARDIOLOGÍA	0300-8932	27	5.126	Q1
REVISTA ESPAÑOLA DE CIRUGÍA ORTOPÉDICA Y TRAUMATOLOGÍA	1988-8856	2	Not Indexed	
REVISTA ESPAÑOLA DE ENFERMEDADES DIGESTIVAS	1130-0108	9	1.858	Q4
REVISTA ESPAÑOLA DE GERIATRÍA Y GERONTOLOGÍA	1578-1747	8	Not Indexed	
REVISTA ESPAÑOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR	2253-654X	4	0.928	Q4
REVISTA ESPAÑOLA DE PATOLOGÍA	1988-561X	2	Not Indexed	
REVISTA ESPAÑOLA DE QUIMIOTERAPIA	0214-3429	3	0.76	Q4
REVISTA ESPAÑOLA DE SALUD PÚBLICA	1135-5727	2	0.635	Q4
REVISTA IBEROAMERICANA DE MICOLOGÍA	1130-1406	2	1.597	Q4
REVISTA LATINO-AMERICANA DE ENFERMAGEM	1518-8345	1	0.979	Q3
REVISTA PORTUGUESA DE CARDIOLOGÍA	0870-2551	1	0.785	Q4
REVISTA ROL DE ENFERMERÍA	0210-5020	2	Not Indexed	
RHEUMATOLOGY	1462-0324	3	5.149	Q1
RHEUMATOLOGY AND THERAPY	2198-6584	1	Not Indexed	
RHEUMATOLOGY INTERNATIONAL	0172-8172	4	2.2	Q3
RMD OPEN	2056-5933	1	Not Indexed	
RQR ENFERMERÍA COMUNITARIA	2253-9832	1	Not Indexed	
SCANDINAVIAN JOURNAL OF MEDICINE & SCIENCE IN SPORTS	0905-7188	2	3.631	Q1
SCIENTIFIC REPORTS	2045-2322	15	4.011	Q1
SEMERGEN	1578-8865	4	Not Indexed	
SEMINARS IN ARTHRITIS AND RHEUMATISM	0049-0172	1	5.072	Q1
SKIN RESEARCH AND TECHNOLOGY	0909-752X	1	1.657	Q3
SLEEP MEDICINE REVIEWS	1087-0792	1	10.517	Q1
SOMATOSENSORY AND MOTOR RESEARCH	0899-0220	2	1.235	Q4
SPANISH JOURNAL OF PSYCHOLOGY	1138-7416	1	0.749	Q4
SPINE	0362-2436	2	2.903	Q1
SPINE DEFORMITY	2212-1358	1	Not Indexed	
SPINE JOURNAL	1529-9430	3	3.196	Q1
STEM CELL RESEARCH	1873-5061	3	3.929	Q1
STEM CELL RESEARCH & THERAPY	1757-6512	1	4.627	Q1

STEM CELLS INTERNATIONAL	1687-966X	1	3.902	Q2
STROKE	0039-2499	2	6.046	Q1
SUPPORTIVE CARE IN CANCER	0941-4355	1	2.754	Q1
TARGETED ONCOLOGY	1776-2596	1	3.683	Q2
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY	1756-283X	1	3.961	Q2
THERAPEUTIC ADVANCES IN HEMATOLOGY	2040-6207	1	3.105	Q2
THERAPEUTIC HYPOTHERMIA AND TEMPERATURE MANAGEMENT	2153-7658	1	1.673	Q4
THROMBOSIS AND HAEMOSTASIS	0340-6245	5	4.733	Q1
THROMBOSIS JOURNAL	1477-9560	1	Not Indexed	
THROMBOSIS RESEARCH	0049-3848	1	3.266	Q2
TOBACCO INDUCED DISEASES	1617-9625	1	1.889	Q3
TORTURE	1997-3322	1	Not Indexed	
TOXINS	2072-6651	1	3.895	Q1
TRANSFUSION	0041-1132	1	3.111	Q2
TRANSFUSION AND APHERESIS SCIENCE	1473-0502	1	1.412	Q4
TRANSLATIONAL ANDROLOGY AND UROLOGY	2223-4683	1	2.113	Q2
TRANSLATIONAL CANCER RESEARCH	2218-676X	1	1.07	Q4
TRANSLATIONAL PSYCHIATRY	2158-3188	1	5.182	Q1
TRANSLATIONAL RESEARCH	1931-5244	1	4.915	Q1
TRANSPLANTATION	0041-1337	1	4.593	Q1
TRENDS IN CANCER	2405-8025	1	8.884	Q1
TRENDS IN MOLECULAR MEDICINE	1471-4914	1	11.028	Q1
TROPICAL DOCTOR	0049-4755	1	0.591	Q4
ULTRASOUND IN MEDICINE AND BIOLOGY	0301-5629	1	2.205	Q2
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS	1078-1439	2	2.863	Q2
UROLOGY	0090-4295	1	1.861	Q3
VACCINE	0264-410X	1	3.269	Q2
VASCULAR PHARMACOLOGY	1537-1891	1	3.33	Q2
VIRCHOWS ARCHIV	0945-6317	1	2.868	Q2
VIRUSES-BASEL	1999-4915	4	3.811	Q2
WORLD JOURNAL OF EMERGENCY SURGERY	1749-7922	2	3.798	Q1
WORLD JOURNAL OF GASTROENTEROLOGY	1007-9327	1	3.411	Q2
WORLD JOURNAL OF STEM CELLS	1948-0210	1	3.534	Q2
WORLD JOURNAL OF UROLOGY	0724-4983	2	2.761	Q2
WORLD PSYCHIATRY	2051-5545	1	34.024	Q1



2.8 Scientific Production

2.8.2 High Impact Publications



Neuroscience Area

Pérez-Sales P, Jan den Otter J, Hardi L, Wenzel T, Diaconu G, Cors G, Kastrup M. WPA Position statement on banning the participation of psychiatrists in the interrogation of detainees. *World Psychiatry*. 2018; 17(2): 237-8. Editorial Material. IF: 34.024; D1

Cuadrado A, Manda G, Hassan A, Alcaraz MJ, Barbas C, Daiber A, Ghezzi P, Leon R, López MG, Oliva B, Pajares M, Rojo AI, Robledinos-Anton N, Valverde AM, Guney E, Schmidt HHHW. Transcription factor NRF2 as a therapeutic target for chronic diseases: A systems medicine approach. *Pharmacol Rev*. 2018; 70(2): 348-383. Review. IF: 18.84; D1

Susser E, **Martínez-Ales G**. Putting psychosis into sociocultural context an international study in 17 locations. *JAMA Psychiatry*. 2018; 75(1): 9-10. Editorial Material. IF: 15.916; D1

Pajares M, Rojo AI, Arias E, Díaz-Carretero A, Cuervo AM, **Cuadrado A**. Transcription factor NFE2L2/NRF2 modulates chaperone-mediated autophagy through the regulation of LAMP2A. *Autophagy*. 2018; 14(8): 1310-22. Article. IF: 11.059; D1

Rojo AI, Pajares M, García-Yagüe AJ, Buendía I, Van Leuven F, Yamamoto M, López MG, **Cuadrado A**. Deficiency in the transcription factor NRF2 worsens inflammatory parameters in a mouse model with combined tauopathy and amyloidopathy. *Redox Biol*. 2018; 18: 173-80. Article. IF: 7.793; D1

Cuadrado A, Kugler S, **Lastres-Becker I**. Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy. *Redox Biol*. 2018; 14: 522-34. Article. IF: 7.793; D1



Cardiovascular Area

Banegas JR, Ruilope LM, Williams B. Ambulatory blood pressure and mortality reply. *New Engl J Med*. 2018; 379(13): 1287-8. Letter. IF: 70.67; D1

Balfagón G, Blanco-Rivero J, Márquez-Rodás I. Preventive therapies for chronic migraine. *New Engl J Med*. 2018; 378(8): 773-4. Letter. IF: 70.67; D1

Banegas JR, Ruilope LM, de la Sierra A, Vinyoles E, Gorostidi M, de la Cruz JJ, Ruiz-Hurtado G, Segura J, Rodríguez-Artalejo F, Williams B. Relationship between clinic and ambulatory blood-pressure measurements and mortality. *New Engl J Med*. 2018; 378(16): 1509-20. Article. IF: 70.67; D1

López-de-Sa E, Juárez M, Armada E, Sánchez-Salado JC, Sánchez PL,



Loma-Osorio P, Sionis A, Monedero MC, Martínez-Selles M, Martín-Benítez JC, Ariza A, Uribarri A, García-Acuna JM, Villa P, Pérez PJ, Storm C, Dee A, **López-Sendón JL**. A multicentre randomized pilot trial on the effectiveness of different levels of cooling in comatose survivors of out-of-hospital cardiac arrest: the FROST-I trial. *Intens Care Med*. 2018; 44(11): 1807-15. Article. IF: 18.967; D1

Ferrari R, Camici PG, Crea F, Danchin N, Fox K, Maggioni AP, Manolis AJ, Marzilli M, Rosano GMC, **López-Sendón JL**. A 'diamond' approach to personalized treatment of angina. *Nat Rev Cardiol*. 2018; 15(2): 120-32. Article. IF: 17.42; D1



Infectious Diseases and Immunity Area

Berenguer J, Gil-Martín A, Jarrín I, Moreno A, Domínguez L, Montes M, Aldámiz-Echevarría T, Téllez MJ, Santos I, Benítez L, Sanz J, Ryan P, Gaspar G, Álvarez B, Losa JE, Torres-Perea R, Barros C, San Martín JV, Arponen S, de Guzmán MT, Monsalvo R, Vegas A, García-Benayas MT, Serrano R, Gotuzzo L, Menéndez MA, Belda LM, Malmierca E, Calvo MJ, Cruz-Martos E, **González-García JJ**. All-oral direct-acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus/HCV-coinfected subjects in real-world practice: Madrid coinfection registry findings. *Hepatology*. 2018; 68(1): 32-47. Article. IF: 14.971; D1

Mulleman D, **Balsa A**. Adalimumab concentration-based tapering strategy: as good as the recommended dosage. *Ann Rheum Dis*. 2018; 77(4): 473-475. Editorial Material. IF: 14.299; D1

Navarro-Compán V, Ramiro S, Landewe R, Dougados M, Miceli-Richard C, Richette P, van der Heijde D. In patients with axial spondyloarthritis inflammation on MRI of the spine is longitudinally related to disease activity only in men: 2 years of the axial spondyloarthritis DESIR cohort. *Ann Rheum Dis*. 2018; 77(3): 470-2. Letter. IF: 14.299; D1

García-Morato MB, Santos FJA, Briones AC, Moreno AB, Mate AD, Domínguez-Soto A, Merino MJB, Molina LD, Cañizales JT, Marin AV, García EV, Rodríguez MF, Sabando DPL, Jiménez-Reinoso A, del Castillo YM, Santaefufemia FJS, de Lucas-Laguna R, Cárdenas PP, Polo LC, Díaz MC, Vales-Gómez M, Santiago ER, Cerdán AF, Blanco JN, Corbi AL, Reyburn HT, Regueiro JR, López-Granados E, **Pena RR**. New human combined immunodeficiency caused by interferon regulatory factor 4 (IRF4) deficiency inherited by uniparental isodisomy. *J Allergy Clin Immunol*. 2018; 141(5): 1924-27. Article. IF: 14.11; D1

Redondo C, Martínez-Feito A, Plasencia-Rodríguez C, Navarro-Compán

Introduction

1

Executive summary

2

2.1 Global Analysis

2.2 Research Structure

2.3 Training Report and Teaching

2.4 Innovation and Transfer Activities

2.5 Quality Committee

2.6 Clinical Trials

2.7 Platforms

2.8 Scientific Production

2.9 CIBERs and RETICs

2.10 Institutional Projects

2.11 Internationalization

2.12 Communication

Information Groups by Area

3

Associated Clinicians

4

Scientific Report

2016
2017
2018



2.8 Scientific Production

V, Nuno-Nuno L, Peiteado D, Villalba A, Jochems A, Pascual-Salcedo D, **Balsa A**. Golimumab tapering strategy based on serum drug levels in patients with spondyloarthritis. *Arthritis Rheumatol*. 2018; 70(8):1356-8. Letter. IF: 9.002; D1



Large System Pathologies Area

Cobo I, Martinelli P, Flández M, Bakiri L, Zhang MF, Carrillo-de-Santa-Pau E, Jia JP, Lobo VJSA, Megias D, Felipe I, del Pozo N, Millan I, Thommesen L, Bruland T, Olson SH, Smith J, Schoonjans K, Bamlet WR, Petersen GM, Malats N, Amundadottir LT, Wagner EF, **Real FX**. Transcriptional regulation by NR5A2 links differentiation and inflammation in the pancreas. *Nature*. 2018; 554(7693): 533-7. Article. IF: 43.07; D1

García-Río F. Spirometry-based diagnostic criteria that are not age-appropriate lack clinical relevance reply. *Am J Resp Crit Care*. 2018; 197(7):964-5. Letter. IF: 16.494; D1

García-Río F. The z-score does not predict mortality because of confounding by age reply. *Am J Resp Crit Care*. 2018; 197(1): 141-2. Letter. IF: 16.494; D1

Vázquez GF, Reiter RJ, Agil A. Melatonin increases brown adipose tissue mass and function in Zucker diabetic fatty rats: implications for obesity control. *J Pineal Res*. 2018; 64(4): e12472. Article. IF: 15.221; D1

Tiana M, Acosta-Iborra B, Puente-Santamaría L, Hernansanz-Agustín P, Worsley-Hunt R, Masson N, García-Río F, Mole D, Ratcliffe P, Wasserman WW, Jiménez B, **del Peso L**. The SIN3A histone deacetylase complex is required for a complete transcriptional response to hypoxia. *Nucleic Acids Res*. 2018; 46(1): 120-33. Article. IF: 11.147; D1



Cancer and Human Molecular Genetics Area

Villahoz S, Yunes-Leites PS, Méndez-Barbero N, Urso K, Bonzon-Kulichenko E, Ortega S, Nistal JF, Vázquez J, Offermanns S, Redondo JM, **Campanero MR**. Conditional deletion of Rcan1 predisposes to hypertension-mediated intramural hematoma and subsequent aneurysm and aortic rupture. *Nat Commun*. 2018; 9: 4795. Article. IF: 11.878; D1

Rodríguez-Laguna L, Ibáñez K, Gordo G, García-Miñaur S, Santos-Simarro F, Agra N, Vallespín E, Fernández-Montano VE, Martín-Arenas R, del Pozo A, González-Pecellin H, Mena R, Rueda-Arenas I, Gómez MV, Villaverde C, Bustamante A, Ayuso C, Ruiz-Pérez VL, Nevado J, Lapunzina P, López-Gutiérrez JC, **Martínez-Glez V**. CLAPO syndrome: identification of somatic activating PIK3CA mutations and delineation of the

natural history and phenotype. *Genet Med*. 2018; 20(8): 882-9. Article. IF: 8.683; D1

Hisado-Oliva A, Ruzafa-Martín A, Sentchordi L, Funari MFA, Bezanilla-López C, Alonso-Bernaldez M, Barraza-García J, Rodríguez-Zabala M, Lerario AM, Benito-Sanz S, Aza-Carmona M, Campos-Barros A, Jorge AAL, **Heath KE**. Mutations in C-natriuretic peptide (NPPC): a novel cause of autosomal dominant short stature. *Genet Med*. 2018; 20(1): 91-7. Article. IF: 8.683; D1

Barriuso J, Custodio A, Afonso R, Alonso V, Astudillo A, Capdevila J, García-Carbonero R, Grande E, Jiménez-Fonseca P, Marazuela M, Rodríguez-Antona C, Aller J. Prognostic and predictive biomarkers for somatostatin analogs peptide receptor radionuclide therapy and serotonin pathway targets in neuroendocrine tumours. *Cancer Treat Rev*. 2018; 70: 209-22. Review. IF: 8.332; D1

Santamaría PG, Floristán A, Fontanals-Cirera B, Vázquez-Naharro A, Santos V, Morales S, Yuste L, Peinado H, García-Gomez A, Portillo F, Hernandez E, **Canó A**. Lysyl oxidase-like 3 is required for melanoma cell survival by maintaining genomic stability. *Cell Death Differ*. 2018; 25(5): 935-50. Article. IF: 8.086; D1



Surgery, Transplant and Health Technologies Area

Suárez-de-la-Rica A, Gilsanz F, Maseda E, Montravers P, Lasocki S, Lescot T, Dupont H. Is very short-course antibiotic therapy possible in postoperative intra-abdominal infections? Discussion on "Short-course antibiotic therapy for critically ill patients treated for postoperative intra-abdominal infection: the DURAPOP randomised clinical trial". Letter. 2018; 44(5):695-6. Letter. IF: 18.967; D1

Maseda E, Grau S, Luque S, Castillo-Mafla MP, Suarez-de-la-Rica A, Montero-Feijoo A, Salgado P, Giménez MJ, García-Bernedo CA, Gilsanz F, Roberts JA. Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese critically ill and morbidly obese critically ill patients. Article. 2018; 22: 94. Article. IF: 6.959; Q1

Martín-Saavedra F, Escudero-Duch C, Prieto M, Sánchez-Casanova S, López D, Arruebo M, Voellmy R, Santamaría J, Vilaboa N. Pro-angiogenic near infrared-responsive hydrogels for deliberate transgene expression. *Acta Biomater*. 2018; 78: 123-36. Article. IF: 6.638; D1

Rodríguez-Merchán EC. Treatment of musculo-skeletal pain in haemophilia. *Blood Rev*. 2018; 32(2): 116-21. Review. IF: 6.125; Q1


Pascual ES, Sánchez AC, **Zurita MB**. Large congenital coronary fistula. Editorial Material. 2018; 71(4): 292. Editorial Material. IF: 5.126; Q1

2.9 CIBERs and RETICs



2.9.1 CIBER- Network Biomedical Research Center

Acronym	CIBER	Funding Organisation	Principal Researcher	IdiPAZ Group	End Date
CIBER-bbn	Networked Biomedical Research Center for Bio-engineering, Biomaterials and Nanomedicine	Carlos III Health Institute	Vilboa Díaz, Nuria Elda	Bone Pathophysiology and biomaterials	31/12/2019
CIBERehd	Networked Biomedical Research Center for Hepatic and Digestive Diseases	Carlos III Health Institute	García-Samaniego Rey, Javier	Associated Clinician	31/12/2019
CIBERer	Networked Biomedical Research Center for Rare Diseases	Carlos III Health Institute	López Trascasa, Margarita	Diagnosis and Treatment of Diseases Associated with Abnormalities of the Complement System	31/12/2018
			Lapunzina Badía, Pablo	Cell Therapy and Gene Metastasis	31/12/2018
CIBERresp	Networked Biomedical Research Center for Public Health and Epidemiology	Carlos III Health Institute	Rodríguez Artalejo, Fernando	Cardiovascular Epidemiology and Nutrition	31/12/2018
CIBERned	Networked Biomedical Research Center for Neurodegenerative Diseases	Carlos III Health Institute	Cuadrado Pastor, Antonio	Neuroprotective Strategies in Neurodegenerative Diseases	31/12/2018
CIBERcv	Networked Biomedical Research Center for Cardiovascular Diseases	Carlos III Health Institute	Salaices Sánchez, Mercedes	Vascular Physiology and Pharmacology	31/12/2022
			Cano García, Amparo	Mechanisms of Tumour Progression	31/12/2022
CIBERonc	Networked Biomedical Research Center for Cancer	Carlos III Health Institute	Muñoz Terol, Alberto	Mechanisms of Tumour Progression	31/12/2022
			Feliú Batlle, Jaime	Trasnlational Oncology	31/12/2022



Introduction **1**

Executive summary **2**

- 2.1 Global Analysis
- 2.2 Research Structure
- 2.3 Training Report and Teaching
- 2.4 Innovation and Transfer Activities
- 2.5 Quality Committee
- 2.6 Clinical Trials
- 2.7 Platforms
- 2.8 Scientific Production
- 2.9 CIBERs and RETICs**
- 2.10 Institutional Projects
- 2.11 Internationalization
- 2.12 Communication

Information Groups by Area **3**

Associated Clinicians **4**

Scientific Report

2016
2017
2018

2.9.2 RECTICs- Networks for Cooperative Research in Health


Funding Organisation	Acronym	CIBER	Funding Organisation	Principal Researcher	IdiPAZ Group	End Date
PT13/0006/0012	ITEMAS	Medical Technology Innovation Platform	Carlos III Health Institute	de Castro Carpeño, Javier	Experimental Therapies and Biomarkers in Cancer	31/12/2018
PT13/0010/0003	ReTBioH	Biobanks Platform	Carlos III Health Institute	Gómez Campelo, Paloma	Innate Immune Response	31/12/2018
PT13/0002/0015	UCICEC	Research and Clinical Trials Units Platform	Carlos III Health Institute	Frías Iniesta, Jesús	Clinical Pharmacology	31/12/2018
PT17/0005/0025	ITEMAS	Plataforma ITEMAS	Carlos III Health Institute	de Castro Carpeño, Javier	Experimental Therapies and Biomarkers in Cancer	31/12/2020
PT17/0015/0025	RNBB	Red de Biobancos	Carlos III Health Institute	Gómez Campelo, Paloma	Innate Immune Response	31/12/2020
PT17/0017/0013	SCReN	Plataforma de Unidades de Investigación Clínica y Ensayos Clínicos	Carlos III Health Institute	Frías Iniesta, Jesús	Clinical Pharmacology	31/12/2020
RD16/0019/0005	INVICTUS PLUS	Vascular and Cerebral Diseases Network	Carlos III Health Institute	Díez Tejedor, Exuperio	Neurology and Cerebrovascular Diseases	31/12/2021
S2013/MIT-2862	MULTIMAT	Materiales multifuncionales para los retos de la sociedad	Autonomous Community of Madrid	Vilaboa Díaz, Nuria Elda	Bone Pathophysiology and Biomaterials	31/12/2018
RD16/0025/0018	RIS	Research Network for AIDS	Carlos III Health Institute	González García, Juan	AIDS and Infectious Diseases	31/12/2021
RD16/0006/0033	ARADYAL	Asthma, Adverse and Allergic Reactions	Carlos III Health Institute	Laguna Martínez, José Julio	Associated Clinician	31/12/2021
RD16/0022/0006	SAMID	Research Network for Maternal and Child Health and Development	Carlos III Health Institute	Martínez Martínez, Leopoldo	Congenital Malformation Surgery	31/12/2021
RD16/0027/0002	RICET	Tropical Disease Cooperative Research Network	Carlos III Health Institute	Mora Rillo, Marta	AIDS and infectious diseases	31/12/2021
RD16/0009/0008	REDINREN	Research Network for Renal Diseases	Carlos III Health Institute	Selgas Gutiérrez, Rafael	Nephrology	31/12/2021
RD16/0022/0004	SAMID	Research Network for Maternal and Child Health and Development	Carlos III Health Institute	Cabañas González, Fernando	Congenital Malformation Surgery	31/12/2021
RD16/0012/0012	RIER	Investigational Network in Inflammation and Rheumatic Diseases	Carlos III Health Institute	Miranda Carús, María Eugenia	Immuno-Rheumatology	31/12/2021
SAF2015-71304-REDT		Research Network NRF2 as a Node of the Pathogenesome	Ministerio de Ciencia, Innovación y Universidades	Cuadrado Pastor, Antonio	Neuroprotective Strategies in Neurodegenerative Diseases	31/12/2019
SAF2017-90604-REDT	NuRCaMeIn	Red Temática de Receptores Nucleares en Cáncer, Metabolismo e Inflamación	Ministerio de Ciencia, Innovación y Universidades	Muñoz Terol, Alberto	Mechanisms of Tumour Progression	31/12/2019

2.10 Institutional Projects



The European Reference Network (ERN) TransplantChild (www.transplantchild.eu) was accredited by the European Commission in 2017 to tackle a low prevalence complex procedure and condition as the paediatric transplantation of all kind of solid organ and hematopoietic stem cell transplantation.

The number of paediatric transplantations performed worldwide continues to increase. Data shows that more than 5.000 children receive some kind of transplant in Europe each year. Regardless the type of transplant, all transplanted children share a common life-long medical condition: the need of immunosuppression treatment to prevent graft rejection. The secondary effects of a life on immunosuppressive treatment can lead to infections, malignancy and chronic rejection. Furthermore, non-adherence to treatment, which is worse in adolescents, can impact in the quality of life of these patients and their families and eventually could lead to chronic rejection and re-transplantation.





2.10 Institutional Projects

Strategic areas

La Paz University Hospital-IdiPAZ, coordinates the resources and existing knowledge from the 18 hospitals from 11 European Member States, involved in the ERN TransplantChild in order to harmonize, generate and disseminate the knowledge related to transplantation throughout Europe, following these strategic areas:



- Facilitate the patient empowerment through its participation in the activities of the network, ease access to information, dissemination of experience, research, exchange of necessary knowledge to facilitate their decision-making.
- Improvements in healthcare: prevention, surgical interventions, patients' follow-up and health care for transplanted patients.
- Improve health outcomes regarding the immune transplant process and phenomena of rejection and tolerance using clinical practice guidelines by multi-professional teams involved in care.
- The gaps identification, alignment and prioritization of areas of research and innovation facilitate continuous improvement in transplant patient care and health outcomes.
- Disseminate knowledge through society and other stakeholders, and clinical teams at different levels (including education and training activities).

IdiPAZ Added Value

La Paz University Hospital has one of the most highly specialized multidisciplinary transplant teams in Europe and is the only one in Spain accredited to do all kind of

paediatric transplants with survival and quality indicators comparable to the best hospitals in the world.

IdiPAZ-La Paz University Hospital' commitment to this network is significant, not only for the members of the Executive Operating Committee, but the groups and departments involved in the activities developed by the network:

- Participation in the screening of publications for the elaboration of the Clinical Practice Guideline in Immunosuppression Management
- Sharing and participation in the discussions of clinical cases in the dedicated European Platform (CPMS)
- Facilitating information of the existing registries for the development of the first European Registry on Paediatric Transplantation (PETER)
- Participation as speakers in the I International Course on Paediatric Transplantation, sharing their knowledge and cases studies.

Members Added Value


The clinical advice must be accessible to all EU hospitals, providing to patients access to the best available diagnosis and treatment procedures, bearing in mind the quality of life of patients and their families. The members of TransplantChild are working together to improve the life of these children in different ways, but we would like to highlight the following:

- Providing and receiving "virtual" advice on challenging cases by using the dedicated Europe-wide consultation technology, responding to the most advanced EU standards in terms of security and data protection..
- Creation of the first European Registry for paediatric transplanted patients (PETER). This will increase research potential but also it will enable ERN to perform multicentre clinical studies and clinical trials.
- Due to the low prevalence of paediatric transplantation scientific evidence is scarce. Putting together the effort and cases from all the members of the network, will allow developing Clinical Practice Guidelines based in the expert's opinions and the evidence gathered together. Also, the preparation of Clinical Audit on PTLD.
- Spread knowledge between professionals involved in paediatric transplantation, but also to patients and patients' relatives. The participation and activities developed by Patients Associations and Advocacy groups, become even more important in TransplantChild since the network is about to deploy Patients Reported Experience (PREMs) and Patients Reported Outcomes (PROMs) Management indicators.



- 2.1 Global Analysis
- 2.2 Research Structure
- 2.3 Training Report and Teaching
- 2.4 Innovation and Transfer Activities
- 2.5 Quality Committee
- 2.6 Clinical Trials
- 2.7 Platforms
- 2.8 Scientific Production
- 2.9 CIBERs and RETICs
- 2.10 Institutional Projects
- 2.11 Internationalization**
- 2.12 Communication

2.11 Internationalization



AMERICA

Argentina
Brazil
Canada
Chile
Ecuador
Honduras
Mexico
United States of America

EUROPA

Austria
Belgium
Bulgaria
Croatia
Czech Republic
Denmark
England
Estonia
Finland
France
Germany
Greece
Hungary
Ireland
Italy
Luxembourg
Netherlands
Norway
Poland
Portugal
Romania
Scotland
Serbia
Sweden
Switzerland
Ukraine
United Kingdom
Wales

AFRICA

Uganda


ASIA

Bangladesh
China
India
Israel
Japan
Lebanon
Philippines
Singapore
South Korea
Taiwan
Thailand
Turkey

OCEANIA

Australia

2.12 Communication



Communication and another scientific dissemination activity

IdiPAZ was present in different media (journals, magazines, webs, radio, TV., etc.), which contributed to highlight the activity developed by the Institute throughout 2018. A number of our researchers have been interviewed by the main mass media to broadcast all the knowledge generated in our institute. Besides, the presence of our news in popular platforms such as: Twitter, Instagram and Facebook help us to expand our research work to society via the most commonly used means today. Along these lines, the scientific direction of our institute is extraordinarily active in social networks and the media, which has made our center one of the best known by society.

IdiPAZ appear in a total of 216 publications of written press, and in our website, "IdiPAZ in the media" it is included a coverage of 394 digital press mentions of this year:

<http://www.idipaz.es/PaginaDinamica.aspx?IdPag=650&Lang=ES>.

Also, eight own news were published at the website of the Insitute (www.idipaz.es), and the Community of Madrid at the website of Consejería de Sanidad included six news from IdiPAZ researchers (<https://www.comunidad.madrid/actualidad>):

- **2018/09/06- Presentado estudio sobre reinfecciones en pacientes con Hepatitis C y VIH en la Comunidad de Madrid.** "El estudio titulado "Reinfección por el VHC después del tratamiento eficaz con antivirales de acción directa frente al VHC en individuos coinfectados por VIH y VHC en Madrid-CoRe" (en inglés: HCV Reinfection Following Effective All-oral DAA Therapy in HIV/HCV Coinfected Individuals in Madrid-CoRe) ha sido presentando en la 22ª Conferencia Internacional sobre el SIDA celebrada en Ámsterdam del 23 al 27 de julio de 2018. Han participado 21 hospitales del Servicio Madrileño de Salud con experiencia en el tratamiento de pacientes con coinfección VIH/VHC."
- **2018/08/03- Contamos con la primera unidad de Terapias Avanzadas para tratar el cáncer en niños y adolescentes.** "El Hospital Universitario La Paz acaba de poner en marcha la Unidad CRIS de Terapias Avanzadas para Cáncer Infantil. Esta unidad, pionera en la Comunidad de Madrid, está situada en la octava planta del Hospital Materno-Infantil y viene a completar al servicio de Hemato-Oncología actual con diez nuevas habitaciones: seis para adolescentes y ensayos clínicos y cuatro diseñadas con aislamiento de última generación para pacientes

inmunodeprimidos y tratamientos complejos. Estas habitaciones se suman a las 16 ya existentes, cuatro de ellas para trasplante de progenitores hematopoyéticos. Además, cuenta con un espacio para ensayos clínicos ubicado en los laboratorios de IdiPAZ, del Instituto de Genética Médica y Molecular (INGEMM) y en la Unidad de Ensayos Clínicos del hospital, UCICEC.

- **2018/08/03- IdiPAZ participa en el Programa Healthstart con dos de los doce proyectos seleccionados.** "El Hospital La Paz, a través del IdiPAZ, participará con dos proyectos en el Programa Healthstart organizado por la Fundación para el Conocimiento madri+d junto con la Plataforma de Innovación en Tecnologías Médicas y Sanitarias (ITEMAS) para impulsar emprendimiento y creación de spin-offs basadas en tecnologías sanitarias. Dos de los doce proyectos seleccionados en esta III Edición del Programa están liderados por personal de IdiPAZ."
- **2018/06/26- El presente y el futuro de la tecnología 3D, a debate en el Hospital La Paz.** "La Plataforma de Innovación del Hospital Universitario La Paz ha celebrado la tercera edición de sus jornadas de innovación. Bajo el título "La Paz 3.D: gestión de la tridimensionalidad" el objetivo ha sido reunir a los profesionales sanitarios y la industria para debatir sobre el presente y futuro de la tridimensionalidad y su gestión en el sector sanitario contrastando experiencias, conocimiento e innovación."
- **2018/06/11- El IdiPAZ coordina el Registro Nacional de Pacientes con Fractura de Cadera.** "El IdiPAZ (Instituto de Investigación de La Paz) coordina el Registro Nacional de Fracturas de Cadera (RNFC) por fragilidad en el anciano. El registro cuenta ya con los datos de más de 7.000 pacientes procedentes de 54 hospitales de la mayoría de las comunidades autónomas de España. El principal objetivo de este registro es mejorar la calidad asistencial. Los resultados se comparan con otros centros tanto nacionales como internacionales."
- **2018/02/12- Se presenta en el Hospital La Paz-IdiPaz un sello dedicado a la investigación biomédica** "La Sociedad Estatal de Correos y Telégrafos presenta en La Paz una colección filatélica dedicada a la investigación biomédica en España, que incluye un sello de 35 x 24.5 mm. y un matasellos. El acto ha contado con la presencia del presidente de Correos, la Secretaria General Técnica del Ministerio de Fomento, la directora general de Investigación de la Consejería de Sanidad y el director científico del Instituto de Investigación de la Paz."

Introduction 1

Executive summary 2

- 2.1 Global Analysis
- 2.2 Research Structure
- 2.3 Training Report and Teaching
- 2.4 Innovation and Transfer Activities
- 2.5 Quality Committe
- 2.6 Clinical Trials
- 2.7 Platforms
- 2.8 Scientific Production
- 2.9 CIBERs and RETICs
- 2.10 Institutional Projects
- 2.11 Internationalization
- 2.12 **Comunication**

Information Groups by Area 3


Associated Clinicians 4

Scientific Report 2016 2017 2018



2.12 Comunication

In the website, the activity has been improving year after year since its implementation in 2011, so at the end of 2018, it exceeded 240,000 visits.



News that includes the work of our researchers, data about courses, grants, and other news of interest to the public, are published in the main social networks, where IdiPAZ has its own profile since October 2018:




@IdipazScience

Currently, the number of followers was 851 on Twitter, 76 on Facebook, and 237 on Instagram.

Regarding to Scientific communication, more than symposiums, workshop, etc. were organized at IdiPAZ in 2018, and finally, Scientific Seminars of IdiPAZ was certified by "Acreditación de Actividades de Formación Continuada de las Profesiones Sanitarias" by the Comunity of Madrid (07-AFOC-003327.1/2018). In 2018, 20 seminars were celebrated.

Coordinators: Laura Saldaña Quero; Paloma Gómez Campelo and Susana García Pérez.

Date	Speaker	Title
12/01/2018	Jaime Millán	Papel de la polaridad del hepatocito en la respuesta inflamatoria del hígado
19/01/2018	Carlos Ramírez	La cuarta R de la experimentación animal
26/01/2018	Anee Miren Andrés	Trasplante intestinal y rechazo: estudio experimental con células troncales mesenquimales derivadas de tejido adiposo para su prevención y perspectivas clínicas futuras en la búsqueda de la tolerancia inmunológica
09/02/2018	José Luis López Sendón Henstchel	¿Qué es la calidad? ¿Para qué sirve? ¿Cómo se mide? ¿Quién la tiene que medir?
16/02/2018	Virginia Amesty	Medicina regenerativa aplicada a la urología



23/02/2018	Daniel Ortega Ponce	Hipertermia magnética y su aplicación en biomedicina
02/03/2018	Silvia Martín Puig	Hypoxia and Cardiovascular System: New Mouse Models to investigate Human Diseases
09/03/2018	Elena Sendagorta Cudós	El futuro ya está aquí
16/03/2018	Jorge Bonastre Julià	Investigación en Cirugía Plástica, una realidad
06/04/2018	Miguel González, M ^a Paz	Hacia el desarrollo de una córnea humanizada por medio de ingeniería celular
13/04/2018	Francisco Garcia Rio	Causas y consecuencias del síndrome de apnea del sueño
20/04/2018	María Luisa Toribio	Leucemia linfoblástica aguda de células T
27/04/2018	Miguel Ángel Rico Daza	Medicamento NCI de terapias avanzadas. Requisitos para su fabricación y aplicación en el HUPHM
18/05/2018	Santiago Rodríguez de Córdoba	Basic concepts about complement, complement related diseases and anti-complement therapies
25/05/2018	Fernando Corrales	Aplicaciones de la proteómica funcional en biomedicina. El caso del hígado
19/10/2018	Rafael Correa Rocha	Terapia celular con células Treg obtenidas de tejido tímico (thyTreg) para prevenir el rechazo en niños trasplantados de corazón. Un nuevo paradigma en el tratamiento de enfermedades inmunológicas
26/10/2018	Arancha Llama Palacios	Estudio de las bacterias periodontales mediante herramientas proteómicas
23/11/2018	Jesús Mingorance Cruz	Análisis cuantitativo de la colonización intestinal por enterobacterias multirresistentes
30/11/2018	Almudena Val Blasco	Role of nucleotide-binding oligomerization domain type I (nod1) in human and experimental heart failure
21/12/2018	Laetitia Pereira	Papel de nuevos mediadores reguladores del calcio intracelular en la enfermedad metabólica

(IdiPAZ)^{10^ñ}

IdiPAZ
Instituto de Investigación
Hospital Universitario La Paz

 **Hospital Universitario
La Paz**
Hospital Carlos III
Hospital Cantoblanco

 **Hospital Universitario La Paz**
Fundación para la Investigación Biomédica
 **Comunidad de Madrid**

 **Hospital Universitario
de Fuenlabrada**

 **Universidad Autónoma
de Madrid**

 **Unión Europea**
Fondo Europeo
de Desarrollo Regional
"Una manera de hacer Europa"

**Scientific
Report**

www.idipaz.es

2016
2017
2018